[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is also known as:\n1. Acrokeratosis paraneoplastic syndrome\n2. Acrokeratosis of the skin\n3. Paraneoplastic acrokeratosis\n4. Acrokeratosis associated with cancer\n5. Acrokeratosis neoplastica\nNote: These synonyms are not exhaustive and may not be mutually exclusive, as some synonyms may overlap or have slightly different meanings.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic syndrome.\n2. Acrokeratosis paraneoplastica is referred to as Acrokeratosis of the skin.\n3. Paraneoplastic acrokeratosis is a synonym for Acrokeratosis paraneoplastica.\n4. Acrokeratosis paraneoplastica can be called Acrokeratosis associated with cancer.\n5. Acrokeratosis neoplastica is another name for Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic syndrome.",
      "Acrokeratosis paraneoplastica is referred to as Acrokeratosis of the skin.",
      "Paraneoplastic acrokeratosis is a synonym for Acrokeratosis paraneoplastica.",
      "Acrokeratosis paraneoplastica can be called Acrokeratosis associated with cancer.",
      "Acrokeratosis neoplastica is another name for Acrokeratosis paraneoplastica."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Acrokeratosis paraneoplastica is not commonly referred to as \"Acrokeratosis of the skin.\" It is a specific paraneoplastic syndrome that affects the skin, but the term \"Acrokeratosis of the skin\" is not a standard name for the condition.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Acrokeratosis neoplastica is not a recognized term for Acrokeratosis paraneoplastica. The correct term is Bazex syndrome, which is another name for Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both genetic disorders that affect brain development and can cause a range of physical and intellectual disabilities. However, they are distinct conditions with some differences in their clinical features and genetic causes.\nSimilarities between Weaver syndrome and Sotos syndrome:\n1. Both disorders are caused by mutations in genes involved in brain development and function.\n2. Both can cause intellectual disability, delayed development, and a range of physical abnormalities.\n3. Both disorders can affect the structure and function of the brain, leading to problems with cognition, motor skills, and behavior.\n4. Both disorders can lead to seizures, feeding and breathing difficulties, and other health problems.\nDifferences between Weaver syndrome and Sotos syndrome:\n1. Genetic cause: Weaver syndrome is caused by mutations in the PTEN gene, while Sotos syndrome is caused by mutations in the NSD1 gene.\n2. Age of onset: Weaver syndrome typically becomes apparent at birth or in early childhood, while Sotos syndrome can be diagnosed at any age but is usually recognized in the first year of life.\n3. Severity of symptoms: Sotos syndrome is generally more severe than Weaver syndrome, with more pronounced intellectual disability, delayed development, and physical abnormalities.\n4. Brain structure: Weaver syndrome is characterized by abnormalities in the structure of the cerebral cortex, while Sotos syndrome can involve changes in the size and shape of various brain structures.\n5. Behavioral problems: Both disorders can lead to behavioral problems, but Sotos syndrome is more likely to cause autism spectrum disorder (ASD) and other neurodevelopmental disorders.\n6. Other health problems: Both disorders can lead to a range of other health problems, but Sotos syndrome is more likely to cause endocrine abnormalities, such as growth hormone deficiency and adrenal insufficiency.\nIn summary, while Weaver syndrome and Sotos syndrome share some similarities, they are distinct genetic disorders with different genetic causes, age of onset, severity of symptoms, brain structure abnormalities, behavioral problems, and other health problems",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome is caused by mutations in the EZH2 gene, not the PTEN gene as stated.\n2. Sotos syndrome is caused by mutations in the NSD1 gene.\n3. Weaver syndrome typically becomes apparent at birth or in early childhood.\n4. Sotos syndrome is usually recognized in the first year of life.\n5. Sotos syndrome is more likely to cause autism spectrum disorder (ASD) and other neurodevelopmental disorders compared to Weaver syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome is caused by mutations in the EZH2 gene, not the PTEN gene as stated.",
      "Sotos syndrome is caused by mutations in the NSD1 gene.",
      "Weaver syndrome typically becomes apparent at birth or in early childhood.",
      "Sotos syndrome is usually recognized in the first year of life.",
      "Sotos syndrome is more likely to cause autism spectrum disorder (ASD) and other neurodevelopmental disorders compared to Weaver syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe fifth statement is difficult to determine as true or false without specific epidemiological data comparing the incidence of autism spectrum disorder (ASD) and other neurodevelopmental disorders in individuals with Sotos syndrome versus those with Weaver syndrome. While both syndromes are associated with an increased risk of developmental disorders, the exact likelihood of ASD in comparison between the two is not specified in the statement provided.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Joint Analysis of Sequence and Function in Protein Analysis) is a widely used database of transcription factor binding site (TFBS) profiles. Here are the releases of the JASPAR database:\n1. JASPAR Release 1 (2000): This was the first release of the JASPAR database, which contained TFBS profiles for 22 transcription factors.\n2. JASPAR Release 2 (2003): This release expanded the database to include TFBS profiles for an additional 22 transcription factors, bringing the total number of factors to 44.\n3. JASPAR Release 3 (2007): In this release, the database was updated to include TFBS profiles for an additional 30 transcription factors, as well as improved algorithms for predicting TFBSs.\n4. JASPAR Release 4 (2010): This release introduced a new format for TFBS profiles, as well as improved algorithms for predicting the binding affinity of TFBSs.\n5. JASPAR Release 5 (2013): This release expanded the database to include TFBS profiles for an additional 35 transcription factors, bringing the total number of factors to 75.\n6. JASPAR Release 6 (2016): This release introduced a new algorithm for predicting TFBSs, as well as improved methods for predicting the binding affinity of TFBSs.\n7. JASPAR Release 7 (2020): This is the latest release of the JASPAR database, which includes TFBS profiles for an additional 10 transcription factors, bringing the total number of factors to 85.\nIt's worth noting that the JASPAR database is constantly being updated and new releases are being made, so the latest version may include additional transcription factors and improved algorithms.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Release 1 was in 2000 and contained transcription factor binding site profiles for 22 transcription factors.\n2. JASPAR Release 2 occurred in 2003 and expanded the database to include profiles for a total of 44 transcription factors.\n3. JASPAR Release 3 was in 2007 and included profiles for an additional 30 transcription factors and improved algorithms for predicting transcription factor binding sites.\n4. JASPAR Release 4 in 2010 introduced a new format for transcription factor binding site profiles and improved algorithms for predicting binding affinity.\n5. JASPAR Release 7, the latest mentioned release as of the answer, was in 2020 and included profiles for a total of 85 transcription factors.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Release 1 was in 2000 and contained transcription factor binding site profiles for 22 transcription factors.",
      "JASPAR Release 2 occurred in 2003 and expanded the database to include profiles for a total of 44 transcription factors.",
      "JASPAR Release 3 was in 2007 and included profiles for an additional 30 transcription factors and improved algorithms for predicting transcription factor binding sites.",
      "JASPAR Release 4 in 2010 introduced a new format for transcription factor binding site profiles and improved algorithms for predicting binding affinity.",
      "JASPAR Release 7, the latest mentioned release as of the answer, was in 2020 and included profiles for a total of 85 transcription factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: JASPAR Release 1 was in 2004 and contained transcription factor binding site profiles for 123 transcription factors.\n2. FALSE [correction]: JASPAR Release 2 occurred in 2006 and expanded the database to include profiles for a total of 113 transcription factors.\n3. FALSE [correction]: JASPAR Release 3 was in 2010 and included profiles for an additional 22 transcription factors, not 30, and it did not specifically mention improved algorithms for predicting transcription factor binding sites.\n4. UNKNOWN: Without specific historical data on JASPAR Release 4, it is not possible to confirm the introduction of a new format for transcription factor binding site profiles and improved algorithms for predicting binding affinity in 2010.\n5. FALSE [correction]: JASPAR Release 7 was in 2018 and included profiles for a total of 579 transcription factors, not 85. The latest release as of my knowledge cutoff in 2023 would be JASPAR 2022.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a protein encoded by the KP4 gene in certain viruses, including the polyomavirus middle T antigen (PyV-MT) and the polyomavirus small T antigen (PyV-ST). The KP4 protein is a key regulator of the viral life cycle and has multiple functions, including:\n1. Inhibition of interferon signaling: The KP4 protein can bind to and inhibit the activity of interferon regulatory factors (IRFs), which are transcription factors that play a crucial role in the antiviral response. By inhibiting IRFs, the KP4 protein can prevent the activation of interferon-stimulated genes, which are involved in the antiviral response.\n2. Inhibition of cellular signaling pathways: The KP4 protein can also inhibit the activation of various cellular signaling pathways, including the PI3K/Akt and MAPK pathways, which are involved in cellular proliferation, survival, and migration.\n3. Modulation of the cell cycle: The KP4 protein can regulate the cell cycle by modulating the expression of cell cycle regulators, such as cyclin-dependent kinases (CDKs) and CDK inhibitors.\n4. Inhibition of apoptosis: The KP4 protein can inhibit the activation of pro-apoptotic proteins, such as BAX and BAK, which are involved in programmed cell death.\n5. Modulation of viral transcription: The KP4 protein can also regulate the transcription of viral genes by interacting with the viral RNA polymerase and other transcription factors.\nOverall, the KP4 protein plays a crucial role in regulating the viral life cycle and evading the host immune response by inhibiting various cellular signaling pathways and regulatory proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein can bind to and inhibit the activity of interferon regulatory factors (IRFs).\n2. The KP4 protein can prevent the activation of interferon-stimulated genes involved in the antiviral response.\n3. The KP4 protein can inhibit the activation of cellular signaling pathways, including the PI3K/Akt and MAPK pathways.\n4. The KP4 protein can regulate the cell cycle by modulating the expression of cell cycle regulators, such as cyclin-dependent kinases (CDKs) and CDK inhibitors.\n5. The KP4 protein can inhibit the activation of pro-apoptotic proteins, such as BAX and BAK.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein can bind to and inhibit the activity of interferon regulatory factors (IRFs).",
      "The KP4 protein can prevent the activation of interferon-stimulated genes involved in the antiviral response.",
      "The KP4 protein can inhibit the activation of cellular signaling pathways, including the PI3K/Akt and MAPK pathways.",
      "The KP4 protein can regulate the cell cycle by modulating the expression of cell cycle regulators, such as cyclin-dependent kinases (CDKs) and CDK inhibitors.",
      "The KP4 protein can inhibit the activation of pro-apoptotic proteins, such as BAX and BAK."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific and pertain to the biological functions of a protein named KP4. Without additional context or scientific references, it is not possible to determine the accuracy of these statements. They would require specific knowledge or research into the KP4 protein and its interactions with cellular components and pathways.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (N-[4-[2-(5-Iodinyloxy)phenyl]butyl]-3-trifluoro-methyl-pyridine-2-carboxamide 1,1-oxide) is a synthetic thyroid hormone analog that has been utilized in both experimental and clinical studies.\nExperimental studies:\nDITPA has been used as a tool to investigate the role of thyroid hormones in various biological processes, including embryonic development, metabolism, and cancer. For example, DITPA has been shown to mimic the effects of thyroid hormones in the regulation of gene expression, and it has been used to study the molecular mechanisms underlying thyroid hormone action.\nClinical studies:\nDITPA has been investigated as a potential therapeutic agent for the treatment of various conditions, including hypothyroidism, hyperthyroidism, and cancer. For example, DITPA has been shown to normalize thyroid function in patients with hypothyroidism, and it has been used as a radioactive tracer for thyroid imaging and therapy. Additionally, DITPA has been investigated as a potential anticancer agent, as it has been shown to inhibit the growth of thyroid cancer cells.\nIt is important to note that while DITPA has been studied extensively in both experimental and clinical settings, it is not currently approved for clinical use by regulatory agencies such as the FDA. Further research is needed to fully understand the safety and efficacy of DITPA in humans before it can be approved for clinical use.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a synthetic thyroid hormone analog.\n2. DITPA has been used in experimental studies to investigate the role of thyroid hormones in embryonic development, metabolism, and cancer.\n3. DITPA has been shown to mimic the effects of thyroid hormones in the regulation of gene expression.\n4. DITPA has been investigated as a potential therapeutic agent for conditions such as hypothyroidism, hyperthyroidism, and cancer.\n5. DITPA is not currently approved for clinical use by regulatory agencies such as the FDA.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a synthetic thyroid hormone analog.",
      "DITPA has been used in experimental studies to investigate the role of thyroid hormones in embryonic development, metabolism, and cancer.",
      "DITPA has been shown to mimic the effects of thyroid hormones in the regulation of gene expression.",
      "DITPA has been investigated as a potential therapeutic agent for conditions such as hypothyroidism, hyperthyroidism, and cancer.",
      "DITPA is not currently approved for clinical use by regulatory agencies such as the FDA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "COUGER (Comprehensive Update of Gene Regulatory Events) is a tool used to analyze and predict the regulatory effects of genetic variants, including single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations, on gene expression. COUGER uses a combination of machine learning algorithms and statistical models to integrate various types of genomic and transcriptomic data, including gene expression profiles, genomic sequence data, and epigenetic marks, to predict the effects of genetic variants on gene regulation.\nCOUGER can be used to identify potential regulatory mechanisms underlying genetic associations with complex diseases, such as cancer, and to predict the effects of genetic variants on gene expression in different cell types and tissues. The tool can also be used to identify potential drug targets and to design personalized medicine approaches based on an individual's genetic profile.\nOverall, COUGER is a powerful tool for understanding the complex interplay between genetic variants and gene regulation, and for identifying potential therapeutic targets for a variety of diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER stands for Comprehensive Update of Gene Regulatory Events.\n2. COUGER is used to analyze and predict the regulatory effects of genetic variants on gene expression.\n3. The tool integrates genomic and transcriptomic data using machine learning algorithms and statistical models.\n4. COUGER can identify potential regulatory mechanisms associated with complex diseases like cancer.\n5. The tool can be used in the design of personalized medicine approaches based on an individual's genetic profile.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER stands for Comprehensive Update of Gene Regulatory Events.",
      "COUGER is used to analyze and predict the regulatory effects of genetic variants on gene expression.",
      "The tool integrates genomic and transcriptomic data using machine learning algorithms and statistical models.",
      "COUGER can identify potential regulatory mechanisms associated with complex diseases like cancer.",
      "The tool can be used in the design of personalized medicine approaches based on an individual's genetic profile."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: COUGER does not stand for Comprehensive Update of Gene Regulatory Events. There is no widely recognized acronym COUGER in the context of genetics or bioinformatics. It's possible that COUGER could be a fictional or less known tool, but without additional context, the meaning of the acronym cannot be confirmed.\n2. UNKNOWN: Without specific information about COUGER, it is not possible to confirm whether it is used to analyze and predict the regulatory effects of genetic variants on gene expression.\n3. UNKNOWN: Without specific information about COUGER, it is not possible to confirm whether the tool integrates genomic and transcriptomic data using machine learning algorithms and statistical models.\n4. UNKNOWN: Without specific information about COUGER, it is not possible to confirm whether it can identify potential regulatory mechanisms associated with complex diseases like cancer.\n5. UNKNOWN: Without specific information about COUGER, it is not possible to confirm whether the tool can be used in the design of personalized medicine approaches based on an individual's genetic profile.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available for treating tick-borne encephalitis (TBE), which is caused by the tick-borne viruses Tick-borne encephalitis virus (TBEV) and Kyasanur Forest disease virus (KFDV). Here are some of the drugs used to treat TBE:\n1. Ribavirin: This drug is an antiviral drug that is commonly used to treat TBE. It has been shown to reduce the severity of symptoms and the duration of illness in patients with TBE.\n2. Aztreonam: This drug is an antibiotic that is sometimes used to treat TBE, particularly in cases where the patient has a secondary bacterial infection.\n3. Corticosteroids: Corticosteroids, such as prednisone, may be used to reduce inflammation in the brain and spinal cord, which can occur in some cases of TBE.\n4. Immunoglobulins: In some cases, immunoglobulins (antibodies) may be given to patients with TBE to help boost their immune system and fight off the virus.\n5. Favipiravir: Favipiravir is an antiviral drug that has been shown to be effective in treating TBE. It works by inhibiting the replication of the virus and reducing the severity of symptoms.\n6. Relenza: Relenza is an antiviral drug that is commonly used to treat TBE. It works by inhibiting the replication of the virus and reducing the severity of symptoms.\n7. Oseltamivir: Oseltamivir is an antiviral drug that is sometimes used to treat TBE. It works by inhibiting the replication of the virus and reducing the severity of symptoms.\n8. Zanamivir: Zanamivir is an antiviral drug that is sometimes used to treat TBE. It works by inhibiting the replication of the virus and reducing the severity of symptoms.\nIt's important to note that the choice of drug and the effectiveness of treatment may vary depending on the severity and location of the infection, as well as the individual patient's medical history and overall health. In some cases, a combination of dru",
    "llama-2-7b-chat-hf_fact_raw": "1. Ribavirin is an antiviral drug used to treat tick-borne encephalitis (TBE).\n2. Aztreonam is an antibiotic sometimes used to treat TBE, especially in cases with a secondary bacterial infection.\n3. Corticosteroids like prednisone may be used to reduce inflammation in the brain and spinal cord in some TBE cases.\n4. Immunoglobulins may be administered to patients with TBE to help boost their immune system.\n5. Favipiravir is an antiviral drug effective in treating TBE by inhibiting the replication of the virus.",
    "llama-2-7b-chat-hf_fact": [
      "Ribavirin is an antiviral drug used to treat tick-borne encephalitis (TBE).",
      "Aztreonam is an antibiotic sometimes used to treat TBE, especially in cases with a secondary bacterial infection.",
      "Corticosteroids like prednisone may be used to reduce inflammation in the brain and spinal cord in some TBE cases.",
      "Immunoglobulins may be administered to patients with TBE to help boost their immune system.",
      "Favipiravir is an antiviral drug effective in treating TBE by inhibiting the replication of the virus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ribavirin is an antiviral drug, but it is not typically used to treat tick-borne encephalitis (TBE). It is more commonly used for hepatitis C and some viral hemorrhagic fevers.\n2. UNKNOWN: While aztreonam is an antibiotic used to treat bacterial infections, there is limited information on its specific use for TBE, especially in cases with a secondary bacterial infection. This would be a specific clinical decision based on the individual case.\n3. TRUE: Corticosteroids like prednisone may be used in the management of TBE to reduce inflammation in the brain and spinal cord, although their use is generally cautious and based on the severity of symptoms.\n4. TRUE: Immunoglobulins, specifically intravenous immunoglobulins (IVIG), may be administered to patients with severe cases of TBE to support the immune response.\n5. FALSE [correction]: Favipiravir is an antiviral drug that has been studied for influenza and other viral infections, but there is no strong evidence supporting its effectiveness in treating TBE specifically. Treatment for TBE primarily focuses on supportive care and managing symptoms.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers and databases that provide DNA shape annotations, including:\n1. Genome Graph Explorer (GGE): This database provides 3D chromatin structure information for various organisms, including humans. It offers interactive visualization and analysis tools for exploring the chromatin landscape.\n2. 3D Genome Browser (3DGB): This database provides 3D chromatin structure information for human and mouse genomes, along with epigenetic marks and transcription factor binding sites. It also offers tools for visualizing and analyzing chromatin interactions.\n3. ChromHMM: This database provides 3D chromatin structure models for various organisms, including humans. It offers tools for visualizing and analyzing chromatin structure and dynamics.\n4. HiC-Pro: This database provides high-resolution chromatin interaction data for various organisms, including humans. It offers tools for visualizing and analyzing chromatin interactions and their implications for gene regulation.\n5. Chromatin Interaction Map (ChIA-Map): This database provides high-resolution chromatin interaction data for various organisms, including humans. It offers tools for visualizing and analyzing chromatin interactions and their implications for gene regulation.\n6. Topologically Associating Domains (TADs): This database provides 3D chromatin structure information for various organisms, including humans. It offers tools for visualizing and analyzing chromatin structure and its implications for gene regulation.\n7. ENCODE: This database provides a comprehensive set of epigenetic marks and chromatin structure data for various organisms, including humans. It offers tools for visualizing and analyzing epigenetic marks and their implications for gene regulation.\n8. Roadmap Epigenomics: This database provides a comprehensive set of epigenetic marks and chromatin structure data for various organisms, including humans. It offers tools for visualizing and analyzing epigenetic marks and their implications for gene regulation.\n9. Chromatin Atlas: This database provides a comprehensive set of chromatin structure and epigenetic marks data for various organisms, including humans. It offers tools for visualizing and analyzing chromatin structure and its implications for gene regulation.\n10. Epigenome Atlas: This database provides a comprehensive set of epigenetic marks and chromatin structure data for various organisms",
    "llama-2-7b-chat-hf_fact_raw": "1. Genome Graph Explorer (GGE) provides 3D chromatin structure information for various organisms, including humans.\n2. 3D Genome Browser (3DGB) provides 3D chromatin structure information for human and mouse genomes.\n3. ChromHMM provides 3D chromatin structure models for various organisms, including humans.\n4. HiC-Pro provides high-resolution chromatin interaction data for various organisms, including humans.\n5. ENCODE provides a comprehensive set of epigenetic marks and chromatin structure data for various organisms, including humans.",
    "llama-2-7b-chat-hf_fact": [
      "Genome Graph Explorer (GGE) provides 3D chromatin structure information for various organisms, including humans.",
      "3D Genome Browser (3DGB) provides 3D chromatin structure information for human and mouse genomes.",
      "ChromHMM provides 3D chromatin structure models for various organisms, including humans.",
      "HiC-Pro provides high-resolution chromatin interaction data for various organisms, including humans.",
      "ENCODE provides a comprehensive set of epigenetic marks and chromatin structure data for various organisms, including humans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information about the Genome Graph Explorer (GGE), it is not possible to confirm whether it provides 3D chromatin structure information for various organisms, including humans.\n2. TRUE: The 3D Genome Browser (3DGB) is known to provide 3D chromatin structure information for human and mouse genomes.\n3. FALSE [correction]: ChromHMM is a computational tool that uses chromatin state data to produce genome-wide chromatin state annotations, but it does not provide 3D chromatin structure models.\n4. TRUE: HiC-Pro is a software package that processes Hi-C data and can provide high-resolution chromatin interaction data, which is relevant to studying the 3D organization of genomes.\n5. TRUE: The ENCODE (Encyclopedia of DNA Elements) project provides a comprehensive set of data on epigenetic marks and chromatin structure, among other genomic information, for various organisms, including humans.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene encodes the enzyme enzyme histone methyltransferase 2 (EZH2), which is involved in regulating gene expression by modifying histone proteins. Mutations in the EZH2 gene have been associated with several syndromes, including:\n1. Beckwith-Wiedemann syndrome (BWS): BWS is a rare genetic disorder characterized by overgrowth, abnormalities in the nervous system, and an increased risk of developing certain cancers. EZH2 mutations are found in approximately 50% of BWS cases.\n2. Silver-Russell syndrome (SRS): SRS is a rare genetic disorder characterized by growth delays, intellectual disability, and various other physical abnormalities. EZH2 mutations have been identified in approximately 20% of SRS cases.\n3. Bourneville's syndrome (BS): BS is a rare genetic disorder characterized by growth delays, intellectual disability, and distinctive facial features. EZH2 mutations have been identified in approximately 10% of BS cases.\n4. Neurofibromatosis type 1 (NF1): NF1 is a neurological disorder characterized by tumors in the nervous system, including brain and spinal cord tumors, and benign growths on nerves. EZH2 mutations have been identified in approximately 5% of NF1 cases.\n5. Juvenile myelomonocytic leukemia (JMML): JMML is a rare and aggressive form of leukemia that typically affects children under the age of 6. EZH2 mutations are found in approximately 20% of JMML cases.\n6. Chronic myeloid leukemia (CML): CML is a type of blood cancer that affects the bone marrow. EZH2 mutations have been identified in approximately 10% of CML cases.\n7. Acute myeloid leukemia (AML): AML is a type of blood cancer that affects the bone marrow. EZH2 mutations have been identified in approximately 5% of AML cases.\n8. Myelodysplastic",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene have been associated with Beckwith-Wiedemann syndrome (BWS), with approximately 50% of BWS cases having EZH2 mutations.\n2. Silver-Russell syndrome (SRS) is associated with EZH2 mutations in approximately 20% of cases.\n3. EZH2 mutations have been identified in approximately 10% of Bourneville's syndrome (BS) cases.\n4. Neurofibromatosis type 1 (NF1) has been associated with EZH2 mutations in approximately 5% of cases.\n5. Juvenile myelomonocytic leukemia (JMML) has EZH2 mutations in approximately 20% of cases.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene have been associated with Beckwith-Wiedemann syndrome (BWS), with approximately 50% of BWS cases having EZH2 mutations.",
      "Silver-Russell syndrome (SRS) is associated with EZH2 mutations in approximately 20% of cases.",
      "EZH2 mutations have been identified in approximately 10% of Bourneville's syndrome (BS) cases.",
      "Neurofibromatosis type 1 (NF1) has been associated with EZH2 mutations in approximately 5% of cases.",
      "Juvenile myelomonocytic leukemia (JMML) has EZH2 mutations in approximately 20% of cases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the EZH2 gene have not been primarily associated with Beckwith-Wiedemann syndrome (BWS). BWS is most commonly associated with changes on chromosome 11p15.5, involving genes like CDKN1C, IGF2, and H19.\n2. UNKNOWN: While Silver-Russell syndrome (SRS) is a disorder involving genetic changes, the specific percentage of SRS cases associated with EZH2 mutations is not well-established in the literature as of my last update.\n3. FALSE [correction]: Bourneville's syndrome, also known as Tuberous Sclerosis, is primarily associated with mutations in the TSC1 and TSC2 genes, not EZH2.\n4. FALSE [correction]: Neurofibromatosis type 1 (NF1) is caused by mutations in the NF1 gene, not typically associated with EZH2 mutations.\n5. TRUE: EZH2 mutations have been identified in a subset of cases of juvenile myelomonocytic leukemia (JMML), although the exact percentage may vary, and the presence of EZH2 mutations in JMML is a topic of ongoing research.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition, including:\n1. p53: The tumor suppressor protein p53 is a well-studied example of a protein that undergoes a dimer-to-tetramer transition. The p53 protein exists as both a dimer and a tetramer, and the transition between these two states is regulated by various cellular signals and stressors.\n2. β-catenin: β-catenin is a key component of the Wnt signaling pathway and undergoes a dimer-to-tetramer transition in response to changes in the cellular environment.\n3. CREB: The cAMP-response element-binding protein (CREB) is a transcription factor that regulates gene expression in response to changes in intracellular cAMP levels. CREB exists as both a dimer and a tetramer, and the transition between these two states is important for its function.\n4. NF-κB: The nuclear factor kappa B (NF-κB) transcription factor is involved in the regulation of inflammation and immune responses. NF-κB exists as both a dimer and a tetramer, and the transition between these two states is important for its function.\n5. FOXO: The forkhead box O (FOXO) transcription factors are involved in the regulation of cellular processes such as metabolism, stress resistance, and longevity. FOXO proteins exist as both dimers and tetramers, and the transition between these two states is important for their function.\n6. STAT3: The signal transducer and activator of transcription 3 (STAT3) transcription factor is involved in the regulation of immune and inflammatory responses. STAT3 exists as both a dimer and a tetramer, and the transition between these two states is important for its function.\n7. HIF1α: The hypoxia-inducible factor 1 alpha (HIF1α) transcription factor is involved in the response to low oxygen levels in cells. HIF1α exists as both a dimer and a tetramer, and the transition between these two states",
    "llama-2-7b-chat-hf_fact_raw": "1. The tumor suppressor protein p53 undergoes a dimer-to-tetramer transition.\n2. β-catenin undergoes a dimer-to-tetramer transition in response to changes in the cellular environment.\n3. The cAMP-response element-binding protein (CREB) exists as both a dimer and a tetramer.\n4. The nuclear factor kappa B (NF-κB) transcription factor exists as both a dimer and a tetramer.\n5. Forkhead box O (FOXO) transcription factors exist as both dimers and tetramers.",
    "llama-2-7b-chat-hf_fact": [
      "The tumor suppressor protein p53 undergoes a dimer-to-tetramer transition.",
      "β-catenin undergoes a dimer-to-tetramer transition in response to changes in the cellular environment.",
      "The cAMP-response element-binding protein (CREB) exists as both a dimer and a tetramer.",
      "The nuclear factor kappa B (NF-κB) transcription factor exists as both a dimer and a tetramer.",
      "Forkhead box O (FOXO) transcription factors exist as both dimers and tetramers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The tumor suppressor protein p53 can indeed undergo a dimer-to-tetramer transition, which is important for its function in DNA binding and transcriptional regulation.\n2. FALSE [correction]: β-catenin does not undergo a dimer-to-tetramer transition. Instead, it is part of the Wnt signaling pathway and can form complexes with other proteins, but it is not known to form tetramers in response to cellular changes.\n3. UNKNOWN: The statement about the cAMP-response element-binding protein (CREB) existing as both a dimer and a tetramer is not clearly established in the literature, and the oligomerization state can depend on various factors. CREB typically functions as a dimer, but whether it can form stable tetramers under physiological conditions is less clear.\n4. TRUE: The nuclear factor kappa B (NF-κB) transcription factor can exist as a dimer, which is the active form that translocates to the nucleus. There is less evidence for stable tetrameric forms of NF-κB in physiological conditions, but it is not impossible that such forms could exist transiently or under specific conditions.\n5. UNKNOWN: Forkhead box O (FOXO) transcription factors are known to function as monomers or dimers. The statement about FOXO transcription factors existing as tetramers is not well-established in the literature, and more evidence would be needed to confirm such a claim.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Phospholamban (PLN) is an anti-apoptotic protein that has been found to interact with the protein Bcl-2. Bcl-2 is a member of the Bcl-2 family of proteins, which are involved in regulating programmed cell death (apoptosis). Bcl-2 functions as an anti-apoptotic protein by inhibiting the activation of caspases, which are enzymes that play a central role in the execution of apoptosis. By interacting with PLN, Bcl-2 can further enhance its anti-apoptotic effects and protect cells from undergoing programmed cell death.",
    "llama-2-7b-chat-hf_fact_raw": "1. Phospholamban (PLN) interacts with the protein Bcl-2.\n2. Bcl-2 is an anti-apoptotic protein.\n3. The Bcl-2 family of proteins is involved in regulating programmed cell death (apoptosis).\n4. Bcl-2 inhibits the activation of caspases, which are enzymes involved in apoptosis.\n5. The interaction between PLN and Bcl-2 can enhance the anti-apoptotic effects of Bcl-2.",
    "llama-2-7b-chat-hf_fact": [
      "Phospholamban (PLN) interacts with the protein Bcl-2.",
      "Bcl-2 is an anti-apoptotic protein.",
      "The Bcl-2 family of proteins is involved in regulating programmed cell death (apoptosis).",
      "Bcl-2 inhibits the activation of caspases, which are enzymes involved in apoptosis.",
      "The interaction between PLN and Bcl-2 can enhance the anti-apoptotic effects of Bcl-2."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe statements regarding Bcl-2 and its role in apoptosis are correct, but without specific context or a source, it's not possible to confirm the interaction between Phospholamban (PLN) and Bcl-2 or the effects of such an interaction. These are highly specific biochemical interactions that would require citation of specific scientific research to verify.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, vitamin D has been shown to reduce the incidence of falls in older people in several clinical trials. Here are some examples:\n1. A 2018 Cochrane review of 16 randomized controlled trials involving over 13,000 older adults found that vitamin D supplementation was associated with a significant reduction in the risk of falls. The review concluded that vitamin D supplementation may be effective in reducing the risk of falls in older adults, particularly in those with low baseline vitamin D levels.\n2. A 2017 meta-analysis of 11 randomized controlled trials involving over 6,000 older adults found that vitamin D supplementation was associated with a reduced risk of falls. The meta-analysis suggested that vitamin D supplementation may be beneficial in reducing the risk of falls in older adults, particularly in those with low vitamin D levels.\n3. A 2014 randomized controlled trial published in the Journal of the American Geriatrics Society found that vitamin D supplementation reduced the incidence of falls in older adults with low vitamin D levels. The study involved 240 community-dwelling older adults aged 65 years or older who were randomly assigned to receive either vitamin D supplements or a placebo for 12 months. The results showed that the incidence of falls was significantly lower in the vitamin D supplemented group compared to the placebo group.\n4. A 2012 randomized controlled trial published in the Journal of Gerontology found that vitamin D supplementation reduced the incidence of falls in older adults with cognitive impairment. The study involved 160 older adults with cognitive impairment who were randomly assigned to receive either vitamin D supplements or a placebo for 12 months. The results showed that the incidence of falls was significantly lower in the vitamin D supplemented group compared to the placebo group.\nIt is important to note that while these studies suggest an association between vitamin D supplementation and a reduced risk of falls in older adults, more research is needed to confirm these findings and establish the optimal dosage and duration of vitamin D supplementation for fall prevention. Additionally, it is important to consult with a",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2018 Cochrane review of 16 randomized controlled trials involving over 13,000 older adults found that vitamin D supplementation was associated with a significant reduction in the risk of falls.\n2. A 2017 meta-analysis of 11 randomized controlled trials involving over 6,000 older adults indicated that vitamin D supplementation was associated with a reduced risk of falls.\n3. A 2014 randomized controlled trial published in the Journal of the American Geriatrics Society showed that vitamin D supplementation reduced the incidence of falls in older adults with low vitamin D levels.\n4. A 2012 randomized controlled trial published in the Journal of Gerontology demonstrated that vitamin D supplementation reduced the incidence of falls in older adults with cognitive impairment.\n5. The 2014 study involved 240 community-dwelling older adults aged 65 years or older who were randomly assigned to receive either vitamin D supplements or a placebo for 12 months.",
    "llama-2-7b-chat-hf_fact": [
      "A 2018 Cochrane review of 16 randomized controlled trials involving over 13,000 older adults found that vitamin D supplementation was associated with a significant reduction in the risk of falls.",
      "A 2017 meta-analysis of 11 randomized controlled trials involving over 6,000 older adults indicated that vitamin D supplementation was associated with a reduced risk of falls.",
      "A 2014 randomized controlled trial published in the Journal of the American Geriatrics Society showed that vitamin D supplementation reduced the incidence of falls in older adults with low vitamin D levels.",
      "A 2012 randomized controlled trial published in the Journal of Gerontology demonstrated that vitamin D supplementation reduced the incidence of falls in older adults with cognitive impairment.",
      "The 2014 study involved 240 community-dwelling older adults aged 65 years or older who were randomly assigned to receive either vitamin D supplements or a placebo for 12 months."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first statement is true based on the information provided, assuming the Cochrane review is accurately represented. However, for statements 2 through 5, without access to the specific studies or meta-analyses mentioned, it is not possible to verify the details of the sample sizes, the years the studies were published, the specific findings, or the characteristics of the study participants. Therefore, the truthfulness of these statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells.\nJarid2 (Jumonji H3-domain-containing protein 2) is a histone H3 lysine 9-specific demethylase that plays a crucial role in regulating chromatin remodeling and gene expression. miR-155 (microRNA-155) is a small non-coding RNA molecule that has been implicated in the regulation of Th17 cell differentiation and function.\nStudies have shown that Jarid2 and miR-155 are co-regulated in Th17 cells, with Jarid2 promoting the expression of miR-155. Specifically, Jarid2 has been shown to demethylate the promoter region of the miR-155 gene, leading to its activation and increased expression. This, in turn, can modulate the differentiation and function of Th17 cells, including the production of pro-inflammatory cytokines such as IL-17A and IL-22.\nIn addition, miR-155 has been shown to target and negatively regulate the expression of pro-inflammatory genes, such as NF-κB and STAT3, which are involved in the differentiation and function of Th17 cells. Therefore, the association between Jarid2 and miR-155 in Th17 cells suggests a complex interplay between these molecules in the regulation of Th17 cell function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is a histone H3 lysine 9-specific demethylase involved in chromatin remodeling and gene expression.\n2. miR-155 is a small non-coding RNA molecule implicated in the regulation of Th17 cell differentiation and function.\n3. Studies have indicated that Jarid2 promotes the expression of miR-155 by demethylating the promoter region of the miR-155 gene.\n4. The interaction between Jarid2 and miR-155 can modulate the differentiation and function of Th17 cells, including the production of cytokines such as IL-17A and IL-22.\n5. miR-155 targets and negatively regulates the expression of pro-inflammatory genes like NF-κB and STAT3, which are involved in Th17 cell differentiation and function.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is a histone H3 lysine 9-specific demethylase involved in chromatin remodeling and gene expression.",
      "miR-155 is a small non-coding RNA molecule implicated in the regulation of Th17 cell differentiation and function.",
      "Studies have indicated that Jarid2 promotes the expression of miR-155 by demethylating the promoter region of the miR-155 gene.",
      "The interaction between Jarid2 and miR-155 can modulate the differentiation and function of Th17 cells, including the production of cytokines such as IL-17A and IL-22.",
      "miR-155 targets and negatively regulates the expression of pro-inflammatory genes like NF-κB and STAT3, which are involved in Th17 cell differentiation and function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Jarid2 is not a histone demethylase; it is a component of the Polycomb repressive complex 2 (PRC2) that is involved in chromatin remodeling and gene expression, but it does not have demethylase activity itself.\n2. TRUE\n3. UNKNOWN: Without specific studies to reference, it is not possible to confirm whether Jarid2 promotes the expression of miR-155 by demethylating the promoter region of the miR-155 gene, especially since Jarid2 is not a demethylase.\n4. UNKNOWN: While Jarid2 and miR-155 may be involved in the differentiation and function of Th17 cells, the specific interaction and its effects on cytokine production like IL-17A and IL-22 would require specific studies to confirm.\n5. FALSE [correction]: miR-155 does not target and negatively regulate the expression of NF-κB and STAT3 directly. Instead, miR-155 can regulate various aspects of the immune response, and its targets can include other molecules that may influence the NF-κB and STAT3 pathways. However, the statement as given is too direct and oversimplifies the complex regulatory roles of miR-155.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 9 genes:\n1. HOXD1\n2. HOXD2\n3. HOXD3\n4. HOXD4\n5. HOXD5\n6. HOXD6\n7. HOXD7\n8. HOXD8\n9. HOXD9\nThese genes are located on chromosome 2 and play important roles in the development and patterning of the embryo, particularly in the formation of the anterior-posterior (head-tail) axis and the establishment of the body plan.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 9 genes.\n2. The genes in the human HoxD cluster are HOXD1, HOXD2, HOXD3, HOXD4, HOXD5, HOXD6, HOXD7, HOXD8, and HOXD9.\n3. These genes are located on chromosome 2.\n4. The HoxD genes are involved in the development and patterning of the embryo.\n5. The HoxD genes contribute to the formation of the anterior-posterior axis and the establishment of the body plan.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 9 genes.",
      "The genes in the human HoxD cluster are HOXD1, HOXD2, HOXD3, HOXD4, HOXD5, HOXD6, HOXD7, HOXD8, and HOXD9.",
      "These genes are located on chromosome 2.",
      "The HoxD genes are involved in the development and patterning of the embryo.",
      "The HoxD genes contribute to the formation of the anterior-posterior axis and the establishment of the body plan."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9 genes, which are HOXD1 through HOXD13, not just HOXD1 through HOXD9.\n2. FALSE [correction]: The genes in the human HoxD cluster are HOXD1 through HOXD13, not just HOXD1 through HOXD9.\n3. FALSE [correction]: These genes are located on chromosome 2q31 (long arm of chromosome 2), not on chromosome 2 as a whole.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein kinase 1 (CK1) is a serine/threonine kinase that plays a crucial role in various cellular processes, including cell signaling, gene expression, and protein phosphorylation. The phosphorylation consensus motifs for CK1 are:\n1. Ser/Thr-Pro-X-Ser/Thr (where X is any amino acid)\nThis consensus motif is recognized by the catalytic subunit of CK1 and is found in many phosphorylation sites in different proteins.\n2. Ser/Thr-Pro-Gly-X-Ser/Thr (where X is any amino acid)\nThis motif is also recognized by the catalytic subunit of CK1 and is involved in the phosphorylation of proteins involved in various cellular processes.\n3. Ser/Thr-Pro-X-X-Ser/Thr (where X is any amino acid)\nThis consensus motif is recognized by the regulatory subunit of CK1 and is involved in the phosphorylation of proteins that are involved in the regulation of CK1 activity.\n4. Ser/Thr-X-X-Ser/Thr (where X is any amino acid)\nThis consensus motif is recognized by the catalytic subunit of CK1 and is involved in the phosphorylation of proteins that are involved in the regulation of CK1 activity.\n5. Ser/Thr-Pro-X-X-Ser/Thr (where X is any amino acid)\nThis consensus motif is recognized by the regulatory subunit of CK1 and is involved in the phosphorylation of proteins that are involved in the regulation of CK1 activity.\nIt's worth noting that these consensus motifs are not specific to CK1 and can be recognized by other kinases as well, so it's important to consider the specific context and the kinase involved in the phosphorylation reaction.",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein kinase 1 (CK1) is a serine/threonine kinase.\n2. The phosphorylation consensus motif for CK1 includes Ser/Thr-Pro-X-Ser/Thr, where X is any amino acid.\n3. Another CK1 phosphorylation consensus motif is Ser/Thr-Pro-Gly-X-Ser/Thr, where X is any amino acid.\n4. A third CK1 phosphorylation consensus motif is Ser/Thr-Pro-X-X-Ser/Thr, where X is any amino acid.\n5. The phosphorylation consensus motifs for CK1 are not specific to CK1 and can be recognized by other kinases as well.",
    "llama-2-7b-chat-hf_fact": [
      "Casein kinase 1 (CK1) is a serine/threonine kinase.",
      "The phosphorylation consensus motif for CK1 includes Ser/Thr-Pro-X-Ser/Thr, where X is any amino acid.",
      "Another CK1 phosphorylation consensus motif is Ser/Thr-Pro-Gly-X-Ser/Thr, where X is any amino acid.",
      "A third CK1 phosphorylation consensus motif is Ser/Thr-Pro-X-X-Ser/Thr, where X is any amino acid.",
      "The phosphorylation consensus motifs for CK1 are not specific to CK1 and can be recognized by other kinases as well."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The phosphorylation consensus motif for CK1 typically includes Ser/Thr followed by acidic residues or other specific sequences, but not necessarily Ser/Thr-Pro-X-Ser/Thr.\n3. FALSE [correction]: There is no widely recognized CK1 phosphorylation consensus motif that includes Ser/Thr-Pro-Gly-X-Ser/Thr.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes several isoforms of the protein, including:\n1. Aspartate beta-hydroxylase (ASPH): This is the main isoform of the enzyme, which is responsible for the first committed step in the synthesis of the amino acid tyrosine.\n2. Tyrosine beta-hydroxylase (TYR): This isoform is produced from the alternative splicing of the ASPH gene and is involved in the synthesis of the amino acid tyrosine.\n3. Dopamine beta-monooxygenase (DBH): This isoform is produced from the alternative splicing of the ASPH gene and is involved in the metabolism of dopamine.\n4. 5-Hydroxytryptamine (5-HT) beta-hydroxylase (5-HTPBH): This isoform is produced from the alternative splicing of the ASPH gene and is involved in the metabolism of serotonin.\n5. Soluble form (sASPH): This isoform is produced by alternative splicing of the ASPH gene and is localized in the cytoplasm.\n6. Membrane-bound form (mASPH): This isoform is produced by alternative splicing of the ASPH gene and is localized in the membrane of certain cells, such as the kidney.\nNote: The isoforms may have different functions, distributions, and subcellular localizations, and some may be specific to certain tissues or developmental stages.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene in humans encodes the main isoform known as aspartate beta-hydroxylase (ASPH).\n2. Tyrosine beta-hydroxylase (TYR) is an isoform produced from the alternative splicing of the ASPH gene.\n3. Dopamine beta-monooxygenase (DBH) is an isoform produced from the alternative splicing of the ASPH gene.\n4. 5-Hydroxytryptamine (5-HT) beta-hydroxylase (5-HTPBH) is an isoform produced from the alternative splicing of the ASPH gene.\n5. The ASPH gene produces both a soluble form (sASPH) and a membrane-bound form (mASPH) through alternative splicing.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene in humans encodes the main isoform known as aspartate beta-hydroxylase (ASPH).",
      "Tyrosine beta-hydroxylase (TYR) is an isoform produced from the alternative splicing of the ASPH gene.",
      "Dopamine beta-monooxygenase (DBH) is an isoform produced from the alternative splicing of the ASPH gene.",
      "5-Hydroxytryptamine (5-HT) beta-hydroxylase (5-HTPBH) is an isoform produced from the alternative splicing of the ASPH gene.",
      "The ASPH gene produces both a soluble form (sASPH) and a membrane-bound form (mASPH) through alternative splicing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Tyrosine hydroxylase (TH) is not an isoform produced from the ASPH gene. It is an enzyme encoded by the TH gene, which is involved in the synthesis of the neurotransmitter dopamine.\n3. FALSE [correction]: Dopamine beta-monooxygenase (DBH) is not an isoform produced from the ASPH gene. DBH is an enzyme that converts dopamine to norepinephrine and is encoded by the DBH gene.\n4. FALSE [correction]: There is no known enzyme called 5-Hydroxytryptamine (5-HT) beta-hydroxylase (5-HTPBH) produced from the ASPH gene. 5-HT refers to serotonin, and its synthesis is not directly related to the ASPH gene.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin was FDA approved on June 28, 2014, for the treatment of type 2 diabetes. It was approved for use in adults with type 2 diabetes to help lower blood sugar levels and reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, or death from cardiovascular causes, in people with type 2 diabetes who have established cardiovascular disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved on June 28, 2014.\n2. The FDA approved empagliflozin for the treatment of type 2 diabetes.\n3. Empagliflozin is used to help lower blood sugar levels in adults with type 2 diabetes.\n4. Empagliflozin is approved to reduce the risk of major adverse cardiovascular events in people with type 2 diabetes who have established cardiovascular disease.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved on June 28, 2014.",
      "The FDA approved empagliflozin for the treatment of type 2 diabetes.",
      "Empagliflozin is used to help lower blood sugar levels in adults with type 2 diabetes.",
      "Empagliflozin is approved to reduce the risk of major adverse cardiovascular events in people with type 2 diabetes who have established cardiovascular disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Empagliflozin was FDA approved on August 1, 2014.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Lon1 is a protein that plays a crucial role in maintaining genome stability and preventing DNA damage in various organisms, including plants. In Arabidopsis, the loss of Lon1 leads to several phenotypic changes and developmental defects. Here are some of the key results of Lon1 loss in Arabidopsis:\n1. Increased sensitivity to DNA-damaging agents: Lon1-deficient Arabidopsis plants are more sensitive to DNA-damaging agents such as UV light, which can lead to increased mutations and genetic instability.\n2. Delayed growth and development: Lon1 loss leads to delayed growth and development, including reduced leaf size and altered leaf shape.\n3. Changes in flowering time: Lon1-deficient Arabidopsis plants flower later than wild-type plants, indicating a delay in floral initiation and development.\n4. Altered root architecture: Lon1 loss results in thicker roots with more lateral branches, indicating a change in root architecture.\n5. Increased sensitivity to oxidative stress: Lon1-deficient Arabidopsis plants are more sensitive to oxidative stress, as indicated by increased accumulation of reactive oxygen species (ROS) and reduced plant survival under stress conditions.\n6. Changes in gene expression: Lon1 loss leads to altered expression of genes involved in various cellular processes, including DNA repair, stress response, and cell cycle regulation.\n7. Increased genome instability: Lon1 deficiency leads to increased genome instability, as indicated by increased mutation rates and chromosomal abnormalities.\n8. Impaired DNA repair: Lon1 loss reduces the ability of Arabidopsis plants to repair DNA damage, leading to increased sensitivity to DNA-damaging agents and increased genome instability.\n9. Changes in mitochondrial function: Lon1 deficiency affects mitochondrial function, leading to reduced respiration and increased production of ROS.\n10. Altered protein synthesis: Lon1 loss affects protein synthesis, leading to changes in the expression of various proteins involved in cellular processes such as signaling, metabolism, and protein degradation.\nOverall, the loss of Lon1",
    "llama-2-7b-chat-hf_fact_raw": "1. Lon1-deficient Arabidopsis plants are more sensitive to DNA-damaging agents such as UV light.\n2. Loss of Lon1 in Arabidopsis leads to delayed growth and development, including reduced leaf size and altered leaf shape.\n3. Lon1-deficient Arabidopsis plants flower later than wild-type plants.\n4. Lon1 loss results in thicker roots with more lateral branches in Arabidopsis.\n5. Lon1-deficient Arabidopsis plants are more sensitive to oxidative stress, as indicated by increased accumulation of reactive oxygen species (ROS).",
    "llama-2-7b-chat-hf_fact": [
      "Lon1-deficient Arabidopsis plants are more sensitive to DNA-damaging agents such as UV light.",
      "Loss of Lon1 in Arabidopsis leads to delayed growth and development, including reduced leaf size and altered leaf shape.",
      "Lon1-deficient Arabidopsis plants flower later than wild-type plants.",
      "Lon1 loss results in thicker roots with more lateral branches in Arabidopsis.",
      "Lon1-deficient Arabidopsis plants are more sensitive to oxidative stress, as indicated by increased accumulation of reactive oxygen species (ROS)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Lon1-deficient Arabidopsis plants are indeed more sensitive to DNA-damaging agents such as UV light due to their compromised ability to maintain mitochondrial function and genome integrity.\n2. TRUE: Loss of Lon1 in Arabidopsis can lead to delayed growth and development, which may manifest as reduced leaf size and altered leaf shape due to the role of Lon1 in protein quality control and regulation of mitochondrial function.\n3. TRUE: Lon1-deficient Arabidopsis plants can flower later than wild-type plants. The Lon1 protease is involved in various aspects of plant development, including flowering time regulation.\n4. UNKNOWN: Without specific research data or references, it is difficult to determine the accuracy of the statement regarding root thickness and lateral branching in Lon1-deficient Arabidopsis plants.\n5. TRUE: Lon1-deficient Arabidopsis plants are more sensitive to oxidative stress, which is consistent with the role of Lon1 in maintaining mitochondrial function and reducing the accumulation of damaged or misfolded proteins that can lead to increased ROS production.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, a linker histone exists in the yeast genome. In yeast, the linker histone is called H3K5ac (histone H3 lysine 5 acetylation). H3K5ac is a linker histone that is specifically enriched in the linker regions between the nucleosomes in the chromatin structure. It plays a crucial role in the regulation of various cellular processes, including transcriptional elongation, chromatin remodeling, and DNA repair.\nIn yeast, H3K5ac is established and maintained by the activity of histone acetyltransferases (HATs) and histone deacetylases (HDACs). The balance between HATs and HDACs determines the level of H3K5ac in the chromatin, and alterations in this balance have been implicated in various diseases, including cancer and neurodegenerative disorders.\nOverall, the presence of a linker histone in the yeast genome is an important factor in regulating chromatin structure and gene expression, and its dysregulation can have significant consequences for cellular function and health.",
    "llama-2-7b-chat-hf_fact_raw": "1. A linker histone called H3K5ac exists in the yeast genome.\n2. H3K5ac is enriched in the linker regions between nucleosomes in the chromatin structure of yeast.\n3. H3K5ac plays a role in transcriptional elongation, chromatin remodeling, and DNA repair in yeast.\n4. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are responsible for establishing and maintaining the levels of H3K5ac in yeast chromatin.\n5. Alterations in the balance between HATs and HDACs, which regulate H3K5ac levels, have been implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "A linker histone called H3K5ac exists in the yeast genome.",
      "H3K5ac is enriched in the linker regions between nucleosomes in the chromatin structure of yeast.",
      "H3K5ac plays a role in transcriptional elongation, chromatin remodeling, and DNA repair in yeast.",
      "Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are responsible for establishing and maintaining the levels of H3K5ac in yeast chromatin.",
      "Alterations in the balance between HATs and HDACs, which regulate H3K5ac levels, have been implicated in various diseases, including cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The correct nomenclature for histone modifications typically includes the histone type (e.g., H3) and the specific amino acid residue and its position (e.g., K4 for lysine 4), followed by the type of modification (e.g., ac for acetylation). H3K5ac would refer to acetylation at the fifth lysine of histone H3. However, the term \"linker histone\" usually refers to histone H1, not H3. H3 is a core histone, not a linker histone.\n\n2. UNKNOWN: Without specific scientific evidence or literature to confirm the enrichment of H3K5ac in the linker regions between nucleosomes in yeast, the truth of this statement cannot be determined.\n\n3. UNKNOWN: The role of H3K5ac in transcriptional elongation, chromatin remodeling, and DNA repair in yeast would need to be supported by specific scientific studies or literature to determine the truth of this statement.\n\n4. TRUE: Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are indeed responsible for the addition and removal of acetyl groups on histones, including H3K5ac, thereby regulating their levels in chromatin.\n\n5. TRUE: It is well-established in scientific literature that alterations in the balance between HATs and HDACs, which regulate histone acetylation levels, have been implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is some evidence to suggest that tomato juice may help lower cholesterol levels.\nStudies have shown that the lycopene and other antioxidants in tomato juice can help reduce cholesterol levels by:\n1. Inhibiting the absorption of dietary cholesterol: Lycopene in tomato juice can bind to bile acids in the gut, reducing their ability to absorb dietary cholesterol.\n2. Reducing cholesterol synthesis: Lycopene can also inhibit the synthesis of cholesterol in the liver by reducing the activity of enzymes involved in cholesterol biosynthesis.\n3. Increasing cholesterol excretion: Lycopene may also increase the excretion of cholesterol in the feces by binding to bile acids and promoting their elimination from the body.\nSome studies that have investigated the effect of tomato juice on cholesterol levels include:\n1. A study published in the Journal of Nutrition in 2005 found that drinking 8 ounces of tomato juice per day for 12 weeks reduced total cholesterol levels by 10% and LDL (bad) cholesterol levels by 13% in healthy adults.\n2. A study published in the American Journal of Clinical Nutrition in 2010 found that drinking 100 ml of tomato juice per day for 12 weeks reduced LDL cholesterol levels by 11% and increased HDL (good) cholesterol levels by 16% in healthy adults with mild hypercholesterolemia.\n3. A study published in the Journal of Lipid Research in 2014 found that consuming a tomato-based beverage enriched with lycopene and other antioxidants for 12 weeks reduced LDL cholesterol levels by 12% and increased HDL cholesterol levels by 10% in healthy adults.\nIt's important to note that while these studies suggest that tomato juice may have a positive effect on cholesterol levels, the overall",
    "llama-2-7b-chat-hf_fact_raw": "1. Lycopene in tomato juice can bind to bile acids in the gut, reducing their ability to absorb dietary cholesterol.\n2. Lycopene can inhibit the synthesis of cholesterol in the liver by reducing the activity of enzymes involved in cholesterol biosynthesis.\n3. A study published in the Journal of Nutrition in 2005 found that drinking 8 ounces of tomato juice per day for 12 weeks reduced total cholesterol levels by 10% and LDL cholesterol levels by 13% in healthy adults.\n4. A study published in the American Journal of Clinical Nutrition in 2010 found that drinking 100 ml of tomato juice per day for 12 weeks reduced LDL cholesterol levels by 11% and increased HDL cholesterol levels by 16% in healthy adults with mild hypercholesterolemia.\n5. A study published in the Journal of Lipid Research in 2014 found that consuming a tomato-based beverage enriched with lycopene and other antioxidants for 12 weeks reduced LDL cholesterol levels by 12% and increased HDL cholesterol levels by 10% in healthy adults.",
    "llama-2-7b-chat-hf_fact": [
      "Lycopene in tomato juice can bind to bile acids in the gut, reducing their ability to absorb dietary cholesterol.",
      "Lycopene can inhibit the synthesis of cholesterol in the liver by reducing the activity of enzymes involved in cholesterol biosynthesis.",
      "A study published in the Journal of Nutrition in 2005 found that drinking 8 ounces of tomato juice per day for 12 weeks reduced total cholesterol levels by 10% and LDL cholesterol levels by 13% in healthy adults.",
      "A study published in the American Journal of Clinical Nutrition in 2010 found that drinking 100 ml of tomato juice per day for 12 weeks reduced LDL cholesterol levels by 11% and increased HDL cholesterol levels by 16% in healthy adults with mild hypercholesterolemia.",
      "A study published in the Journal of Lipid Research in 2014 found that consuming a tomato-based beverage enriched with lycopene and other antioxidants for 12 weeks reduced LDL cholesterol levels by 12% and increased HDL cholesterol levels by 10% in healthy adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Lycopene, a compound found in tomatoes, has been shown to bind to bile acids, which can reduce the reabsorption of bile acids and consequently lower cholesterol absorption in the gut.\n2. TRUE: Lycopene has been reported to inhibit the activity of HMG-CoA reductase, an enzyme involved in cholesterol synthesis in the liver.\n3. UNKNOWN: Without access to the specific study from the Journal of Nutrition in 2005, I cannot verify the accuracy of the results mentioned. The effects of tomato juice on cholesterol levels would need to be confirmed by reviewing the actual study.\n4. UNKNOWN: Similar to statement 3, the accuracy of the results from the study published in the American Journal of Clinical Nutrition in 2010 cannot be verified without reviewing the study itself.\n5. UNKNOWN: The results of the study published in the Journal of Lipid Research in 2014 cannot be confirmed without direct access to the study to verify the findings.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Heat shock proteins (HSPs) are a family of proteins that play a crucial role in protecting cells against various types of stress, including heat stress, oxidative stress, and protein misfolding. Two specific HSPs, Hsp70 and Hsp110, have been shown to play a role in mRNA stability.\nHsp70 is a chaperone protein that helps to protect cells against protein misfolding and aggregation. It has been shown to bind to mRNA and regulate its stability by preventing degradation by the RNA exosome, a complex of proteins that degrade mRNA. Hsp70 can also promote mRNA translation by interacting with the ribosome and facilitating the initiation of protein synthesis.\nHsp110 is another chaperone protein that has been shown to play a role in mRNA stability. Hsp110 is involved in the degradation of misfolded proteins and can also interact with mRNA, where it helps to prevent degradation by the RNA exosome. Hsp110 has been shown to regulate the stability of specific mRNAs, including those involved in the unfolded protein response (UPR), a cellular response to protein misfolding.\nBoth Hsp70 and Hsp110 can affect mRNA stability by preventing degradation by the RNA exosome, which is a complex of proteins that degrade mRNA. By protecting mRNA from degradation, HSPs can regulate the amount of protein produced from a particular mRNA, which can have important implications for cellular function and disease. For example, HSPs have been implicated in the development of cancer, where they can help to protect cancer cells from the effects of chemotherapy by stabilizing key oncogenic mRNAs.\nIn summary, Hsp70 and Hsp110 are two heat shock proteins that play a role in regulating mRNA stability by protecting mRNA from degradation by the RNA exosome. By doing so, they can regulate the amount of protein produced from a particular mRNA, which can have important implications for cellular function and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 is a chaperone protein that helps protect cells against protein misfolding and aggregation.\n2. Hsp70 has been shown to bind to mRNA and regulate its stability by preventing degradation by the RNA exosome.\n3. Hsp70 can promote mRNA translation by interacting with the ribosome and facilitating the initiation of protein synthesis.\n4. Hsp110 is involved in the degradation of misfolded proteins and can interact with mRNA to prevent its degradation by the RNA exosome.\n5. Hsp110 has been shown to regulate the stability of specific mRNAs involved in the unfolded protein response (UPR).",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 is a chaperone protein that helps protect cells against protein misfolding and aggregation.",
      "Hsp70 has been shown to bind to mRNA and regulate its stability by preventing degradation by the RNA exosome.",
      "Hsp70 can promote mRNA translation by interacting with the ribosome and facilitating the initiation of protein synthesis.",
      "Hsp110 is involved in the degradation of misfolded proteins and can interact with mRNA to prevent its degradation by the RNA exosome.",
      "Hsp110 has been shown to regulate the stability of specific mRNAs involved in the unfolded protein response (UPR)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hsp70 has been shown to bind to mRNA and regulate its stability, but it is not typically known for preventing degradation by the RNA exosome. Instead, it is involved in the folding of nascent polypeptides and the refolding of misfolded proteins.\n3. TRUE\n4. FALSE [correction]: Hsp110 is a nucleotide exchange factor that works in conjunction with Hsp70 to refold misfolded proteins, but it is not directly involved in the degradation of misfolded proteins nor is it typically known to interact with mRNA to prevent its degradation by the RNA exosome.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "There are three isoforms of deiodinase enzymes present in skeletal muscle:\n1. Deiodinase type 1 (D1): D1 is the primary deiodinase isoform in skeletal muscle, and it is responsible for converting T4 to T3. T3 is the active form of thyroid hormone in muscle cells, and it plays a crucial role in regulating muscle contraction and metabolism.\n2. Deiodinase type 2 (D2): D2 is also present in skeletal muscle, but it is less abundant than D1. D2 is involved in the conversion of both T4 and T3 to their inactive metabolites, reverse triiodothyronine (rT3) and thyroxine-5'-monodeiodinase (T4-5'-Mon).\n3. Deiodinase type 3 (D3): D3 is found in very low levels in skeletal muscle compared to D1 and D2. D3 is primarily involved in the conversion of T4 to T3 in the brain and other tissues, but it can also be found in other tissues, including muscle.\nIt's worth noting that the activity of these deiodinases can be influenced by various factors, such as thyroid hormone levels, nutrient availability, and oxidative stress, which can affect muscle function and metabolism.",
    "llama-2-7b-chat-hf_fact_raw": "1. Deiodinase type 1 (D1) is present in skeletal muscle and is responsible for converting T4 to T3.\n2. Deiodinase type 2 (D2) is present in skeletal muscle and is involved in the conversion of T4 and T3 to their inactive metabolites.\n3. Deiodinase type 3 (D3) is found in very low levels in skeletal muscle compared to D1 and D2.\n4. D3 is primarily involved in the conversion of T4 to T3 in the brain and other tissues but is also found in skeletal muscle.\n5. The activity of deiodinases in skeletal muscle can be influenced by factors such as thyroid hormone levels, nutrient availability, and oxidative stress.",
    "llama-2-7b-chat-hf_fact": [
      "Deiodinase type 1 (D1) is present in skeletal muscle and is responsible for converting T4 to T3.",
      "Deiodinase type 2 (D2) is present in skeletal muscle and is involved in the conversion of T4 and T3 to their inactive metabolites.",
      "Deiodinase type 3 (D3) is found in very low levels in skeletal muscle compared to D1 and D2.",
      "D3 is primarily involved in the conversion of T4 to T3 in the brain and other tissues but is also found in skeletal muscle.",
      "The activity of deiodinases in skeletal muscle can be influenced by factors such as thyroid hormone levels, nutrient availability, and oxidative stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Deiodinase type 1 (D1) is not primarily present in skeletal muscle; it is mainly found in the liver and kidneys and is responsible for converting T4 to T3.\n2. FALSE [correction]: Deiodinase type 2 (D2) is present in the central nervous system, including the brain, and in the brown adipose tissue, among other tissues, and is responsible for converting T4 to the active hormone T3, not to their inactive metabolites.\n3. TRUE\n4. FALSE [correction]: D3 is primarily involved in the inactivation of thyroid hormones by converting T4 to reverse T3 (rT3) and T3 to T2, not in the conversion of T4 to T3. While D3 is found in the brain and other tissues, its role is not in producing T3 but rather in regulating the local availability of active thyroid hormones through inactivation.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Inflammatory caspase proteins are a group of proteins that play a crucial role in the regulation of inflammation. Here are some of the most well-known inflammatory caspase proteins:\n1. Caspase-1: Also known as interleukin-1 beta (IL-1β) converter, caspase-1 is a key enzyme involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and tumor necrosis factor-alpha (TNF-α).\n2. Caspase-3: This caspase is involved in the cleavage of a variety of proteins, including the pro-inflammatory cytokines IL-1β and TNF-α, as well as the cell adhesion molecule L-selectin.\n3. Caspase-7: Caspase-7 is involved in the regulation of apoptosis and inflammation, and has been shown to play a role in the clearance of viral infections.\n4. Caspase-8: Also known as Fas-activated caspase, caspase-8 is activated in response to the death receptor Fas (CD95) and plays a role in the regulation of apoptosis and inflammation.\n5. Caspase-9: Caspase-9 is involved in the regulation of apoptosis and inflammation, and has been implicated in a variety of diseases, including cancer and autoimmune disorders.\n6. Caspase-12: Caspase-12 is activated in response to endoplasmic reticulum (ER) stress and plays a role in the regulation of inflammation and cell death.\n7. Caspase-13: Caspase-13 is involved in the regulation of inflammation and has been shown to play a role in the clearance of apoptotic cells.\nThese are just a few examples of the many inflammatory caspase proteins that have been identified, and there are likely many more that have not yet been discovered.",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.\n2. Caspase-3 is involved in the cleavage of a variety of proteins, including IL-1β and TNF-α.\n3. Caspase-7 plays a role in the regulation of apoptosis and inflammation.\n4. Caspase-8 is activated in response to the death receptor Fas (CD95) and is involved in the regulation of apoptosis and inflammation.\n5. Caspase-12 is activated in response to endoplasmic reticulum stress and plays a role in the regulation of inflammation and cell death.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.",
      "Caspase-3 is involved in the cleavage of a variety of proteins, including IL-1β and TNF-α.",
      "Caspase-7 plays a role in the regulation of apoptosis and inflammation.",
      "Caspase-8 is activated in response to the death receptor Fas (CD95) and is involved in the regulation of apoptosis and inflammation.",
      "Caspase-12 is activated in response to endoplasmic reticulum stress and plays a role in the regulation of inflammation and cell death."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-3 is involved in the cleavage of a variety of proteins, but it is not involved in the cleavage of IL-1β and TNF-α. These cytokines are processed by caspase-1.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between the aurora B kinase and the polycomb protein Ring1B. Ring1B is a member of the polycomb repressive complex 2 (PRC2), which is involved in the epigenetic regulation of gene expression by modifying histones.\nAurora B kinase is a key regulator of the spindle checkpoint, which ensures that chromosomes are properly aligned and segregated during cell division. However, recent studies have shown that Aurora B also plays a role in the regulation of PRC2 and the epigenetic landscape of chromatin.\nOne study found that Aurora B phosphorylates Ring1B on specific residues, leading to its nuclear accumulation and activation of PRC2. This suggests that Aurora B may play a role in the regulation of PRC2-mediated epigenetic silencing, particularly during the G2/M checkpoint.\nAnother study found that Ring1B is required for the proper localization and activity of Aurora B during mitosis. The study showed that Ring1B interacts with Aurora B and promotes its localization to kinetochores, where it regulates the proper segregation of chromosomes.\nTaken together, these studies suggest that there is a complex interplay between Aurora B and Ring1B in the regulation of chromatin dynamics and epigenetic gene silencing during cell division. Further research is needed to fully understand the mechanisms underlying this interaction and its implications for cellular processes and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ring1B is a member of the polycomb repressive complex 2 (PRC2), which is involved in epigenetic regulation of gene expression by modifying histones.\n2. Aurora B kinase is a key regulator of the spindle checkpoint during cell division.\n3. Aurora B kinase has been shown to play a role in the regulation of PRC2 and the epigenetic landscape of chromatin.\n4. Aurora B phosphorylates Ring1B on specific residues, which leads to Ring1B's nuclear accumulation and activation of PRC2.\n5. Ring1B is required for the proper localization and activity of Aurora B during mitosis, and it promotes Aurora B's localization to kinetochores.",
    "llama-2-7b-chat-hf_fact": [
      "Ring1B is a member of the polycomb repressive complex 2 (PRC2), which is involved in epigenetic regulation of gene expression by modifying histones.",
      "Aurora B kinase is a key regulator of the spindle checkpoint during cell division.",
      "Aurora B kinase has been shown to play a role in the regulation of PRC2 and the epigenetic landscape of chromatin.",
      "Aurora B phosphorylates Ring1B on specific residues, which leads to Ring1B's nuclear accumulation and activation of PRC2.",
      "Ring1B is required for the proper localization and activity of Aurora B during mitosis, and it promotes Aurora B's localization to kinetochores."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ring1B is a member of the polycomb repressive complex 1 (PRC1), not PRC2, which is involved in epigenetic regulation of gene expression by modifying histones.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Aurora B is required for the proper localization and activity of PRC1 components during mitosis, and it promotes the localization of PRC1 components to centromeres, not the other way around.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are sequences that are not part of the consensus splice site sequences but are still recognized by the splicing machinery. These motifs can be found in both the donor and acceptor splice sites and play a role in the splicing process. Some of the most frequent non-canonical sequence motifs found in vertebrates include:\nDonor splice site non-canonical motifs:\n1. GU-rich sequences: GU-rich sequences are found in the donor splice site and are enriched in guanine and uridine nucleotides. These sequences can act as a binding site for the splicing machinery and enhance the recognition of the donor splice site.\n2. GT-rich sequences: GT-rich sequences are found in the donor splice site and are enriched in guanine and thymine nucleotides. These sequences can also act as a binding site for the splicing machinery and enhance the recognition of the donor splice site.\n3. AU-rich sequences: AU-rich sequences are found in the donor splice site and are enriched in adenine and uridine nucleotides. These sequences can act as a binding site for the splicing machinery and enhance the recognition of the donor splice site.\n4. G-quadruplex forming sequences: G-quadruplex forming sequences are found in the donor splice site and are characterized by the formation of G-rich quartets. These sequences can act as a binding site for the splicing machinery and enhance the recognition of the donor splice site.\nAcceptor splice site non-canonical motifs:\n1. AG-rich sequences: AG-rich sequences are found in the acceptor splice site and are enriched in adenine and guanine nucleotides. These sequences can act as a binding site for the splicing machinery and enhance the recognition of the acceptor splice site.\n2. UG-rich sequences: UG-rich sequences are found in the acceptor splice site and are enriched in uridine and guanine nucleotides. These",
    "llama-2-7b-chat-hf_fact_raw": "1. GU-rich sequences are non-canonical motifs found in the donor splice site of vertebrates and are enriched in guanine and uridine nucleotides.\n2. GT-rich sequences are non-canonical motifs found in the donor splice site of vertebrates and are enriched in guanine and thymine nucleotides.\n3. AU-rich sequences are non-canonical motifs found in the donor splice site of vertebrates and are enriched in adenine and uridine nucleotides.\n4. G-quadruplex forming sequences are non-canonical motifs found in the donor splice site of vertebrates and are characterized by the formation of G-rich quartets.\n5. AG-rich sequences are non-canonical motifs found in the acceptor splice site of vertebrates and are enriched in adenine and guanine nucleotides.",
    "llama-2-7b-chat-hf_fact": [
      "GU-rich sequences are non-canonical motifs found in the donor splice site of vertebrates and are enriched in guanine and uridine nucleotides.",
      "GT-rich sequences are non-canonical motifs found in the donor splice site of vertebrates and are enriched in guanine and thymine nucleotides.",
      "AU-rich sequences are non-canonical motifs found in the donor splice site of vertebrates and are enriched in adenine and uridine nucleotides.",
      "G-quadruplex forming sequences are non-canonical motifs found in the donor splice site of vertebrates and are characterized by the formation of G-rich quartets.",
      "AG-rich sequences are non-canonical motifs found in the acceptor splice site of vertebrates and are enriched in adenine and guanine nucleotides."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GT-rich sequences are not typically characterized as non-canonical motifs in the donor splice site of vertebrates; instead, the canonical motif is GT (guanine and thymine) at the 5' end of the intron (the donor site).\n3. UNKNOWN: While AU-rich elements (AREs) are known to be involved in mRNA decay, their specific enrichment in the donor splice site as non-canonical motifs is not well-established without additional context.\n4. TRUE: G-quadruplex forming sequences are non-canonical structures that can form in G-rich regions, including potential locations within splice sites, although their presence and function in donor splice sites would require specific context to confirm.\n5. TRUE: AG-rich sequences are indeed found in the acceptor splice site of vertebrates, with the AG dinucleotide being part of the canonical motif at the 3' end of the intron (the acceptor site).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "S6K1 (S6 kinase 1) is acetylated in response to several different cellular signals, including:\n1. Insulin/IGF-1 signaling: Insulin and insulin-like growth factor 1 (IGF-1) can activate the PI3K/Akt signaling pathway, which ultimately leads to the acetylation of S6K1.\n2. Nutrient availability: The availability of nutrients, such as amino acids, can activate the mTORC1 signaling pathway, which can lead to the acetylation of S6K1.\n3. Growth factors: Certain growth factors, such as epidermal growth factor (EGF), can activate the PI3K/Akt signaling pathway and lead to the acetylation of S6K1.\n4. Cellular stress: S6K1 can also be acetylated in response to cellular stress, such as oxidative stress or heat shock, which can activate the unfolded protein response (UPR) pathway.\n5. Hormonal signaling: Hormonal signaling, such as estrogen signaling, can also activate the PI3K/Akt signaling pathway and lead to the acetylation of S6K1.",
    "llama-2-7b-chat-hf_fact_raw": "1. Insulin and insulin-like growth factor 1 (IGF-1) signaling can lead to the acetylation of S6K1.\n2. The availability of nutrients, such as amino acids, can activate the mTORC1 signaling pathway, resulting in the acetylation of S6K1.\n3. Certain growth factors, like epidermal growth factor (EGF), can activate the PI3K/Akt signaling pathway and lead to the acetylation of S6K1.\n4. Cellular stress, such as oxidative stress or heat shock, can activate the unfolded protein response (UPR) pathway and result in the acetylation of S6K1.\n5. Hormonal signaling, including estrogen signaling, can activate the PI3K/Akt signaling pathway and lead to the acetylation of S6K1.",
    "llama-2-7b-chat-hf_fact": [
      "Insulin and insulin-like growth factor 1 (IGF-1) signaling can lead to the acetylation of S6K1.",
      "The availability of nutrients, such as amino acids, can activate the mTORC1 signaling pathway, resulting in the acetylation of S6K1.",
      "Certain growth factors, like epidermal growth factor (EGF), can activate the PI3K/Akt signaling pathway and lead to the acetylation of S6K1.",
      "Cellular stress, such as oxidative stress or heat shock, can activate the unfolded protein response (UPR) pathway and result in the acetylation of S6K1.",
      "Hormonal signaling, including estrogen signaling, can activate the PI3K/Akt signaling pathway and lead to the acetylation of S6K1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement is specific and requires specialized knowledge in biochemistry and cell biology. Without the specific context or reference, it's difficult to verify the accuracy of the statement regarding the acetylation of S6K1 by insulin and IGF-1 signaling.\n2. TRUE: The availability of nutrients, such as amino acids, is known to activate the mTORC1 signaling pathway, which can lead to the phosphorylation of S6K1. However, the statement mentions acetylation, which is a different post-translational modification than phosphorylation. The statement is true regarding activation and phosphorylation, but the specificity of acetylation would require further verification from a reliable source.\n3. TRUE: Growth factors like EGF can activate the PI3K/Akt signaling pathway, which is involved in various cellular processes including protein synthesis and cell growth. This pathway can lead to the phosphorylation of S6K1. As with the previous statement, the mention of acetylation specifically would need to be verified.\n4. UNKNOWN: Cellular stress can indeed activate various stress response pathways, including the unfolded protein response (UPR). However, whether this leads to the acetylation of S6K1 is not commonly known and would require specific scientific evidence to confirm.\n5. TRUE: Hormonal signaling, including estrogen signaling, can activate the PI3K/Akt signaling pathway. This pathway is involved in a wide range of cellular responses, including those to hormones like estrogen. However, as with the other statements, while the pathway activation is correct, the specific mention of leading to the acetylation of S6K1 would need to be verified.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the CACNA1A gene. This gene encodes a subunit of the calcium channel complex at the nerve terminal, specifically the alpha-1A subunit. The mutations in the CACNA1A gene lead to a loss of function of the calcium channel, which is essential for the proper transmission of signals between nerve cells (neurons) and muscle cells. As a result, individuals with EA6 experience recurrent episodes of ataxia, which is characterized by a wide range of symptoms including:\n* Unsteadiness and lack of coordination\n* Difficulty with walking, balance, and gait\n* Slurred speech and difficulty with swallowing\n* Nystagmus (involuntary eye movements)\n* Muscle weakness and fatigue\n* Cognitive impairment and memory problems\n* Seizures\n* Vision problems\nThe episodes of ataxia in EA6 can vary in frequency and severity, and can last from minutes to hours, depending on the individual. The disorder typically becomes apparent in adulthood, although some cases may present in childhood. There is currently no cure for EA6, and treatment is focused on managing the symptoms and preventing falls and injuries.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is caused by mutations in the CACNA1A gene.\n2. The CACNA1A gene encodes the alpha-1A subunit of the calcium channel complex at the nerve terminal.\n3. Mutations in the CACNA1A gene lead to a loss of function of the calcium channel.\n4. Individuals with EA6 experience recurrent episodes of ataxia.\n5. The disorder typically becomes apparent in adulthood, but some cases may present in childhood.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is caused by mutations in the CACNA1A gene.",
      "The CACNA1A gene encodes the alpha-1A subunit of the calcium channel complex at the nerve terminal.",
      "Mutations in the CACNA1A gene lead to a loss of function of the calcium channel.",
      "Individuals with EA6 experience recurrent episodes of ataxia.",
      "The disorder typically becomes apparent in adulthood, but some cases may present in childhood."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Mutations in the CACNA1A gene can lead to either a loss or gain of function of the calcium channel, depending on the specific mutation.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add a methyl group to specific residues on histone proteins, which can alter chromatin structure and affect gene expression. While the best-studied chromomethylases are found in plants, there is evidence for their presence in animal genomes as well.\nSeveral studies have identified chromomethylases in various animal species, including mammals. For example:\n1. In mammals, the enzyme KMT1E (also known as SETDB1) is a histone-lysine N-methyltransferase that is involved in the methylation of histone H3 lysine 9 (H3K9) and is associated with the regulation of gene expression, cell fate determination, and stem cell maintenance.\n2. In birds, the enzyme G9a (also known as KMT1A) is a histone-lysine N-methyltransferase that is involved in the methylation of histone H3 lysine 9 (H3K9) and is essential for the regulation of gene expression during embryonic development.\n3. In fish, the enzyme SETDB1 has been shown to be involved in the regulation of gene expression and development, and mutations in the gene have been linked to developmental abnormalities in zebrafish.\nWhile the functions of chromomethylases in animals are not as well understood as those in plants, it is clear that they play important roles in regulating gene expression and chromatin structure in various animal species. Further research is needed to fully elucidate the mechanisms by which chromomethylases contribute to animal development and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are enzymes that add a methyl group to specific residues on histone proteins.\n2. KMT1E (SETDB1) is a histone-lysine N-methyltransferase involved in methylation of histone H3 lysine 9 (H3K9) in mammals.\n3. The enzyme G9a (KMT1A) is involved in the methylation of histone H3 lysine 9 (H3K9) in birds.\n4. Mutations in the SETDB1 gene have been linked to developmental abnormalities in zebrafish.\n5. Chromomethylases play roles in regulating gene expression and chromatin structure in various animal species.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are enzymes that add a methyl group to specific residues on histone proteins.",
      "KMT1E (SETDB1) is a histone-lysine N-methyltransferase involved in methylation of histone H3 lysine 9 (H3K9) in mammals.",
      "The enzyme G9a (KMT1A) is involved in the methylation of histone H3 lysine 9 (H3K9) in birds.",
      "Mutations in the SETDB1 gene have been linked to developmental abnormalities in zebrafish.",
      "Chromomethylases play roles in regulating gene expression and chromatin structure in various animal species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases are enzymes that add a methyl group to specific residues on DNA, not histone proteins. Histone methyltransferases are the enzymes that methylate histone proteins.\n2. TRUE\n3. FALSE [correction]: The enzyme G9a (also known as EHMT2 or KMT1C) is involved in the methylation of histone H3 lysine 9 (H3K9) in mammals, not specifically in birds. While it is possible that a homologous enzyme performs a similar function in birds, the statement as it stands is too specific and implies a distinction that is not established.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "There are several packages available in R/Bioconductor for the analysis of transcription factor binding sites (TFBS) data. Here are some of the most popular ones:\n1. TFBSpred: This package uses a machine learning approach to predict TFBSs in a given DNA sequence. It can be used to predict the binding sites of multiple transcription factors simultaneously.\n2. TRANSFAC: This package contains a comprehensive collection of transcription factor binding site data, which can be used to predict TFBSs in a given DNA sequence. It also provides tools for motif discovery and motif analysis.\n3. TFSEARCH: This package uses a probabilistic approach to predict TFBSs in a given DNA sequence. It can be used to identify the binding sites of both known and novel transcription factors.\n4. MEME: This package uses a motif discovery approach to identify short DNA sequences (motifs) that are conserved across multiple protein sequences. These motifs can be used to predict TFBSs in a given DNA sequence.\n5. HMMER: This package uses a hidden Markov model (HMM) to predict TFBSs in a given DNA sequence. It can be used to identify the binding sites of both known and novel transcription factors.\n6. ChIPseek: This package uses a Bayesian approach to predict TFBSs in a given DNA sequence. It can be used to identify the binding sites of both known and novel transcription factors.\n7. DeepSEA: This package uses a deep learning approach to predict TFBSs in a given DNA sequence. It can be used to identify the binding sites of both known and novel transcription factors.\n8. TFBS-predict: This package uses a machine learning approach to predict TFBSs in a given DNA sequence. It can be used to predict the binding sites of multiple transcription factors simultaneously.\n9. TF-Plex: This package uses a Bayesian approach to predict TFBSs in a given DNA sequence. It can be used to identify the binding sites of both known and novel transcription factors.\n10. ChromHMM: This package uses a HMM to predict TFBSs in a given DNA sequence. It can be used to identify the binding sites of both known and novel transcription factors.\nThese packages can be used to analyze T",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBSpred is an R/Bioconductor package that predicts transcription factor binding sites using a machine learning approach.\n2. TRANSFAC is an R/Bioconductor package that contains a collection of transcription factor binding site data and provides tools for motif discovery and analysis.\n3. MEME is an R/Bioconductor package that identifies conserved short DNA sequences for motif discovery to predict transcription factor binding sites.\n4. HMMER is an R/Bioconductor package that uses hidden Markov models to predict transcription factor binding sites in DNA sequences.\n5. DeepSEA is an R/Bioconductor package that employs a deep learning approach to predict transcription factor binding sites in DNA sequences.",
    "llama-2-7b-chat-hf_fact": [
      "TFBSpred is an R/Bioconductor package that predicts transcription factor binding sites using a machine learning approach.",
      "TRANSFAC is an R/Bioconductor package that contains a collection of transcription factor binding site data and provides tools for motif discovery and analysis.",
      "MEME is an R/Bioconductor package that identifies conserved short DNA sequences for motif discovery to predict transcription factor binding sites.",
      "HMMER is an R/Bioconductor package that uses hidden Markov models to predict transcription factor binding sites in DNA sequences.",
      "DeepSEA is an R/Bioconductor package that employs a deep learning approach to predict transcription factor binding sites in DNA sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TRANSFAC is a database that contains a collection of transcription factor binding site data, but it is not an R/Bioconductor package. It provides tools for motif discovery and analysis, but these tools are not part of R/Bioconductor.\n3. FALSE [correction]: MEME is a tool for motif discovery that identifies conserved short DNA sequences, but it is not an R/Bioconductor package. It is available as a standalone program and as part of the MEME Suite of tools for motif-based sequence analysis.\n4. FALSE [correction]: HMMER is a software suite that uses hidden Markov models to search sequence databases for sequence homologs, and to make sequence alignments, but it is not an R/Bioconductor package and is not specifically focused on predicting transcription factor binding sites.\n5. FALSE [correction]: DeepSEA is a deep learning-based framework that predicts the effects of noncoding variants on DNA sequences, including transcription factor binding sites, but it is not an R/Bioconductor package. It is available as a standalone tool.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Sarcopenia is the progressive loss of muscle mass and strength that occurs with aging. While there are no FDA-approved drugs for the prevention of sarcopenia, several clinical trials are underway to evaluate the effectiveness of various interventions in preventing or slowing the progression of sarcopenia. Here are some of the ongoing clinical trials for the prevention of sarcopenia:\n1. Resistance Training and Nutritional Interventions to Prevent Sarcopenia (RATS): This randomized controlled trial is evaluating the effectiveness of resistance training and nutritional interventions in preventing sarcopenia in older adults.\n2. Effects of Long-Term Resistance Training on Sarcopenia in Frail Older Adults (FIT-Sarcopenia): This randomized controlled trial is examining the effects of long-term resistance training on sarcopenia in frail older adults.\n3. Nutritional Interventions to Prevent Sarcopenia in Older Adults (NUTRI-Sarcopenia): This randomized controlled trial is evaluating the effectiveness of various nutritional interventions in preventing sarcopenia in older adults.\n4. Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults (EXP-Sarcopenia): This randomized controlled trial is examining the effects of exercise and nutrition interventions on sarcopenia in older adults.\n5. Sarcopenia Prevention with Dietary Interventions (SPIDI): This randomized controlled trial is evaluating the effectiveness of dietary interventions in preventing sarcopenia in older adults.\n6. Effects of Metformin on Sarcopenia in Older Adults (METS-Sarcopenia): This randomized controlled trial is examining the effects of metformin, a drug commonly used to treat type 2 diabetes, on sarcopenia in older adults.\n7. Vitamin D and Omega-3 Fatty Acid Supplementation to Prevent Sarcopenia (VITAL-Sarcopenia): This randomized controlled trial is evaluating the effectiveness of",
    "llama-2-7b-chat-hf_fact_raw": "1. The RATS trial is a randomized controlled trial evaluating resistance training and nutritional interventions for preventing sarcopenia in older adults.\n2. The FIT-Sarcopenia trial is a randomized controlled trial examining the effects of long-term resistance training on sarcopenia in frail older adults.\n3. The NUTRI-Sarcopenia trial is a randomized controlled trial evaluating the effectiveness of various nutritional interventions in preventing sarcopenia in older adults.\n4. The EXP-Sarcopenia trial is a randomized controlled trial examining the effects of exercise and nutrition interventions on sarcopenia in older adults.\n5. The METS-Sarcopenia trial is a randomized controlled trial examining the effects of metformin on sarcopenia in older adults.",
    "llama-2-7b-chat-hf_fact": [
      "The RATS trial is a randomized controlled trial evaluating resistance training and nutritional interventions for preventing sarcopenia in older adults.",
      "The FIT-Sarcopenia trial is a randomized controlled trial examining the effects of long-term resistance training on sarcopenia in frail older adults.",
      "The NUTRI-Sarcopenia trial is a randomized controlled trial evaluating the effectiveness of various nutritional interventions in preventing sarcopenia in older adults.",
      "The EXP-Sarcopenia trial is a randomized controlled trial examining the effects of exercise and nutrition interventions on sarcopenia in older adults.",
      "The METS-Sarcopenia trial is a randomized controlled trial examining the effects of metformin on sarcopenia in older adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the trials mentioned, it is not possible to determine the accuracy of these statements. The names of the trials (RATS, FIT-Sarcopenia, NUTRI-Sarcopenia, EXP-Sarcopenia, METS-Sarcopenia) do not provide enough context to verify the claims made in the statements. Additional information from reliable sources would be required to assess the truthfulness of each statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins that provide information on the structural and functional properties of these proteins. Some of the most popular databases include:\n1. Membrane Protein Data Bank (MPDB): This database contains structural and functional information on membrane proteins, including their three-dimensional structures, binding sites, and functional sites.\n2. Protein Data Bank (PDB): The PDB is a comprehensive database of 3D structures of proteins, peptides, and nucleic acids. It also includes structures of membrane proteins, which can be accessed through the \"Membrane Proteins\" category.\n3. Membrane Protein Structural Alignment Database (MPSA): This database provides structural alignment of membrane protein structures, allowing researchers to identify similarities and differences between different membrane proteins.\n4. Membrane Protein Functional Alignment Database (MPFA): This database provides functional alignment of membrane protein sequences, allowing researchers to identify functional sites and predict the functions of membrane proteins.\n5. Membrane Protein Interaction Database (MPID): This database provides information on the interactions between membrane proteins and other proteins, including binding partners, functional sites, and protein-protein interactions.\n6. Membrane Protein Topology Database (MPTD): This database provides information on the topology of membrane proteins, including their transmembrane segments, intracellular loops, and extracellular domains.\n7. Membrane Protein Function Prediction Database (MPFP): This database provides predictions of the functions of membrane proteins based on their sequences and structural features.\n8. Membrane Protein-Ligand Interaction Database (MPLID): This database provides information on the interactions between membrane proteins and small molecules, including ligands, inhibitors, and agonists.\n9. Membrane Protein-Nucleic Acid Interaction Database (MPNAID): This database provides information on the interactions between membrane proteins and nucleic acids, including DNA, RNA, and microRNAs.\n10. Membrane Protein-Protein Interaction Database (MPPI): This database provides information on the interactions between membrane proteins and other proteins, including binding partners, functional sites,",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Data Bank (MPDB) contains structural and functional information on membrane proteins.\n2. The Protein Data Bank (PDB) is a comprehensive database that includes 3D structures of proteins, peptides, nucleic acids, and membrane proteins.\n3. The Membrane Protein Structural Alignment Database (MPSA) provides structural alignment of membrane protein structures.\n4. The Membrane Protein Interaction Database (MPID) offers information on interactions between membrane proteins and other proteins.\n5. The Membrane Protein Topology Database (MPTD) provides information on the topology of membrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Data Bank (MPDB) contains structural and functional information on membrane proteins.",
      "The Protein Data Bank (PDB) is a comprehensive database that includes 3D structures of proteins, peptides, nucleic acids, and membrane proteins.",
      "The Membrane Protein Structural Alignment Database (MPSA) provides structural alignment of membrane protein structures.",
      "The Membrane Protein Interaction Database (MPID) offers information on interactions between membrane proteins and other proteins.",
      "The Membrane Protein Topology Database (MPTD) provides information on the topology of membrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are true based on the typical content and purpose of such databases. The Protein Data Bank (PDB) is indeed a comprehensive database that includes 3D structures of a wide range of biological molecules, including membrane proteins. The Membrane Protein Data Bank (MPDB) and the Membrane Protein Structural Alignment Database (MPSA) are specialized databases that focus on membrane proteins, with MPDB providing structural and functional information, and MPSA providing structural alignments.\n\nHowever, without specific knowledge of the existence and content of the Membrane Protein Interaction Database (MPID) and the Membrane Protein Topology Database (MPTD), it is not possible to confirm the accuracy of statements 4 and 5. These databases may exist and serve the functions described, but without current and specific information, their existence and content cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys. Rivaroxaban is metabolized by the liver and kidneys through the cytochrome P450 (CYP) enzyme system and other enzymes. The major metabolic pathway of rivaroxaban is through CYP2C9, and to a lesser extent, CYP3A4. The kidneys play a significant role in the elimination of rivaroxaban, with approximately 70-80% of the drug being recovered in the urine as the active metabolite, Rivaroxaban-N-oxide.\nThe kidneys also play a role in the regulation of rivaroxaban's pharmacokinetics, as the drug undergoes extensive tubular secretion and enterohepatic recirculation. The kidneys can also affect the efficacy of rivaroxaban by influencing the distribution and distribution-dependent clearance of the drug.\nTherefore, kidney function and disease can impact the pharmacokinetics and pharmacodynamics of rivaroxaban, and monitoring of kidney function is important in patients receiving this drug.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized by the liver and kidneys.\n2. The cytochrome P450 (CYP) enzyme system is involved in the metabolism of rivaroxaban.\n3. The major metabolic pathway of rivaroxaban is through CYP2C9, and to a lesser extent, CYP3A4.\n4. Approximately 70-80% of rivaroxaban is recovered in the urine as the active metabolite, Rivaroxaban-N-oxide.\n5. Kidney function and disease can impact the pharmacokinetics and pharmacodynamics of rivaroxaban.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized by the liver and kidneys.",
      "The cytochrome P450 (CYP) enzyme system is involved in the metabolism of rivaroxaban.",
      "The major metabolic pathway of rivaroxaban is through CYP2C9, and to a lesser extent, CYP3A4.",
      "Approximately 70-80% of rivaroxaban is recovered in the urine as the active metabolite, Rivaroxaban-N-oxide.",
      "Kidney function and disease can impact the pharmacokinetics and pharmacodynamics of rivaroxaban."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The major metabolic pathway of rivaroxaban is through CYP3A4/5, and to a lesser extent, CYP2J2. CYP2C9 is not a major enzyme involved in the metabolism of rivaroxaban.\n4. FALSE [correction]: Approximately one-third of a rivaroxaban dose is excreted unchanged by the kidneys, while the rest is metabolized in the liver. Rivaroxaban-N-oxide is not the active metabolite; it is a minor inactive metabolite.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRα2 (thyroid hormone receptor alpha 2) is a nuclear receptor that plays a crucial role in regulating gene expression in the heart in response to thyroid hormone signaling. Studies have shown that TRα2 regulates a variety of genes involved in cardiac function, including:\n1. Atrial natriuretic factor (ANF): TRα2 regulates the expression of ANF, a hormone that helps regulate blood pressure and fluid balance in the body.\n2. Beta-myosin heavy chain (MHC-β): TRα2 regulates the expression of MHC-β, which is essential for the contraction of cardiac muscle fibers.\n3. Connexin 43 (Cx43): TRα2 regulates the expression of Cx43, a gap junction protein that plays a critical role in the coordination of cardiac contraction and relaxation.\n4. Hypoxia-inducible factor 1-alpha (HIF-1α): TRα2 regulates the expression of HIF-1α, a transcription factor that plays a critical role in response to hypoxia and is involved in the regulation of angiogenesis and metabolism.\n5. Krox-20 (Krox-20): TRα2 regulates the expression of Krox-20, a transcription factor that is involved in the regulation of cardiac differentiation and maturation.\n6. Mitochondrial uncoupling protein 1 (UCP1): TRα2 regulates the expression of UCP1, a protein that plays a critical role in the regulation of mitochondrial function and energy metabolism.\n7. Nuclear factor of kappa light chain enhancer in B cells 2 (NF-κB2): TRα2 regulates the expression of NF-κB2, a transcription factor that plays a critical role in the regulation of inflammation and immune response.\n8. Phospholamban (PLN): TRα2 regulates the expression of PLN, a protein that plays a critical role in the regulation of cardiac contractility and relaxation.\n9. Protein kinase B (Akt): TRα2 regulates the expression of Akt, a",
    "llama-2-7b-chat-hf_fact_raw": "1. TRα2 regulates the expression of Atrial natriuretic factor (ANF), which is involved in blood pressure and fluid balance regulation.\n2. TRα2 regulates the expression of Beta-myosin heavy chain (MHC-β), which is essential for cardiac muscle fiber contraction.\n3. TRα2 regulates the expression of Connexin 43 (Cx43), a gap junction protein important for cardiac contraction and relaxation coordination.\n4. TRα2 regulates the expression of Hypoxia-inducible factor 1-alpha (HIF-1α), a transcription factor involved in response to hypoxia.\n5. TRα2 regulates the expression of Phospholamban (PLN), a protein that influences cardiac contractility and relaxation.",
    "llama-2-7b-chat-hf_fact": [
      "TRα2 regulates the expression of Atrial natriuretic factor (ANF), which is involved in blood pressure and fluid balance regulation.",
      "TRα2 regulates the expression of Beta-myosin heavy chain (MHC-β), which is essential for cardiac muscle fiber contraction.",
      "TRα2 regulates the expression of Connexin 43 (Cx43), a gap junction protein important for cardiac contraction and relaxation coordination.",
      "TRα2 regulates the expression of Hypoxia-inducible factor 1-alpha (HIF-1α), a transcription factor involved in response to hypoxia.",
      "TRα2 regulates the expression of Phospholamban (PLN), a protein that influences cardiac contractility and relaxation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific to the field of molecular biology and the regulation of gene expression by the thyroid hormone receptor alpha 2 (TRα2). Without the specific scientific context or research findings that these statements are based on, it is not possible to accurately determine the truthfulness of these statements. They would require reference to specific scientific studies or literature to verify.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "There are several biomedical question answering systems available, including:\n1. PubMed: PubMed is a comprehensive database of biomedical literature maintained by the National Library of Medicine. It provides a search engine for accessing and retrieving biomedical literature, including articles, books, and other publications.\n2. Google Scholar: Google Scholar is a free search engine that indexes scholarly literature across many disciplines and sources, including articles, theses, books, and conference papers. It provides a way to search for and access biomedical literature.\n3. MetaMap: MetaMap is a biomedical natural language processing (NLP) system that can answer questions about gene and protein information, including their functions, interactions, and diseases associated with them.\n4. BioGRID: BioGRID is a database of biological interactions, including protein-protein interactions, gene regulation, and metabolic pathways. It provides a way to query and retrieve information about biological interactions and processes.\n5. DrugBank: DrugBank is a comprehensive database of drugs, including their chemical structures, pharmacological actions, and therapeutic uses. It provides a way to query and retrieve information about drugs and their interactions with biological systems.\n6. UniProt: UniProt is a comprehensive database of protein information, including their sequences, structures, functions, and interactions. It provides a way to query and retrieve information about proteins and their roles in biological processes.\n7. Gene Ontology: Gene Ontology is a resource that provides a standardized vocabulary for describing the functions of genes and proteins. It provides a way to query and retrieve information about the functions of genes and proteins.\n8. ChEA: ChEA is a database of chemical-protein interactions, including information about the binding of small molecules to proteins and the effects of these interactions on protein function. It provides a way to query and retrieve information about the interactions between small molecules and proteins.\n9. Reactome: Reactome is a database of biological reactions and pathways, including information about the enzymes, cofactors, and small molecules involved in these reactions. It provides a way to query and retrieve information about biological reactions and pathways.\n10. KEGG: KEGG is",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed is a database of biomedical literature maintained by the National Library of Medicine.\n2. Google Scholar is a search engine that indexes scholarly literature across many disciplines, including biomedical literature.\n3. MetaMap is a biomedical natural language processing system that provides information about genes and proteins.\n4. BioGRID is a database that includes information on biological interactions such as protein-protein interactions and metabolic pathways.\n5. DrugBank is a comprehensive database that provides information about drugs, including their chemical structures and pharmacological actions.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed is a database of biomedical literature maintained by the National Library of Medicine.",
      "Google Scholar is a search engine that indexes scholarly literature across many disciplines, including biomedical literature.",
      "MetaMap is a biomedical natural language processing system that provides information about genes and proteins.",
      "BioGRID is a database that includes information on biological interactions such as protein-protein interactions and metabolic pathways.",
      "DrugBank is a comprehensive database that provides information about drugs, including their chemical structures and pharmacological actions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: MetaMap is a tool that maps biomedical text to concepts in the Unified Medical Language System (UMLS), not specifically providing information about genes and proteins.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The transcription factor that activates the betalain pathway is called BETAINE ALDEHYDE OXIDASE 1 (BAO1). BAO1 is a transcription factor that regulates the expression of genes involved in the biosynthesis of betalains, which are a class of natural pigments that are involved in plant defense responses. BAO1 is activated in response to various abiotic and biotic stresses, and it regulates the expression of genes involved in the biosynthesis of betalains, such as CYP79B1 and CYP83A1. The activation of BAO1 leads to the accumulation of betalains in the plant, which can help protect against pathogens and abiotic stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. BETAINE ALDEHYDE OXIDASE 1 (BAO1) is a transcription factor that activates the betalain pathway.\n2. BAO1 regulates the expression of genes involved in the biosynthesis of betalains.\n3. Betalains are a class of natural pigments involved in plant defense responses.\n4. BAO1 is activated in response to various abiotic and biotic stresses.\n5. The activation of BAO1 leads to the accumulation of betalains in the plant.",
    "llama-2-7b-chat-hf_fact": [
      "BETAINE ALDEHYDE OXIDASE 1 (BAO1) is a transcription factor that activates the betalain pathway.",
      "BAO1 regulates the expression of genes involved in the biosynthesis of betalains.",
      "Betalains are a class of natural pigments involved in plant defense responses.",
      "BAO1 is activated in response to various abiotic and biotic stresses.",
      "The activation of BAO1 leads to the accumulation of betalains in the plant."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BETAINE ALDEHYDE OXIDASE 1 (BAO1) is not a transcription factor; it is an enzyme involved in the biosynthesis of betalains.\n2. FALSE [correction]: BAO1 does not regulate the expression of genes; it catalyzes the oxidation of betalamic acid to betalains.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Global quantitative phosphoproteomic analyses involve the enrichment and analysis of phosphorylated peptides from protein samples. Several technologies are available for enriching phosphorylated peptides, and the choice of technology depends on the specific research question and experimental design. Here are some of the preferred technologies for phosphoproteome analysis:\n1. IMAC (Immobilized Metal Affinity Chromatography): IMAC is a widely used method for enriching phosphorylated peptides. It utilizes metal ions (e.g., Ni2+ or Cu2+) immobilized on a resin to selectively bind phosphorylated peptides.\n2. TiO2-based enrichment: Titanium dioxide (TiO2) is a highly efficient enrichment material for phosphorylated peptides. TiO2-based enrichment methods use the hydroxyl group on the TiO2 surface to selectively bind phosphorylated peptides.\n3. Hydrophobic interaction chromatography (HIC): HIC is a method that separates peptides based on their hydrophobicity. Phosphorylated peptides, which are generally more hydrophobic than non-phosphorylated peptides, can be enriched using HIC.\n4. Reversed-phase HPLC: Reversed-phase HPLC is a widely used method for separating and enriching peptides based on their hydrophobicity. Phosphorylated peptides can be enriched by using a reverse-phase column and a hydrophilic mobile phase.\n5. Microfluidic-based enrichment: Microfluidic-based enrichment methods use miniaturized channels and chambers to separate and enrich phosphorylated peptides. These methods can provide higher resolution and sensitivity than traditional enrichment methods.\n6. Enzymatic enrichment: Enzymatic enrichment methods use enzymes to selectively cleave non-phosphorylated peptides, resulting in enrichment of phosphorylated peptides. These methods can be particularly useful for studying specific phosphorylation sites.\n7.",
    "llama-2-7b-chat-hf_fact_raw": "1. IMAC is a method used for enriching phosphorylated peptides that involves metal ions immobilized on a resin.\n2. Titanium dioxide (TiO2) is used as an enrichment material for phosphorylated peptides in TiO2-based enrichment methods.\n3. Hydrophobic interaction chromatography (HIC) separates peptides based on hydrophobicity and can enrich phosphorylated peptides.\n4. Reversed-phase HPLC is a method for separating and enriching peptides, including phosphorylated peptides, based on hydrophobicity.\n5. Microfluidic-based enrichment methods use miniaturized channels and chambers to separate and enrich phosphorylated peptides.",
    "llama-2-7b-chat-hf_fact": [
      "IMAC is a method used for enriching phosphorylated peptides that involves metal ions immobilized on a resin.",
      "Titanium dioxide (TiO2) is used as an enrichment material for phosphorylated peptides in TiO2-based enrichment methods.",
      "Hydrophobic interaction chromatography (HIC) separates peptides based on hydrophobicity and can enrich phosphorylated peptides.",
      "Reversed-phase HPLC is a method for separating and enriching peptides, including phosphorylated peptides, based on hydrophobicity.",
      "Microfluidic-based enrichment methods use miniaturized channels and chambers to separate and enrich phosphorylated peptides."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Hydrophobic interaction chromatography (HIC) separates peptides based on hydrophobicity but is not specifically used to enrich phosphorylated peptides. Phosphorylated peptides are more commonly enriched using methods like IMAC or TiO2-based enrichment.\n4. FALSE [correction]: Reversed-phase HPLC is a method for separating peptides based on hydrophobicity, but it is not specifically used for enriching phosphorylated peptides. It is a general peptide separation technique.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "The Palmini classification is used to rate the severity of a specific type of developmental disorder called intellectual disability. The Palmini classification system categorizes intellectual disability into six different levels of severity, based on the individual's cognitive and adaptive functioning abilities. The disorder that is rated by the Palmini classification is intellectual disability, also known as intellectual disability or developmental disability.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Palmini classification is used to rate the severity of intellectual disability.\n2. Intellectual disability is a type of developmental disorder.\n3. The Palmini classification system categorizes intellectual disability into six different levels of severity.\n4. The classification is based on cognitive and adaptive functioning abilities.",
    "llama-2-7b-chat-hf_fact": [
      "The Palmini classification is used to rate the severity of intellectual disability.",
      "Intellectual disability is a type of developmental disorder.",
      "The Palmini classification system categorizes intellectual disability into six different levels of severity.",
      "The classification is based on cognitive and adaptive functioning abilities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Palmini classification is used to categorize different types of epilepsy, not the severity of intellectual disability.\n2. TRUE\n3. FALSE [correction]: The Palmini classification does not categorize intellectual disability; it is related to epilepsy. Intellectual disability is commonly categorized into four different levels of severity: mild, moderate, severe, and profound.\n4. TRUE [contextual correction]: While the statement is true for the classification of intellectual disability, it is not true for the Palmini classification, which is related to epilepsy. Intellectual disability classification is indeed based on cognitive and adaptive functioning abilities.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, some viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory condition that affects the thyroid gland and is characterized by the sudden onset of symptoms such as fever, pain, and swelling in the neck, as well as an elevated levels of thyroid hormones in the blood. While the exact cause of subacute thyroiditis is not fully understood, several viruses have been linked to the condition:\n1. Viruses that infect the thyroid gland directly: Some viruses, such as the thyroid gland-specific virus (TGSV), have been shown to directly infect the thyroid gland and cause inflammation and damage to the gland.\n2. Viruses that weaken the immune system: Viruses that weaken the immune system, such as human immunodeficiency virus (HIV), can increase the risk of developing subacute thyroiditis. This is because the immune system plays a crucial role in regulating the inflammatory response in the thyroid gland.\n3. Respiratory viruses: Respiratory viruses, such as influenza and respiratory syncytial virus (RSV), have been linked to the development of subacute thyroiditis. This is thought to be due to the fact that these viruses can spread to the thyroid gland through the bloodstream or through the spread of inflammatory mediators.\n4. Herpesviruses: Herpesviruses, such as herpes simplex virus (HSV) and Epstein-Barr virus (EBV), have also been implicated in the development of subacute thyroiditis. These viruses can remain dormant in the thyroid gland for years before reactivating and causing inflammation.\nIt is important to note that the exact mechanisms by which viruses contribute to the development of subacute thyroiditis are not fully understood and require further research. However, identifying the role of viruses in the etiology of this condition can help in the development of new diagnostic tests and treatments.",
    "llama-2-7b-chat-hf_fact_raw": "1. Subacute thyroiditis is an inflammatory condition that affects the thyroid gland.\n2. Symptoms of subacute thyroiditis include fever, pain, and swelling in the neck, as well as elevated levels of thyroid hormones in the blood.\n3. The thyroid gland-specific virus (TGSV) has been shown to directly infect the thyroid gland.\n4. Human immunodeficiency virus (HIV) can increase the risk of developing subacute thyroiditis by weakening the immune system.\n5. Influenza and respiratory syncytial virus (RSV) have been linked to the development of subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact": [
      "Subacute thyroiditis is an inflammatory condition that affects the thyroid gland.",
      "Symptoms of subacute thyroiditis include fever, pain, and swelling in the neck, as well as elevated levels of thyroid hormones in the blood.",
      "The thyroid gland-specific virus (TGSV) has been shown to directly infect the thyroid gland.",
      "Human immunodeficiency virus (HIV) can increase the risk of developing subacute thyroiditis by weakening the immune system.",
      "Influenza and respiratory syncytial virus (RSV) have been linked to the development of subacute thyroiditis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There is no known virus called the \"thyroid gland-specific virus (TGSV)\" that has been shown to directly infect the thyroid gland. Subacute thyroiditis is thought to be caused by a viral infection, but the specific virus is not typically identified.\n4. UNKNOWN: While HIV can affect the immune system and potentially increase the risk of various infections and conditions, there is no direct and widely recognized link between HIV specifically increasing the risk of developing subacute thyroiditis. More research would be needed to confirm such a relationship.\n5. UNKNOWN: While viral infections can be associated with subacute thyroiditis, the direct link between influenza and RSV specifically causing subacute thyroiditis is not well-established and would require more specific evidence to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Yes, STAT3 (Signal Transducer and Activator of Transcription 3) is involved in EIF2AK2-dependent suppression of autophagy. EIF2AK2 (Eukaryotic Initiation Factor 2-Associated Kinase 2) is a kinase that phosphorylates and inhibits the translation initiation factor eIF2α, leading to the suppression of global protein synthesis. STAT3 is a transcription factor that is activated downstream of EIF2AK2 and plays a role in regulating autophagy.\nStudies have shown that EIF2AK2 activation leads to the phosphorylation and inhibition of STAT3, which in turn inhibits the transcriptional activation of autophagy-related genes, such as ATG5 and ATG7. This suggests that EIF2AK2-mediated suppression of protein synthesis can also indirectly regulate autophagy by inhibiting the activity of STAT3.\nIn addition, STAT3 has been shown to negatively regulate autophagy by binding to the promoter regions of autophagy-related genes and recruiting histone deacetylases (HDACs) to repress their transcription. Therefore, the inhibition of STAT3 by EIF2AK2 may also contribute to the suppression of autophagy.\nIn summary, EIF2AK2-mediated suppression of protein synthesis can indirectly regulate autophagy by inhibiting the activity of STAT3, which in turn represses the transcription of autophagy-related genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is involved in EIF2AK2-dependent suppression of autophagy.\n2. EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2α, leading to the suppression of global protein synthesis.\n3. Activation of EIF2AK2 leads to the phosphorylation and inhibition of STAT3.\n4. STAT3 inhibits the transcriptional activation of autophagy-related genes, such as ATG5 and ATG7.\n5. STAT3 can negatively regulate autophagy by binding to the promoter regions of autophagy-related genes and recruiting histone deacetylases to repress their transcription.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is involved in EIF2AK2-dependent suppression of autophagy.",
      "EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2α, leading to the suppression of global protein synthesis.",
      "Activation of EIF2AK2 leads to the phosphorylation and inhibition of STAT3.",
      "STAT3 inhibits the transcriptional activation of autophagy-related genes, such as ATG5 and ATG7.",
      "STAT3 can negatively regulate autophagy by binding to the promoter regions of autophagy-related genes and recruiting histone deacetylases to repress their transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: Activation of EIF2AK2 leads to the phosphorylation of eIF2α, not the phosphorylation and inhibition of STAT3.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool specifically designed for the analysis of genomic data, particularly for the analysis of next-generation sequencing (NGS) data. It is used to identify and characterize genomic variations, including single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations.\nTheatre can be used for a variety of genomic analyses, including:\n1. Genome assembly: Theatre can be used to improve the assembly of genomes from NGS data by correcting errors and gaps in the assembly.\n2. Variant calling: Theatre can be used to identify and prioritize variants in a genome, including SNPs, insertions, deletions, and copy number variations.\n3. Gene expression analysis: Theatre can be used to analyze RNA-seq data to identify differentially expressed genes and to understand the regulation of gene expression.\n4. Genetic association studies: Theatre can be used to identify genetic variants associated with complex diseases by analyzing genotype and phenotype data.\n5. Cancer genomics: Theatre can be used to identify somatic mutations in cancer genomes and to understand the genetic changes that occur during tumor development and progression.\n6. Population genetics: Theatre can be used to study the genetic structure of populations and to identify genetic variations that are associated with specific populations or populations.\n7. Forensic genomics: Theatre can be used to analyze DNA samples in forensic cases to identify individuals and to solve crimes.\n8. Personalized medicine: Theatre can be used to analyze genomic data from individual patients to identify genetic variations that may affect drug response or disease susceptibility.\n9. Plant and animal genomics: Theatre can be used to analyze genomic data from plants and animals to understand the evolution of genes and genomes and to identify genetic variations that may be associated with specific traits.\n10. Microbial genomics: Theatre can be used to analyze genomic data from microbes to understand the evolution of microbial genomes and to identify genetic variations that may be associated with specific traits or disease.\nIn summary, Theatre is a powerful tool for genomic analysis, offering a range of features and capabilities that make it ideal for a variety of applications, from basic research to clinical diagnostics. Its ability to integrate and analyze large amounts",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool designed for the analysis of genomic data, including next-generation sequencing (NGS) data.\n2. Theatre can be used to improve genome assembly from NGS data by correcting errors and gaps.\n3. Theatre can identify and prioritize genomic variations such as single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations.\n4. Theatre can analyze RNA-seq data to identify differentially expressed genes.\n5. Theatre can be used in personalized medicine to analyze genomic data from individual patients to identify genetic variations that may affect drug response or disease susceptibility.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool designed for the analysis of genomic data, including next-generation sequencing (NGS) data.",
      "Theatre can be used to improve genome assembly from NGS data by correcting errors and gaps.",
      "Theatre can identify and prioritize genomic variations such as single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations.",
      "Theatre can analyze RNA-seq data to identify differentially expressed genes.",
      "Theatre can be used in personalized medicine to analyze genomic data from individual patients to identify genetic variations that may affect drug response or disease susceptibility."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or information about the software tool named \"Theatre,\" it is not possible to determine the accuracy of these statements. \"Theatre\" is not a widely recognized software tool in the field of genomics based on the knowledge available up to early 2023, and the name could be hypothetical or specific to a particular study or organization. Therefore, without further details, the truthfulness of these statements cannot be assessed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the specific implementation and the length of the sequences. However, the general complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\nThe basic idea of the Smith-Waterman algorithm is to compute the similarity between two sequences by computing the dot product of the two sequences and comparing the resulting vector with a threshold value. This process is repeated for each possible window size, and the maximum score is used to determine the best alignment.\nThe time complexity of this process can be broken down as follows:\n1. Computing the dot product of the two sequences: This takes O(n^2) time, since the dot product of two n-long sequences is an n^2 matrix multiplication.\n2. Comparing the resulting vector with a threshold value: This takes O(1) time, since it is a simple comparison.\n3. Repeating the process for each possible window size: This takes O(n^2) time, since there are n^2 possible window sizes.\nTherefore, the overall time complexity of the Smith-Waterman algorithm is O(n^2).\nIt's worth noting that this is the worst-case time complexity, and in practice, the actual time complexity can be much faster for smaller sequences and with better algorithms. Also, there are several optimizations and variations of the Smith-Waterman algorithm that can further reduce the time complexity, such as using a sliding window approach or using a more efficient algorithm like the Needleman-Wunsch algorithm.",
    "llama-2-7b-chat-hf_fact_raw": "1. The general complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\n2. The Smith-Waterman algorithm computes the similarity between two sequences by computing the dot product of the two sequences.\n3. The process of comparing the resulting vector with a threshold value takes O(1) time.\n4. The process of computing the dot product of the two sequences takes O(n^2) time.\n5. The process is repeated for each possible window size, which takes O(n^2) time.",
    "llama-2-7b-chat-hf_fact": [
      "The general complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.",
      "The Smith-Waterman algorithm computes the similarity between two sequences by computing the dot product of the two sequences.",
      "The process of comparing the resulting vector with a threshold value takes O(1) time.",
      "The process of computing the dot product of the two sequences takes O(n^2) time.",
      "The process is repeated for each possible window size, which takes O(n^2) time."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The Smith-Waterman algorithm has a general complexity of O(n^2), where n is the length of the shorter sequence, as it involves a dynamic programming approach that fills in a matrix based on the lengths of the two sequences being compared.\n\n2. FALSE [correction]: The Smith-Waterman algorithm does not compute the similarity between two sequences by computing the dot product of the two sequences. Instead, it uses dynamic programming to compute the optimal local alignment score between two sequences, which involves scoring matches, mismatches, and gaps, and then finding the path with the highest score in a scoring matrix.\n\n3. UNKNOWN: This statement is vague because it does not specify what vector is being referred to or the context in which a threshold value is being used. The Smith-Waterman algorithm typically involves comparing scores in a matrix to determine the optimal alignment, not comparing a vector to a threshold value.\n\n4. FALSE [correction]: The process of computing the dot product of two sequences is not a step in the Smith-Waterman algorithm. The time complexity of the Smith-Waterman algorithm is O(n^2) due to the dynamic programming matrix computation, not due to computing a dot product.\n\n5. FALSE [correction]: The statement is incorrect in the context of the Smith-Waterman algorithm. The algorithm does not repeat the process for each possible window size. Instead, it fills a single matrix based on the lengths of the two sequences. The complexity of filling this matrix is O(n^2), but this is not due to repeating the process for different window sizes. The concept of window sizes is more relevant to algorithms that involve sliding windows, which is not the case for Smith-Waterman.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 (Fluid Vesicle-Associated Chromatin-Reticulum 1) is a member of the Solute Carrier (SLC) family of transport proteins. Specifically, FLVCR1 is a member of the SLC22A family, which is also known as the ATP-binding cassette (ABC) transporter superfamily. This family of proteins is involved in the transport of a wide range of molecules across cellular membranes, including ions, sugars, and amino acids.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 stands for Fluid Vesicle-Associated Chromatin-Reticulum 1.\n2. FLVCR1 is a member of the Solute Carrier (SLC) family of transport proteins.\n3. FLVCR1 belongs to the SLC22A family.\n4. The SLC22A family is also known as the ATP-binding cassette (ABC) transporter superfamily.\n5. The SLC family of proteins is involved in the transport of molecules across cellular membranes, including ions, sugars, and amino acids.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 stands for Fluid Vesicle-Associated Chromatin-Reticulum 1.",
      "FLVCR1 is a member of the Solute Carrier (SLC) family of transport proteins.",
      "FLVCR1 belongs to the SLC22A family.",
      "The SLC22A family is also known as the ATP-binding cassette (ABC) transporter superfamily.",
      "The SLC family of proteins is involved in the transport of molecules across cellular membranes, including ions, sugars, and amino acids."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 stands for Feline Leukemia Virus, subgroup C, Receptor 1.\n2. FALSE [correction]: FLVCR1 is not a member of the Solute Carrier (SLC) family of transport proteins; it is a member of the Major Facilitator Superfamily (MFS).\n3. FALSE [correction]: FLVCR1 does not belong to the SLC22A family; it is part of the Major Facilitator Superfamily (MFS).\n4. FALSE [correction]: The SLC22A family is not known as the ATP-binding cassette (ABC) transporter superfamily. The ABC transporter superfamily is a different family of transport proteins, known as the ABC family.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "GATA-1 is a transcription factor that plays a crucial role in regulating the expression of genes involved in erythroid cell development and maturation. The biotinylation tagging approach has been used to identify GATA-1 interacting partners and understand the molecular mechanisms underlying its function. Some of the known interacting partners of GATA-1 include:\n1. HDAC1: GATA-1 has been shown to interact with histone deacetylase 1 (HDAC1), which is a repressor of gene expression. The interaction between GATA-1 and HDAC1 may play a role in regulating the expression of erythroid-specific genes.\n2. CBFA2T1: CBFA2T1 is a chromodomain-containing protein that is involved in the regulation of gene expression during erythropoiesis. GATA-1 has been shown to interact with CBFA2T1 and recruit it to specific genomic regions.\n3. KRAS: GATA-1 has been shown to interact with KRAS, a GTPase that is involved in signal transduction pathways. The interaction between GATA-1 and KRAS may play a role in regulating the progression of erythroid cells through the cell cycle.\n4. NF-E2: NF-E2 is a transcription factor that is involved in the regulation of globin gene expression. GATA-1 has been shown to interact with NF-E2 and recruit it to specific genomic regions.\n5. TFAP2A: TFAP2A is a transcription factor that is involved in the regulation of erythroid cell development. GATA-1 has been shown to interact with TFAP2A and regulate its activity.\n6. CBX3: CBX3 is a chromodomain-containing protein that is involved in the regulation of gene expression during erythropoiesis. GATA-1 has been shown to interact with CBX3 and regulate its activity.\n7. RFX1: RFX1 is a transcription factor that is involved in the regulation of globin gene expression. GATA-1 has been shown to interact with RFX1 and regulate its activity.\n8. TAL1",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 interacts with histone deacetylase 1 (HDAC1), which is involved in the repression of gene expression.\n2. GATA-1 has been shown to interact with CBFA2T1, a chromodomain-containing protein that regulates gene expression during erythropoiesis.\n3. KRAS, a GTPase involved in signal transduction pathways, is known to interact with GATA-1.\n4. NF-E2, a transcription factor that regulates globin gene expression, interacts with GATA-1.\n5. GATA-1 interacts with TFAP2A, a transcription factor involved in erythroid cell development.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 interacts with histone deacetylase 1 (HDAC1), which is involved in the repression of gene expression.",
      "GATA-1 has been shown to interact with CBFA2T1, a chromodomain-containing protein that regulates gene expression during erythropoiesis.",
      "KRAS, a GTPase involved in signal transduction pathways, is known to interact with GATA-1.",
      "NF-E2, a transcription factor that regulates globin gene expression, interacts with GATA-1.",
      "GATA-1 interacts with TFAP2A, a transcription factor involved in erythroid cell development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: GATA-1 is known to interact with histone deacetylase 1 (HDAC1), which plays a role in the repression of gene expression, particularly in the context of hematopoiesis.\n2. TRUE: GATA-1 has been shown to interact with CBFA2T1 (also known as ETO), a protein that can regulate gene expression during erythropoiesis.\n3. FALSE [correction]: KRAS is a GTPase involved in signal transduction pathways, but there is no well-established interaction between KRAS and GATA-1. GATA-1 is primarily involved in hematopoiesis, while KRAS is more broadly involved in cell signaling and cancer.\n4. TRUE: NF-E2 is a transcription factor that regulates globin gene expression, and it has been shown to interact with GATA-1 in the regulation of erythroid cell development.\n5. UNKNOWN: While TFAP2A (AP-2 alpha) is a transcription factor involved in cell development and differentiation, including roles in erythroid cell development, the direct interaction between GATA-1 and TFAP2A is not well-established in the literature and may require more specific context to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 (TATA box-binding protein-associated factor 10) is a subunit of the TFIID complex, which is the primary transcriptional activator of RNA polymerase II (RNAPII) in eukaryotic cells. GATA1 is a transcription factor that plays a crucial role in regulating gene expression during erythroid cell differentiation. When TAF10 interacts with GATA1, it enhances the ability of GATA1 to recruit RNAPII to the promoter region of target genes and activate their transcription. This interaction is important for the proper regulation of globin gene expression during erythropoiesis and ensures the proper maturation of red blood cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 is a subunit of the TFIID complex.\n2. The TFIID complex is the primary transcriptional activator of RNA polymerase II in eukaryotic cells.\n3. GATA1 is a transcription factor that regulates gene expression during erythroid cell differentiation.\n4. The interaction between TAF10 and GATA1 enhances GATA1's ability to recruit RNA polymerase II to the promoter region of target genes.\n5. The interaction between TAF10 and GATA1 is important for the regulation of globin gene expression during erythropoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 is a subunit of the TFIID complex.",
      "The TFIID complex is the primary transcriptional activator of RNA polymerase II in eukaryotic cells.",
      "GATA1 is a transcription factor that regulates gene expression during erythroid cell differentiation.",
      "The interaction between TAF10 and GATA1 enhances GATA1's ability to recruit RNA polymerase II to the promoter region of target genes.",
      "The interaction between TAF10 and GATA1 is important for the regulation of globin gene expression during erythropoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are accurate based on general scientific knowledge. TAF10 is indeed a subunit of the TFIID complex, which is a key component in the initiation of transcription by RNA polymerase II in eukaryotic cells. GATA1 is a well-known transcription factor involved in erythroid cell differentiation. However, without specific scientific references or additional context, the exact nature of the interaction between TAF10 and GATA1 and its effects on RNA polymerase II recruitment and globin gene expression during erythropoiesis cannot be confirmed as true or false, hence the response \"UNKNOWN\" for statements 4 and 5.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. A DSS is a computer-based system that provides healthcare professionals with clinical decision-making support by analyzing patient data and providing recommendations for diagnosis, treatment, and management of chronic pain. Some of the key features of chronic pain DSS include:\n1. Pain assessment and measurement tools: These tools help healthcare professionals evaluate the severity and location of pain, as well as monitor changes in pain over time.\n2. Personalized treatment plans: Based on the patient's medical history, current symptoms, and other factors, the DSS can generate a personalized treatment plan that takes into account the patient's preferences and goals.\n3. Medication management: The DSS can help healthcare professionals manage medications used to treat chronic pain, including opioids and non-opioid analgesics, by providing dosing recommendations and monitoring for potential side effects.\n4. Alternative therapies: Some DSS may offer recommendations for alternative therapies such as physical therapy, acupuncture, or cognitive-behavioral therapy.\n5. Patient education: The DSS may provide patient education materials and resources to help patients understand their condition, manage their pain, and make informed decisions about their care.\n6. Remote monitoring: Some DSS may allow for remote monitoring of patients, enabling healthcare professionals to track changes in pain levels and adjust treatment plans as needed.\n7. Predictive analytics: Some DSS may use predictive analytics to identify patients at risk of developing chronic pain or experiencing a worsening of their condition, allowing for early intervention and prevention.\n8. Integration with electronic health records (EHRs): Some DSS may integrate with EHRs to access patient medical history and other relevant data, improving the accuracy and effectiveness of pain management.\n9. Clinical decision support: Some DSS may provide clinical decision support, such as alerts and reminders, to help healthcare professionals make informed decisions about pain management.\n10. Patient engagement: Some DSS may provide patient engagement tools, such as patient portals or mobile apps, to enable patients to take a more active role in managing their chronic pain.\nSome",
    "llama-2-7b-chat-hf_fact_raw": "1. Decision support systems (DSS) for chronic pain management are computer-based systems that assist healthcare professionals in clinical decision-making by analyzing patient data.\n2. Chronic pain DSS can generate personalized treatment plans based on the patient's medical history, current symptoms, and other factors.\n3. These systems may help manage medications for chronic pain, including providing dosing recommendations and monitoring for potential side effects.\n4. Some chronic pain DSS offer recommendations for alternative therapies such as physical therapy, acupuncture, or cognitive-behavioral therapy.\n5. Certain DSS for chronic pain management may integrate with electronic health records (EHRs) to access patient medical history and other relevant data.",
    "llama-2-7b-chat-hf_fact": [
      "Decision support systems (DSS) for chronic pain management are computer-based systems that assist healthcare professionals in clinical decision-making by analyzing patient data.",
      "Chronic pain DSS can generate personalized treatment plans based on the patient's medical history, current symptoms, and other factors.",
      "These systems may help manage medications for chronic pain, including providing dosing recommendations and monitoring for potential side effects.",
      "Some chronic pain DSS offer recommendations for alternative therapies such as physical therapy, acupuncture, or cognitive-behavioral therapy.",
      "Certain DSS for chronic pain management may integrate with electronic health records (EHRs) to access patient medical history and other relevant data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a protein that is localized primarily in the cytoplasm and nucleus of cells. It can be found in a variety of cell types, including endothelial cells, which are the cells that line blood vessels and play a key role in angiogenesis (the formation of new blood vessels). Angiogenin has been shown to play a role in the regulation of angiogenesis, and it is thought to play a key role in the process of tumor angiogenesis, or the formation of new blood vessels in tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is a protein that is localized primarily in the cytoplasm and nucleus of cells.\n2. Angiogenin can be found in endothelial cells.\n3. Endothelial cells line blood vessels and are involved in angiogenesis.\n4. Angiogenin plays a role in the regulation of angiogenesis.\n5. Angiogenin is thought to play a key role in tumor angiogenesis.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is a protein that is localized primarily in the cytoplasm and nucleus of cells.",
      "Angiogenin can be found in endothelial cells.",
      "Endothelial cells line blood vessels and are involved in angiogenesis.",
      "Angiogenin plays a role in the regulation of angiogenesis.",
      "Angiogenin is thought to play a key role in tumor angiogenesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine is a drug that has been shown to have a specific effect on kinase signaling activation in the heart. Ranolazine works by inhibiting the activity of the enzyme ATP-citrate lyase (ACL), which is involved in the degradation of citrate to acetyl-CoA in the citric acid cycle. By inhibiting ACL, ranolazine increases the levels of citrate in the heart, which in turn activates the protein kinase B (Akt) signaling pathway.\nAkt is a key regulator of cell survival and metabolism, and its activation has been shown to play a protective role in the heart during times of stress or injury. When the heart is under stress, such as during ischemia or inflammation, the levels of citrate in the heart decrease, leading to a decrease in Akt activity. By increasing citrate levels and activating the Akt pathway, ranolazine helps to protect the heart against injury and promote cardiovascular health.\nIn addition to its effects on the Akt pathway, ranolazine has also been shown to activate the extracellular signal-regulated kinase (ERK) pathway, which is involved in cell proliferation and differentiation. This suggests that ranolazine may have a broader impact on cellular signaling in the heart, beyond its effects on the Akt pathway.\nOverall, the activation of the Akt pathway by ranolazine is an important mechanism by which the drug exerts its protective effects on the heart, and may contribute to its therapeutic potential in the treatment of cardiovascular disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine inhibits the activity of the enzyme ATP-citrate lyase (ACL).\n2. Inhibition of ACL by ranolazine increases the levels of citrate in the heart.\n3. Increased citrate levels in the heart activate the protein kinase B (Akt) signaling pathway.\n4. Activation of the Akt pathway by ranolazine plays a protective role in the heart during stress or injury.\n5. Ranolazine also activates the extracellular signal-regulated kinase (ERK) pathway, which is involved in cell proliferation and differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine inhibits the activity of the enzyme ATP-citrate lyase (ACL).",
      "Inhibition of ACL by ranolazine increases the levels of citrate in the heart.",
      "Increased citrate levels in the heart activate the protein kinase B (Akt) signaling pathway.",
      "Activation of the Akt pathway by ranolazine plays a protective role in the heart during stress or injury.",
      "Ranolazine also activates the extracellular signal-regulated kinase (ERK) pathway, which is involved in cell proliferation and differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine inhibits the late sodium current in the heart, not the activity of the enzyme ATP-citrate lyase (ACL).\n2. UNKNOWN: The statement is based on the incorrect premise that ranolazine inhibits ACL. Since ranolazine does not inhibit ACL, the effect on citrate levels in the heart is not directly related to ACL inhibition by ranolazine.\n3. UNKNOWN: Since the premise that ranolazine affects citrate levels by inhibiting ACL is incorrect, the subsequent effect on the Akt signaling pathway is not established.\n4. UNKNOWN: While ranolazine may have protective effects on the heart, the statement's connection to the Akt pathway activation by ranolazine is not established due to the incorrect premise about ACL inhibition.\n5. UNKNOWN: The statement about ranolazine activating the ERK pathway is not directly supported or refuted by the provided context. Ranolazine's effects on the ERK pathway would need to be verified with specific scientific evidence.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "No, the regulation of Vsr endonuclease is not entirely independent of the growth phase of bacteria. While Vsr is constitutively expressed in many bacteria, its activity is regulated in response to changes in the growth phase.\nDuring the logarithmic growth phase, Vsr is actively processed and degraded, leading to a decrease in its activity. This is mediated by the protease VipA, which cleaves Vsr in the middle of its catalytic domain. As a result, Vsr activity is low during the logarithmic growth phase.\nIn contrast, during the stationary growth phase, Vsr expression is upregulated, leading to an increase in its activity. This is thought to be due to the depletion of the protease VipA, which is required for Vsr processing and degradation. As VipA levels decrease, Vsr is less susceptible to degradation and its activity increases.\nTherefore, while Vsr is constitutively expressed in many bacteria, its activity is regulated in response to changes in the growth phase, with lower activity during the logarithmic growth phase and higher activity during the stationary growth phase.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is not entirely independent of the growth phase of bacteria.\n2. Vsr endonuclease is constitutively expressed in many bacteria.\n3. Vsr endonuclease activity decreases during the logarithmic growth phase due to processing and degradation.\n4. The protease VipA cleaves Vsr in the middle of its catalytic domain, which leads to a decrease in Vsr activity during the logarithmic growth phase.\n5. Vsr endonuclease activity increases during the stationary growth phase due to upregulation of its expression and depletion of the protease VipA.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is not entirely independent of the growth phase of bacteria.",
      "Vsr endonuclease is constitutively expressed in many bacteria.",
      "Vsr endonuclease activity decreases during the logarithmic growth phase due to processing and degradation.",
      "The protease VipA cleaves Vsr in the middle of its catalytic domain, which leads to a decrease in Vsr activity during the logarithmic growth phase.",
      "Vsr endonuclease activity increases during the stationary growth phase due to upregulation of its expression and depletion of the protease VipA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Vsr endonuclease activity typically increases during the logarithmic growth phase due to the high activity of DNA repair mechanisms during active cell division.\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and responses to statements 3, 4, and 5 are based on general knowledge about bacterial growth phases and DNA repair enzymes. However, without specific information on Vsr endonuclease and the protease VipA, it is not possible to confirm the details about their interaction and regulation. Therefore, statements 4 and 5 are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several computational tools and methods that can be used to predict the structure and function of beta-barrel transmembrane proteins. Here are some of the commonly used tools:\n1. SignalP: SignalP is a widely used tool for predicting the signal peptides in proteins. It can also be used to predict the transmembrane helices in beta-barrel proteins.\n2. TMHMM: TMHMM is a tool that can predict the transmembrane helices in a protein based on its amino acid sequence. It can also predict the type of transmembrane helices (e.g., alpha-helices, beta-barrels, or glycosylated helices) and the orientation of the transmembrane helices.\n3. PredictProtein: PredictProtein is a web server that can predict various features of proteins, including transmembrane helices. It uses a combination of sequence analysis and machine learning algorithms to predict the transmembrane structure of a protein.\n4. PHD-TOPO: PHD-TOPO is a tool that can predict the topology of a protein, including the transmembrane helices. It uses a combination of sequence analysis and machine learning algorithms to predict the transmembrane structure of a protein.\n5. I-TASSER: I-TASSER is a web server that can predict the structure of a protein from its amino acid sequence. It can also predict the transmembrane helices in beta-barrel proteins.\n6. SMART: SMART is a web server that can predict various features of proteins, including transmembrane helices. It uses a combination of sequence analysis and machine learning algorithms to predict the transmembrane structure of a protein.\n7. TMProServer: TMProServer is a web server that can predict the transmembrane helices in a protein based on its amino acid sequence. It also predicts the type of transmembrane helices and the orientation of the transmembrane helices.\n8. Protter: Protter is a web server that can predict the transmembrane helices in a protein based on its amino acid sequence. It also predicts the type of transmembrane helices and the orientation of the transmembrane helices.\n9. Transmembrane Helix Pred",
    "llama-2-7b-chat-hf_fact_raw": "1. SignalP is a tool used for predicting signal peptides and transmembrane helices in proteins.\n2. TMHMM predicts transmembrane helices in proteins based on amino acid sequences.\n3. PredictProtein is a web server that predicts various protein features, including transmembrane helices, using sequence analysis and machine learning.\n4. PHD-TOPO predicts the topology of proteins, including transmembrane helices, using sequence analysis and machine learning.\n5. I-TASSER is a web server that predicts protein structure from amino acid sequences and can predict transmembrane helices in beta-barrel proteins.",
    "llama-2-7b-chat-hf_fact": [
      "SignalP is a tool used for predicting signal peptides and transmembrane helices in proteins.",
      "TMHMM predicts transmembrane helices in proteins based on amino acid sequences.",
      "PredictProtein is a web server that predicts various protein features, including transmembrane helices, using sequence analysis and machine learning.",
      "PHD-TOPO predicts the topology of proteins, including transmembrane helices, using sequence analysis and machine learning.",
      "I-TASSER is a web server that predicts protein structure from amino acid sequences and can predict transmembrane helices in beta-barrel proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SignalP is a tool used for predicting the presence and location of signal peptide cleavage sites in amino acid sequences of proteins, but it does not predict transmembrane helices.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is used to classify disorders that affect the structure and function of the brain, particularly those related to developmental disabilities. The Galassi classification system is used to categorize these disorders into four main categories:\n1. Intellectual disability: This category includes disorders characterized by below-average intelligence and cognitive abilities, such as Down syndrome and Fragile X syndrome.\n2. Autism spectrum disorder: This category includes disorders characterized by difficulties with social interaction, communication, and repetitive behaviors, such as autism spectrum disorder and Asperger syndrome.\n3. ADHD: This category includes disorders characterized by attention deficit hyperactivity disorder, such as attention deficit hyperactivity disorder and attention deficit disorder.\n4. Other neurodevelopmental disorders: This category includes disorders that do not fit into the other three categories, such as Tourette syndrome, obsessive-compulsive disorder, and anxiety disorders.\nIt's important to note that these categories are not mutually exclusive, and individuals may have co-occurring disorders within the same category or across different categories.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Galassi classification system is used to classify disorders related to developmental disabilities affecting the brain's structure and function.\n2. Intellectual disability is one of the categories in the Galassi classification system, including disorders like Down syndrome and Fragile X syndrome.\n3. Autism spectrum disorder is a category in the Galassi classification that includes conditions such as autism spectrum disorder and Asperger syndrome.\n4. ADHD is a category within the Galassi classification system that encompasses attention deficit hyperactivity disorder and attention deficit disorder.\n5. The Galassi classification system includes a category for other neurodevelopmental disorders, which covers conditions like Tourette syndrome, obsessive-compulsive disorder, and anxiety disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The Galassi classification system is used to classify disorders related to developmental disabilities affecting the brain's structure and function.",
      "Intellectual disability is one of the categories in the Galassi classification system, including disorders like Down syndrome and Fragile X syndrome.",
      "Autism spectrum disorder is a category in the Galassi classification that includes conditions such as autism spectrum disorder and Asperger syndrome.",
      "ADHD is a category within the Galassi classification system that encompasses attention deficit hyperactivity disorder and attention deficit disorder.",
      "The Galassi classification system includes a category for other neurodevelopmental disorders, which covers conditions like Tourette syndrome, obsessive-compulsive disorder, and anxiety disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification system is used to classify different types of cerebral cysts, not disorders related to developmental disabilities affecting the brain's structure and function.\n2. FALSE [correction]: Since the Galassi classification system is for cerebral cysts, it does not include categories for intellectual disabilities or specific disorders like Down syndrome and Fragile X syndrome.\n3. FALSE [correction]: Autism spectrum disorder is not a category in the Galassi classification system, as this system does not pertain to neurodevelopmental disorders.\n4. FALSE [correction]: ADHD is not a category within the Galassi classification system, as this system is not related to classifying neurodevelopmental disorders.\n5. FALSE [correction]: The Galassi classification system does not include a category for other neurodevelopmental disorders, as it is not a system for classifying such conditions.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Hrachovy syndrome, is a rare genetic disorder that affects the development of the brain and nervous system. Here are some common features of Shapiro syndrome:\n1. Delayed or absent speech and language development: Children with Shapiro syndrome often experience delays or complete lack of speech and language development, which can range from mild to severe.\n2. Intellectual disability: Individuals with Shapiro syndrome may have mild to severe intellectual disability, which can affect their cognitive and adaptive functioning.\n3. Cerebral anomalies: Shapiro syndrome is characterized by various cerebral anomalies, including hydrocephalus (fluid accumulation in the brain), cerebral atrophy (reduced brain size), and ventriculomegaly (enlarged ventricles in the brain).\n4. Spasticity and muscle weakness: Individuals with Shapiro syndrome may experience spasticity and muscle weakness, particularly in the legs and lower back.\n5. Distinctive facial features: Children with Shapiro syndrome may have distinctive facial features, including a flat nasal bridge, narrow eyes, and a small jaw.\n6. Skeletal abnormalities: Shapiro syndrome can cause various skeletal abnormalities, including short stature, scoliosis (curvature of the spine), and joint contractures (limited joint mobility).\n7. Eye abnormalities: Individuals with Shapiro syndrome may experience eye abnormalities, such as microphthalmia (small eyes), cataracts, and glaucoma.\n8. Hearing loss: Some individuals with Shapiro syndrome may experience hearing loss or impairment.\n9. Autism spectrum disorder: Some individuals with Shapiro syndrome may be diagnosed with autism spectrum disorder (ASD), which can affect social interaction, communication, and behavior.\n10. Seizures: Shapiro syndrome can cause seizures, which can range from mild to severe and can occur at any age.\nIt's important to note that the severity and presentation of Shapiro syndrome can vary",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is a rare genetic disorder that affects the development of the brain and nervous system.\n2. Children with Shapiro syndrome often experience delays or complete lack of speech and language development.\n3. Individuals with Shapiro syndrome may have mild to severe intellectual disability.\n4. Shapiro syndrome is characterized by various cerebral anomalies, including hydrocephalus, cerebral atrophy, and ventriculomegaly.\n5. Shapiro syndrome can cause seizures in affected individuals.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is a rare genetic disorder that affects the development of the brain and nervous system.",
      "Children with Shapiro syndrome often experience delays or complete lack of speech and language development.",
      "Individuals with Shapiro syndrome may have mild to severe intellectual disability.",
      "Shapiro syndrome is characterized by various cerebral anomalies, including hydrocephalus, cerebral atrophy, and ventriculomegaly.",
      "Shapiro syndrome can cause seizures in affected individuals."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is not primarily a genetic disorder; it is a rare neurologic condition characterized by recurrent episodes of hypothermia, hyperhidrosis, and agenesis of the corpus callosum.\n2. UNKNOWN: While speech and language development issues can occur in individuals with various neurological conditions, there is no specific information provided that directly associates these symptoms with Shapiro syndrome.\n3. UNKNOWN: Intellectual disability can be associated with many neurological conditions, but there is no specific information provided that directly associates the severity of intellectual disability with Shapiro syndrome.\n4. FALSE [correction]: Shapiro syndrome is not characterized by cerebral anomalies like hydrocephalus, cerebral atrophy, and ventriculomegaly. It is characterized by the triad of symptoms mentioned earlier, including agenesis of the corpus callosum, which is a specific brain anomaly.\n5. UNKNOWN: While seizures can occur in individuals with various neurological conditions, there is no specific information provided that directly associates seizures with Shapiro syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 (BRAG-1-related gene 1) is a gene that has been associated with several diseases, including:\n1. Charcot-Marie-Tooth disease (CMT): BRAG1 mutations are a common cause of CMT, a group of inherited disorders that affect the peripheral nervous system, causing muscle weakness, numbness, and loss of coordination.\n2. Hereditary sensory and autonomic neuropathy (HSAN): BRAG1 mutations have also been linked to HSAN, a group of rare genetic disorders that affect the nerves responsible for sensation, movement, and autonomic functions.\n3. Other neurological disorders: BRAG1 mutations have been identified in other neurological disorders, such as spinocerebellar ataxia and spinobulbar muscular atrophy.\n4. Cancer: BRAG1 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and lung cancer, and high levels of BRAG1 expression have been associated with poor prognosis in some cases.\nIt is worth noting that the specific disease associated with BRAG1 mutations can vary depending on the location and nature of the mutation, as well as the individual's genetic background.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in BRAG1 are a common cause of Charcot-Marie-Tooth disease.\n2. BRAG1 mutations have been linked to Hereditary sensory and autonomic neuropathy.\n3. BRAG1 mutations have been identified in neurological disorders such as spinocerebellar ataxia and spinobulbar muscular atrophy.\n4. BRAG1 is overexpressed in various types of cancer, including breast, ovarian, and lung cancer.\n5. High levels of BRAG1 expression have been associated with poor prognosis in some cancer cases.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in BRAG1 are a common cause of Charcot-Marie-Tooth disease.",
      "BRAG1 mutations have been linked to Hereditary sensory and autonomic neuropathy.",
      "BRAG1 mutations have been identified in neurological disorders such as spinocerebellar ataxia and spinobulbar muscular atrophy.",
      "BRAG1 is overexpressed in various types of cancer, including breast, ovarian, and lung cancer.",
      "High levels of BRAG1 expression have been associated with poor prognosis in some cancer cases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the PMP22, MPZ, MFN2, and GJB1 genes are more commonly associated with Charcot-Marie-Tooth disease, not BRAG1.\n2. UNKNOWN: Without specific literature references, it is difficult to confirm or deny the link between BRAG1 mutations and Hereditary sensory and autonomic neuropathy.\n3. UNKNOWN: The association of BRAG1 mutations with neurological disorders such as spinocerebellar ataxia and spinobulbar muscular atrophy is not well-established and would require specific literature references to confirm.\n4. UNKNOWN: The statement about BRAG1 being overexpressed in various types of cancer would require specific scientific literature to confirm its accuracy.\n5. UNKNOWN: The association between high levels of BRAG1 expression and poor prognosis in some cancer cases is a specific claim that would require validation through scientific studies.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "The main inhibitor of protein phosphatase 1 (PP1) is the protein called PP1-specific inhibitor 1 (PIN1). PIN1 is a serine/threonine protein phosphatase that specifically binds to and inhibits the activity of PP1, thereby regulating various cellular processes such as cell signaling, DNA damage response, and apoptosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. PP1-specific inhibitor 1 (PIN1) is the main inhibitor of protein phosphatase 1 (PP1).\n2. PIN1 is a serine/threonine protein phosphatase.\n3. PIN1 specifically binds to and inhibits the activity of PP1.\n4. PIN1 regulates various cellular processes including cell signaling, DNA damage response, and apoptosis.",
    "llama-2-7b-chat-hf_fact": [
      "PP1-specific inhibitor 1 (PIN1) is the main inhibitor of protein phosphatase 1 (PP1).",
      "PIN1 is a serine/threonine protein phosphatase.",
      "PIN1 specifically binds to and inhibits the activity of PP1.",
      "PIN1 regulates various cellular processes including cell signaling, DNA damage response, and apoptosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PP1-specific inhibitor 1 (PIN1) is not the main inhibitor of protein phosphatase 1 (PP1). PIN1 is actually a peptidyl-prolyl cis-trans isomerase that regulates the function of its target proteins by isomerizing specific phosphorylated Ser/Thr-Pro bonds, not by inhibiting PP1.\n2. FALSE [correction]: PIN1 is not a serine/threonine protein phosphatase. It is a peptidyl-prolyl cis-trans isomerase.\n3. FALSE [correction]: PIN1 does not bind to and inhibit the activity of PP1. Instead, it interacts with phosphorylated proteins at serine/threonine-proline motifs and catalyzes cis-trans isomerization.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria accumulate mutations in their genomes during stationary phase, which is the period of slow growth or minimal growth rate that occurs in the late log phase of bacterial growth. In Bacillus subtilis, several mechanisms have been identified that underlie adaptive mutagenesis:\n1. DNA damage and repair: During stationary phase, bacteria experience increased DNA damage due to the accumulation of reactive oxygen species (ROS) and the degradation of DNA repair pathways. To cope with this damage, bacteria activate mutagenic mechanisms, such as base excision repair, nucleotide excision repair, and mutL-mutS homologue (MutS) recombination, which can result in the accumulation of mutations.\n2. Transcriptional errors: During stationary phase, the expression of certain genes involved in DNA repair, such as the mutS and mutL genes, is reduced. As a result, transcriptional errors can occur, leading to the accumulation of mutations.\n3. DNA recombination: Stationary-phase bacteria have an increased recombination rate, which can lead to the exchange of genetic material between different chromosomal locations, resulting in the accumulation of mutations.\n4. Telomere shortening: Telomeres, the repetitive DNA sequences that protect the ends of chromosomes, shorten during stationary phase. As telomeres shorten, the genetic material near the telomeres can become exposed, leading to the accumulation of mutations.\n5. Horizontal gene transfer: Stationary-phase bacteria can undergo horizontal gene transfer, which involves the transfer of genetic material from one bacterium to another. This can result in the acquisition of new mutations.\n6. Genomic instability: Stationary-phase bacteria can experience genomic instability, which can lead to the accumulation of mutations. This instability can result from the degradation of DNA repair pathways and the activation of mutagenic mechanisms.\n7. Epigenetic modifications: Epigenetic modifications, such as DNA methylation and histone modification, can also contribute to the accumulation of mutations during stationary phase",
    "llama-2-7b-chat-hf_fact_raw": "1. During the stationary phase, Bacillus subtilis bacteria experience increased DNA damage due to the accumulation of reactive oxygen species (ROS).\n2. In Bacillus subtilis, DNA repair pathways such as base excision repair, nucleotide excision repair, and MutS recombination are activated during the stationary phase.\n3. The expression of genes involved in DNA repair, like mutS and mutL, is reduced during the stationary phase in Bacillus subtilis.\n4. Stationary-phase Bacillus subtilis bacteria have an increased recombination rate, which can lead to the exchange of genetic material and accumulation of mutations.\n5. Horizontal gene transfer can occur in stationary-phase Bacillus subtilis, leading to the acquisition of new mutations.",
    "llama-2-7b-chat-hf_fact": [
      "During the stationary phase, Bacillus subtilis bacteria experience increased DNA damage due to the accumulation of reactive oxygen species (ROS).",
      "In Bacillus subtilis, DNA repair pathways such as base excision repair, nucleotide excision repair, and MutS recombination are activated during the stationary phase.",
      "The expression of genes involved in DNA repair, like mutS and mutL, is reduced during the stationary phase in Bacillus subtilis.",
      "Stationary-phase Bacillus subtilis bacteria have an increased recombination rate, which can lead to the exchange of genetic material and accumulation of mutations.",
      "Horizontal gene transfer can occur in stationary-phase Bacillus subtilis, leading to the acquisition of new mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: During the stationary phase, bacteria such as Bacillus subtilis can experience increased DNA damage due to various stressors, including the accumulation of reactive oxygen species (ROS).\n2. TRUE: In response to DNA damage, bacteria like Bacillus subtilis activate DNA repair pathways, including base excision repair, nucleotide excision repair, and recombinational repair (which involves MutS), during the stationary phase to maintain genomic integrity.\n3. FALSE [correction]: The expression of genes involved in DNA repair, like mutS and mutL, is typically upregulated or maintained during the stationary phase in Bacillus subtilis to cope with increased DNA damage.\n4. TRUE: Stationary-phase Bacillus subtilis bacteria can have an increased recombination rate, which can lead to the exchange of genetic material and potentially the accumulation of mutations, as part of a stress response to maintain genetic diversity.\n5. TRUE: Horizontal gene transfer is a process that can occur in bacteria, including Bacillus subtilis, during the stationary phase, allowing them to acquire new genetic traits, which may include beneficial mutations.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erucismatosis, is a rare genetic disorder that affects the skin and eyes. It is caused by mutations in the Erucum gene, which is responsible for producing a protein called erucum. This protein plays a critical role in the structure and function of the skin and eyes.\nThe symptoms of erucism can vary in severity and may include:\n* Blistering and crusting of the skin, particularly on the face, arms, and legs\n* Eye problems, such as cataracts, glaucoma, and vision loss\n* Skin thickening and hardening\n* Increased risk of infection\n* Delayed wound healing\nThe exact cause of erucism is not fully understood, but it is believed to be inherited in an autosomal recessive pattern, meaning that a person must inherit two copies of the mutated gene, one from each parent, to develop the condition.\nThere is currently no cure for erucism, but various treatments can help manage the symptoms. These may include:\n* Topical creams and ointments to reduce skin blistering and crusting\n* Eye drops to treat eye problems\n* Antibiotics to prevent and treat infections\n* Pain management medications to reduce discomfort\n* Physical therapy to improve wound healing\nIt is important to note that erucism is a rare condition, and the exact prevalence is not well established. However, it is believed to affect approximately 1 in 100,000 to 1 in 50,000 individuals worldwide.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is a rare genetic disorder that affects the skin and eyes.\n2. It is caused by mutations in the Erucum gene.\n3. The protein erucum, which is affected by mutations in the Erucum gene, plays a critical role in the structure and function of the skin and eyes.\n4. Erucism is believed to be inherited in an autosomal recessive pattern.\n5. The estimated prevalence of erucism is approximately 1 in 100,000 to 1 in 50,000 individuals worldwide.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is a rare genetic disorder that affects the skin and eyes.",
      "It is caused by mutations in the Erucum gene.",
      "The protein erucum, which is affected by mutations in the Erucum gene, plays a critical role in the structure and function of the skin and eyes.",
      "Erucism is believed to be inherited in an autosomal recessive pattern.",
      "The estimated prevalence of erucism is approximately 1 in 100,000 to 1 in 50,000 individuals worldwide."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Erucism is not a known genetic disorder. It seems to be a made-up term or a misspelling. If you meant \"albinism,\" it is a genetic disorder that affects the skin, hair, and eyes.\n2. FALSE [correction]: Since erucism is not a recognized genetic disorder, there is no Erucum gene responsible for it. In the case of albinism, mutations in several genes can cause the condition, including TYR, OCA2, TYRP1, and SLC45A2.\n3. FALSE [correction]: As erucism is not a recognized condition, there is no protein named erucum associated with it. In albinism, the affected proteins are involved in the production and distribution of melanin, which affects the color of the skin, hair, and eyes.\n4. UNKNOWN: Since erucism is not a recognized genetic disorder, we cannot determine its inheritance pattern. However, most forms of albinism are inherited in an autosomal recessive pattern.\n5. UNKNOWN: As erucism is not a recognized condition, there is no estimated prevalence. The prevalence of albinism varies depending on the type and population but is generally considered rare.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide (HCTZ) is a diuretic medication that is commonly used to treat a variety of conditions, including:\n1. Hypertension (high blood pressure): HCTZ is often used to treat mild to moderate hypertension, as it can help to reduce blood pressure by increasing urine production and removing excess fluid from the body.\n2. Heart failure: HCTZ can help to reduce fluid buildup in the body, which can occur in people with heart failure.\n3. Edema (swelling): HCTZ is used to treat edema (swelling) caused by fluid buildup in the body, which can occur due to various conditions such as liver disease, kidney disease, or cancer.\n4. Nephrotic syndrome: HCTZ can help to reduce fluid buildup in the body in people with nephrotic syndrome, a condition characterized by the loss of large amounts of protein in the urine.\n5. Diabetes insipidus: HCTZ can help to treat diabetes insipidus, a condition that causes the body to produce too much urine.\n6. Hyperlipidemia (elevated cholesterol levels): HCTZ may be used to treat hyperlipidemia (elevated cholesterol levels) by reducing the amount of cholesterol produced in the liver.\n7. Cystitis: HCTZ may be used to treat cystitis, a bladder infection caused by bacteria.\n8. Prophylaxis of migraine: HCTZ may be used to prevent migraine headaches by reducing the frequency and severity of migraine attacks.\nIt's important to note that HCTZ should only be used under the guidance of a healthcare professional, as it can have potential side effects and drug interactions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide (HCTZ) is used to treat mild to moderate hypertension.\n2. HCTZ is used to reduce fluid buildup in people with heart failure.\n3. HCTZ is used to treat edema caused by conditions such as liver disease, kidney disease, or cancer.\n4. HCTZ can help to reduce fluid buildup in people with nephrotic syndrome.\n5. HCTZ is used to treat diabetes insipidus, which causes the body to produce too much urine.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide (HCTZ) is used to treat mild to moderate hypertension.",
      "HCTZ is used to reduce fluid buildup in people with heart failure.",
      "HCTZ is used to treat edema caused by conditions such as liver disease, kidney disease, or cancer.",
      "HCTZ can help to reduce fluid buildup in people with nephrotic syndrome.",
      "HCTZ is used to treat diabetes insipidus, which causes the body to produce too much urine."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: HCTZ is not typically used to treat diabetes insipidus; instead, it is a condition characterized by excessive urination due to a lack of antidiuretic hormone (ADH) or a resistance to ADH, and treatments usually involve the hormone desmopressin or other approaches, not diuretics like HCTZ.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of urinary incontinence. Silicon-based materials have been developed and used in various forms to treat urinary incontinence, including:\n1. Silicone gel slings: These are the most commonly used silicon-based materials for the treatment of urinary incontinence. They are made of a silicone gel that is inserted into the pelvic area to support the urethra and prevent leakage.\n2. Silicone-coated meshes: These are made of a mesh material that is coated with a layer of silicone. They are used to treat stress urinary incontinence by supporting the urethra and preventing leakage.\n3. Silicone catheters: These are used to treat urinary retention and are made of a silicone material that is inserted into the urethra to drain urine.\n4. Silicone-based adhesives: These are used to treat fistula-related urinary incontinence. They are applied to the fistula site to seal it and prevent leakage.\n5. Silicone-based creams and gels: These are used to treat vaginal dryness and pain during sex, which can be caused by urinary incontinence.\nIt is important to note that silicon-based treatments for urinary incontinence are not suitable for everyone and should only be used under the guidance of a healthcare professional. Additionally, these treatments may have potential side effects, such as infection or discomfort, and should be carefully monitored and managed.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon-based materials have been developed for the treatment of urinary incontinence.\n2. Silicone gel slings are used to support the urethra and prevent leakage in the treatment of urinary incontinence.\n3. Silicone-coated meshes are used to treat stress urinary incontinence by supporting the urethra.\n4. Silicone catheters are used to treat urinary retention by draining urine.\n5. Silicone-based adhesives are applied to fistula sites to seal them and prevent leakage related to urinary incontinence.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon-based materials have been developed for the treatment of urinary incontinence.",
      "Silicone gel slings are used to support the urethra and prevent leakage in the treatment of urinary incontinence.",
      "Silicone-coated meshes are used to treat stress urinary incontinence by supporting the urethra.",
      "Silicone catheters are used to treat urinary retention by draining urine.",
      "Silicone-based adhesives are applied to fistula sites to seal them and prevent leakage related to urinary incontinence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Silicone-based adhesives may be used in medical applications, but they are not typically applied to fistula sites for the treatment of urinary incontinence. Instead, surgical repair is the common treatment for fistulas.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "There is a controversial association between the moon cycle and the risk of rupture of intracranial aneurysms. Some studies have suggested that the incidence of rupture of intracranial aneurysms may increase during the full moon phase, while others have found no association.\nOne of the earliest and most well-known studies on this topic was published in 1979 by K. M. H. Chang and colleagues. The authors retrospectively analyzed the clinical data of 100 patients with ruptured aneurysms and found that 60% of the ruptures occurred during the full moon phase. However, the study had several limitations, including a small sample size and a lack of control for potential confounding factors.\nSince then, several other studies have been conducted, but the results have been inconsistent. Some studies have found a significant association between the full moon and aneurysm rupture, while others have found no association. For example, a study published in 2013 by Y. M. Kim and colleagues found that the incidence of rupture was higher during the full moon phase in a cohort of 140 patients with unruptured aneurysms. However, a larger study published in 2017 by J. R. H. Kim and colleagues found no association between the full moon and aneurysm rupture in a cohort of 1,000 patients.\nThere are several possible explanations for the inconsistent findings in the literature. One possibility is that the association between the full moon and aneurysm rupture is due to chance or bias. For example, the timing of aneurysm rupture may be influenced by factors such as the patient's age, sex, and comorbidities, which could confound the association with the full moon phase. Another possibility is that the association is real but is due to a non-lunar factor, such as changes in atmospheric pressure or humidity.\nIn summary, while there is some evidence to suggest that the full moon may be associated with an increased risk of aneurysm rupture, the evidence is inconsistent and inconclusive. Further research is needed to determine whether there is a real association between the moon cycle and aneurysm rupture, and to identify any potential",
    "llama-2-7b-chat-hf_fact_raw": "1. Some studies have suggested an increased incidence of rupture of intracranial aneurysms during the full moon phase.\n2. A study by K. M. H. Chang and colleagues in 1979 found that 60% of ruptures occurred during the full moon phase, but the study had limitations such as a small sample size.\n3. A study published in 2013 by Y. M. Kim and colleagues found a higher incidence of rupture during the full moon phase in a cohort of 140 patients with unruptured aneurysms.\n4. A larger study published in 2017 by J. R. H. Kim and colleagues found no association between the full moon and aneurysm rupture in a cohort of 1,000 patients.\n5. The inconsistent findings in the literature may be due to factors such as chance, bias, or non-lunar factors like changes in atmospheric pressure or humidity.",
    "llama-2-7b-chat-hf_fact": [
      "Some studies have suggested an increased incidence of rupture of intracranial aneurysms during the full moon phase.",
      "A study by K. M. H. Chang and colleagues in 1979 found that 60% of ruptures occurred during the full moon phase, but the study had limitations such as a small sample size.",
      "A study published in 2013 by Y. M. Kim and colleagues found a higher incidence of rupture during the full moon phase in a cohort of 140 patients with unruptured aneurysms.",
      "A larger study published in 2017 by J. R. H. Kim and colleagues found no association between the full moon and aneurysm rupture in a cohort of 1,000 patients.",
      "The inconsistent findings in the literature may be due to factors such as chance, bias, or non-lunar factors like changes in atmospheric pressure or humidity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Some studies have indeed suggested a correlation between the lunar cycle and various health events, including the rupture of intracranial aneurysms.\n2. UNKNOWN: Without access to the specific study by K. M. H. Chang from 1979, it is not possible to confirm the accuracy of the statement regarding the percentage of ruptures during the full moon phase or the limitations of the study.\n3. UNKNOWN: Without access to the specific study published in 2013 by Y. M. Kim and colleagues, it is not possible to confirm the findings regarding the incidence of rupture during the full moon phase in a cohort of 140 patients with unruptured aneurysms.\n4. UNKNOWN: Without access to the specific study published in 2017 by J. R. H. Kim and colleagues, it is not possible to confirm the findings regarding the lack of association between the full moon and aneurysm rupture in a cohort of 1,000 patients.\n5. TRUE: The statement reflects a common understanding in scientific research that inconsistent findings can be due to various factors, including chance, bias, and other confounding variables.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, the HuR protein (also known as ELAVL1) has been shown to regulate the splicing process in various cell types. HuR is a RNA-binding protein that plays a critical role in the regulation of mRNA metabolism, including pre-mRNA splicing, mRNA stability, and translation.\nHuR has been shown to bind to specific splice sites in the pre-mRNA and regulate the splicing process by either promoting or inhibiting the removal of introns and the inclusion of exons. HuR can also regulate the splicing of alternative splice sites, leading to the production of different isoforms of mRNAs.\nIn addition, HuR has been shown to regulate the expression of spliceosome components, such as U2 snRNA and U12 snRNA, which are essential for pre-mRNA splicing. HuR can also modulate the activity of other splicing factors, such as SR proteins and hnRNPs, to further regulate the splicing process.\nOverall, HuR plays a critical role in regulating the splicing process and is involved in many cellular processes, including cell proliferation, differentiation, and survival. Dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HuR protein, also known as ELAVL1, regulates the splicing process in various cell types.\n2. HuR is a RNA-binding protein that is involved in the regulation of mRNA metabolism, including pre-mRNA splicing, mRNA stability, and translation.\n3. HuR can bind to specific splice sites in the pre-mRNA and influence the splicing process by promoting or inhibiting the removal of introns and the inclusion of exons.\n4. HuR is capable of regulating the expression of spliceosome components, such as U2 snRNA and U12 snRNA.\n5. Dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The HuR protein, also known as ELAVL1, regulates the splicing process in various cell types.",
      "HuR is a RNA-binding protein that is involved in the regulation of mRNA metabolism, including pre-mRNA splicing, mRNA stability, and translation.",
      "HuR can bind to specific splice sites in the pre-mRNA and influence the splicing process by promoting or inhibiting the removal of introns and the inclusion of exons.",
      "HuR is capable of regulating the expression of spliceosome components, such as U2 snRNA and U12 snRNA.",
      "Dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HuR protein, also known as ELAVL1, is not primarily known for regulating the splicing process; it is mainly involved in regulating mRNA stability and translation.\n2. TRUE\n3. FALSE [correction]: While HuR is involved in mRNA metabolism, it does not typically bind to specific splice sites to influence splicing directly. Its primary role is in mRNA stability and translation, not the splicing process itself.\n4. UNKNOWN: Without specific evidence, it is unclear whether HuR directly regulates the expression of spliceosome components like U2 snRNA and U12 snRNA.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha (Pa) is a protein that plays a crucial role in various cellular processes, including cell growth, differentiation, and survival. The c-terminal peptide of prothymosin alpha (CT-Pa) is a truncated form of the full-length Pa protein, which is generated through proteolytic processing. CT-Pa has been shown to have several distinct functions, including:\n1. Cell cycle regulation: CT-Pa has been shown to inhibit cell cycle progression and induce cell cycle arrest in G1/S and G2/M phases.\n2. Apoptosis: CT-Pa has been shown to induce apoptosis in various cell types, including cancer cells, through a mechanism that involves the activation of caspase-3 and -7.\n3. Angiogenesis: CT-Pa has been shown to inhibit angiogenesis, the formation of new blood vessels, by suppressing the expression of vascular endothelial growth factor (VEGF) and other pro-angiogenic factors.\n4. Inflammation: CT-Pa has been shown to have anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines, such as TNF-alpha and IL-1 beta.\n5. Neuroprotection: CT-Pa has been shown to have neuroprotective effects by protecting against oxidative stress-induced neuronal death and promoting the survival of neurons in various models of neurodegenerative diseases.\n6. Cardiovascular protection: CT-Pa has been shown to have cardiovascular protective effects by reducing inflammation and oxidative stress in the cardiovascular system, and by improving cardiac function in various animal models of cardiovascular disease.\n7. Tumor immunotherapy: CT-Pa has been shown to have potential as a tumor immunotherapeutic agent by stimulating the immune system to recognize and attack cancer cells.\n8. Muscle regeneration: CT-Pa has been shown to promote muscle regeneration and repair in various animal models of muscle damage.\n9. Bone healing: CT-Pa has been shown to enhance bone healing by",
    "llama-2-7b-chat-hf_fact_raw": "1. The c-terminal peptide of prothymosin alpha (CT-Pa) inhibits cell cycle progression and induces cell cycle arrest in G1/S and G2/M phases.\n2. CT-Pa induces apoptosis in various cell types, including cancer cells, through a mechanism that involves the activation of caspase-3 and -7.\n3. CT-Pa inhibits angiogenesis by suppressing the expression of vascular endothelial growth factor (VEGF) and other pro-angiogenic factors.\n4. CT-Pa has anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines, such as TNF-alpha and IL-1 beta.\n5. CT-Pa has neuroprotective effects by protecting against oxidative stress-induced neuronal death and promoting the survival of neurons in various models of neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact": [
      "The c-terminal peptide of prothymosin alpha (CT-Pa) inhibits cell cycle progression and induces cell cycle arrest in G1/S and G2/M phases.",
      "CT-Pa induces apoptosis in various cell types, including cancer cells, through a mechanism that involves the activation of caspase-3 and -7.",
      "CT-Pa inhibits angiogenesis by suppressing the expression of vascular endothelial growth factor (VEGF) and other pro-angiogenic factors.",
      "CT-Pa has anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines, such as TNF-alpha and IL-1 beta.",
      "CT-Pa has neuroprotective effects by protecting against oxidative stress-induced neuronal death and promoting the survival of neurons in various models of neurodegenerative diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The c-terminal peptide of prothymosin alpha (CT-Pa) is known to have cell cycle inhibitory effects, which can lead to cell cycle arrest in the G1/S and G2/M phases.\n2. TRUE: CT-Pa can induce apoptosis in various cell types, including cancer cells, and the mechanism often involves the activation of caspases, such as caspase-3 and -7.\n3. TRUE: CT-Pa has been reported to inhibit angiogenesis, and one of the mechanisms is through the suppression of VEGF and other pro-angiogenic factors.\n4. TRUE: CT-Pa has been shown to have anti-inflammatory effects, which include the inhibition of pro-inflammatory cytokines like TNF-alpha and IL-1 beta.\n5. TRUE: CT-Pa has demonstrated neuroprotective effects in various studies, including protection against oxidative stress-induced neuronal death and promoting neuron survival in models of neurodegenerative diseases.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Cystatin C is a protein that is involved in the regulation of protein degradation in the body. It is a cysteine protease inhibitor that is expressed in many tissues, including the brain, and is involved in the regulation of various cellular processes, including protein degradation, cell signaling, and neurotransmission.\nThe fibrillization of cystatin C is a process by which the protein aggregates and forms insoluble fibrils that are toxic to cells. The fibrillization of cystatin C has been implicated in a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.\nOne peptide that has been shown to play a pivotal role in the fibrillization of cystatin C is the peptide sequence RRQQARRRR, which is located in the N-terminal region of the protein. This peptide has been shown to be responsible for the formation of amyloid fibrils in vitro and in vivo, and has been implicated in the pathogenesis of cystatin C-related neurodegenerative diseases.\nOther peptides that have been implicated in the fibrillization of cystatin C include the peptide sequence RRQQARRRRQ, which is located in the C-terminal region of the protein, and the peptide sequence RRQQARRRRR, which is located in the N-terminal region of the protein.\nIt is worth noting that the fibrillization of cystatin C is a complex process that is influenced by a variety of factors, including the presence of other proteins, the pH and temperature of the environment, and the presence of metal ions. Therefore, the exact mechanisms by which the different peptides contribute to the fibrillization of cystatin C are still not fully understood and are the subject of ongoing research.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cystatin C is a cysteine protease inhibitor expressed in many tissues, including the brain.\n2. The fibrillization of cystatin C has been implicated in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.\n3. The peptide sequence RRQQARRRR, located in the N-terminal region of cystatin C, plays a pivotal role in its fibrillization.\n4. The peptide sequence RRQQARRRR has been shown to be responsible for the formation of amyloid fibrils in vitro and in vivo.\n5. The fibrillization of cystatin C is influenced by factors such as the presence of other proteins, pH, temperature, and metal ions.",
    "llama-2-7b-chat-hf_fact": [
      "Cystatin C is a cysteine protease inhibitor expressed in many tissues, including the brain.",
      "The fibrillization of cystatin C has been implicated in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.",
      "The peptide sequence RRQQARRRR, located in the N-terminal region of cystatin C, plays a pivotal role in its fibrillization.",
      "The peptide sequence RRQQARRRR has been shown to be responsible for the formation of amyloid fibrils in vitro and in vivo.",
      "The fibrillization of cystatin C is influenced by factors such as the presence of other proteins, pH, temperature, and metal ions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The peptide sequence RRQQARRRR is not associated with cystatin C. The actual sequence implicated in cystatin C fibrillization is not specified in the provided statements, and such a sequence would need to be verified with scientific literature.\n4. FALSE [correction]: Since the peptide sequence RRQQARRRR is not associated with cystatin C, it cannot be responsible for the formation of amyloid fibrils in cystatin C. The statement is incorrect as it pertains to cystatin C.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Yes, the concentration of protein HIF-1α (Hypoxia-Inducible Factor-1 alpha) can increase after the administration of the cytoprotective prodrug amifostine (ethyol).\nHIF-1α is a transcription factor that plays a critical role in response to hypoxia, and its activity is regulated by prolyl hydroxylation. Amifostine, as a prodrug, is converted to the active metabolite ethylpalmitate, which inhibits the prolyl hydroxylase enzyme, PHD-2, leading to increased HIF-1α activity.\nStudies have shown that administration of amifostine/ethyol can increase the expression of HIF-1α in various tissues, including the lung, liver, and kidney, in response to hypoxia or other forms of cellular stress. This increase in HIF-1α expression is thought to contribute to the cytoprotective effects of amifostine/ethyol by enhancing the expression of genes involved in antioxidant defenses, glucose metabolism, and angiogenesis.\nIn summary, the administration of amifostine/ethyol can increase the concentration of protein HIF-1α, which plays a crucial role in response to hypoxia and other cellular stressors.",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of protein HIF-1α can increase after the administration of the cytoprotective prodrug amifostine (ethyol).\n2. HIF-1α is a transcription factor that is critical in the body's response to hypoxia.\n3. Amifostine is converted into the active metabolite ethylpalmitate.\n4. Ethylpalmitate inhibits the prolyl hydroxylase enzyme, PHD-2, which leads to increased HIF-1α activity.\n5. Administration of amifostine/ethyol has been shown to increase the expression of HIF-1α in tissues such as the lung, liver, and kidney in response to hypoxia or cellular stress.",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of protein HIF-1α can increase after the administration of the cytoprotective prodrug amifostine (ethyol).",
      "HIF-1α is a transcription factor that is critical in the body's response to hypoxia.",
      "Amifostine is converted into the active metabolite ethylpalmitate.",
      "Ethylpalmitate inhibits the prolyl hydroxylase enzyme, PHD-2, which leads to increased HIF-1α activity.",
      "Administration of amifostine/ethyol has been shown to increase the expression of HIF-1α in tissues such as the lung, liver, and kidney in response to hypoxia or cellular stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The concentration of HIF-1α can indeed increase after the administration of certain cytoprotective agents like amifostine, which is used to protect tissues from the toxic effects of chemotherapy and radiation therapy.\n2. TRUE: HIF-1α (Hypoxia-Inducible Factor 1-alpha) is a transcription factor that plays a crucial role in the cellular response to hypoxia (low oxygen conditions).\n3. FALSE [correction]: Amifostine is converted into the active metabolite WR-1065, not ethylpalmitate.\n4. UNKNOWN: The statement about ethylpalmitate inhibiting PHD-2 is difficult to verify without additional context because the active metabolite of amifostine is WR-1065. However, it is known that certain compounds can inhibit prolyl hydroxylase enzymes, leading to increased HIF-1α activity, but whether ethylpalmitate has this function is not specified here.\n5. TRUE: Administration of amifostine has been shown to increase the expression of HIF-1α in various tissues, which is part of the protective mechanism against hypoxia and cellular stress.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase that deposits the following histone marks:\n1. H3K79me3: Set7 specifically methylates histone H3 at lysine 79 (H3K79me3), which is a repressive mark that is involved in the regulation of gene expression, particularly in the context of transcriptional elongation.\n2. H3K27me3: Set7 also methylates histone H3 at lysine 27 (H3K27me3), which is a repressive mark that plays a role in the regulation of stem cell self-renewal, differentiation, and cell fate determination.\n3. H2A.Z: Set7 can also methylate histone H2A at various lysines, including H2A.Z, which is a variant of histone H2A that is enriched at actively transcribed genes and plays a role in the regulation of gene expression.\nOverall, Set7 plays a crucial role in regulating chromatin structure and gene expression by depositing these different histone marks, which can influence the accessibility of transcription factors to DNA and the recruitment of chromatin-modifying enzymes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase.\n2. Set7 methylates histone H3 at lysine 79 (H3K79me3).\n3. H3K79me3 is a repressive mark involved in the regulation of gene expression, particularly in transcriptional elongation.\n4. Set7 also methylates histone H3 at lysine 27 (H3K27me3).\n5. H3K27me3 plays a role in the regulation of stem cell self-renewal, differentiation, and cell fate determination.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase.",
      "Set7 methylates histone H3 at lysine 79 (H3K79me3).",
      "H3K79me3 is a repressive mark involved in the regulation of gene expression, particularly in transcriptional elongation.",
      "Set7 also methylates histone H3 at lysine 27 (H3K27me3).",
      "H3K27me3 plays a role in the regulation of stem cell self-renewal, differentiation, and cell fate determination."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 specifically methylates histone H3 at lysine 4 (H3K4), not lysine 79.\n3. FALSE [correction]: H3K79 methylation is generally associated with active transcription, not repression. Moreover, Set7 is not responsible for methylation at H3K79.\n4. FALSE [correction]: Set7 does not methylate histone H3 at lysine 27 (H3K27); this methylation is associated with the Polycomb group protein EZH2.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Hepcidin is a small peptide hormone that plays a key role in regulating iron metabolism in the body. The protein structure of hepcidin consists of 15 amino acids, and it is predicted to have 4 disulfide bonds. These disulfide bonds are crucial for the proper folding and stability of the protein, and they help to form the distinctive tertiary structure of hepcidin.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin is a peptide hormone involved in regulating iron metabolism.\n2. The protein structure of hepcidin consists of 15 amino acids.\n3. Hepcidin is predicted to have 4 disulfide bonds.\n4. Disulfide bonds contribute to the proper folding and stability of the hepcidin protein.\n5. Disulfide bonds help form the tertiary structure of hepcidin.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin is a peptide hormone involved in regulating iron metabolism.",
      "The protein structure of hepcidin consists of 15 amino acids.",
      "Hepcidin is predicted to have 4 disulfide bonds.",
      "Disulfide bonds contribute to the proper folding and stability of the hepcidin protein.",
      "Disulfide bonds help form the tertiary structure of hepcidin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The protein structure of hepcidin consists of 25 amino acids.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "DNAJC11 encodes a protein called DJ-1 (Disease susceptibility gene 1), which is also known as Parkin-interacting protein 1 (PIN1). DJ-1 is a mitochondrial protein that plays a crucial role in the regulation of mitochondrial dynamics and function, particularly in the context of Parkinson's disease.\nThe localization of DJ-1/DNAJC11 is primarily mitochondrial, with the protein being targeted to the inner mitochondrial membrane. From there, it interacts with various mitochondrial proteins, including parkin, to modulate mitochondrial function and regulate the clearance of damaged mitochondria.\nDysregulation of DJ-1 has been implicated in various neurodegenerative diseases, including Parkinson's disease, and it is thought to play a role in the pathogenesis of these disorders by disrupting the normal function of mitochondria in neurons.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is called DJ-1, also known as Parkin-interacting protein 1 (PIN1).\n2. DJ-1 is a mitochondrial protein.\n3. DJ-1 plays a role in the regulation of mitochondrial dynamics and function.\n4. The localization of DJ-1/DNAJC11 is primarily mitochondrial, targeting the inner mitochondrial membrane.\n5. Dysregulation of DJ-1 has been implicated in various neurodegenerative diseases, including Parkinson's disease.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is called DJ-1, also known as Parkin-interacting protein 1 (PIN1).",
      "DJ-1 is a mitochondrial protein.",
      "DJ-1 plays a role in the regulation of mitochondrial dynamics and function.",
      "The localization of DJ-1/DNAJC11 is primarily mitochondrial, targeting the inner mitochondrial membrane.",
      "Dysregulation of DJ-1 has been implicated in various neurodegenerative diseases, including Parkinson's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The protein encoded by the gene DNAJC11 is not called DJ-1. DJ-1 is actually encoded by the PARK7 gene, while DNAJC11 encodes a different protein that is a member of the DnaJ/Hsp40 family.\n2. TRUE: DJ-1 is indeed found in mitochondria, among other cellular locations.\n3. TRUE: DJ-1 is known to play a role in the regulation of mitochondrial dynamics and function.\n4. FALSE [correction]: The localization of DJ-1 is not primarily mitochondrial, nor does it specifically target the inner mitochondrial membrane. DJ-1 is found in various cellular compartments, including the cytoplasm, nucleus, and mitochondria, but it is not exclusively mitochondrial.\n5. TRUE: Dysregulation of DJ-1 has been implicated in various neurodegenerative diseases, including Parkinson's disease.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Ultraconserved elements (UEs) are short, highly conserved regions of the genome that are thought to be involved in regulating gene expression and other cellular processes. Copy number variants (CNVs) are genetic changes that involve the gain or loss of genetic material, typically involving tens of thousands of base pairs of DNA.\nThere is evidence to suggest that UEs are depleted among CNVs. Several studies have found that UEs are overrepresented in the genomes of individuals with CNVs, particularly in regions that are not affected by the CNV. This suggests that UEs may be more likely to be preserved in the face of genetic variation, perhaps due to their functional importance.\nOne study published in the journal Nature in 2015 found that UEs were depleted among CNVs in a sample of individuals with autism spectrum disorder (ASD). The study found that UEs were overrepresented in regions of the genome that were not affected by CNVs, but that they were underrepresented in regions that were affected by CNVs.\nAnother study published in the journal American Journal of Human Genetics in 2017 found similar results in a sample of individuals with intellectual disability. The study found that UEs were depleted among CNVs, particularly in regions that were involved in gene expression.\nIt is worth noting that these studies were small and more research is needed to confirm these findings and understand the implications of UEs being depleted among CNVs. However, these studies suggest that UEs may play a more important role in regulating gene expression and other cellular processes than previously thought, and that they may be more resistant to the disruptive effects of CNVs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UEs) are highly conserved regions of the genome.\n2. Copy number variants (CNVs) involve the gain or loss of genetic material, typically involving tens of thousands of base pairs of DNA.\n3. Studies have found that UEs are overrepresented in regions of the genome not affected by CNVs.\n4. A study published in Nature in 2015 found that UEs were depleted among CNVs in individuals with autism spectrum disorder (ASD).\n5. A study published in the American Journal of Human Genetics in 2017 found that UEs were depleted among CNVs in individuals with intellectual disability.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UEs) are highly conserved regions of the genome.",
      "Copy number variants (CNVs) involve the gain or loss of genetic material, typically involving tens of thousands of base pairs of DNA.",
      "Studies have found that UEs are overrepresented in regions of the genome not affected by CNVs.",
      "A study published in Nature in 2015 found that UEs were depleted among CNVs in individuals with autism spectrum disorder (ASD).",
      "A study published in the American Journal of Human Genetics in 2017 found that UEs were depleted among CNVs in individuals with intellectual disability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are accurate descriptions of ultraconserved elements and copy number variants, and the general relationship between UEs and CNVs. However, without specific references to the studies mentioned in statements 4 and 5, it is not possible to verify the accuracy of these claims. Therefore, the truthfulness of statements 4 and 5 is unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Has2 (Haspin) is a protein kinase that plays a crucial role in the regulation of mitosis. Has2/Haspin kinase is specifically activated during mitosis and phosphorylates and activates the protein Kin4/Sty1 (also known as STY1 or TAK1), which is a key regulator of mitosis.\nTherefore, the substrate of Haspin kinase during mitosis is Kin4/Sty1.",
    "llama-2-7b-chat-hf_fact_raw": "1. Haspin kinase plays a crucial role in the regulation of mitosis.\n2. Haspin kinase is specifically activated during mitosis.\n3. Haspin kinase phosphorylates and activates the protein Kin4/Sty1.\n4. Kin4/Sty1 is also known as STY1 or TAK1.\n5. Kin4/Sty1 is a key regulator of mitosis.",
    "llama-2-7b-chat-hf_fact": [
      "Haspin kinase plays a crucial role in the regulation of mitosis.",
      "Haspin kinase is specifically activated during mitosis.",
      "Haspin kinase phosphorylates and activates the protein Kin4/Sty1.",
      "Kin4/Sty1 is also known as STY1 or TAK1.",
      "Kin4/Sty1 is a key regulator of mitosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Haspin kinase phosphorylates histone H3 at threonine 3 (H3T3ph) during mitosis, not the protein Kin4/Sty1.\n4. FALSE [correction]: Kin4/Sty1 is not also known as STY1 or TAK1. STY1 is a stress-activated protein kinase in fission yeast, and TAK1 (TGF-beta activated kinase 1) is a different kinase involved in inflammatory signaling pathways.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate through a mechanism that is distinct from other RNA viruses. Here is a simplified overview of the mechanism of viroid replication:\n1. Attachment: The viroid attaches to the host cell membrane through its 5' end.\n2. Endosomal sorting: The viroid is endocytosed by the host cell through a process called endosomal sorting, which involves the viroid being engulfed by a membrane-bound structure called an endosome.\n3. Acidification: Once inside the endosome, the viroid is acidified, which causes the RNA to become more hydrophobic and more easily released from the endosome.\n4. Release: The viroid is released from the endosome and enters the cytoplasm, where it can begin to replicate.\n5. Replication: The viroid replicates by using the host cell's RNA polymerase II enzyme to transcribe its genetic material. The resulting RNA is then translated into proteins that help to replicate the viroid.\n6. Assembly: The newly synthesized viroid RNA is assembled into a protein-RNA complex, which is then released from the host cell through a process called lysis.\n7. Transmission: The released viroid can then infect other host cells through a process called transmission, which involves the viroid attaching to the new host cell membrane and initiating the replication cycle.\nOverall, the mechanism of viroid replication is a complex process that involves the interaction of several different cellular structures and enzymes. Understanding the mechanisms of viroid replication is important for developing effective strategies for controlling viroid infections.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules.\n2. Viroids replicate using the host cell's RNA polymerase II enzyme.\n3. The replication process of viroids involves attachment to the host cell membrane, endosomal sorting, acidification, release into the cytoplasm, replication, assembly, and transmission.\n4. The viroid attaches to the host cell membrane through its 5' end.\n5. The newly synthesized viroid RNA is assembled into a protein-RNA complex before being released from the host cell.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules.",
      "Viroids replicate using the host cell's RNA polymerase II enzyme.",
      "The replication process of viroids involves attachment to the host cell membrane, endosomal sorting, acidification, release into the cytoplasm, replication, assembly, and transmission.",
      "The viroid attaches to the host cell membrane through its 5' end.",
      "The newly synthesized viroid RNA is assembled into a protein-RNA complex before being released from the host cell."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The replication process described is more characteristic of a virus's life cycle. Viroids do not encode proteins and do not follow the typical viral entry or assembly pathways. They replicate in the host cell nucleus or chloroplasts using RNA polymerase II (in the nucleus) without the need for a protein coat.\n4. UNKNOWN: The specific mechanism of how viroids enter host cells is not well understood, and the statement about the 5' end attachment is not a well-established fact in viroid biology.\n5. FALSE [correction]: Viroids do not form protein-RNA complexes as they do not encode for proteins. They exist solely as small, circular RNA molecules.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Fibronectin is a protein that has been suggested as a potential serum biomarker for Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness.\nStudies have shown that levels of fibronectin in the blood of DMD patients are significantly higher than in healthy individuals, potentially due to the excessive degradation of the protein in the muscles of DMD patients.\nFurthermore, fibronectin levels have been found to be elevated in the serum of DMD patients at an early age, even before the onset of muscle weakness, suggesting that it may serve as an early diagnostic marker for the disease.\nHowever, it is important to note that the use of fibronectin as a biomarker for DMD is still in its early stages, and more research is needed to fully understand its diagnostic and prognostic value.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin has been suggested as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Duchenne muscular dystrophy is characterized by progressive muscle degeneration and weakness.\n3. Studies indicate that fibronectin levels in the blood of DMD patients are significantly higher than in healthy individuals.\n4. Elevated fibronectin levels in the serum of DMD patients can be detected at an early age, even before the onset of muscle weakness.\n5. The use of fibronectin as a biomarker for DMD is still in the research phase and not yet fully established.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin has been suggested as a potential serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Duchenne muscular dystrophy is characterized by progressive muscle degeneration and weakness.",
      "Studies indicate that fibronectin levels in the blood of DMD patients are significantly higher than in healthy individuals.",
      "Elevated fibronectin levels in the serum of DMD patients can be detected at an early age, even before the onset of muscle weakness.",
      "The use of fibronectin as a biomarker for DMD is still in the research phase and not yet fully established."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "The DeepBlue epigenomic data server is a comprehensive resource that contains data from various epigenome projects, including:\n1. The ENCODE (ENCyclopedia Of DNA Elements) Project: This project is a large-scale effort to map all of the functional elements in the human genome, including promoters, enhancers, and other regulatory elements.\n2. The Roadmap Epigenomics Project: This project is focused on generating comprehensive maps of epigenetic marks across multiple tissues and cell types, including DNA methylation, histone modifications, and chromatin structure.\n3. The Human Epigenome Project: This project aims to create a comprehensive map of the epigenetic landscape of human cells, including DNA methylation, histone modifications, and other epigenetic marks.\n4. The Mouse Epigenome Project: This project is focused on generating a detailed map of the epigenetic landscape of the mouse genome, including DNA methylation, histone modifications, and other epigenetic marks.\n5. The Epigenomics of Disease Project: This project is focused on understanding the role of epigenetic changes in human disease, including cancer, neurological disorders, and metabolic disorders.\n6. The Epigenetic Regulation of Stem Cell Pluripotency Project: This project is focused on understanding the epigenetic mechanisms that regulate stem cell pluripotency and differentiation.\n7. The Epigenetic Regulation of Gene Expression Project: This project is focused on understanding the epigenetic mechanisms that regulate gene expression, including the role of DNA methylation, histone modifications, and other epigenetic marks.\n8. The Epigenetic Regulation of Immune Cell Function Project: This project is focused on understanding the epigenetic mechanisms that regulate immune cell function, including the role of epigenetic marks in T cell and B cell differentiation and activation.\n9. The Epigenetic Regulation of Brain Development and Function Project: This project is focused on understanding the epigenetic mechanisms that regulate brain development and function, including the role of epigenetic marks in neuronal differentiation and synaptic plasticity.\n10. The Epigenetic Regulation of Cancer Project: This project is focused on understanding the epigen",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE (ENCyclopedia Of DNA Elements) Project.\n2. The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server.\n3. Data from the Human Epigenome Project are contained in the DeepBlue epigenomic data server.\n4. The DeepBlue epigenomic data server includes data from the Mouse Epigenome Project.\n5. The Epigenomics of Disease Project is one of the epigenome projects whose data are available on the DeepBlue epigenomic data server.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE (ENCyclopedia Of DNA Elements) Project.",
      "The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server.",
      "Data from the Human Epigenome Project are contained in the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server includes data from the Mouse Epigenome Project.",
      "The Epigenomics of Disease Project is one of the epigenome projects whose data are available on the DeepBlue epigenomic data server."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe DeepBlue epigenomic data server is known to contain data from various epigenomic projects, including ENCODE and the Roadmap Epigenomics Project. However, without specific information about the inclusion of data from the Human Epigenome Project, the Mouse Epigenome Project, or the Epigenomics of Disease Project in the DeepBlue server, the status of these statements cannot be determined with certainty.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "One tool that employs self-organizing maps (SOMs) for analyzing synonymous codon usage is the \"Synonymous Codon Usage Predictor\" (SCUP) tool. SCUP uses SOMs to represent the codon usage patterns of a given gene or set of genes in a lower-dimensional space, allowing for the identification of patterns and trends in codon usage that may be indicative of functional or evolutionary significance.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"Synonymous Codon Usage Predictor\" (SCUP) tool employs self-organizing maps (SOMs) for analyzing synonymous codon usage.\n2. SCUP represents the codon usage patterns of a gene or set of genes in a lower-dimensional space.\n3. SCUP allows for the identification of patterns and trends in codon usage.",
    "llama-2-7b-chat-hf_fact": [
      "The \"Synonymous Codon Usage Predictor\" (SCUP) tool employs self-organizing maps (SOMs) for analyzing synonymous codon usage.",
      "SCUP represents the codon usage patterns of a gene or set of genes in a lower-dimensional space.",
      "SCUP allows for the identification of patterns and trends in codon usage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 (Microtubule-Associated Protein 1 Light Chain 1, also known as EB1) is a protein that plays a crucial role in the regulation of microtubule dynamics and cellular behavior. It is a component of the plus-end tracking protein complex, which is involved in the regulation of microtubule stability and dynamics, and is also involved in cell signaling and the regulation of the cytoskeleton. MINDY-1 is overexpressed in many types of cancer, and has been implicated in cancer cell migration, invasion, and metastasis. It is also a potential therapeutic target for cancer treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a protein that is involved in the regulation of microtubule dynamics and cellular behavior.\n2. MINDY-1 is a component of the plus-end tracking protein complex.\n3. The plus-end tracking protein complex is involved in the regulation of microtubule stability and dynamics.\n4. MINDY-1 is overexpressed in many types of cancer.\n5. MINDY-1 has been implicated in cancer cell migration, invasion, and metastasis.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a protein that is involved in the regulation of microtubule dynamics and cellular behavior.",
      "MINDY-1 is a component of the plus-end tracking protein complex.",
      "The plus-end tracking protein complex is involved in the regulation of microtubule stability and dynamics.",
      "MINDY-1 is overexpressed in many types of cancer.",
      "MINDY-1 has been implicated in cancer cell migration, invasion, and metastasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MINDY-1 is not a protein; it is a nickname for a class of deubiquitinating enzymes, specifically MIU-containing novel DUB family-1.\n2. FALSE [correction]: MINDY-1, as a deubiquitinating enzyme, is not a component of the plus-end tracking protein complex. Plus-end tracking proteins, also known as +TIPs, are a different set of proteins involved in microtubule dynamics.\n3. TRUE: The plus-end tracking protein complex is indeed involved in the regulation of microtubule stability and dynamics.\n4. UNKNOWN: Without specific research data or references, it is not possible to confirm whether MINDY-1 is overexpressed in many types of cancer.\n5. UNKNOWN: Similarly, without specific evidence, it cannot be determined if MINDY-1 has been implicated in cancer cell migration, invasion, and metastasis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, including:\n1. PhyloBayes: This software package is a Bayesian phylogenetic framework for inferring the evolutionary history of genes or genomic regions. It can be used to identify conserved genomic regions and to infer their functional significance.\n2. PhastCons: This software package is a widely used tool for identifying conserved regions in a genome. It uses a hidden Markov model to infer the probability of a region being conserved across different species.\n3. ConServe: This software package is a web-based tool for identifying and analyzing conserved regions in a genome. It uses a combination of phylogenetic and functional data to identify conserved regions and to predict their functional significance.\n4. GERP: This software package is a genome-wide method for identifying conserved regions in a genome. It uses a combination of phylogenetic and genomic data to identify regions that are highly conserved across different species.\n5. Prodigal: This software package is a genome-wide method for identifying conserved regions in a genome. It uses a combination of phylogenetic and genomic data to identify regions that are highly conserved across different species.\n6. MUSCLE: This software package is a multiple sequence alignment tool that can be used to identify conserved regions in a genome. It can be used to align multiple sequences and to identify regions that are highly conserved across different species.\n7. MAFFT: This software package is a multiple sequence alignment tool that can be used to identify conserved regions in a genome. It can be used to align multiple sequences and to identify regions that are highly conserved across different species.\n8. BLAST: This software package is a widely used tool for comparing a query sequence to a database of known sequences. It can be used to identify conserved regions in a genome by comparing a query sequence to a database of known sequences and identifying regions that are highly conserved.\n9. HMMER: This software package is a widely used tool for identifying conserved regions in a genome. It uses a hidden Markov model to infer the probability of a region being conserved across different species.\n10. GLIMMER: This software package is a widely",
    "llama-2-7b-chat-hf_fact_raw": "1. PhyloBayes is a software package used for inferring the evolutionary history of genes or genomic regions.\n2. PhastCons is a tool that uses a hidden Markov model to identify conserved regions in a genome.\n3. ConServe is a web-based tool for identifying and analyzing conserved regions in a genome.\n4. GERP is a method for identifying conserved regions in a genome using phylogenetic and genomic data.\n5. MUSCLE is a multiple sequence alignment tool used to identify conserved regions in a genome.",
    "llama-2-7b-chat-hf_fact": [
      "PhyloBayes is a software package used for inferring the evolutionary history of genes or genomic regions.",
      "PhastCons is a tool that uses a hidden Markov model to identify conserved regions in a genome.",
      "ConServe is a web-based tool for identifying and analyzing conserved regions in a genome.",
      "GERP is a method for identifying conserved regions in a genome using phylogenetic and genomic data.",
      "MUSCLE is a multiple sequence alignment tool used to identify conserved regions in a genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There is no widely recognized web-based tool named ConServe for identifying and analyzing conserved regions in a genome. However, there are other tools like ConSurf that are used for this purpose.\n4. TRUE\n5. TRUE [clarification]: While MUSCLE is indeed a multiple sequence alignment tool, it is not specifically used to identify conserved regions in a genome. Instead, it aligns sequences, which can then be analyzed by other tools or methods to identify conserved regions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "The PIEZO2 gene has been associated with several diseases, including:\n1. Epilepsy: Mutations in the PIEZO2 gene have been identified as a cause of some forms of epilepsy, including those with a genetic basis.\n2. Hearing loss: PIEZO2 mutations have been linked to various forms of hearing loss, including profound sensorineural hearing loss.\n3. Cerebral cavernous malformations (CCMs): Some studies have found that PIEZO2 mutations are associated with an increased risk of developing CCMs, which are abnormal blood vessels in the brain that can cause a range of neurological symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene have been identified as a cause of some forms of epilepsy.\n2. PIEZO2 mutations have been linked to various forms of hearing loss, including profound sensorineural hearing loss.\n3. PIEZO2 mutations are associated with an increased risk of developing cerebral cavernous malformations (CCMs).",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene have been identified as a cause of some forms of epilepsy.",
      "PIEZO2 mutations have been linked to various forms of hearing loss, including profound sensorineural hearing loss.",
      "PIEZO2 mutations are associated with an increased risk of developing cerebral cavernous malformations (CCMs)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nThe statements provided require specific scientific knowledge about the PIEZO2 gene and its associated conditions. Without access to current and specific genetic research, it is not possible to confirm the accuracy of these statements. Therefore, the response to each statement is UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization promotes the degradation of extracellular matrix (ECM) components, such as collagen and fibronectin. The ERAP1-ERAP2 dimer is a protease complex that is involved in the proteolytic degradation of these ECM components, which is important for maintaining tissue homeostasis and regulating cellular behavior. Specifically, ERAP1-ERAP2 dimerization promotes the degradation of ECM components by cleaving them into smaller peptides that can be further degraded by other proteases. This process is important for maintaining tissue architecture and regulating cellular behavior, such as cell migration and differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the degradation of extracellular matrix components.\n2. Collagen and fibronectin are among the ECM components degraded by the ERAP1-ERAP2 dimer.\n3. The ERAP1-ERAP2 dimer is a protease complex.\n4. The degradation of ECM components by the ERAP1-ERAP2 dimer involves cleaving them into smaller peptides.\n5. This degradation process is important for maintaining tissue architecture and regulating cellular behavior.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the degradation of extracellular matrix components.",
      "Collagen and fibronectin are among the ECM components degraded by the ERAP1-ERAP2 dimer.",
      "The ERAP1-ERAP2 dimer is a protease complex.",
      "The degradation of ECM components by the ERAP1-ERAP2 dimer involves cleaving them into smaller peptides.",
      "This degradation process is important for maintaining tissue architecture and regulating cellular behavior."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements regarding ERAP1-ERAP2 dimerization and its specific role in the degradation of extracellular matrix (ECM) components such as collagen and fibronectin are highly specific and would require specialized knowledge or a specific source to confirm their accuracy. Without the context of a specific scientific study or source, it is not possible to determine the truth of these statements. However, the general roles of protease complexes in degrading ECM components and the importance of this process in maintaining tissue architecture and regulating cellular behavior are well-established concepts in cell biology.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two proteins that play important roles in the regulation of gallbladder development and function.\nR-spondin 1 is a secreted protein that is involved in the regulation of gallbladder morphogenesis and the maintenance of gallbladder function. It is expressed in the liver and bile ducts, where it promotes the proliferation and differentiation of gallbladder cells, and also regulates the expression of genes involved in bile acid synthesis and transport. In non-damaged gallbladders, R-spondin 1 helps to maintain the normal structure and function of the gallbladder by regulating the proliferation and differentiation of gallbladder cells, and by promoting the secretion of bile acids into the bile ducts.\nNoggin is a secreted protein that is involved in the regulation of cellular signaling pathways involved in the development and maintenance of the gallbladder. It is expressed in the liver and bile ducts, where it inhibits the activity of bone morphogenetic proteins (BMPs), which are important regulators of gallbladder development and function. In non-damaged gallbladders, Noggin helps to regulate the normal proliferation and differentiation of gallbladder cells, and also promotes the secretion of bile acids into the bile ducts.\nIn summary, R-spondin 1 and Noggin are two proteins that play important roles in the regulation of gallbladder development and function in non-damaged gallbladders. R-spondin 1 promotes the proliferation and differentiation of gallbladder cells, and regulates the expression of genes involved in bile acid synthesis and transport, while Noggin inhibits the activity of BMPs and regulates the proliferation and differentiation of gallbladder cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 is involved in the regulation of gallbladder morphogenesis and the maintenance of gallbladder function.\n2. R-spondin 1 is expressed in the liver and bile ducts and promotes the proliferation and differentiation of gallbladder cells.\n3. R-spondin 1 regulates the expression of genes involved in bile acid synthesis and transport.\n4. Noggin is involved in the regulation of cellular signaling pathways important for gallbladder development and maintenance.\n5. Noggin inhibits the activity of bone morphogenetic proteins (BMPs) and is expressed in the liver and bile ducts.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 is involved in the regulation of gallbladder morphogenesis and the maintenance of gallbladder function.",
      "R-spondin 1 is expressed in the liver and bile ducts and promotes the proliferation and differentiation of gallbladder cells.",
      "R-spondin 1 regulates the expression of genes involved in bile acid synthesis and transport.",
      "Noggin is involved in the regulation of cellular signaling pathways important for gallbladder development and maintenance.",
      "Noggin inhibits the activity of bone morphogenetic proteins (BMPs) and is expressed in the liver and bile ducts."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: R-spondin 1 is known to be involved in the regulation of various organ morphogenesis, including the gallbladder, and can play a role in maintaining organ function.\n2. TRUE: R-spondin 1 is indeed expressed in the liver and bile ducts and has been shown to promote the proliferation and differentiation of various cell types, which could include gallbladder cells.\n3. UNKNOWN: While R-spondin 1 is involved in Wnt signaling, which can impact a variety of cellular processes, the specific statement about the regulation of genes involved in bile acid synthesis and transport would require more specific evidence to confirm.\n4. TRUE: Noggin is a known antagonist of BMP signaling, which is important for the development and maintenance of various tissues, including the gallbladder.\n5. TRUE: Noggin does inhibit the activity of BMPs and has been shown to be expressed in various tissues, including the liver and bile ducts, which could be relevant to gallbladder development and function.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme that requires four subunits to function:\n1. p47phox: This subunit is the catalytic subunit that generates ROS through the transfer of electrons from NADPH to oxygen.\n2. p67phox: This subunit is involved in the transfer of electrons from p47phox to oxygen and also plays a role in the assembly and stability of the enzyme complex.\n3. Nox5: This subunit is the core subunit that provides the structural framework for the enzyme complex and is responsible for the binding of p47phox and p67phox.\n4. Rac1: This subunit is involved in the regulation of the enzyme activity and is required for the proper localization of the enzyme complex to the plasma membrane.\nTogether, these four subunits work cooperatively to generate ROS through the transfer of electrons from NADPH to oxygen, leading to the production of superoxide anions and other ROS.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme.\n2. NOX5 requires four subunits to function.\n3. The p47phox subunit is the catalytic subunit that generates reactive oxygen species (ROS).\n4. The p67phox subunit is involved in electron transfer and enzyme complex stability.\n5. The Rac1 subunit is involved in the regulation of NOX5 enzyme activity and its localization to the plasma membrane.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme.",
      "NOX5 requires four subunits to function.",
      "The p47phox subunit is the catalytic subunit that generates reactive oxygen species (ROS).",
      "The p67phox subunit is involved in electron transfer and enzyme complex stability.",
      "The Rac1 subunit is involved in the regulation of NOX5 enzyme activity and its localization to the plasma membrane."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is not a heterotetrameric enzyme; it is a homologous enzyme that does not require p22phox or the cytosolic subunits (p47phox, p67phox, p40phox, Rac) for its activity.\n2. FALSE [correction]: NOX5 does not require four subunits to function; it functions independently without the need for additional subunits.\n3. FALSE [correction]: The p47phox subunit is not the catalytic subunit of NOX5; it is associated with other NOX family members like NOX2. NOX5 itself is the catalytic subunit that generates reactive oxygen species (ROS).\n4. FALSE [correction]: The p67phox subunit is not involved in NOX5; it is associated with other NOX family members like NOX2. NOX5 does not require p67phox for its activity.\n5. FALSE [correction]: The Rac1 subunit is not involved in the regulation of NOX5 enzyme activity; Rac1 is involved with other NOX family members like NOX1, NOX2, and NOX3. NOX5 is regulated differently and does not require Rac1 for its activity or localization.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are two proteins that are connected in the regulation of iron metabolism. Furin is a protease enzyme that is involved in the processing and activation of several proteins, including hepcidin. Hepcidin, on the other hand, is a hormone that regulates iron absorption and distribution in the body by binding to iron-responsive elements (IREs) in iron-handling proteins and inducing their degradation.\nStudies have shown that furin plays a role in the regulation of hepcidin expression and activity. Furin can process and activate hepcidin precursors, such as hepcidin-pro-peptide, to produce the active form of hepcidin. Additionally, furin has been shown to regulate the stability and localization of hepcidin in certain cell types, such as hepatocytes and macrophages.\nFurin's role in hepcidin regulation is important in the regulation of iron homeostasis in the body. Hepcidin is a key regulator of iron absorption and distribution, and furin's ability to process and activate hepcidin helps to ensure that hepcidin is present in the appropriate concentration to regulate iron metabolism. Dysregulation of furin and hepcidin has been implicated in a variety of diseases, including iron-related disorders and cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease enzyme involved in the processing and activation of several proteins, including hepcidin.\n2. Hepcidin is a hormone that regulates iron absorption and distribution in the body.\n3. Furin plays a role in the regulation of hepcidin expression and activity.\n4. Furin can process and activate hepcidin precursors to produce the active form of hepcidin.\n5. Dysregulation of furin and hepcidin has been implicated in various diseases, including iron-related disorders and cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease enzyme involved in the processing and activation of several proteins, including hepcidin.",
      "Hepcidin is a hormone that regulates iron absorption and distribution in the body.",
      "Furin plays a role in the regulation of hepcidin expression and activity.",
      "Furin can process and activate hepcidin precursors to produce the active form of hepcidin.",
      "Dysregulation of furin and hepcidin has been implicated in various diseases, including iron-related disorders and cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nFurin is indeed a protease enzyme that is involved in the activation of various proteins, including precursors of hormones. Hepcidin is a hormone that plays a key role in iron homeostasis. Furin can be involved in the regulation of hepcidin, and dysregulation of these proteins can be implicated in diseases related to iron metabolism and other conditions, including cancer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster, also known as the \"Gal\" gene cluster. This gene cluster contains approximately 20 genes that are involved in the breakdown and synthesis of glucose, and it is responsible for the majority of glucose metabolism in yeast. The Gal gene cluster includes genes involved in the transport of glucose into the cell, the conversion of glucose to glucose-6-phosphate, the conversion of glucose-6-phosphate to fructose-6-phosphate, and the conversion of fructose-6-phosphate to glyceraldehyde-3-phosphate and pyruvate. The Gal gene cluster is an important example of a metabolic gene cluster in yeast, and it has been the subject of extensive research in the field of molecular biology.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster.\n2. The glycolysis/gluconeogenesis gene cluster in yeast is also known as the \"Gal\" gene cluster.\n3. The \"Gal\" gene cluster contains approximately 20 genes.\n4. These genes are involved in the breakdown and synthesis of glucose in yeast.\n5. The Gal gene cluster is responsible for the majority of glucose metabolism in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster.",
      "The glycolysis/gluconeogenesis gene cluster in yeast is also known as the \"Gal\" gene cluster.",
      "The \"Gal\" gene cluster contains approximately 20 genes.",
      "These genes are involved in the breakdown and synthesis of glucose in yeast.",
      "The Gal gene cluster is responsible for the majority of glucose metabolism in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific data or a reference to the particular yeast species and its genome, it is difficult to confirm whether the glycolysis/gluconeogenesis gene cluster is the largest metabolic gene cluster in yeast.\n\n2. FALSE [correction]: The \"Gal\" gene cluster typically refers to the genes involved in galactose metabolism, not glycolysis/gluconeogenesis.\n\n3. UNKNOWN: The exact number of genes in the \"Gal\" gene cluster can vary depending on the organism and the definition of the cluster boundaries. Without specific information, it is not possible to confirm the number of genes.\n\n4. TRUE: Genes involved in glycolysis/gluconeogenesis are indeed responsible for the breakdown (glycolysis) and synthesis (gluconeogenesis) of glucose in yeast.\n\n5. FALSE [correction]: The Gal gene cluster is not responsible for the majority of glucose metabolism in yeast; it is involved in galactose metabolism. The majority of glucose metabolism would be attributed to the genes involved in glycolysis and gluconeogenesis, but not specifically the \"Gal\" gene cluster.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT (Long Non-Coding RNA in Myeloid Lineage Transcription) is a long non-coding RNA (lncRNA) that plays a crucial role in the regulation of myeloid cell differentiation and function. Here are some of the key functions of LIMT lncRNA:\n1. Regulation of Myeloid Cell Differentiation: LIMT lncRNA has been shown to regulate the differentiation of myeloid cells, including macrophages and granulocytes, by modulating the expression of genes involved in these processes.\n2. Modulation of Inflammation: LIMT lncRNA has been shown to inhibit the production of pro-inflammatory cytokines, such as TNF-alpha, by macrophages, which can help to reduce inflammation in response to infection or injury.\n3. Regulation of Cell Adhesion and Migration: LIMT lncRNA has been shown to regulate the expression of genes involved in cell adhesion and migration, which are important for the proper functioning of immune cells.\n4. Modulation of Cell Survival: LIMT lncRNA has been shown to regulate the expression of genes involved in cell survival, which is important for the proper functioning of immune cells.\n5. Regulation of Immune Cell Function: LIMT lncRNA has been shown to regulate the function of immune cells, including T cells and B cells, by modulating the expression of genes involved in these processes.\nOverall, the role of LIMT lncRNA is to regulate the function of immune cells, including myeloid cells, by modulating the expression of genes involved in differentiation, inflammation, cell adhesion, migration, and survival. Dysregulation of LIMT lncRNA has been implicated in a number of immune-related diseases, including autoimmune disorders and cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT lncRNA regulates the differentiation of myeloid cells, including macrophages and granulocytes.\n2. LIMT lncRNA inhibits the production of pro-inflammatory cytokines, such as TNF-alpha, by macrophages.\n3. LIMT lncRNA regulates the expression of genes involved in cell adhesion and migration.\n4. LIMT lncRNA regulates the expression of genes involved in cell survival.\n5. Dysregulation of LIMT lncRNA has been implicated in immune-related diseases, including autoimmune disorders and cancer.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT lncRNA regulates the differentiation of myeloid cells, including macrophages and granulocytes.",
      "LIMT lncRNA inhibits the production of pro-inflammatory cytokines, such as TNF-alpha, by macrophages.",
      "LIMT lncRNA regulates the expression of genes involved in cell adhesion and migration.",
      "LIMT lncRNA regulates the expression of genes involved in cell survival.",
      "Dysregulation of LIMT lncRNA has been implicated in immune-related diseases, including autoimmune disorders and cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the roles that long non-coding RNAs (lncRNAs) like LIMT can play in cellular processes. LncRNAs are known to be involved in the regulation of various biological functions, including differentiation, immune response, gene expression related to cell adhesion, migration, and survival. Dysregulation of lncRNAs has been implicated in a variety of diseases, including immune-related diseases. However, without specific references to scientific literature or studies that confirm these statements for LIMT lncRNA, the responses are based on general knowledge about lncRNAs and should be taken with caution.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "There are several R packages and bioconductor packages that can be used for performing SNP enrichment analysis. Some of the popular ones include:\n1. Plink: Plink is a popular R package for performing genome-wide association studies (GWAS) and SNP enrichment analysis. It can be used to analyze both genotype and phenotype data.\n2. GSEA (Gene Set Enrichment Analysis): GSEA is a bioconductor package that can be used to perform gene set enrichment analysis for a list of SNPs. It can also be used to identify pathways and gene sets that are enriched among the top-ranked SNPs.\n3. SnpTag: SnpTag is a bioconductor package that can be used to perform SNP tagging, which is the process of identifying the set of SNPs that are most closely associated with a particular trait or disease.\n4. Enrichr: Enrichr is a bioconductor package that can be used to perform gene set enrichment analysis for a list of SNPs. It can also be used to identify pathways and gene sets that are enriched among the top-ranked SNPs.\n5. GATK (Genome Analysis Toolkit): GATK is a popular software toolkit for genetic analysis, which includes tools for SNP enrichment analysis.\n6. HAPLOVIEW: HAPLOVIEW is a bioconductor package that can be used to perform haplotype-based association analysis and SNP enrichment analysis.\n7. MAGENTA: MAGENTA is a bioconductor package that can be used to perform gene-set enrichment analysis for a list of SNPs.\n8. R/Bioconductor package \"SNP_Enrich\": SNP_Enrich is a R package that can be used to perform SNP enrichment analysis for a list of SNPs.\n9. R/Bioconductor package \"Enrich\": Enrich is a R package that can be used to perform gene set enrichment analysis for a list of SNPs.\n10. R/Bioconductor package \"SNP_Enrichment\": SNP_Enrichment is a R package that",
    "llama-2-7b-chat-hf_fact_raw": "1. Plink is an R package used for performing genome-wide association studies and SNP enrichment analysis.\n2. GSEA is a bioconductor package used for gene set enrichment analysis for a list of SNPs.\n3. SnpTag is a bioconductor package used for SNP tagging.\n4. Enrichr is a bioconductor package used for gene set enrichment analysis for a list of SNPs.\n5. GATK includes tools for SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact": [
      "Plink is an R package used for performing genome-wide association studies and SNP enrichment analysis.",
      "GSEA is a bioconductor package used for gene set enrichment analysis for a list of SNPs.",
      "SnpTag is a bioconductor package used for SNP tagging.",
      "Enrichr is a bioconductor package used for gene set enrichment analysis for a list of SNPs.",
      "GATK includes tools for SNP enrichment analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GSEA (Gene Set Enrichment Analysis) is not a Bioconductor package but a computational method that determines whether a set of genes shows statistically significant, concordant differences between two biological states. It is not specifically used for a list of SNPs but rather for gene sets.\n3. UNKNOWN\n4. FALSE [correction]: Enrichr is a web-based tool, not a Bioconductor package, used for gene set enrichment analysis. It is designed to be a comprehensive resource for curated gene sets and to provide various interactive functionalities to investigate these sets.\n5. FALSE [correction]: GATK (Genome Analysis Toolkit) includes tools primarily for variant discovery and genotyping to find SNPs and indels in exome or whole-genome sequencing data. It is not specifically used for SNP enrichment analysis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are the intermediate progenitors of ependymal cells in the developing brain. The key players involved in the specification of radial glial cells to ependymal cells include:\n1. Notch signaling pathway: Notch is a transmembrane receptor that plays a crucial role in the regulation of cell fate decisions, including the specification of radial glial cells to ependymal cells. The Notch pathway is activated in radial glial cells and promotes their conversion to ependymal cells.\n2. Wnt signaling pathway: Wnt signaling is also involved in the regulation of radial glial cell fate decisions. Wnt/β-catenin signaling promotes the maintenance of radial glial cells and inhibits their conversion to ependymal cells.\n3. BMP signaling pathway: BMP (Bone Morphogenetic Protein) signaling is also important in regulating the fate of radial glial cells. BMP signaling inhibits the conversion of radial glial cells to ependymal cells and promotes their maintenance as radial glial cells.\n4. Shh signaling pathway: Shh (Sonic Hedgehog) signaling is involved in the regulation of radial glial cell fate decisions. Shh signaling promotes the conversion of radial glial cells to ependymal cells.\n5. FGF (Fibroblast Growth Factor) signaling pathway: FGF signaling is involved in the regulation of radial glial cell fate decisions. FGF signaling promotes the conversion of radial glial cells to ependymal cells.\n6. EGFR (Epidermal Growth Factor Receptor) signaling pathway: EGFR signaling is involved in the regulation of radial glial cell fate decisions. EGFR signaling promotes the conversion of radial glial cells to ependymal cells.\n7. PI3K/Akt signaling pathway: PI3K/Akt signaling pathway is involved in the regulation of radial glial cell fate decisions. PI3K/Akt signaling promotes the conversion of radial glial cells to ependymal cells.\n8. MicroRNAs (miRNAs):",
    "llama-2-7b-chat-hf_fact_raw": "1. Radial glial cells are intermediate progenitors of ependymal cells in the developing brain.\n2. The Notch signaling pathway plays a role in the specification of radial glial cells to ependymal cells.\n3. Wnt/β-catenin signaling is involved in maintaining radial glial cells and inhibiting their conversion to ependymal cells.\n4. BMP (Bone Morphogenetic Protein) signaling inhibits the conversion of radial glial cells to ependymal cells.\n5. Shh (Sonic Hedgehog) signaling promotes the conversion of radial glial cells to ependymal cells.",
    "llama-2-7b-chat-hf_fact": [
      "Radial glial cells are intermediate progenitors of ependymal cells in the developing brain.",
      "The Notch signaling pathway plays a role in the specification of radial glial cells to ependymal cells.",
      "Wnt/β-catenin signaling is involved in maintaining radial glial cells and inhibiting their conversion to ependymal cells.",
      "BMP (Bone Morphogenetic Protein) signaling inhibits the conversion of radial glial cells to ependymal cells.",
      "Shh (Sonic Hedgehog) signaling promotes the conversion of radial glial cells to ependymal cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Radial glial cells are indeed progenitor cells that give rise to various cell types in the developing brain, including ependymal cells.\n2. TRUE: The Notch signaling pathway is known to play a crucial role in the specification and differentiation of neural cells, including the differentiation of radial glial cells.\n3. TRUE: Wnt/β-catenin signaling is implicated in the maintenance of radial glial cell identity and can inhibit their differentiation into other cell types, such as ependymal cells.\n4. UNKNOWN: While BMP signaling is involved in neural development and differentiation, the specific effect of BMP signaling on the conversion of radial glial cells to ependymal cells can vary and may depend on the context and timing. Without specific information from the passage, the effect of BMP signaling on this conversion is not clear.\n5. UNKNOWN: Shh (Sonic Hedgehog) signaling is a key regulator in the development of the central nervous system, including the patterning of neural progenitors. However, the specific role of Shh signaling in the conversion of radial glial cells to ependymal cells is not stated, and without additional context, it is difficult to determine the accuracy of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of glioma, which is a type of brain tumor, that are characterized by the absence of specific tumor markers, such as estrogen receptors (ER), progesterone receptors (PR), and HER2/neu. These tumors are called \"triple negative\" because they do not express any of these markers, which are typically used to diagnose and treat other types of breast cancer.\nTriple negative gliomas are aggressive and malignant, and they tend to have a poor prognosis compared to other types of gliomas. They are more common in younger adults and in people with a family history of glioma.\nSome common characteristics of triple negative gliomas include:\n1. Lack of expression of ER, PR, and HER2/neu: Triple negative gliomas do not express these markers, which are used to diagnose and treat other types of cancer.\n2. High proliferation rate: Triple negative gliomas tend to have a high rate of cell division, which can contribute to their aggressive nature.\n3. Poor differentiation: Triple negative gliomas do not have well-defined cell structures, which can make them difficult to diagnose and treat.\n4. Frequent mutations in genes such as P53 and TP53: Triple negative gliomas often have mutations in genes that regulate cell growth and division, such as the P53 and TP53 genes.\n5. Associated with poor prognosis: Triple negative gliomas tend to have a poor prognosis compared to other types of gliomas, possibly due to their aggressive nature and lack of targeted therapies.\n6. More common in younger adults: Triple negative gliomas are more common in younger adults, possibly due to the higher proliferation rate of stem cells in younger individuals.\n7. More common in people with a family history of glioma: Triple negative gliomas are more common in people with a family history of glioma, possibly due to genetic mutations that increase the risk of developing these tumors.\n8. Associated with radiation sensitivity: Triple negative gliomas are more sensitive to radiation therapy than other types of gliomas, which can be used to treat these tumors.\n9. Associated with",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas are characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2/neu.\n2. Triple negative gliomas are aggressive and malignant with a poor prognosis compared to other types of gliomas.\n3. Triple negative gliomas are more common in younger adults and in people with a family history of glioma.\n4. These tumors often have mutations in genes such as P53 and TP53.\n5. Triple negative gliomas are more sensitive to radiation therapy than other types of gliomas.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas are characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2/neu.",
      "Triple negative gliomas are aggressive and malignant with a poor prognosis compared to other types of gliomas.",
      "Triple negative gliomas are more common in younger adults and in people with a family history of glioma.",
      "These tumors often have mutations in genes such as P53 and TP53.",
      "Triple negative gliomas are more sensitive to radiation therapy than other types of gliomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Triple negative gliomas are characterized by the absence of IDH1/2 mutations, 1p/19q co-deletion, and ATRX loss. The term \"triple negative\" is more commonly associated with breast cancer, which is characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2/neu.\n2. TRUE: Triple negative gliomas are generally considered aggressive and malignant with a poor prognosis compared to other types of gliomas.\n3. UNKNOWN: The prevalence of triple negative gliomas in younger adults and in people with a family history of glioma is not clearly stated, and such information may vary. More specific epidemiological data is needed to confirm this statement.\n4. TRUE: Gliomas, including triple negative gliomas, often have mutations in genes such as TP53 and ATRX, which are associated with tumor progression and poor prognosis.\n5. FALSE [correction]: The sensitivity of triple negative gliomas to radiation therapy can vary, and they are not necessarily more sensitive to radiation therapy than other types of gliomas. Treatment sensitivity is influenced by various factors, including molecular and genetic characteristics of the tumor.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 (Topoisomerase II-associated protein AZ1) is a protein that plays a crucial role in the regulation of DNA replication and repair. It is a component of the topoisomerase II complex, which is responsible for relieving DNA tension during replication and repair. TOPAZ1 is a histone chaperone that helps to recruit and stabilize topoisomerase II on chromatin, allowing it to carry out its enzymatic functions. It also plays a role in the regulation of transcriptional elongation and the maintenance of genome stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 stands for Topoisomerase II-associated protein AZ1.\n2. TOPAZ1 is involved in the regulation of DNA replication and repair.\n3. It is a component of the topoisomerase II complex.\n4. TOPAZ1 functions as a histone chaperone.\n5. TOPAZ1 helps in the regulation of transcriptional elongation and maintenance of genome stability.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 stands for Topoisomerase II-associated protein AZ1.",
      "TOPAZ1 is involved in the regulation of DNA replication and repair.",
      "It is a component of the topoisomerase II complex.",
      "TOPAZ1 functions as a histone chaperone.",
      "TOPAZ1 helps in the regulation of transcriptional elongation and maintenance of genome stability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TOPAZ1 stands for Testis and Ovary Specific PAZ Domain Containing 1.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "The expression of GATA-1 isoforms is controlled by multiple genes and factors, but the primary regulator of GATA-1 isoform expression is the transcription factor GATA-1 itself. GATA-1 is a zinc finger transcription factor that recognizes and binds to specific DNA sequences in the promoter and enhancer regions of GATA-1 gene, and regulates its own expression through a negative feedback loop.\nIn addition to GATA-1, other transcription factors such as NF-κB, AP-1, and c-Myc can also regulate GATA-1 isoform expression by binding to specific DNA sequences and modulating the activity of GATA-1. These transcription factors can either activate or repress GATA-1 expression by modifying the chromatin structure and recruiting other transcription factors or coactivators.\nFurthermore, the expression of GATA-1 isoforms can also be regulated by post-transcriptional modifications such as phosphorylation and ubiquitination, which can affect the stability and localization of GATA-1 proteins. Overall, the regulation of GATA-1 isoform expression is a complex process that involves multiple layers of regulation, including transcriptional, post-transcriptional, and epigenetic mechanisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The primary regulator of GATA-1 isoform expression is the transcription factor GATA-1 itself.\n2. GATA-1 is a zinc finger transcription factor that binds to specific DNA sequences in the promoter and enhancer regions of the GATA-1 gene.\n3. GATA-1 regulates its own expression through a negative feedback loop.\n4. Other transcription factors such as NF-κB, AP-1, and c-Myc can regulate GATA-1 isoform expression.\n5. Post-transcriptional modifications like phosphorylation and ubiquitination can also regulate the expression of GATA-1 isoforms.",
    "llama-2-7b-chat-hf_fact": [
      "The primary regulator of GATA-1 isoform expression is the transcription factor GATA-1 itself.",
      "GATA-1 is a zinc finger transcription factor that binds to specific DNA sequences in the promoter and enhancer regions of the GATA-1 gene.",
      "GATA-1 regulates its own expression through a negative feedback loop.",
      "Other transcription factors such as NF-κB, AP-1, and c-Myc can regulate GATA-1 isoform expression.",
      "Post-transcriptional modifications like phosphorylation and ubiquitination can also regulate the expression of GATA-1 isoforms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE - While the primary statement is about GATA-1 regulating itself, it is known in biology that multiple transcription factors can interact and regulate the expression of genes, including those encoding other transcription factors. Therefore, it is plausible that NF-κB, AP-1, and c-Myc could have roles in regulating GATA-1 isoform expression, although the specific interactions would need to be confirmed with scientific literature for absolute certainty.\n5. TRUE - Post-transcriptional modifications such as phosphorylation and ubiquitination are well-known mechanisms that can regulate the stability, localization, and function of proteins, including transcription factors like GATA-1.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a sequencing-based method used to identify and characterize the RNA molecules present in a given sample. The term \"MIRA\" stands for \"mRNA-derived intronic RNA assay.\"\nIntrons are non-coding regions of DNA that are located within genes and are removed during the splicing process, resulting in the production of mature mRNA. MIRA-seq is based on the principle that the splicing process can be used to identify the RNA molecules present in a sample, including both mRNA and non-coding RNA (ncRNA) molecules.\nThe MIRA-seq protocol involves the following steps:\n1. Sample preparation: The sample is first prepared by isolating the RNA molecules from the cells or tissues of interest.\n2. Library preparation: The RNA molecules are then converted into a sequencing library using a series of enzymatic reactions that result in the generation of complementary DNA (cDNA).\n3. Sequencing: The cDNA library is then sequenced using Next-Generation Sequencing (NGS) technologies, such as Illumina or PacBio.\n4. Data analysis: The resulting sequencing data is then analyzed using bioinformatic tools to identify and quantify the different RNA molecules present in the sample.\nMIRA-seq has several advantages over other RNA sequencing methods, including:\n1. Sensitivity: MIRA-seq is highly sensitive and can detect low-abundance RNA molecules that may be missed by other sequencing methods.\n2. Specificity: MIRA-seq can specifically identify RNA molecules based on their splicing patterns, which can help to distinguish between different RNA molecules with similar sequences.\n3. Ease of use: The MIRA-seq protocol is relatively straightforward and does not require extensive computational resources or specialized equipment.\n4. Cost-effective: MIRA-seq is a cost-effective method compared to other RNA sequencing methods, such as RNA-seq, which require the sequencing of the entire transcriptome.\nIn summary, MIRA-seq is a powerful tool for identifying and characterizing the RNA molecules present in a given sample, and it has",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq stands for \"mRNA-derived intronic RNA assay.\"\n2. MIRA-seq is used to identify and characterize RNA molecules, including mRNA and non-coding RNA (ncRNA), in a sample.\n3. The MIRA-seq protocol includes sample preparation, library preparation, sequencing using Next-Generation Sequencing technologies, and data analysis.\n4. MIRA-seq is highly sensitive and can detect low-abundance RNA molecules.\n5. MIRA-seq is considered cost-effective compared to other RNA sequencing methods like RNA-seq.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq stands for \"mRNA-derived intronic RNA assay.\"",
      "MIRA-seq is used to identify and characterize RNA molecules, including mRNA and non-coding RNA (ncRNA), in a sample.",
      "The MIRA-seq protocol includes sample preparation, library preparation, sequencing using Next-Generation Sequencing technologies, and data analysis.",
      "MIRA-seq is highly sensitive and can detect low-abundance RNA molecules.",
      "MIRA-seq is considered cost-effective compared to other RNA sequencing methods like RNA-seq."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq stands for \"methylation-interacting RNA sequencing.\"\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST (rilonacept) is a prescription medication used to treat a rare genetic disorder called cryopyrin-associated periodic syndrome (CAPS) in adults and children aged 12 years and older. CAPS is a group of inherited disorders characterized by recurring episodes of fever, pain, and swelling in the joints and other parts of the body. ARCALYST works by blocking the activity of a protein called interleukin-1 (IL-1) which is involved in the inflammation that occurs in CAPS. By blocking the activity of IL-1, ARCALYST helps to reduce the frequency and severity of CAPS attacks.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST (rilonacept) is a prescription medication.\n2. ARCALYST is used to treat cryopyrin-associated periodic syndrome (CAPS).\n3. ARCALYST is indicated for use in adults and children aged 12 years and older.\n4. CAPS is characterized by recurring episodes of fever, pain, and swelling in the joints and other parts of the body.\n5. ARCALYST works by blocking the activity of interleukin-1 (IL-1), which is involved in CAPS-related inflammation.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST (rilonacept) is a prescription medication.",
      "ARCALYST is used to treat cryopyrin-associated periodic syndrome (CAPS).",
      "ARCALYST is indicated for use in adults and children aged 12 years and older.",
      "CAPS is characterized by recurring episodes of fever, pain, and swelling in the joints and other parts of the body.",
      "ARCALYST works by blocking the activity of interleukin-1 (IL-1), which is involved in CAPS-related inflammation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: ARCALYST is indicated for use in adults and children aged 12 and older for the treatment of Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are two subtypes of CAPS. However, the exact age indication may vary based on regulatory approval and changes in prescribing information, so it's important to consult the most current medical guidelines or prescribing information.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Robertsonian translocations involve the exchange of a portion of one acrocentric chromosome (chromosomes 1, 9, 10, 13, 15, 16, and 21) for a corresponding portion of another acrocentric chromosome. Here are the human acrocentric chromosomes that are involved in Robertsonian translocations:\n1. Chromosome 13: This is the most common chromosome involved in Robertsonian translocations, accounting for approximately 50% of all translocations.\n2. Chromosome 15: Chromosome 15 is the second most common chromosome involved in Robertsonian translocations, accounting for approximately 25% of all translocations.\n3. Chromosome 16: Chromosome 16 is involved in approximately 10% of Robertsonian translocations.\n4. Chromosome 21: Chromosome 21 is the smallest acrocentric chromosome and is involved in approximately 5% of Robertsonian translocations.\n5. Chromosome 9: Chromosome 9 is involved in approximately 5% of Robertsonian translocations.\n6. Chromosome 10: Chromosome 10 is involved in approximately 5% of Robertsonian translocations.\nIt's worth noting that the frequency of Robertsonian translocations involving each acrocentric chromosome can vary depending on the population being studied and the specific type of translocation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromosomes 1, 9, 10, 13, 15, 16, and 21 are human acrocentric chromosomes.\n2. Chromosome 13 is involved in approximately 50% of all Robertsonian translocations.\n3. Chromosome 15 is involved in approximately 25% of all Robertsonian translocations.\n4. Chromosome 16 is involved in approximately 10% of Robertsonian translocations.\n5. Chromosome 21 is involved in approximately 5% of Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "Chromosomes 1, 9, 10, 13, 15, 16, and 21 are human acrocentric chromosomes.",
      "Chromosome 13 is involved in approximately 50% of all Robertsonian translocations.",
      "Chromosome 15 is involved in approximately 25% of all Robertsonian translocations.",
      "Chromosome 16 is involved in approximately 10% of Robertsonian translocations.",
      "Chromosome 21 is involved in approximately 5% of Robertsonian translocations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Chromosome 15 is involved in approximately 10% of all Robertsonian translocations.\n4. FALSE [correction]: Chromosome 16 is involved in approximately 25% of Robertsonian translocations.\n5. FALSE [correction]: Chromosome 21 is involved in a significant percentage of Robertsonian translocations, particularly in Down syndrome cases, but not as low as 5%. The exact percentage can vary, but it is known to be one of the more commonly involved chromosomes in Robertsonian translocations.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, depending on the specific task and the type of data available. Here are a few options:\n1. `brainTumor`: This package provides a set of tools for analyzing brain tumor data, including image segmentation, feature extraction, and survival analysis. It can be used to identify and classify pediatric brain tumors based on MRI scans.\n2. `pediatricTumor`: This package is specifically designed for the analysis of pediatric tumors, including brain tumors. It provides functions for data preprocessing, feature extraction, and survival analysis, as well as tools for visualizing and interpreting the results.\n3. `RNAseqTumor`: This package is focused on the analysis of RNA sequencing data for tumor identification and classification. It can be used to identify differentially expressed genes and pathways in pediatric brain tumors compared to normal brain tissue.\n4. `survivalTumor`: This package provides functions for survival analysis of tumor data, including Kaplan-Meier estimation and Cox proportional hazards modeling. It can be used to identify prognostic markers and predict patient outcomes in pediatric brain tumors.\n5. `brainTumorMix`: This package is a collection of functions for analyzing brain tumor data, including image segmentation, feature extraction, and survival analysis. It can be used to identify and classify pediatric brain tumors based on MRI scans, and to predict patient outcomes.\nIt's important to note that these packages are just a few examples of the many R packages available for analyzing pediatric brain tumors, and the specific package used will depend on the research question and the type of data available.",
    "llama-2-7b-chat-hf_fact_raw": "1. The `brainTumor` R package provides tools for analyzing brain tumor data, including image segmentation, feature extraction, and survival analysis.\n2. The `pediatricTumor` R package is designed for the analysis of pediatric tumors, including brain tumors, and includes functions for data preprocessing and survival analysis.\n3. The `RNAseqTumor` R package is used for the analysis of RNA sequencing data to identify and classify pediatric brain tumors.\n4. The `survivalTumor` R package offers functions for survival analysis of tumor data, such as Kaplan-Meier estimation and Cox proportional hazards modeling.\n5. The `brainTumorMix` R package includes functions for analyzing brain tumor data, predicting patient outcomes, and classifying pediatric brain tumors based on MRI scans.",
    "llama-2-7b-chat-hf_fact": [
      "The `brainTumor` R package provides tools for analyzing brain tumor data, including image segmentation, feature extraction, and survival analysis.",
      "The `pediatricTumor` R package is designed for the analysis of pediatric tumors, including brain tumors, and includes functions for data preprocessing and survival analysis.",
      "The `RNAseqTumor` R package is used for the analysis of RNA sequencing data to identify and classify pediatric brain tumors.",
      "The `survivalTumor` R package offers functions for survival analysis of tumor data, such as Kaplan-Meier estimation and Cox proportional hazards modeling.",
      "The `brainTumorMix` R package includes functions for analyzing brain tumor data, predicting patient outcomes, and classifying pediatric brain tumors based on MRI scans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific knowledge of the `brainTumor` R package and its features, it is not possible to confirm the accuracy of this statement.\n2. UNKNOWN: The existence and features of the `pediatricTumor` R package cannot be confirmed without additional information.\n3. UNKNOWN: The statement about the `RNAseqTumor` R package and its use for RNA sequencing data analysis in pediatric brain tumors cannot be verified without further context.\n4. UNKNOWN: The `survivalTumor` R package and its functions for survival analysis are not verifiable without more information.\n5. UNKNOWN: The details regarding the `brainTumorMix` R package and its capabilities cannot be confirmed without additional data or context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Yes, NEMO (Nuclear Envelope-Associated Protein, also known as IKKγ) is a zinc finger protein. NEMO is a key component of the IκB kinase (IKK) complex, which plays a central role in the regulation of inflammation and immune responses. NEMO contains a number of zinc finger motifs, which are responsible for its DNA-binding activity and play a role in its function as a transcriptional regulator.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO is also known as IKKγ.\n2. NEMO is a zinc finger protein.\n3. NEMO is a key component of the IκB kinase (IKK) complex.\n4. The IKK complex is involved in the regulation of inflammation and immune responses.\n5. NEMO contains zinc finger motifs that contribute to its DNA-binding activity.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO is also known as IKKγ.",
      "NEMO is a zinc finger protein.",
      "NEMO is a key component of the IκB kinase (IKK) complex.",
      "The IKK complex is involved in the regulation of inflammation and immune responses.",
      "NEMO contains zinc finger motifs that contribute to its DNA-binding activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: NEMO is not characterized as a zinc finger protein; it is an essential regulatory component of the IκB kinase (IKK) complex.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: NEMO does not contain zinc finger motifs that contribute to DNA-binding activity; instead, it is involved in the regulation of the NF-κB pathway.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (Transcription Factor IIS) can affect nucleosome positioning. TFIIS is a transcriptional elongation factor that plays a crucial role in the initiation of transcription in eukaryotic cells. It has been shown to interact with nucleosomes and modulate their positioning on the DNA, thereby influencing the accessibility of the DNA to the transcriptional machinery.\nStudies have shown that TFIIS can displace nucleosomes from the promoter region of actively transcribed genes, allowing for the binding of other transcription factors and the initiation of transcription. TFIIS can also interact with histone-modifying enzymes, such as histone acetyltransferases, to alter the chromatin structure and create a more accessible chromatin environment for transcription.\nIn addition, TFIIS has been shown to regulate the expression of genes involved in the maintenance of chromatin structure and gene expression, such as genes involved in histone modification and chromatin remodeling. By modulating the positioning of nucleosomes and the expression of these genes, TFIIS can influence the overall chromatin landscape and play a role in the regulation of gene expression.\nIn summary, TFIIS can affect nucleosome positioning by interacting with nucleosomes and modulating their positioning on the DNA, thereby influencing the accessibility of the DNA to the transcriptional machinery and the expression of genes involved in chromatin structure and gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS (Transcription Factor IIS) can affect nucleosome positioning.\n2. TFIIS plays a role in the initiation of transcription in eukaryotic cells.\n3. TFIIS has been shown to displace nucleosomes from the promoter region of actively transcribed genes.\n4. TFIIS can interact with histone-modifying enzymes, such as histone acetyltransferases.\n5. TFIIS regulates the expression of genes involved in histone modification and chromatin remodeling.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS (Transcription Factor IIS) can affect nucleosome positioning.",
      "TFIIS plays a role in the initiation of transcription in eukaryotic cells.",
      "TFIIS has been shown to displace nucleosomes from the promoter region of actively transcribed genes.",
      "TFIIS can interact with histone-modifying enzymes, such as histone acetyltransferases.",
      "TFIIS regulates the expression of genes involved in histone modification and chromatin remodeling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: TFIIS can affect nucleosome positioning as it is involved in the process of transcription elongation, which can lead to changes in nucleosome structure and positioning.\n2. TRUE: TFIIS plays a role in the elongation phase of transcription in eukaryotic cells by reactivating RNA polymerase II when it becomes stalled at a DNA lesion or a tightly bound nucleosome.\n3. UNKNOWN: While TFIIS is known to be involved in transcription elongation, the specific statement about displacing nucleosomes from the promoter region of actively transcribed genes is not universally established and would require specific experimental evidence to confirm.\n4. UNKNOWN: The interaction of TFIIS with histone-modifying enzymes like histone acetyltransferases is not a widely established fact and would require specific references to confirm its validity.\n5. UNKNOWN: The regulation of gene expression by TFIIS, specifically genes involved in histone modification and chromatin remodeling, is a specific claim that would require targeted evidence to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Origins of replication in yeast (Saccharomyces cerevisiae) typically fire late in the cell cycle, specifically during the S phase of the cell cycle. This means that the replication of the DNA at these origins of replication occurs after the G1/S checkpoint has been passed and the cell has entered the S phase.\nThe late firing of origins of replication near yeast centromeres is thought to be due to the presence of specific chromatin structures and epigenetic modifications that inhibit the activity of the origins of replication until the cell has progressed to a certain stage of the cell cycle. These structures and modifications include histone modifications such as histone 3 lysine 4 trimethylation (H3K4me3) and histone 3 lysine 27 trimethylation (H3K27me3), as well as the presence of non-histone chromatin proteins such as HP1 and SUV39H1. These factors create a \"barrier\" to transcriptional initiation at the origins of replication, which prevents them from firing prematurely.\nIn addition, the distance between the origins of replication and the centromere is also thought to play a role in their late firing. The centromere is a specialized region of DNA that is involved in the separation of chromosomes during mitosis, and it is located far enough away from the origins of replication that it can only be reached by the replication machinery after the cell has progressed to the S phase.\nOverall, the late firing of origins of replication near yeast centromeres is an important mechanism for ensuring that DNA replication occurs in a coordinated and regulated manner during the cell cycle.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication in yeast (Saccharomyces cerevisiae) typically fire late in the cell cycle during the S phase.\n2. The replication at these origins occurs after the G1/S checkpoint has been passed.\n3. Specific chromatin structures and epigenetic modifications, such as histone 3 lysine 4 trimethylation (H3K4me3) and histone 3 lysine 27 trimethylation (H3K27me3), inhibit the activity of the origins of replication until a certain stage of the cell cycle.\n4. Non-histone chromatin proteins like HP1 and SUV39H1 contribute to the late firing of origins of replication near yeast centromeres.\n5. The centromere is a specialized region of DNA involved in the separation of chromosomes during mitosis.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication in yeast (Saccharomyces cerevisiae) typically fire late in the cell cycle during the S phase.",
      "The replication at these origins occurs after the G1/S checkpoint has been passed.",
      "Specific chromatin structures and epigenetic modifications, such as histone 3 lysine 4 trimethylation (H3K4me3) and histone 3 lysine 27 trimethylation (H3K27me3), inhibit the activity of the origins of replication until a certain stage of the cell cycle.",
      "Non-histone chromatin proteins like HP1 and SUV39H1 contribute to the late firing of origins of replication near yeast centromeres.",
      "The centromere is a specialized region of DNA involved in the separation of chromosomes during mitosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Origins of replication in yeast (Saccharomyces cerevisiae) typically fire during the S phase, which is consistent with the timing of DNA replication in the cell cycle.\n2. TRUE: The replication at these origins does indeed occur after the G1/S checkpoint has been passed, which is a control mechanism that ensures cells are ready to enter the S phase and replicate DNA.\n3. UNKNOWN: While specific chromatin structures and epigenetic modifications can influence the activity of origins of replication, the statement is too specific regarding the effects of H3K4me3 and H3K27me3 on yeast origins of replication without additional context. These modifications are known to have roles in gene expression and chromatin organization, but their direct effect on the timing of origin firing in yeast would require specific evidence.\n4. FALSE [correction]: HP1 and SUV39H1 are chromatin proteins associated with heterochromatin formation and gene silencing in higher eukaryotes, not typically in yeast (Saccharomyces cerevisiae). Yeast does not have direct homologs of these proteins, and their role in the late firing of origins of replication near centromeres is not established in yeast.\n5. TRUE: The centromere is indeed a specialized region of DNA that is crucial for the proper segregation of chromosomes during cell division, including mitosis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences, also known as GA-rich sequences, are specific DNA sequences found in the genomes of mammals that are enriched in guanine-adenine (GA) pairs. These sequences have several distinct properties:\n1. High GA content: Mammalian GA-sequences are characterized by a high content of GA pairs, typically ranging from 30% to 60% of the sequence.\n2. Short sequence length: GA-sequences are generally shorter than other DNA sequences, with lengths ranging from 10 to 100 nucleotides.\n3. Average GA frequency: The frequency of GA pairs in these sequences is higher than in other regions of the genome, but lower than in GC-rich sequences.\n4. Average GA pair distance: The distance between GA pairs in GA-rich sequences is shorter than in other regions of the genome.\n5. Low AT content: Mammalian GA-sequences have a low content of adenine (AT) pairs, typically less than 20%.\n6. High GC content: These sequences have a high content of GC pairs, typically ranging from 30% to 60%.\n7. Enrichment in gene-rich regions: GA-rich sequences are often found in regions of the genome that are rich in genes, such as gene bodies and introns.\n8. Enrichment in regulatory regions: GA-rich sequences are also found in regions of the genome that are involved in regulating gene expression, such as promoters and enhancers.\n9. Role in chromatin structure: GA-rich sequences can contribute to the formation of higher-order chromatin structures, such as chromatin loops and topologically associating domains (TADs).\n10. Evolutionary conservation: GA-rich sequences are highly conserved across mammalian species, indicating their functional importance.\nThese properties of mammalian GA-sequences suggest that they play a role in regulating gene expression, chromatin structure, and other cellular processes, although the exact mechanisms of their function are still not fully understood.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences are characterized by a high content of guanine-adenine (GA) pairs, typically ranging from 30% to 60% of the sequence.\n2. GA-sequences in mammals are generally shorter than other DNA sequences, with lengths ranging from 10 to 100 nucleotides.\n3. The frequency of GA pairs in mammalian GA-rich sequences is higher than in other regions of the genome, but lower than in GC-rich sequences.\n4. Mammalian GA-sequences are often found in gene-rich regions of the genome, such as gene bodies and introns.\n5. GA-rich sequences in mammals are highly conserved across mammalian species, indicating their functional importance.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences are characterized by a high content of guanine-adenine (GA) pairs, typically ranging from 30% to 60% of the sequence.",
      "GA-sequences in mammals are generally shorter than other DNA sequences, with lengths ranging from 10 to 100 nucleotides.",
      "The frequency of GA pairs in mammalian GA-rich sequences is higher than in other regions of the genome, but lower than in GC-rich sequences.",
      "Mammalian GA-sequences are often found in gene-rich regions of the genome, such as gene bodies and introns.",
      "GA-rich sequences in mammals are highly conserved across mammalian species, indicating their functional importance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about the content of guanine-adenine (GA) pairs in mammalian GA-sequences being typically from 30% to 60% of the sequence is not a standard characterization and would require specific genomic data to verify.\n2. FALSE [correction]: GA-sequences in mammals can vary greatly in length and are not necessarily shorter than other DNA sequences. They can be short, but they can also form longer repetitive elements or be part of larger genomic regions.\n3. UNKNOWN: The comparison of the frequency of GA pairs in GA-rich sequences to other regions of the genome and GC-rich sequences would require specific data for verification.\n4. TRUE: Mammalian GA-sequences are often found in gene-rich regions of the genome, including gene bodies and introns, where they may play roles in gene regulation.\n5. UNKNOWN: The conservation of GA-rich sequences across mammalian species can indicate functional importance, but the degree of conservation would need to be evaluated with comparative genomic data to confirm this statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "The mouse genome contains 12 Groucho-related genes (GRG), also known as Groucho-like genes (Glrs). These genes are:\n1. Grm1 (Groucho-related gene 1)\n2. Grm2 (Groucho-related gene 2)\n3. Grm3 (Groucho-related gene 3)\n4. Grm4 (Groucho-related gene 4)\n5. Grm5 (Groucho-related gene 5)\n6. Grm6 (Groucho-related gene 6)\n7. Grm7 (Groucho-related gene 7)\n8. Grm8 (Groucho-related gene 8)\n9. Grm9 (Groucho-related gene 9)\n10. Grm10 (Groucho-related gene 10)\n11. Grm11 (Groucho-related gene 11)\n12. Grm12 (Groucho-related gene 12)\nThese genes are involved in various cellular processes, including transcriptional regulation, signal transduction, and cell adhesion, and are named based on their structural similarity to the Groucho protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse genome contains 12 Groucho-related genes (GRG).\n2. Groucho-related genes are also known as Groucho-like genes (Glrs).\n3. The genes are named Grm1 through Grm12, representing Groucho-related gene 1 to Groucho-related gene 12.\n4. Groucho-related genes are involved in transcriptional regulation.\n5. Groucho-related genes are involved in signal transduction and cell adhesion.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse genome contains 12 Groucho-related genes (GRG).",
      "Groucho-related genes are also known as Groucho-like genes (Glrs).",
      "The genes are named Grm1 through Grm12, representing Groucho-related gene 1 to Groucho-related gene 12.",
      "Groucho-related genes are involved in transcriptional regulation.",
      "Groucho-related genes are involved in signal transduction and cell adhesion."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: The genes named Grm1 through Grm12 represent the glutamate receptor, metabotropic 1 to 12, not Groucho-related genes.\n4. TRUE\n5. FALSE [correction]: Groucho-related genes are primarily known for their role in transcriptional repression, not signal transduction and cell adhesion. However, it should be noted that the glutamate receptors (Grm1-Grm12) are indeed involved in signal transduction.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II (RNAPII) is the main enzyme responsible for transcribing DNA into RNA in eukaryotic cells. RNAPII is a complex of several subunits, including the core subunits RNAPII-A and RNAPII-B, as well as additional subunits that are recruited during transcription.\nOf these subunits, the RNAPII-A subunit (also known as RPB1) carries the RNA cleavage activity. RNAPII-A contains a conserved RNA-binding domain called the cleavage domain, which is responsible for recognizing and cleaving RNA substrates during transcription elongation.\nIn brief, RNAPII-A acts as a \"molecular scissors\" during transcription, cutting the RNA transcript at specific sites to generate mature RNA molecules with the correct length and structure. This process is essential for proper RNA processing and maturation, and any defects in RNA cleavage can lead to a range of RNA processing disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II (RNAPII) is responsible for transcribing DNA into RNA in eukaryotic cells.\n2. RNAPII is composed of several subunits, including core subunits RNAPII-A and RNAPII-B.\n3. The RNAPII-A subunit, also known as RPB1, carries the RNA cleavage activity.\n4. RNAPII-A contains a conserved RNA-binding domain known as the cleavage domain.\n5. The cleavage domain in RNAPII-A is responsible for recognizing and cleaving RNA substrates during transcription elongation.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II (RNAPII) is responsible for transcribing DNA into RNA in eukaryotic cells.",
      "RNAPII is composed of several subunits, including core subunits RNAPII-A and RNAPII-B.",
      "The RNAPII-A subunit, also known as RPB1, carries the RNA cleavage activity.",
      "RNAPII-A contains a conserved RNA-binding domain known as the cleavage domain.",
      "The cleavage domain in RNAPII-A is responsible for recognizing and cleaving RNA substrates during transcription elongation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The RNAPII-A subunit, also known as RPB1, does not carry the RNA cleavage activity. The RNA cleavage activity is associated with other factors involved in RNA processing, such as the cleavage and polyadenylation specificity factor (CPSF) in eukaryotes.\n4. FALSE [correction]: RNAPII-A (RPB1) does not contain a conserved RNA-binding domain known as the cleavage domain. The cleavage domain is not a characteristic of RNA polymerase II subunits but rather of other proteins involved in RNA processing.\n5. FALSE [correction]: The cleavage domain responsible for recognizing and cleaving RNA substrates during transcription elongation is not a feature of RNAPII-A (RPB1). This activity is typically associated with other proteins involved in the cleavage and polyadenylation of pre-mRNA.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder caused by mutations in the PTPN11 gene. The PTPN11 gene provides instructions for making a protein called SHP-2 (Shc-Hematopoietic Protein-2), which is a tyrosine phosphatase that plays a critical role in signaling pathways involved in the development and function of various tissues, including the brain, heart, and immune system.\nMutations in the PTPN11 gene can lead to the production of a dysfunctional SHP-2 protein, which can disrupt the normal functioning of these signaling pathways, leading to the development of Ohdo syndrome. The genetic changes that cause Ohdo syndrome can occur spontaneously or can be inherited from one or both parents.\nThe PTPN11 gene is located on chromosome 12q13.3, and mutations in this gene have been identified as the primary cause of Ohdo syndrome in approximately 70% of affected individuals. The remaining cases may be caused by mutations in other genes that have not yet been identified.\nThe genetic changes that cause Ohdo syndrome can result in a variety of symptoms, including developmental delays, intellectual disability, seizures, delayed speech and language development, and a distinctive facial appearance. Treatment for Ohdo syndrome typically involves a combination of medications and other therapies to manage symptoms and improve quality of life.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a rare genetic disorder caused by mutations in the PTPN11 gene.\n2. The PTPN11 gene is responsible for making a protein called SHP-2, which is involved in signaling pathways for the development and function of various tissues.\n3. Mutations in the PTPN11 gene can lead to the production of a dysfunctional SHP-2 protein.\n4. Approximately 70% of Ohdo syndrome cases are caused by mutations in the PTPN11 gene located on chromosome 12q13.3.\n5. Symptoms of Ohdo syndrome can include developmental delays, intellectual disability, seizures, and a distinctive facial appearance.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a rare genetic disorder caused by mutations in the PTPN11 gene.",
      "The PTPN11 gene is responsible for making a protein called SHP-2, which is involved in signaling pathways for the development and function of various tissues.",
      "Mutations in the PTPN11 gene can lead to the production of a dysfunctional SHP-2 protein.",
      "Approximately 70% of Ohdo syndrome cases are caused by mutations in the PTPN11 gene located on chromosome 12q13.3.",
      "Symptoms of Ohdo syndrome can include developmental delays, intellectual disability, seizures, and a distinctive facial appearance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome is a rare genetic disorder, but it is not typically caused by mutations in the PTPN11 gene. It is often associated with mutations in other genes such as MED12 or KAT6B.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Since Ohdo syndrome is not typically caused by mutations in the PTPN11 gene, the statement about the percentage of cases caused by mutations in this gene is incorrect. The PTPN11 gene mutations are associated with Noonan syndrome, not Ohdo syndrome.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "There are several R/Bioconductor packages that have been developed for the analysis of psychiatric disease genes. Some of the popular packages include:\n1. PsychGen: This package provides tools for the analysis of genetic data in psychiatric disorders. It includes functions for imputation, gene-level association testing, and pathway analysis.\n2. PsychArray: This package provides tools for the analysis of genetic data in psychiatric disorders using the Affymetrix PsychArray chip. It includes functions for imputation, gene-level association testing, and pathway analysis.\n3. GWAsPsych: This package provides tools for the analysis of genome-wide association studies (GWAS) data in psychiatric disorders. It includes functions for imputation, gene-level association testing, and pathway analysis.\n4. PsychGWAS: This package provides tools for the analysis of GWAS data in psychiatric disorders. It includes functions for imputation, gene-level association testing, and pathway analysis.\n5. RPBiomark: This package provides tools for the analysis of genetic data in psychiatric disorders using the Illumina OmniExpress array. It includes functions for imputation, gene-level association testing, and pathway analysis.\n6. PsychGenome: This package provides tools for the analysis of genetic data in psychiatric disorders using the Illumina HumanExome BeadChip. It includes functions for imputation, gene-level association testing, and pathway analysis.\n7. PsychArrayGen: This package provides tools for the analysis of genetic data in psychiatric disorders using the Affymetrix PsychArray chip. It includes functions for imputation, gene-level association testing, and pathway analysis.\n8. PsychGWASGen: This package provides tools for the analysis of GWAS data in psychiatric disorders. It includes functions for imputation, gene-level association testing, and pathway analysis.\n9. PsychGenPro: This package provides tools for the analysis of genetic data in psychiatric disorders using the Illumina HumanExome BeadChip. It includes functions for imputation, gene-level association testing, and pathway analysis.\n10. PsychArrayPro: This package provides tools for the analysis of genetic data in psychiatric",
    "llama-2-7b-chat-hf_fact_raw": "1. The PsychGen package is developed for the analysis of genetic data in psychiatric disorders and includes functions for imputation, gene-level association testing, and pathway analysis.\n2. The PsychArray package is designed for analyzing genetic data in psychiatric disorders using the Affymetrix PsychArray chip and includes similar functions.\n3. GWAsPsych is a package that provides tools for the analysis of genome-wide association studies data in psychiatric disorders.\n4. RPBiomark is a package that offers tools for analyzing genetic data in psychiatric disorders using the Illumina OmniExpress array.\n5. PsychGenome is a package developed for the analysis of genetic data in psychiatric disorders using the Illumina HumanExome BeadChip.",
    "llama-2-7b-chat-hf_fact": [
      "The PsychGen package is developed for the analysis of genetic data in psychiatric disorders and includes functions for imputation, gene-level association testing, and pathway analysis.",
      "The PsychArray package is designed for analyzing genetic data in psychiatric disorders using the Affymetrix PsychArray chip and includes similar functions.",
      "GWAsPsych is a package that provides tools for the analysis of genome-wide association studies data in psychiatric disorders.",
      "RPBiomark is a package that offers tools for analyzing genetic data in psychiatric disorders using the Illumina OmniExpress array.",
      "PsychGenome is a package developed for the analysis of genetic data in psychiatric disorders using the Illumina HumanExome BeadChip."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific and pertain to bioinformatics tools and packages that may exist for genetic data analysis in psychiatric disorders. Without access to current and specific databases or repositories of bioinformatics tools, it is not possible to verify the accuracy of these statements. Therefore, the truthfulness of these statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Swirl sign is a radiological sign that is commonly observed in patients with intracerebral hemorrhage (ICH). It is characterized by a spiral or swirling pattern of blood within the hemisphere, typically in the peripheral regions.\nThe swirl sign is caused by the movement of blood within the hemisphere due to the rupture of the blood vessel. When the blood vessel ruptures, it creates a cavity that fills with blood, which then moves through the brain due to the pressure gradient. This movement creates a swirling pattern of blood that can be visualized on CT or MRI scans.\nThe swirl sign is important because it can provide information about the location and extent of the hemorrhage, as well as the underlying cause. For example, a swirl sign that is located in the frontal lobe may indicate that the hemorrhage is due to a rupture of the aneurysm in the anterior cerebral artery.\nThe swirl sign can be observed in various types of intracerebral hemorrhage, including:\n1. Cerebral amyloid angiopathy: This is a degenerative disorder that affects the blood vessels in the brain, leading to hemorrhages.\n2. Moyamoya disease: This is a rare condition that is caused by narrowing or blockage of the internal carotid artery and its branches, leading to decreased blood flow to the brain.\n3. Cerebral vasculitis: This is a inflammatory disorder that affects the blood vessels in the brain, leading to hemorrhages.\n4. Arteriovenous malformations (AVMs): These are abnormal connections between arteries and veins in the brain, which can lead to hemorrhages.\n5. Traumatic brain injury: This can cause hemorrhages due to the injury to the blood vessels in the brain.\nThe swirl sign is typically observed on CT or MRI scans, and its appearance can vary depending on the location and size of the hemorrhage. In some cases, the swirl sign may be subtle and difficult to detect, while in other cases it may be more prominent and easier to identify.\nThe swirl sign is important in the diagnosis and management of",
    "llama-2-7b-chat-hf_fact_raw": "1. Swirl sign is a radiological sign observed in patients with intracerebral hemorrhage (ICH).\n2. It is characterized by a spiral or swirling pattern of blood within the hemisphere, typically in the peripheral regions.\n3. The swirl sign can be visualized on CT or MRI scans.\n4. Cerebral amyloid angiopathy, Moyamoya disease, cerebral vasculitis, arteriovenous malformations (AVMs), and traumatic brain injury can all present with swirl sign in intracerebral hemorrhage.\n5. The swirl sign can provide information about the location and extent of the hemorrhage, as well as the underlying cause.",
    "llama-2-7b-chat-hf_fact": [
      "Swirl sign is a radiological sign observed in patients with intracerebral hemorrhage (ICH).",
      "It is characterized by a spiral or swirling pattern of blood within the hemisphere, typically in the peripheral regions.",
      "The swirl sign can be visualized on CT or MRI scans.",
      "Cerebral amyloid angiopathy, Moyamoya disease, cerebral vasculitis, arteriovenous malformations (AVMs), and traumatic brain injury can all present with swirl sign in intracerebral hemorrhage.",
      "The swirl sign can provide information about the location and extent of the hemorrhage, as well as the underlying cause."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The swirl sign is characterized by a heterogeneous appearance within a hematoma with areas of low attenuation, which may represent active bleeding, not necessarily a spiral or swirling pattern.\n3. TRUE\n4. FALSE [correction]: While cerebral amyloid angiopathy and arteriovenous malformations can be associated with intracerebral hemorrhage, the swirl sign is not specifically indicative of any one of these conditions, including Moyamoya disease, cerebral vasculitis, or traumatic brain injury. It is more generally associated with active bleeding within a hematoma.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA-binding protein 1) is a transcription factor that plays a crucial role in regulating plant growth and development. ROF1 expression is induced by a variety of environmental and developmental cues in Arabidopsis. Some of the known inducers of ROF1 expression include:\n1. Light: ROF1 expression is increased in response to light, particularly blue light.\n2. Temperature: ROF1 expression is induced at high temperatures (25-30°C) and repressed at low temperatures (10-15°C).\n3. Water availability: ROF1 expression is induced in response to drought stress and repressed in response to water availability.\n4. Hormones: ROF1 expression is induced by abscisic acid (ABA) and repressed by ethylene.\n5. Developmental cues: ROF1 expression is induced during embryogenesis and flower development, and repressed in mature plants.\n6. Defense against pathogens: ROF1 expression is induced in response to bacterial infection.\n7. Oxidative stress: ROF1 expression is induced in response to oxidative stress.\n8. Nutrient availability: ROF1 expression is induced in response to nitrogen and phosphorus availability.\n9. Aging: ROF1 expression is induced in old plants.\nThese inducers can activate ROF1 expression through different mechanisms, including transcriptional activation, post-transcriptional modification, and protein-protein interactions. Understanding the inducers of ROF1 expression can provide insights into the regulation of plant growth and development and may have practical applications in agriculture and biotechnology.",
    "llama-2-7b-chat-hf_fact_raw": "1. ROF1 expression in Arabidopsis is increased in response to light, particularly blue light.\n2. ROF1 expression is induced at high temperatures ranging from 25-30°C and repressed at low temperatures ranging from 10-15°C.\n3. ROF1 expression is induced in response to drought stress and repressed in response to water availability.\n4. ROF1 expression is induced by the hormone abscisic acid (ABA) and repressed by ethylene.\n5. ROF1 expression is induced during embryogenesis and flower development in Arabidopsis.",
    "llama-2-7b-chat-hf_fact": [
      "ROF1 expression in Arabidopsis is increased in response to light, particularly blue light.",
      "ROF1 expression is induced at high temperatures ranging from 25-30°C and repressed at low temperatures ranging from 10-15°C.",
      "ROF1 expression is induced in response to drought stress and repressed in response to water availability.",
      "ROF1 expression is induced by the hormone abscisic acid (ABA) and repressed by ethylene.",
      "ROF1 expression is induced during embryogenesis and flower development in Arabidopsis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific to the expression patterns of the ROF1 gene in Arabidopsis under various conditions. Without access to the specific scientific studies or data that these statements are based on, it is not possible to accurately determine the truthfulness of these claims. These are highly specialized details that would require expert knowledge in plant molecular biology and the specific research on ROF1 gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "The most common cause of hereditary renal amyloidosis is the protein AL amyloid precursor protein (APT). Also known as wild-type ApoE, APT is a transmembrane protein that plays a crucial role in lipid metabolism and is implicated in the pathogenesis of several neurodegenerative diseases, including Alzheimer's disease. In some cases, mutations in the APT gene can lead to the accumulation of APT in the kidneys, resulting in the formation of amyloid fibrils and the development of hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein AL amyloid precursor protein (APT) is the most common cause of hereditary renal amyloidosis.\n2. APT is also known as wild-type ApoE.\n3. APT is a transmembrane protein involved in lipid metabolism.\n4. Mutations in the APT gene can lead to the accumulation of APT in the kidneys.\n5. The accumulation of APT in the kidneys can result in the formation of amyloid fibrils and the development of hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_fact": [
      "The protein AL amyloid precursor protein (APT) is the most common cause of hereditary renal amyloidosis.",
      "APT is also known as wild-type ApoE.",
      "APT is a transmembrane protein involved in lipid metabolism.",
      "Mutations in the APT gene can lead to the accumulation of APT in the kidneys.",
      "The accumulation of APT in the kidneys can result in the formation of amyloid fibrils and the development of hereditary renal amyloidosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The protein AL amyloid precursor is not known as APT but as light chains produced by plasma cells. The most common cause of hereditary renal amyloidosis is actually mutations in the genes encoding for transthyretin (TTR), fibrinogen A alpha-chain, apolipoprotein A-I, and apolipoprotein A-II, not AL amyloid.\n2. FALSE [correction]: APT is not known as wild-type ApoE. ApoE (Apolipoprotein E) is a different protein involved in lipid metabolism, and wild-type refers to the normal variant of a gene as found in nature.\n3. UNKNOWN: The statement refers to APT as a transmembrane protein involved in lipid metabolism, but since APT is not a recognized abbreviation for a specific protein, the statement's accuracy cannot be determined. If the statement is referring to ApoE, then it would be true that ApoE is involved in lipid metabolism, but it is not primarily a transmembrane protein.\n4. FALSE [correction]: Since APT is not a recognized protein related to hereditary renal amyloidosis, mutations in an APT gene would not lead to the accumulation of APT in the kidneys. However, mutations in the genes for proteins such as transthyretin (TTR) can lead to the accumulation of amyloidogenic proteins in the kidneys.\n5. FALSE [correction]: As previously stated, APT is not a recognized protein associated with hereditary renal amyloidosis. The accumulation of amyloidogenic proteins in the kidneys, due to mutations in other genes (like TTR, fibrinogen A alpha-chain, apolipoprotein A-I, and apolipoprotein A-II), can result in the formation of amyloid fibrils and the development of hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed using various proteomics techniques. The hippocampus is a complex brain structure involved in memory formation, spatial navigation, and emotion regulation, and its proteome is thought to be involved in these functions.\nSeveral studies have used proteomics approaches to investigate the hippocampal proteome in mice, including:\n1. Two-dimensional gel electrophoresis (2DGE): This technique separates proteins based on their molecular weight and isoelectric point, allowing researchers to identify and quantify different proteins in the hippocampus. For example, a study published in the journal Nature in 2007 used 2DGE to identify over 1,000 proteins in the hippocampus of mice, including proteins involved in synaptic plasticity and neurotransmission.\n2. Mass spectrometry-based proteomics: This technique involves digesting proteins with enzymes and then analyzing the resulting peptides using mass spectrometry. This approach has been used to identify and quantify thousands of proteins in the hippocampus, including proteins involved in synaptic function, neurotransmission, and inflammation.\n3. Label-free quantitative proteomics: This technique allows researchers to quantify proteins in a sample without labeling them, using statistical methods to correct for variations in protein abundance. A study published in the journal Nature Communications in 2017 used label-free quantitative proteomics to analyze the hippocampal proteome of mice and identified over 100 proteins that were differentially expressed between control and Alzheimer's disease-model mice.\n4. Protein microarray analysis: This technique involves hybridizing labeled proteins to a glass slide spotted with thousands of different protein probes, allowing researchers to measure the relative abundance of multiple proteins in a single sample. A study published in the journal Molecular Psychiatry in 2016 used protein microarray analysis to compare the hippocampal proteomes of mice with and without chronic stress, identifying proteins involved in stress response pathways and synaptic plasticity.\nThese and",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed using two-dimensional gel electrophoresis (2DGE), which separates proteins based on molecular weight and isoelectric point.\n2. A study published in the journal Nature in 2007 identified over 1,000 proteins in the hippocampus of mice using 2DGE.\n3. Mass spectrometry-based proteomics has been used to identify and quantify thousands of proteins in the mouse hippocampus.\n4. Label-free quantitative proteomics was used in a study published in Nature Communications in 2017 to analyze the hippocampal proteome of mice, identifying over 100 proteins differentially expressed between control and Alzheimer's disease-model mice.\n5. Protein microarray analysis was used in a study published in Molecular Psychiatry in 2016 to compare the hippocampal proteomes of mice with and without chronic stress.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed using two-dimensional gel electrophoresis (2DGE), which separates proteins based on molecular weight and isoelectric point.",
      "A study published in the journal Nature in 2007 identified over 1,000 proteins in the hippocampus of mice using 2DGE.",
      "Mass spectrometry-based proteomics has been used to identify and quantify thousands of proteins in the mouse hippocampus.",
      "Label-free quantitative proteomics was used in a study published in Nature Communications in 2017 to analyze the hippocampal proteome of mice, identifying over 100 proteins differentially expressed between control and Alzheimer's disease-model mice.",
      "Protein microarray analysis was used in a study published in Molecular Psychiatry in 2016 to compare the hippocampal proteomes of mice with and without chronic stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (without access to the specific article from Nature in 2007, the exact number of proteins identified cannot be confirmed)\n3. TRUE (Mass spectrometry-based proteomics is a common technique used for protein identification and quantification)\n4. UNKNOWN (without access to the specific article from Nature Communications in 2017, the use of label-free quantitative proteomics and the findings cannot be confirmed)\n5. UNKNOWN (without access to the specific article from Molecular Psychiatry in 2016, the use of protein microarray analysis and the findings cannot be confirmed)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "No, mouse chromosomes are not acrocentric. Acrocentric chromosomes are characterized by a centromere that is located near the center of the chromosome, and mouse chromosomes do not fit this definition.\nIn mammals, including mice, the centromere is typically located near the telomere, the end of the chromosome. This is in contrast to acrocentric chromosomes, which have a centromere located near the center of the chromosome.\nSo, while mouse chromosomes are not acrocentric, they are still complex and contain a variety of structural elements, including centromeres, telomeres, and satellite repeats. These structural elements play important roles in the stability and transmission of the genetic material during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are not acrocentric.\n2. Acrocentric chromosomes have a centromere located near the center of the chromosome.\n3. In mammals, including mice, the centromere is typically located near the telomere.\n4. Telomeres are located at the end of chromosomes.\n5. Mouse chromosomes contain structural elements such as centromeres, telomeres, and satellite repeats.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are not acrocentric.",
      "Acrocentric chromosomes have a centromere located near the center of the chromosome.",
      "In mammals, including mice, the centromere is typically located near the telomere.",
      "Telomeres are located at the end of chromosomes.",
      "Mouse chromosomes contain structural elements such as centromeres, telomeres, and satellite repeats."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mouse chromosomes are acrocentric.\n2. FALSE [correction]: Acrocentric chromosomes have a centromere located near one end of the chromosome, not near the center.\n3. FALSE [correction]: In mammals, including mice, the centromere is not typically located near the telomere. Acrocentric chromosomes have centromeres close to one end, but not typically near the telomeres, which are at the very end of the chromosomes.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "There are several siRNA-based drugs that are currently in clinical trials for the treatment of pancreatic cancer. Some of the most notable ones include:\n1. ONC205: ONC205 is an siRNA-based drug that targets the protein PD-L1 (programmed death-ligand 1), which is often overexpressed in pancreatic cancer. ONC205 is being developed by OncoGenex Pharmaceuticals and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\n2. OGX-011: OGX-011 is an siRNA-based drug that targets the protein PD-1 (programmed death-1), which is also overexpressed in pancreatic cancer. OGX-011 is being developed by OncoGenex Pharmaceuticals and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\n3. TK216: TK216 is an siRNA-based drug that targets the protein KRAS (Kirsten rat sarcoma viral oncogene homolog), which is commonly mutated in pancreatic cancer. TK216 is being developed by Takeda Pharmaceuticals and is currently in Phase 1 clinical trials for the treatment of pancreatic cancer.\n4. ARN-509: ARN-509 is an siRNA-based drug that targets the protein MLF1 (myeloid leukemia factor 1), which is overexpressed in pancreatic cancer. ARN-509 is being developed by Arrowhead Research Corporation and is currently in Phase 1 clinical trials for the treatment of pancreatic cancer.\n5. ASG-20: ASG-20 is an siRNA-based drug that targets the protein P53 (tumor suppressor protein 53), which is frequently mutated in pancreatic cancer. ASG-20 is being developed by Ascletis Pharmaceuticals and is currently in Phase 1 clinical trials for the treatment of pancreatic cancer.\nIt's important to note that these drugs are still in",
    "llama-2-7b-chat-hf_fact_raw": "1. ONC205 is an siRNA-based drug targeting PD-L1 and is in Phase 2 clinical trials for pancreatic cancer treatment.\n2. OGX-011 is an siRNA-based drug targeting PD-1 and is in Phase 2 clinical trials for pancreatic cancer treatment.\n3. TK216 is an siRNA-based drug targeting KRAS and is in Phase 1 clinical trials for pancreatic cancer treatment.\n4. ARN-509 is an siRNA-based drug targeting MLF1 and is in Phase 1 clinical trials for pancreatic cancer treatment.\n5. ASG-20 is an siRNA-based drug targeting P53 and is in Phase 1 clinical trials for pancreatic cancer treatment.",
    "llama-2-7b-chat-hf_fact": [
      "ONC205 is an siRNA-based drug targeting PD-L1 and is in Phase 2 clinical trials for pancreatic cancer treatment.",
      "OGX-011 is an siRNA-based drug targeting PD-1 and is in Phase 2 clinical trials for pancreatic cancer treatment.",
      "TK216 is an siRNA-based drug targeting KRAS and is in Phase 1 clinical trials for pancreatic cancer treatment.",
      "ARN-509 is an siRNA-based drug targeting MLF1 and is in Phase 1 clinical trials for pancreatic cancer treatment.",
      "ASG-20 is an siRNA-based drug targeting P53 and is in Phase 1 clinical trials for pancreatic cancer treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: OGX-011, also known as custirsen, is an antisense oligonucleotide, not an siRNA-based drug, and it targets clusterin, not PD-1. It has been investigated in clinical trials for various types of cancer, including prostate and lung cancer, but its development has faced challenges.\n3. UNKNOWN\n4. FALSE [correction]: ARN-509, also known as apalutamide, is not an siRNA-based drug. It is an androgen receptor inhibitor used in the treatment of prostate cancer, not targeting MLF1.\n5. UNKNOWN\n\nNote: The development status of drugs can change rapidly, and without up-to-date information, it is difficult to confirm the current phase of clinical trials for specific drugs and their targets. Therefore, the responses to statements 1, 3, and 5 are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG (Hexokinase Pyruvate Glucose) pore is a transmembrane protein complex that plays a crucial role in regulating glucose metabolism and energy homeostasis in cells. The HPG pore is composed of several subunits, including Hexokinase (HK), Pyruvate Kinase (PK), and Glucose-6-phosphatase (G6Pase).\nThe HPG pore functions as a gatekeeper for glucose metabolism, controlling the flow of glucose molecules between the cytosol and the mitochondria. When glucose enters the HPG pore, it is phosphorylated by HK to form glucose-6-phosphate (G6P). G6P is then converted to G6Pase, which hydrolyzes the G6P molecule to produce glucose-6-phosphate dehydrogenase (G6PDH), which is then converted to NADPH and pyruvate.\nThe HPG pore is also involved in the regulation of glycolysis, glycogen synthesis, and gluconeogenesis. It plays a key role in maintaining glucose homeostasis in the body by controlling the amount of glucose available for energy production and storage.\nDysregulation of the HPG pore has been implicated in various diseases, including diabetes, obesity, and cancer. For example, mutations in the HK subunit of the HPG pore can lead to impaired glucose metabolism and insulin resistance, while overexpression of the PK subunit has been linked to cancer.\nOverall, the HPG pore is a critical component of glucose metabolism and plays a central role in maintaining energy homeostasis in cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore is a transmembrane protein complex involved in regulating glucose metabolism and energy homeostasis in cells.\n2. The HPG pore is composed of several subunits, including Hexokinase (HK), Pyruvate Kinase (PK), and Glucose-6-phosphatase (G6Pase).\n3. The HPG pore controls the flow of glucose molecules between the cytosol and the mitochondria.\n4. Dysregulation of the HPG pore has been implicated in various diseases, such as diabetes, obesity, and cancer.\n5. Mutations in the Hexokinase subunit of the HPG pore can lead to impaired glucose metabolism and insulin resistance.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore is a transmembrane protein complex involved in regulating glucose metabolism and energy homeostasis in cells.",
      "The HPG pore is composed of several subunits, including Hexokinase (HK), Pyruvate Kinase (PK), and Glucose-6-phosphatase (G6Pase).",
      "The HPG pore controls the flow of glucose molecules between the cytosol and the mitochondria.",
      "Dysregulation of the HPG pore has been implicated in various diseases, such as diabetes, obesity, and cancer.",
      "Mutations in the Hexokinase subunit of the HPG pore can lead to impaired glucose metabolism and insulin resistance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HPG pore is not a recognized term in biochemistry or cell biology. The statement seems to be a mix-up with the mitochondrial pore, also known as the permeability transition pore complex (PTPC), which is involved in regulating metabolic processes and energy homeostasis in cells.\n\n2. FALSE [correction]: Since the HPG pore is not a recognized term, the composition listed is incorrect. Hexokinase (HK) and Pyruvate Kinase (PK) are enzymes involved in glycolysis, and Glucose-6-phosphatase (G6Pase) is an enzyme involved in gluconeogenesis and glycogenolysis, but they are not subunits of a transmembrane protein complex known as the HPG pore.\n\n3. FALSE [correction]: As the HPG pore is not a recognized entity, it does not control the flow of glucose molecules between the cytosol and the mitochondria. However, glucose transport into mitochondria is regulated by different mechanisms, including glucose transporters on the mitochondrial membrane.\n\n4. FALSE [correction]: Since the HPG pore does not exist, dysregulation of it cannot be implicated in various diseases. However, dysregulation of glucose metabolism and mitochondrial function can indeed be implicated in diseases such as diabetes, obesity, and cancer.\n\n5. FALSE [correction]: Mutations in the Hexokinase subunit would not be described as mutations in the HPG pore since the HPG pore is not a recognized structure. However, mutations in hexokinase can lead to altered glucose metabolism and have been associated with diseases such as insulin resistance and other metabolic disorders.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes (959NG) initiative is a large-scale effort to sequence and analyze the genomes of 959 species of nematode worms, which are a group of microscopic worms that are ubiquitous in soil, water, and plant environments. The initiative was launched in 2017 by the University of California, Riverside (UCR) and the University of California, San Diego (UCSD), with funding from the National Institutes of Health (NIH).\nNematodes are important model organisms in biology and medicine, as they have a simple and transparent body structure that makes them easy to study. They are also important pests of crops, and many species are known to transmit plant diseases. The 959NG initiative aims to provide a comprehensive understanding of the evolution, diversity, and biology of nematodes, which will inform strategies for managing their impact on agriculture and human health.\nThe 959NG initiative involves sequencing the genomes of nematodes from all major clades, including parasitic, free-living, and plant-parasitic species. The project also includes the analysis of gene expression, epigenetics, and other genomic features, as well as the development of new computational tools and methods for analyzing nematode genomic data.\nThe 959NG initiative is expected to have significant impacts on several areas of research, including:\n1. Nematode biology and ecology: The 959NG initiative will provide a comprehensive understanding of the evolution, diversity, and biology of nematodes, which will inform strategies for managing their impact on agriculture and human health.\n2. Plant-nematode interactions: The initiative will shed light on the complex interactions between nematodes and their plant hosts, which will inform strategies for managing plant diseases caused by nematodes.\n3. Disease control: The 959NG initiative will identify new targets for disease control, including genes that are essential for nematode survival and reproduction, which could be targeted for control.\n4. Biotechnology: The initiative will identify new genes and gene functions that could be exploited for",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematode worms.\n2. The initiative was launched in 2017 by the University of California, Riverside and the University of California, San Diego.\n3. Funding for the 959 Nematode Genomes initiative is provided by the National Institutes of Health.\n4. The initiative includes sequencing genomes from all major clades of nematodes, such as parasitic, free-living, and plant-parasitic species.\n5. The project also involves the analysis of gene expression, epigenetics, and the development of new computational tools for analyzing nematode genomic data.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematode worms.",
      "The initiative was launched in 2017 by the University of California, Riverside and the University of California, San Diego.",
      "Funding for the 959 Nematode Genomes initiative is provided by the National Institutes of Health.",
      "The initiative includes sequencing genomes from all major clades of nematodes, such as parasitic, free-living, and plant-parasitic species.",
      "The project also involves the analysis of gene expression, epigenetics, and the development of new computational tools for analyzing nematode genomic data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The 959 Nematode Genomes initiative, also known as the 959 Nematode Genomes project or the \"Worm 959\" project, was launched by the National Human Genome Research Institute (NHGRI), a part of the National Institutes of Health (NIH), not specifically by the University of California, Riverside and the University of California, San Diego.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Here are a few examples:\n1. NIPTpack: This package provides a comprehensive set of tools for the analysis of NIPT data, including data preprocessing, sample classification, and genetic risk assessment. It also includes functions for visualizing the results and interpreting the findings.\n2. Prenatix: This package is specifically designed for the analysis of NIPT data and provides a range of functions for quality control, sample classification, and genetic risk assessment. It also includes tools for visualizing the results and interpreting the findings.\n3. NIPT-Analysis: This package provides a set of functions for the analysis of NIPT data, including data preprocessing, sample classification, and genetic risk assessment. It also includes tools for visualizing the results and interpreting the findings.\n4. PrenaTest: This package provides a set of functions for the analysis of NIPT data, including data preprocessing, sample classification, and genetic risk assessment. It also includes tools for visualizing the results and interpreting the findings.\n5. NIPT-R: This package provides a set of functions for the analysis of NIPT data, including data preprocessing, sample classification, and genetic risk assessment. It also includes tools for visualizing the results and interpreting the findings.\nIt is important to note that these packages are constantly evolving, and new packages may be developed in the future to specifically address the analysis of NIPT data.",
    "llama-2-7b-chat-hf_fact_raw": "1. NIPTpack is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. Prenatix is an R package designed for the analysis of NIPT data.\n3. NIPT-Analysis is an R package that provides functions for analyzing NIPT data.\n4. PrenaTest is an R package that includes functions for the analysis of NIPT data.\n5. NIPT-R is an R package developed for analyzing NIPT data.",
    "llama-2-7b-chat-hf_fact": [
      "NIPTpack is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "Prenatix is an R package designed for the analysis of NIPT data.",
      "NIPT-Analysis is an R package that provides functions for analyzing NIPT data.",
      "PrenaTest is an R package that includes functions for the analysis of NIPT data.",
      "NIPT-R is an R package developed for analyzing NIPT data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no widely recognized R package named Prenatix for the analysis of NIPT data. This could be a fictional or less known package, or it might be a typo or confusion with another package.\n3. UNKNOWN: Without more information, it's unclear whether \"NIPT-Analysis\" is an actual R package. The name suggests it could be related to NIPT data analysis, but without confirmation, its existence cannot be verified.\n4. FALSE [correction]: PrenaTest is not an R package; it is actually a brand name for a commercial NIPT offered by a company called LifeCodexx.\n5. UNKNOWN: Similar to statement 3, without more information, it's unclear whether \"NIPT-R\" is an actual R package. The name suggests it could be related to NIPT data analysis, but without confirmation, its existence cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome is a rare genetic disorder that affects the development of the brain and nervous system. It is characterized by a range of symptoms that can vary in severity and impact the individual's quality of life. Here are some of the key features of Achenbach's syndrome:\n1. Delayed or absent development of speech and language skills: Children with Achenbach's syndrome may experience significant delays in developing speech and language skills, or in some cases, may not develop these skills at all.\n2. Intellectual disability: Individuals with Achenbach's syndrome often have intellectual disability, which can range from mild to severe.\n3. Cerebral anomalies: Achenbach's syndrome is often associated with abnormalities in the structure and function of the brain, including enlarged ventricles, narrowing of the corpus callosum, and abnormalities in brain volume.\n4. Distinctive facial features: People with Achenbach's syndrome may have distinctive facial features, including a small head, narrow eyes, a flat nasal bridge, and a prominent forehead.\n5. Growth delays: Children with Achenbach's syndrome may experience delays in growth and development, both in terms of height and weight.\n6. Motor skill delays: Individuals with Achenbach's syndrome may experience delays in developing fine motor skills, such as grasping and manipulating objects, as well as gross motor skills, such as walking and balance.\n7. Vision problems: Some individuals with Achenbach's syndrome may experience vision problems, including strabismus (crossed eyes) and nystagmus (involuntary eye movements).\n8. Hearing loss: Some individuals with Achenbach's syndrome may experience hearing loss or impairment.\n9. Seizures: Some individuals with Achenbach's syndrome may experience seizures, which can be a significant source of concern and disability.\n10. Other health problems: Achenbach's syndrome can also be associated with a range of other health problems, including delayed development of the teeth, bone abnormalities, and an increased risk of infections.\nIt's important to note that Achen",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "There are several algorithms that can be used for the detection of long repeat expansions in genomic DNA. Some of the commonly used algorithms include:\n1. RepeatMasker: This is a widely used algorithm that uses a combination of sequence similarity and k-mer frequency to identify repeat elements in a genome.\n2. GATAware: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repeat elements, and also takes into account the presence of GATA-type transcription factor binding sites.\n3. RepeatScout: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repeat elements, and also uses a hidden Markov model to predict the probability of each repeat element being a full repeat or a fragment.\n4. LINE-SAT: This algorithm uses a hidden Markov model to predict the probability of each repeat element being a full repeat or a fragment, and also takes into account the presence of LINE-1 transposable elements in the genome.\n5. GoldenGate: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repeat elements, and also uses a hidden Markov model to predict the probability of each repeat element being a full repeat or a fragment.\n6. RepeatHunter: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repeat elements, and also uses a hidden Markov model to predict the probability of each repeat element being a full repeat or a fragment.\n7. Tandem Repeats Finder (TRF): This algorithm is specifically designed to identify tandem repeats, which are a type of long repeat expansion. It uses a combination of sequence similarity and k-mer frequency to identify repeat elements, and also takes into account the length of the repeat elements.\n8. MarkDup: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repeat elements, and also takes into account the presence of specific repeat-related transcription factor binding sites.\n9. RepetitionFinder: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repeat elements, and also takes into account the length of the repeat elements.\n10. RepeatProphet: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repeat elements, and also uses a hidden Markov model to predict the probability of each repeat element being a full repeat or a fragment.\nIt'",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm that identifies repeat elements in a genome using sequence similarity and k-mer frequency.\n2. GATAware is an algorithm that identifies repeat elements and considers GATA-type transcription factor binding sites.\n3. RepeatScout is an algorithm that identifies repeat elements using sequence similarity, k-mer frequency, and a hidden Markov model.\n4. LINE-SAT is an algorithm that predicts repeat elements using a hidden Markov model and considers LINE-1 transposable elements.\n5. Tandem Repeats Finder (TRF) is designed to identify tandem repeats using sequence similarity, k-mer frequency, and considers the length of repeat elements.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is an algorithm that identifies repeat elements in a genome using sequence similarity and k-mer frequency.",
      "GATAware is an algorithm that identifies repeat elements and considers GATA-type transcription factor binding sites.",
      "RepeatScout is an algorithm that identifies repeat elements using sequence similarity, k-mer frequency, and a hidden Markov model.",
      "LINE-SAT is an algorithm that predicts repeat elements using a hidden Markov model and considers LINE-1 transposable elements.",
      "Tandem Repeats Finder (TRF) is designed to identify tandem repeats using sequence similarity, k-mer frequency, and considers the length of repeat elements."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no widely recognized algorithm called \"GATAware\" for identifying repeat elements in genomics. The name seems to be a play on the GATA type of transcription factors, but it does not correspond to a known repeat identification algorithm.\n3. FALSE [correction]: RepeatScout is an algorithm that identifies repeat elements in genomic sequences, but it does not use sequence similarity or a hidden Markov model. Instead, it builds repeat consensus sequences from l-mers that appear more frequently than expected by chance.\n4. UNKNOWN: \"LINE-SAT\" does not correspond to a widely recognized algorithm in the field of genomics. LINE-1 elements are a type of transposable element, and there are algorithms designed to predict such elements, but without more context, it's unclear whether \"LINE-SAT\" is a real algorithm or what its specific methodologies might be.\n5. TRUE: Tandem Repeats Finder (TRF) is indeed designed to identify tandem repeats in DNA sequences. It uses pattern matching and statistical models to find and analyze tandem repeats, considering factors such as the length and sequence similarity of the repeats. However, the statement about k-mer frequency is not a standard description of TRF's methodology.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 has been implicated in the development and progression of several types of brain tumors, including:\n1. Glioblastoma (GBM): Neuroligin-3 has been shown to be overexpressed in glioblastoma, the most common and aggressive form of primary brain cancer. Overexpression of neuroligin-3 has been linked to poor prognosis and resistance to chemotherapy in GBM patients.\n2. Medulloblastoma: Neuroligin-3 is also overexpressed in medulloblastoma, a type of pediatric brain cancer that arises in the cerebellum.\n3. Meningioma: Neuroligin-3 has been detected in meningioma, a benign brain tumor that arises from the meninges, the protective membranes covering the brain and spinal cord.\n4. Pineal parenchymal tumors: Neuroligin-3 has been found to be overexpressed in pineal parenchymal tumors, which are rare tumors that arise in the pineal gland.\n5. Neuroendocrine tumors: Neuroligin-3 has been implicated in the development of neuroendocrine tumors, which are tumors that arise from the neuroendocrine cells that produce hormones.\nOverall, the overexpression of neuroligin-3 has been linked to the development and progression of various types of brain tumors, and targeting this protein may be a potential therapeutic strategy for the treatment of these tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 is overexpressed in glioblastoma, a common and aggressive form of primary brain cancer.\n2. Overexpression of neuroligin-3 in glioblastoma is linked to poor prognosis and resistance to chemotherapy.\n3. Neuroligin-3 is overexpressed in medulloblastoma, a pediatric brain cancer that originates in the cerebellum.\n4. Neuroligin-3 has been detected in meningioma, which is a benign brain tumor arising from the meninges.\n5. Neuroligin-3 is overexpressed in pineal parenchymal tumors, which are rare tumors of the pineal gland.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 is overexpressed in glioblastoma, a common and aggressive form of primary brain cancer.",
      "Overexpression of neuroligin-3 in glioblastoma is linked to poor prognosis and resistance to chemotherapy.",
      "Neuroligin-3 is overexpressed in medulloblastoma, a pediatric brain cancer that originates in the cerebellum.",
      "Neuroligin-3 has been detected in meningioma, which is a benign brain tumor arising from the meninges.",
      "Neuroligin-3 is overexpressed in pineal parenchymal tumors, which are rare tumors of the pineal gland."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Neuroligin-3 has been found to be overexpressed in glioblastoma and is associated with tumor progression.\n2. TRUE: Studies have suggested that overexpression of neuroligin-3 in glioblastoma is linked to poor prognosis and may contribute to resistance to chemotherapy.\n3. UNKNOWN: While neuroligin-3 has been studied in various brain cancers, without specific evidence or studies cited, it is unclear whether it is overexpressed in medulloblastoma specifically.\n4. UNKNOWN: Similarly, without specific evidence, it is difficult to determine whether neuroligin-3 has been detected in meningioma.\n5. UNKNOWN: The overexpression of neuroligin-3 in pineal parenchymal tumors is not commonly documented, and without specific evidence, the statement's accuracy cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles in bacteria are typically around 10-50 nanometers (nm) in diameter, although they can range in size from around 5 nm to over 100 nm in some species. To put that in perspective, the diameter of a typical bacterial cell is around 1-5 micrometers (μm), so gas vesicles are only a tiny fraction of the size of the cell itself. Despite their small size, gas vesicles play a crucial role in the survival and function of many bacteria, particularly those that live in environments with high oxygen levels or other stressful conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles in bacteria typically have a diameter of around 10-50 nanometers (nm).\n2. The size of gas vesicles can range from around 5 nm to over 100 nm in some bacterial species.\n3. The diameter of a typical bacterial cell is around 1-5 micrometers (μm).\n4. Gas vesicles are a tiny fraction of the size of the bacterial cell itself.\n5. Gas vesicles are important for the survival and function of many bacteria, especially in high oxygen environments or other stressful conditions.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles in bacteria typically have a diameter of around 10-50 nanometers (nm).",
      "The size of gas vesicles can range from around 5 nm to over 100 nm in some bacterial species.",
      "The diameter of a typical bacterial cell is around 1-5 micrometers (μm).",
      "Gas vesicles are a tiny fraction of the size of the bacterial cell itself.",
      "Gas vesicles are important for the survival and function of many bacteria, especially in high oxygen environments or other stressful conditions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gas vesicles in bacteria typically have a diameter of around 45-200 nanometers (nm).\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Gas vesicles are important for the survival and function of many bacteria, especially in environments where buoyancy is advantageous, such as in aquatic environments where they can help the bacteria position themselves in the water column for optimal light or nutrient access. They are not specifically for high oxygen environments or other stressful conditions, although they can play a role in response to such conditions.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that play important roles in regulating gene expression by modifying chromatin structure. Here are the four BET proteins:\n1. BET1 (Bromodomain-Containing Protein 1)\n2. BET2 (Bromodomain-Containing Protein 2)\n3. BET3 (Bromodomain-Containing Protein 3)\n4. BET4 (Bromodomain-Containing Protein 4)\nThese proteins contain a bromodomain, a structural motif that recognizes and binds to acetylated lysine residues on histone proteins, and are involved in various cellular processes such as transcriptional activation, chromatin remodeling, and gene regulation. Dysregulation of BET proteins has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. BET proteins are a family of proteins that regulate gene expression by modifying chromatin structure.\n2. There are four BET proteins: BET1, BET2, BET3, and BET4.\n3. BET proteins contain a bromodomain that recognizes and binds to acetylated lysine residues on histone proteins.\n4. BET proteins are involved in transcriptional activation, chromatin remodeling, and gene regulation.\n5. Dysregulation of BET proteins has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact": [
      "BET proteins are a family of proteins that regulate gene expression by modifying chromatin structure.",
      "There are four BET proteins: BET1, BET2, BET3, and BET4.",
      "BET proteins contain a bromodomain that recognizes and binds to acetylated lysine residues on histone proteins.",
      "BET proteins are involved in transcriptional activation, chromatin remodeling, and gene regulation.",
      "Dysregulation of BET proteins has been implicated in various diseases, including cancer and neurological disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are four BET family members: BRD2, BRD3, BRD4, and BRDT.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning algorithms that have been developed for the prediction of protein subcellular localization. Some of the most popular ones include:\n1. DeepLoc: This is a deep learning-based method that uses a convolutional neural network (CNN) to predict the subcellular localization of proteins. It was developed by the Zhang lab at the University of California, Los Angeles (UCLA) and was published in the journal Nature Communications in 2018.\n2. LocNet: This is another deep learning-based method that uses a CNN to predict protein subcellular localization. It was developed by the Liu lab at the University of California, San Diego (UCSD) and was published in the journal Nature Machine Intelligence in 2018.\n3. PSORT-III-DEEP: This is a deep learning-based method that uses a combination of CNN and recurrent neural network (RNN) to predict protein subcellular localization. It was developed by the Gao lab at the University of California, San Diego (UCSD) and was published in the journal Nucleic Acids Research in 2019.\n4. DSSR: This is a deep learning-based method that uses a combination of CNN and RNN to predict protein subcellular localization. It was developed by the Zhang lab at the University of California, San Diego (UCSD) and was published in the journal Bioinformatics in 2020.\n5. PLOC: This is a deep learning-based method that uses a combination of CNN and RNN to predict protein subcellular localization. It was developed by the Chen lab at the University of California, Berkeley (UC Berkeley) and was published in the journal Nature Communications in 2020.\nThese are some of the most popular deep learning-based methods for predicting protein subcellular localization. There are other methods as well, and the choice of method will depend on the specific needs and requirements of the researcher.",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepLoc is a deep learning-based method for predicting protein subcellular localization using a convolutional neural network (CNN).\n2. DeepLoc was developed by the Zhang lab at the University of California, Los Angeles (UCLA).\n3. LocNet is a deep learning-based method for predicting protein subcellular localization using a CNN, developed by the Liu lab at the University of California, San Diego (UCSD).\n4. PSORT-III-DEEP is a deep learning-based method that combines CNN and recurrent neural network (RNN) for predicting protein subcellular localization, developed by the Gao lab at UCSD.\n5. PLOC is a deep learning-based method for predicting protein subcellular localization that combines CNN and RNN, developed by the Chen lab at the University of California, Berkeley (UC Berkeley).",
    "llama-2-7b-chat-hf_fact": [
      "DeepLoc is a deep learning-based method for predicting protein subcellular localization using a convolutional neural network (CNN).",
      "DeepLoc was developed by the Zhang lab at the University of California, Los Angeles (UCLA).",
      "LocNet is a deep learning-based method for predicting protein subcellular localization using a CNN, developed by the Liu lab at the University of California, San Diego (UCSD).",
      "PSORT-III-DEEP is a deep learning-based method that combines CNN and recurrent neural network (RNN) for predicting protein subcellular localization, developed by the Gao lab at UCSD.",
      "PLOC is a deep learning-based method for predicting protein subcellular localization that combines CNN and RNN, developed by the Chen lab at the University of California, Berkeley (UC Berkeley)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: DeepLoc was developed by researchers at the Technical University of Denmark.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and unknown responses are due to the lack of specific information available up to my knowledge cutoff date in 2023. The development of specific deep learning methods and the associated labs can be highly specialized information that may not be widely documented or may have emerged after my last update.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "I apologize, but I couldn't find any information on \"MULTOVL\". It's possible that it's a misspelling or a made-up term. Can you please provide more context or clarify the term you are referring to?",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Yes, Growth Differentiation Factor 15 (GDF15) has been identified as a potential biomarker for metformin treatment. Metformin is a widely used medication for type 2 diabetes, and its mechanism of action involves activating the AMP-activated protein kinase (AMPK) pathway, which regulates glucose and lipid metabolism.\nStudies have shown that GDF15 levels are increased in response to metformin treatment in both in vitro and in vivo models. For example, one study found that GDF15 levels were significantly higher in the serum of patients with type 2 diabetes treated with metformin compared to those not treated with the drug. Another study found that GDF15 levels were increased in mice treated with metformin and that this increase was associated with improved glucose tolerance and insulin sensitivity.\nGDF15 has been shown to have a variety of physiological functions, including the regulation of glucose and lipid metabolism, inflammation, and cell survival. Therefore, its increase in response to metformin treatment may serve as a biomarker for the drug's effectiveness in improving glucose and lipid metabolism, as well as its potential anti-inflammatory and anti-oxidant effects.\nHowever, it is important to note that GDF15 is not specific to metformin and can be elevated in response to other factors, such as obesity, insulin resistance, and inflammation. Therefore, further studies are needed to validate GDF15 as a biomarker for metformin treatment and to determine its clinical utility in this context.",
    "llama-2-7b-chat-hf_fact_raw": "1. Growth Differentiation Factor 15 (GDF15) has been identified as a potential biomarker for metformin treatment.\n2. Metformin is a medication used for treating type 2 diabetes and works by activating the AMP-activated protein kinase (AMPK) pathway.\n3. Studies have indicated that GDF15 levels increase in response to metformin treatment in both in vitro and in vivo models.\n4. One study observed that patients with type 2 diabetes treated with metformin had significantly higher GDF15 levels in their serum compared to those not treated with the drug.\n5. GDF15 is involved in the regulation of glucose and lipid metabolism, inflammation, and cell survival.",
    "llama-2-7b-chat-hf_fact": [
      "Growth Differentiation Factor 15 (GDF15) has been identified as a potential biomarker for metformin treatment.",
      "Metformin is a medication used for treating type 2 diabetes and works by activating the AMP-activated protein kinase (AMPK) pathway.",
      "Studies have indicated that GDF15 levels increase in response to metformin treatment in both in vitro and in vivo models.",
      "One study observed that patients with type 2 diabetes treated with metformin had significantly higher GDF15 levels in their serum compared to those not treated with the drug.",
      "GDF15 is involved in the regulation of glucose and lipid metabolism, inflammation, and cell survival."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGDF15 is indeed a protein that has been implicated in various biological processes including those mentioned in statement 5. It is known to be involved in the regulation of body weight, appetite, and energy balance, which are related to glucose and lipid metabolism. It also has roles in inflammation and cell survival.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Yes, recursive splicing is more common in short introns. Recursive splicing, also known as intron circular splicing, is a type of splicing event in which the splicing reaction produces a circular RNA molecule that can then be spliced again, resulting in the formation of a longer RNA molecule. This process is favored in short introns, which are typically less than 100 nucleotides in length, as they have a higher probability of forming circular RNA molecules.\nThe reason for this preference is that short introns have a higher concentration of U6 small nuclear RNA (snRNA) binding sites, which are the recognition sites for the splicing machinery. When the splicing machinery encounters multiple U6 snRNA binding sites in a short intron, it can become trapped in a cycle of splicing and re-splicing, leading to the formation of recursive splicing products.\nIn contrast, longer introns have fewer U6 snRNA binding sites, making it less likely for the splicing machinery to become trapped in a recursive splicing cycle. Instead, these introns are more likely to be spliced in a single direction, resulting in a linear RNA molecule.\nIt's worth noting that while recursive splicing is more common in short introns, it can still occur in longer introns, especially if they have a high concentration of U6 snRNA binding sites. However, the likelihood of recursive splicing decreases as the length of the intron increases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Short introns are typically less than 100 nucleotides in length.\n3. Short introns have a higher concentration of U6 small nuclear RNA (snRNA) binding sites.\n4. The likelihood of recursive splicing decreases as the length of the intron increases.\n5. Recursive splicing can result in the formation of a longer RNA molecule.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns.",
      "Short introns are typically less than 100 nucleotides in length.",
      "Short introns have a higher concentration of U6 small nuclear RNA (snRNA) binding sites.",
      "The likelihood of recursive splicing decreases as the length of the intron increases.",
      "Recursive splicing can result in the formation of a longer RNA molecule."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing is more common in long introns.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: Recursive splicing results in the removal of introns and the joining of exons, which would not result in a longer RNA molecule but rather a mature, shorter mRNA molecule.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "TALE-iD is a method used for identifying the functional elements in the genome, particularly the enhancers and silencers. Enhancers are sequences that can increase the expression of a gene, while silencers are sequences that can decrease the expression of a gene. TALE-iD uses a technique called transcriptional activation loop engineering (TALE) to identify these functional elements by creating a TALE protein that recognizes a specific sequence in the genome and activates or represses the expression of a nearby gene.\nThe TALE-iD method involves the following steps:\n1. Designing the TALE protein: The TALE protein is designed to recognize a specific sequence in the genome, typically a 10-15 base pair (bp) palindromic sequence.\n2. Expressing the TALE protein: The TALE protein is expressed in cells along with a reporter gene, which is used to measure the activity of the TALE protein.\n3. Identifying the functional elements: The cells are then treated with the TALE protein, and the activity of the reporter gene is measured. The sequences that are bound by the TALE protein are identified as functional elements.\n4. Validating the results: The identified functional elements are validated using other techniques such as ChIP-seq or luciferase assays to confirm their activity.\nThe TALE-iD method is a powerful tool for identifying functional elements in the genome, particularly those that are involved in regulating gene expression. It has been used to identify enhancers and silencers in various organisms, including humans, and has potential applications in fields such as drug discovery and personalized medicine.",
    "llama-2-7b-chat-hf_fact_raw": "1. TALE-iD is used for identifying functional elements in the genome, such as enhancers and silencers.\n2. Enhancers are sequences that can increase the expression of a gene.\n3. Silencers are sequences that can decrease the expression of a gene.\n4. The TALE-iD method uses transcriptional activation loop engineering to identify functional elements by creating a TALE protein that recognizes a specific sequence in the genome.\n5. The TALE-iD method has been used to identify enhancers and silencers in various organisms, including humans.",
    "llama-2-7b-chat-hf_fact": [
      "TALE-iD is used for identifying functional elements in the genome, such as enhancers and silencers.",
      "Enhancers are sequences that can increase the expression of a gene.",
      "Silencers are sequences that can decrease the expression of a gene.",
      "The TALE-iD method uses transcriptional activation loop engineering to identify functional elements by creating a TALE protein that recognizes a specific sequence in the genome.",
      "The TALE-iD method has been used to identify enhancers and silencers in various organisms, including humans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The TALE-iD method uses transcription activator-like effectors (TALEs) to identify functional elements by binding to specific sequences in the genome, not by creating a TALE protein through transcriptional activation loop engineering.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing. Some of the popular ones include:\n1. CL-Image: CL-Image is a Lisp library for image processing. It provides a set of functions for image manipulation, processing, and analysis, including filtering, resizing, and thresholding.\n2. ImageTK: ImageTK is a Lisp toolkit for image processing. It provides a set of functions for image processing, analysis, and visualization, including image filtering, segmentation, and feature extraction.\n3. Lisp-Image: Lisp-Image is a Lisp library for image processing. It provides a set of functions for image manipulation, processing, and analysis, including filtering, resizing, and thresholding.\n4. LispyImage: LispyImage is a Lisp library for image processing. It provides a set of functions for image manipulation, processing, and analysis, including filtering, resizing, and thresholding.\n5. Picture: Picture is a Lisp library for image processing. It provides a set of functions for image manipulation, processing, and analysis, including filtering, resizing, and thresholding.\n6. Lisp-Image-J: Lisp-Image-J is a Lisp library for image processing. It provides a set of functions for image manipulation, processing, and analysis, including filtering, resizing, and thresholding.\n7. ImageLisp: ImageLisp is a Lisp library for image processing. It provides a set of functions for image manipulation, processing, and analysis, including filtering, resizing, and thresholding.\n8. Lisp-Image-Viewer: Lisp-Image-Viewer is a Lisp library for image processing. It provides a set of functions for image manipulation, processing, and analysis, including filtering, resizing, and thresholding.\n9. Image-Lisp: Image-Lisp is a Lisp library for image processing. It provides a set of functions for image manipulation, processing, and analysis, including filtering, resizing, and thresholding.\n10. Lisp-Image-Tools: Lisp-Image-Tools is a Lisp library for image processing. It provides a set of functions for image manipulation, processing, and analysis, including filtering, resizing, and thresholding.\nIt's worth noting that this is not an exhaustive list,",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-Image is a Lisp library for image processing that includes functions for filtering, resizing, and thresholding.\n2. ImageTK is a Lisp toolkit for image processing that includes functions for filtering, segmentation, and feature extraction.\n3. Lisp-Image is a Lisp library for image processing that includes functions for filtering, resizing, and thresholding.\n4. LispyImage is a Lisp library for image processing that includes functions for filtering, resizing, and thresholding.\n5. Picture is a Lisp library for image processing that includes functions for filtering, resizing, and thresholding.",
    "llama-2-7b-chat-hf_fact": [
      "CL-Image is a Lisp library for image processing that includes functions for filtering, resizing, and thresholding.",
      "ImageTK is a Lisp toolkit for image processing that includes functions for filtering, segmentation, and feature extraction.",
      "Lisp-Image is a Lisp library for image processing that includes functions for filtering, resizing, and thresholding.",
      "LispyImage is a Lisp library for image processing that includes functions for filtering, resizing, and thresholding.",
      "Picture is a Lisp library for image processing that includes functions for filtering, resizing, and thresholding."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are about Lisp libraries for image processing, but without specific information about the existence or features of these libraries, it is not possible to verify the accuracy of the statements. Therefore, the truthfulness of these statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "The yeast species Saccharomyces cerevisiae (baker's yeast) has a genome that is thought to have undergone a whole genome duplication (WGD) event early in its evolutionary history. This event, known as the \"S. cerevisiae WGD,\" occurred around 100-150 million years ago and resulted in the duplication of approximately 1,000-2,000 genes.\nThe S. cerevisiae WGD is thought to have been driven by a variety of factors, including the need for increased protein production and the evolution of new metabolic pathways. The duplication event is believed to have occurred once in the S. cerevisiae lineage, and the genes that were duplicated have since been evolving independently.\nIt is worth noting that the exact number of genes that were duplicated during the S. cerevisiae WGD is still a matter of debate, and some studies have suggested that the number of duplicated genes may be lower or higher than the commonly cited range of 1,000-2,000 genes. However, the general consensus is that the S. cerevisiae WGD did occur and had a significant impact on the evolution of the yeast genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Saccharomyces cerevisiae (baker's yeast) is believed to have undergone a whole genome duplication event early in its evolutionary history.\n2. The whole genome duplication event in Saccharomyces cerevisiae is known as the \"S. cerevisiae WGD.\"\n3. The S. cerevisiae WGD is estimated to have occurred around 100-150 million years ago.\n4. The S. cerevisiae WGD resulted in the duplication of approximately 1,000-2,000 genes.\n5. The exact number of genes duplicated during the S. cerevisiae WGD is a matter of debate among studies.",
    "llama-2-7b-chat-hf_fact": [
      "Saccharomyces cerevisiae (baker's yeast) is believed to have undergone a whole genome duplication event early in its evolutionary history.",
      "The whole genome duplication event in Saccharomyces cerevisiae is known as the \"S. cerevisiae WGD.\"",
      "The S. cerevisiae WGD is estimated to have occurred around 100-150 million years ago.",
      "The S. cerevisiae WGD resulted in the duplication of approximately 1,000-2,000 genes.",
      "The exact number of genes duplicated during the S. cerevisiae WGD is a matter of debate among studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The S. cerevisiae WGD is estimated to have occurred around 100-150 million years ago, but more recent estimates suggest it occurred approximately 100 million years ago.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor β (Esrrb) is a nuclear receptor that binds to the complex formed by the estrogen response element (ERα) and the estrogen-responsive element (ERE). The ERα/ERE complex is a cis-acting element that mediates the response of target genes to estrogen signaling. Esrrb recognizes and binds to this complex, leading to the regulation of gene expression in response to estrogen signaling.",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) is a nuclear receptor.\n2. Esrrb binds to the complex formed by the estrogen response element (ERα) and the estrogen-responsive element (ERE).\n3. The ERα/ERE complex is a cis-acting element.\n4. The ERα/ERE complex mediates the response of target genes to estrogen signaling.\n5. Binding of Esrrb to the ERα/ERE complex leads to the regulation of gene expression in response to estrogen signaling.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) is a nuclear receptor.",
      "Esrrb binds to the complex formed by the estrogen response element (ERα) and the estrogen-responsive element (ERE).",
      "The ERα/ERE complex is a cis-acting element.",
      "The ERα/ERE complex mediates the response of target genes to estrogen signaling.",
      "Binding of Esrrb to the ERα/ERE complex leads to the regulation of gene expression in response to estrogen signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Esrrb does not bind to the complex formed by the estrogen receptor alpha (ERα) and the estrogen response element (ERE). Instead, it binds to its own specific DNA response elements.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Binding of Esrrb to its specific DNA response elements leads to the regulation of gene expression, but this is not necessarily in response to estrogen signaling, as Esrrb is known to bind to other elements and is not solely dependent on estrogen.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 (Zinc finger CCHC-type zinc finger 17) is a protein that plays a crucial role in the regulation of gene expression, particularly in the context of stem cell maintenance and differentiation. It is a transcriptional repressor that is involved in the control of various cellular processes, including cell fate determination, proliferation, and survival.\nZCCHC17 has been shown to play a key role in the maintenance of stem cell self-renewal and pluripotency, particularly in embryonic stem cells. It regulates the expression of genes involved in these processes, such as Nanog and Oct4, and is required for the maintenance of stem cell self-renewal in culture. ZCCHC17 also plays a role in the regulation of cell fate decisions, particularly in the context of neural stem cell differentiation. It has been shown to repress the expression of genes involved in neural differentiation, such as Nurr1, and is required for the maintenance of neural progenitor cell self-renewal.\nIn addition to its role in stem cell biology, ZCCHC17 has also been implicated in cancer, where it can act as a tumor suppressor by regulating the expression of genes involved in cell cycle arrest and apoptosis.\nIn summary, ZCCHC17 is a transcriptional repressor that plays a crucial role in the regulation of gene expression, particularly in the context of stem cell maintenance and differentiation. It is involved in the control of various cellular processes, including cell fate determination, proliferation, and survival, and its dysregulation has been implicated in various diseases, including cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a protein that plays a role in the regulation of gene expression.\n2. ZCCHC17 is involved in stem cell maintenance and differentiation, particularly in embryonic stem cells.\n3. The protein regulates the expression of genes such as Nanog and Oct4, which are important for stem cell self-renewal.\n4. ZCCHC17 represses the expression of genes involved in neural differentiation, such as Nurr1.\n5. ZCCHC17 has been implicated as a tumor suppressor by regulating genes involved in cell cycle arrest and apoptosis.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a protein that plays a role in the regulation of gene expression.",
      "ZCCHC17 is involved in stem cell maintenance and differentiation, particularly in embryonic stem cells.",
      "The protein regulates the expression of genes such as Nanog and Oct4, which are important for stem cell self-renewal.",
      "ZCCHC17 represses the expression of genes involved in neural differentiation, such as Nurr1.",
      "ZCCHC17 has been implicated as a tumor suppressor by regulating genes involved in cell cycle arrest and apoptosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first statement is true as ZCCHC17, also known as zinc finger CCHC-type containing 17, is indeed a protein that can be involved in the regulation of gene expression. However, without specific scientific literature or context to confirm the roles mentioned in statements 2 through 5, the accuracy of these statements cannot be determined. These roles are highly specific and would require validation through experimental evidence or authoritative sources.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is a large protein structure that spans the nuclear envelope in eukaryotic cells, connecting the nucleus to the cytoplasm. The NPC is composed of several proteins, including:\n1. Nucleoporins: These are the main proteins that make up the NPC. There are 33 nucleoporins in humans, which are encoded by the NPC1-NPC33 genes. These proteins form a complex that spans the nuclear envelope and forms the central channel through which molecules can pass.\n2. Spectrin: Spectrin is a cytoskeletal protein that helps to stabilize the NPC and maintain its structure.\n3. Nup107: Nup107 is a nucleoporin that is involved in the assembly and maintenance of the NPC.\n4. Nup153: Nup153 is another nucleoporin that plays a role in the transport of molecules across the nuclear envelope.\n5. Nup50: Nup50 is a nucleoporin that is involved in the assembly and maintenance of the NPC.\n6. Nup210: Nup210 is a nucleoporin that is involved in the transport of molecules across the nuclear envelope.\n7. Nup98: Nup98 is a nucleoporin that is involved in the assembly and maintenance of the NPC.\n8. Nup133: Nup133 is a nucleoporin that is involved in the transport of molecules across the nuclear envelope.\nThese proteins work together to form a complex that regulates the transport of molecules between the nucleus and cytoplasm, and plays a crucial role in maintaining the integrity of the cell.",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore complex (NPC) is a large protein structure that spans the nuclear envelope in eukaryotic cells.\n2. There are 33 nucleoporins in humans, which are encoded by the NPC1-NPC33 genes.\n3. Spectrin is a cytoskeletal protein that helps to stabilize the nuclear pore complex.\n4. Nup107, Nup153, Nup50, Nup210, Nup98, and Nup133 are all nucleoporins involved in the assembly, maintenance, and transport of molecules across the nuclear envelope.\n5. The nuclear pore complex regulates the transport of molecules between the nucleus and cytoplasm and plays a crucial role in maintaining the integrity of the cell.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore complex (NPC) is a large protein structure that spans the nuclear envelope in eukaryotic cells.",
      "There are 33 nucleoporins in humans, which are encoded by the NPC1-NPC33 genes.",
      "Spectrin is a cytoskeletal protein that helps to stabilize the nuclear pore complex.",
      "Nup107, Nup153, Nup50, Nup210, Nup98, and Nup133 are all nucleoporins involved in the assembly, maintenance, and transport of molecules across the nuclear envelope.",
      "The nuclear pore complex regulates the transport of molecules between the nucleus and cytoplasm and plays a crucial role in maintaining the integrity of the cell."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are around 30 different nucleoporins in humans, but they are not encoded by genes named NPC1-NPC33. The number of nucleoporins and their gene names are not a simple 1:1 correspondence with such a naming convention.\n3. FALSE [correction]: Spectrin is a cytoskeletal protein, but it is not primarily known for stabilizing the nuclear pore complex. It is more commonly associated with the stability and elasticity of the plasma membrane.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a specific inhibitor of the topoisomerase II (Topo II) enzyme. Topo II is a type of topoisomerase that relaxes DNA supercoils and resolves topological constraints in DNA, playing a crucial role in various cellular processes such as DNA replication, transcription, and repair. Gepotidacin binds to the active site of Topo II and inhibits its activity, leading to the accumulation of supercoiled DNA and the induction of cell death in cancer cells. Therefore, Gepotidacin is a Topo II inhibitor.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is an inhibitor of the topoisomerase II (Topo II) enzyme.\n2. Topoisomerase II is involved in relaxing DNA supercoils and resolving topological constraints in DNA.\n3. Topoisomerase II plays a role in DNA replication, transcription, and repair.\n4. Gepotidacin binds to the active site of Topo II and inhibits its activity.\n5. The inhibition of Topo II by gepotidacin leads to the accumulation of supercoiled DNA and can induce cell death in cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is an inhibitor of the topoisomerase II (Topo II) enzyme.",
      "Topoisomerase II is involved in relaxing DNA supercoils and resolving topological constraints in DNA.",
      "Topoisomerase II plays a role in DNA replication, transcription, and repair.",
      "Gepotidacin binds to the active site of Topo II and inhibits its activity.",
      "The inhibition of Topo II by gepotidacin leads to the accumulation of supercoiled DNA and can induce cell death in cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is an inhibitor of bacterial type II topoisomerases, which include DNA gyrase (topoisomerase II) and topoisomerase IV, not the human topoisomerase II enzyme.\n2. TRUE\n3. TRUE\n4. UNKNOWN: Without specific information on the mechanism of gepotidacin, it is unclear whether it binds to the active site of Topo II or another site to exert its inhibitory effect.\n5. UNKNOWN: The statement may be true in the context of bacterial cells, as the inhibition of bacterial topoisomerases can lead to cell death. However, it is unclear whether the statement is referring to cancer cells specifically, as gepotidacin is primarily studied for its antibacterial activity, not anticancer activity.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Single-Pass Workflow) is a machine learning (ML) architecture that enables fast and efficient training of deep neural networks (DNNs) on a variety of platforms, including GPUs, TPUs, and CPUs. It was introduced by Google in 2019 as an extension of the Canvas framework, which provides a flexible and modular framework for building and training ML models.\nThe main idea behind Canvas SPW is to simplify the training process of DNNs by eliminating the need for multiple passes through the data. Traditionally, DNN training involves multiple passes through the data, each pass consisting of a forward pass through the network followed by an backward pass to compute gradients. This can be computationally expensive, especially for large datasets and complex networks.\nCanvas SPW addresses this issue by performing all the computations required for training a DNN in a single pass through the data. This is achieved by using a novel technique called \"spatially-adaptive batching,\" which dynamically adjusts the batch size of the data based on the complexity of the network and the available computational resources. By using a smaller batch size for complex networks and larger batch sizes for simpler networks, Canvas SPW can reduce the overall training time while maintaining the accuracy of the model.\nIn addition to spatially-adaptive batching, Canvas SPW also uses a number of other techniques to improve the efficiency of the training process, including:\n1. Model parallelism: Canvas SPW can distribute the training process across multiple GPUs or TPUs, allowing for faster training of large models.\n2. Gradient parallelism: Canvas SPW can compute gradients in parallel across multiple GPUs or TPUs, reducing the overall training time.\n3. Mixed-precision training: Canvas SPW can use lower-precision data types (e.g., float16) for some of the computations during training, which can reduce the memory usage and improve the training speed.\n4. Efficient use of memory: Canvas SPW can reduce the memory usage during training by using techniques such as gradient checkpointing and weight sparsification.\nOverall, Canvas SPW is a powerful tool for training deep neural networks, and it has been shown to achieve state-of-the-art performance on a number of benchmark datasets while also reducing the training time.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW (Single-Pass Workflow) is a machine learning architecture introduced by Google in 2019.\n2. Canvas SPW is designed to enable fast and efficient training of deep neural networks on platforms such as GPUs, TPUs, and CPUs.\n3. The architecture eliminates the need for multiple passes through the data, traditionally required in deep neural network training.\n4. Canvas SPW uses a technique called \"spatially-adaptive batching\" to dynamically adjust the batch size during training.\n5. Canvas SPW incorporates model parallelism, gradient parallelism, mixed-precision training, and efficient memory usage techniques to improve training efficiency.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW (Single-Pass Workflow) is a machine learning architecture introduced by Google in 2019.",
      "Canvas SPW is designed to enable fast and efficient training of deep neural networks on platforms such as GPUs, TPUs, and CPUs.",
      "The architecture eliminates the need for multiple passes through the data, traditionally required in deep neural network training.",
      "Canvas SPW uses a technique called \"spatially-adaptive batching\" to dynamically adjust the batch size during training.",
      "Canvas SPW incorporates model parallelism, gradient parallelism, mixed-precision training, and efficient memory usage techniques to improve training efficiency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are about a specific machine learning architecture called Canvas SPW, which is claimed to be introduced by Google in 2019. However, without additional context or a reliable source to verify these claims, it is not possible to determine the accuracy of the statements. Therefore, the truthfulness of these statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "STING (STimulator of Interferon Genes) is a cytoplasmic DNA sensor that plays a crucial role in the innate immune response to viral infections. STING agonists are compounds or molecules that activate STING and stimulate the production of interferons and other immune molecules. Here are some examples of STING agonists:\n1. Poly IC: Poly IC is a synthetic agonist of STING that has been shown to activate STING and induce the production of interferons in various cell types.\n2. CpG DNA: CpG DNA is a specific type of DNA that contains the dinucleotide CpG, which is found in the genomes of most bacteria and viruses. CpG DNA is a potent STING agonist that can activate STING and induce the production of interferons.\n3. Small molecule agonists: Several small molecules have been identified as STING agonists, including the compounds BX795 and BX912. These molecules bind to STING and activate its activity, leading to the production of interferons and other immune molecules.\n4. Toll-like receptor (TLR) agonists: TLRs are pattern recognition receptors that recognize pathogen-associated molecular patterns (PAMPs) and play a crucial role in the innate immune response. Some TLR agonists, such as flagellin and lipopolysaccharide, can also activate STING and induce the production of interferons.\n5. Viral mimics: Some viral mimics, such as polybrene, can activate STING and induce the production of interferons. Polybrene is a synthetic compound that mimics the structure of DNA and can bind to STING, leading to its activation.\n6. CARA-CD: CARA-CD is a small molecule that has been shown to activate STING and induce the production of interferons in various cell types.\n7. GSK-872: GSK-872 is a small molecule that has been shown to activate STING and induce the production of interferons in",
    "llama-2-7b-chat-hf_fact_raw": "1. Poly IC is a synthetic agonist of STING that induces the production of interferons.\n2. CpG DNA contains the dinucleotide CpG and is a potent STING agonist that can activate STING.\n3. BX795 and BX912 are small molecules identified as STING agonists.\n4. Toll-like receptor agonists, such as flagellin and lipopolysaccharide, can activate STING.\n5. CARA-CD is a small molecule that activates STING and induces the production of interferons.",
    "llama-2-7b-chat-hf_fact": [
      "Poly IC is a synthetic agonist of STING that induces the production of interferons.",
      "CpG DNA contains the dinucleotide CpG and is a potent STING agonist that can activate STING.",
      "BX795 and BX912 are small molecules identified as STING agonists.",
      "Toll-like receptor agonists, such as flagellin and lipopolysaccharide, can activate STING.",
      "CARA-CD is a small molecule that activates STING and induces the production of interferons."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Poly IC is a synthetic analog of double-stranded RNA that acts as an agonist for TLR3, not STING, and induces the production of interferons.\n2. FALSE [correction]: CpG DNA contains the dinucleotide CpG and is recognized by TLR9, not STING. It is a potent immune stimulant but not a direct STING agonist.\n3. FALSE [correction]: BX795 and BX912 are small molecules that were initially identified as inhibitors of TBK1, not as STING agonists.\n4. FALSE [correction]: Toll-like receptor agonists, such as flagellin (TLR5 agonist) and lipopolysaccharide (TLR4 agonist), do not directly activate STING. They activate their respective Toll-like receptors.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Splicing-by-Loss-of-Inhibition-of-Cyclin-Dependent-Kinase-Activation Gag) is a protein complex that plays a crucial role in the regulation of gene expression by modulating the splicing of pre-mRNA.\nThe SLIC-CAGE complex is composed of several subunits, including the catalytic subunit SLIC (Splicing-by-Loss-of-Inhibition-of-Cyclin-Dependent-Kinase), the adaptor protein CAGE (Cyclin-Dependent Kinase Activation Gag), and other subunits that modulate the complex's activity.\nThe SLIC-CAGE complex functions by binding to specific sequences in the pre-mRNA and recruiting the splicing machinery to remove introns and join exons. The complex uses a mechanism of splicing-by-loss-of-inhibition, which involves the inhibition of the splicing machinery by the SLIC subunit, leading to the skipping of certain exons and the production of alternative splice variants.\nSLIC-CAGE plays a critical role in the regulation of gene expression, particularly in the context of cellular stress, differentiation, and development. The complex has been implicated in a variety of biological processes, including the regulation of cell proliferation, apoptosis, and migration, as well as the response to DNA damage and the maintenance of genome stability.\nDysregulation of the SLIC-CAGE complex has been implicated in a number of diseases, including cancer, neurodegenerative disorders, and developmental disorders. Therefore, understanding the mechanisms of SLIC-CAGE regulation and its role in disease is an area of ongoing research and potential therapeutic targeting.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a protein complex that regulates gene expression by modulating the splicing of pre-mRNA.\n2. The SLIC-CAGE complex includes the catalytic subunit SLIC and the adaptor protein CAGE, among other subunits.\n3. The complex functions by binding to pre-mRNA and recruiting splicing machinery to remove introns and join exons.\n4. SLIC-CAGE is involved in biological processes such as cell proliferation, apoptosis, migration, DNA damage response, and genome stability maintenance.\n5. Dysregulation of the SLIC-CAGE complex has been implicated in diseases like cancer, neurodegenerative disorders, and developmental disorders.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a protein complex that regulates gene expression by modulating the splicing of pre-mRNA.",
      "The SLIC-CAGE complex includes the catalytic subunit SLIC and the adaptor protein CAGE, among other subunits.",
      "The complex functions by binding to pre-mRNA and recruiting splicing machinery to remove introns and join exons.",
      "SLIC-CAGE is involved in biological processes such as cell proliferation, apoptosis, migration, DNA damage response, and genome stability maintenance.",
      "Dysregulation of the SLIC-CAGE complex has been implicated in diseases like cancer, neurodegenerative disorders, and developmental disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific to molecular biology, and without the proper context or reference to scientific literature, it is not possible to verify the accuracy of these claims. The SLIC-CAGE complex is not a widely recognized term in publicly available scientific literature as of my knowledge cutoff date, and it may be a hypothetical or a very recent discovery not yet broadly discussed. Therefore, I cannot confirm or correct these statements without additional information.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (LEM-domain-containing protein 3) is a protein that plays multiple roles in various cellular processes. Here are some of the known roles of LEM-3:\n1. Chromatin remodeling: LEM-3 is involved in the remodeling of chromatin structure, which is essential for proper gene expression and cellular function. It does this by interacting with chromatin-remodeling complexes and altering the conformation of chromatin.\n2. Transcriptional regulation: LEM-3 regulates transcriptional activity by interacting with transcription factors and modulating their activity. It does this by binding to specific DNA sequences and recruiting transcription factors to specific gene promoters.\n3. Cell cycle progression: LEM-3 plays a role in the regulation of the cell cycle, particularly in the G1/S transition. It does this by interacting with key regulators of the cell cycle, such as cyclin-dependent kinases (CDKs) and retinoblastoma protein (Rb).\n4. Apoptosis: LEM-3 has been shown to promote apoptosis (programmed cell death) in certain contexts. It does this by interacting with pro-apoptotic proteins and modulating their activity.\n5. Cellular stress response: LEM-3 is involved in the response to cellular stress, particularly oxidative stress. It does this by interacting with key regulators of the stress response, such as heat shock proteins and DNA damage response proteins.\n6. Neurodegeneration: LEM-3 has been implicated in the pathogenesis of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It does this by interacting with key proteins involved in neurodegeneration, such as amyloid-β and tau protein.\nIn summary, LEM-3 is a multifunctional protein that plays a complex role in various cellular processes, including chromatin remodeling, transcriptional regulation, cell cycle progression, apoptosis, cellular stress response, and neurodegeneration.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in the remodeling of chromatin structure.\n2. LEM-3 regulates transcriptional activity by interacting with transcription factors and modulating their activity.\n3. LEM-3 plays a role in the regulation of the cell cycle, particularly in the G1/S transition.\n4. LEM-3 has been shown to promote apoptosis in certain contexts.\n5. LEM-3 is involved in the response to cellular stress, particularly oxidative stress.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in the remodeling of chromatin structure.",
      "LEM-3 regulates transcriptional activity by interacting with transcription factors and modulating their activity.",
      "LEM-3 plays a role in the regulation of the cell cycle, particularly in the G1/S transition.",
      "LEM-3 has been shown to promote apoptosis in certain contexts.",
      "LEM-3 is involved in the response to cellular stress, particularly oxidative stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statement about LEM-3 being involved in the remodeling of chromatin structure is true, as LEM domain proteins are known to be involved in chromatin organization and nuclear integrity. However, without specific references to scientific literature or more detailed information, it is difficult to confirm the exact roles of LEM-3 in regulating transcriptional activity, cell cycle regulation, apoptosis, and response to cellular stress. These functions can be highly context-dependent and may vary across different organisms or cell types. Therefore, the remaining statements are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "TmVar is a software tool for the analysis of transcriptional regulation. Here are some of the releases of TmVar:\n1. TmVar 1.0: This was the initial release of TmVar, which provided a basic framework for the analysis of transcriptional regulation.\n2. TmVar 1.5: This release added new features to TmVar, including the ability to analyze the regulation of gene expression at the level of individual cells.\n3. TmVar 2.0: This release introduced a new graphical user interface (GUI) for TmVar, making it easier to use and more user-friendly.\n4. TmVar 2.5: This release added support for the analysis of large-scale gene expression data sets, including those generated by microarray and RNA-seq technologies.\n5. TmVar 3.0: This release introduced a new algorithm for the inference of transcriptional regulatory networks (TRNs) from gene expression data, which allows for the prediction of direct and indirect interactions between transcription factors and their target genes.\n6. TmVar 3.5: This release added new features for the analysis of chromatin structure and epigenetic marks, including support for the analysis of histone modification data.\n7. TmVar 4.0: This release introduced a new framework for the analysis of transcriptional regulation that integrates data from multiple sources, including gene expression, chromatin structure, and epigenetic marks.\n8. TmVar 4.5: This release added new features for the analysis of non-coding RNA transcripts, including the ability to predict the function of long non-coding RNAs (lncRNAs) and the ability to analyze the regulation of lncRNA expression.\n9. TmVar 5.0: This release introduced a new algorithm for the prediction of transcriptional regulatory interactions, which allows for the prediction of both direct and indirect interactions between transcription factors and their target genes.\n10. TmVar 5.5: This release added new features for the analysis of gene expression data in the context of cancer, including the ability to identify cancer-specific regulatory elements and the ability to predict the response of cancer cells to drugs.",
    "llama-2-7b-chat-hf_fact_raw": "1. TmVar 1.0 was the initial release of TmVar.\n2. TmVar 2.0 introduced a new graphical user interface (GUI).\n3. TmVar 2.5 added support for the analysis of large-scale gene expression data sets.\n4. TmVar 3.0 introduced a new algorithm for the inference of transcriptional regulatory networks from gene expression data.\n5. TmVar 4.5 added new features for the analysis of non-coding RNA transcripts.",
    "llama-2-7b-chat-hf_fact": [
      "TmVar 1.0 was the initial release of TmVar.",
      "TmVar 2.0 introduced a new graphical user interface (GUI).",
      "TmVar 2.5 added support for the analysis of large-scale gene expression data sets.",
      "TmVar 3.0 introduced a new algorithm for the inference of transcriptional regulatory networks from gene expression data.",
      "TmVar 4.5 added new features for the analysis of non-coding RNA transcripts."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or a source to verify the details about the versions and features of TmVar, it is not possible to determine the truthfulness of these statements. TmVar could refer to a software tool or database, but without additional information, the veracity of the statements about its version history and features cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There are several databases that contain information on somatic mutations in normal cells. Here are a few examples:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. While TCGA primarily focuses on cancer mutations, it also includes some information on normal cell mutations.\n2. The 1000 Genomes Project: The 1000 Genomes Project is a large-scale genomics project that aims to catalogue the genetic variation in the human population. While the project primarily focuses on common genetic variants, it also includes some information on rare mutations, including those found in normal cells.\n3. The Genome Aggregation Database (GAD): GAD is a database that catalogues genomic variations, including somatic mutations, in a variety of cell types, including normal cells. GAD includes data from a variety of sources, including TCGA, the 1000 Genomes Project, and other research studies.\n4. The ClinVar database: ClinVar is a database that catalogues genomic variations associated with human diseases, including somatic mutations in normal cells. ClinVar includes data from a variety of sources, including TCGA, GAD, and other research studies.\n5. The Mutational Load database: Mutational Load is a database that catalogues the frequency and distribution of somatic mutations in normal human tissues. The database includes data from a variety of sources, including TCGA and other research studies.\nIt's important to note that while these databases provide valuable information on somatic mutations in normal cells, they are not exhaustive and may not cover all possible mutations. Additionally, the frequency and distribution of somatic mutations can vary depending on the tissue or cell type, and even within the same tissue or cell type, there may be significant variation in the types and frequencies of mutations present.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n2. The 1000 Genomes Project is a large-scale genomics project that aims to catalogue genetic variation in the human population.\n3. The Genome Aggregation Database (GAD) catalogues genomic variations, including somatic mutations, in a variety of cell types, including normal cells.\n4. The ClinVar database catalogues genomic variations associated with human diseases, including somatic mutations in normal cells.\n5. The Mutational Load database catalogues the frequency and distribution of somatic mutations in normal human tissues.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The 1000 Genomes Project is a large-scale genomics project that aims to catalogue genetic variation in the human population.",
      "The Genome Aggregation Database (GAD) catalogues genomic variations, including somatic mutations, in a variety of cell types, including normal cells.",
      "The ClinVar database catalogues genomic variations associated with human diseases, including somatic mutations in normal cells.",
      "The Mutational Load database catalogues the frequency and distribution of somatic mutations in normal human tissues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Genome Aggregation Database (gnomAD) catalogues genomic variations, but it focuses on germline variants found in the general population, not somatic mutations in a variety of cell types, including normal cells.\n4. TRUE, but with a clarification: The ClinVar database catalogues genomic variations associated with human diseases, but it primarily focuses on germline mutations rather than somatic mutations in normal cells.\n5. UNKNOWN: There is no widely recognized database specifically named \"Mutational Load database\" that is known for cataloguing the frequency and distribution of somatic mutations in normal human tissues. This statement cannot be verified without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available that have been implemented in Java. Here are some of them:\n1. NetworkX: NetworkX is a Python library for creating, manipulating, and analyzing complex networks, including graphs. It has a Java interface, allowing users to use NetworkX from Java applications.\n2. JGraphT: JGraphT is a Java library for creating and manipulating graphs. It provides a simple API for creating and traversing graphs, as well as a number of utility methods for working with graphs.\n3. GraphML: GraphML is a Java library for parsing and generating Graph Markup Language (GML), a standard for representing graphs in XML format. It can be used to read and write graphs in GML format, as well as to perform basic graph operations such as traversal and manipulation.\n4. JGrapht: JGrapht is a Java library for creating and manipulating graphs. It provides a simple API for creating and traversing graphs, as well as a number of utility methods for working with graphs.\n5. GraphStream: GraphStream is a Java library for creating and manipulating graphs. It provides a simple API for creating and traversing graphs, as well as a number of utility methods for working with graphs.\n6. Java Graph Library (JGL): JGL is a Java library for creating and manipulating graphs. It provides a simple API for creating and traversing graphs, as well as a number of utility methods for working with graphs.\nThese libraries can be used for various graph-related tasks such as graph analysis, graph visualization, and graph-based algorithms. It is important to note that the functionality and ease of use of these libraries may vary, so it is recommended to try out a few of them to see which one best suits your needs.",
    "llama-2-7b-chat-hf_fact_raw": "1. NetworkX is a Python library with a Java interface for creating, manipulating, and analyzing complex networks.\n2. JGraphT is a Java library for creating and manipulating graphs with a simple API.\n3. GraphML is a Java library for parsing and generating Graph Markup Language (GML).\n4. GraphStream is a Java library for creating and manipulating graphs with a simple API.\n5. Java Graph Library (JGL) is a Java library for creating and manipulating graphs with a simple API.",
    "llama-2-7b-chat-hf_fact": [
      "NetworkX is a Python library with a Java interface for creating, manipulating, and analyzing complex networks.",
      "JGraphT is a Java library for creating and manipulating graphs with a simple API.",
      "GraphML is a Java library for parsing and generating Graph Markup Language (GML).",
      "GraphStream is a Java library for creating and manipulating graphs with a simple API.",
      "Java Graph Library (JGL) is a Java library for creating and manipulating graphs with a simple API."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NetworkX is a Python library for creating, manipulating, and analyzing complex networks. It does not have a Java interface.\n2. TRUE\n3. FALSE [correction]: GraphML is not a Java library; it is an XML-based file format for graphs. Libraries like JGraphT can parse and generate GraphML, but GraphML itself is not a library.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "The SHERLOCKv2 platform is an advancement over the original SHERLOCK platform and integrates several new technologies to improve its sensitivity, specificity, and ease of use. Here are the four main advances integrated into the SHERLOCKv2 platform:\n1. Improved nucleic acid amplification: SHERLOCKv2 uses a new nucleic acid amplification technique called \"Mutation-Specific Amplification\" (MSA), which is more sensitive and specific than the original SHERLOCK platform's \"Mutation-Specific PCR\" (MSP). MSA can detect even low levels of mutations in the sample, while MSP can be prone to false positives.\n2. Enhanced signal detection: SHERLOCKv2 uses a new detection method called \"Nucleic Acid Circuitry\" (NAC), which is more sensitive and accurate than the original platform's \"Nucleic Acid Sequence-Based Amplification\" (NASBA) method. NAC can detect the presence of mutations in the sample more easily, even in the presence of background noise.\n3. Simplified workflow: The SHERLOCKv2 platform has a simplified workflow compared to the original platform, with fewer steps and reagents required. This makes it easier to use and more cost-effective, while still maintaining the high sensitivity and specificity of the test.\n4. Multiplexing capabilities: SHERLOCKv2 can detect multiple mutations in a single reaction, allowing for the simultaneous detection of multiple mutations in a single test. This is an improvement over the original platform, which could only detect one mutation at a time. The multiplexing capabilities of SHERLOCKv2 make it a more powerful tool for detecting multiple mutations in a single test, which can be useful in a variety of applications.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 uses a nucleic acid amplification technique called \"Mutation-Specific Amplification\" (MSA).\n2. The platform employs a detection method known as \"Nucleic Acid Circuitry\" (NAC).\n3. SHERLOCKv2 has a simplified workflow with fewer steps and reagents compared to the original platform.\n4. SHERLOCKv2 has the capability to detect multiple mutations in a single reaction.\n5. The original SHERLOCK platform could only detect one mutation at a time.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 uses a nucleic acid amplification technique called \"Mutation-Specific Amplification\" (MSA).",
      "The platform employs a detection method known as \"Nucleic Acid Circuitry\" (NAC).",
      "SHERLOCKv2 has a simplified workflow with fewer steps and reagents compared to the original platform.",
      "SHERLOCKv2 has the capability to detect multiple mutations in a single reaction.",
      "The original SHERLOCK platform could only detect one mutation at a time."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The original SHERLOCK platform could detect multiple targets by using different CRISPR enzymes or by running parallel reactions.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender algorithm is a heuristic algorithm used to find the shortest path in a graph. It was developed by David E. Culler and John L. Rexford in 1993. The algorithm is designed to work well on graphs with a large number of nodes and edges, and it is particularly useful for finding the shortest path in a graph with a large number of parallel edges.\nThe Bartender algorithm works by first partitioning the graph into smaller subgraphs, called \"bartenders,\" based on the distance from the source node. Each bartender is responsible for finding the shortest path to the sink node in the subgraph it is responsible for. The algorithm then combines the paths found by each bartender to find the overall shortest path in the graph.\nThe steps of the Bartender algorithm are as follows:\n1. Partition the graph into bartenders: The algorithm starts by partitioning the graph into a fixed number of bartenders, each containing a subset of the nodes in the graph. The size of the bartenders is determined by the size of the graph and the desired level of accuracy.\n2. Compute the shortest path in each bartender: Each bartender computes the shortest path from the source node to the sink node in its subgraph. This is done using a shortest-path algorithm, such as Dijkstra's algorithm or Bellman-Ford algorithm.\n3. Combine the paths from each bartender: Once the shortest path has been computed in each bartender, the algorithm combines the paths to find the overall shortest path in the graph. This is done by finding the shortest path that connects the shortest paths found in each bartender.\n4. Repeat the process: The algorithm repeats the process of partitioning the graph into bartenders, computing the shortest path in each bartender, and combining the paths until the overall shortest path in the graph is found.\nThe Bartender algorithm has several advantages over other shortest-path algorithms, including:\n* Scalability: The algorithm can handle large graphs with a large number of nodes and edges, making it particularly useful for applications where the graph is too large to fit in memory.\n* Flexibility: The algorithm can be used with different shortest-path algorithms, such as Dijkstra's algorithm or Bellman-",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm was developed by David E. Culler and John L. Rexford in 1993.\n2. It is a heuristic algorithm used for finding the shortest path in a graph.\n3. The Bartender algorithm is designed to work well on graphs with a large number of nodes and edges.\n4. The algorithm partitions the graph into smaller subgraphs called \"bartenders\" based on the distance from the source node.\n5. Each bartender is responsible for finding the shortest path to the sink node within its subgraph.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm was developed by David E. Culler and John L. Rexford in 1993.",
      "It is a heuristic algorithm used for finding the shortest path in a graph.",
      "The Bartender algorithm is designed to work well on graphs with a large number of nodes and edges.",
      "The algorithm partitions the graph into smaller subgraphs called \"bartenders\" based on the distance from the source node.",
      "Each bartender is responsible for finding the shortest path to the sink node within its subgraph."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no widely recognized Bartender algorithm developed by David E. Culler and John L. Rexford in 1993. This statement seems to be incorrect or about a very obscure or fictional algorithm.\n2. UNKNOWN: Since the Bartender algorithm mentioned does not appear to be a recognized algorithm, the claim about it being a heuristic algorithm for finding the shortest path in a graph cannot be verified.\n3. UNKNOWN: As the Bartender algorithm is not established in the field, there is no information available to confirm or deny its design for graphs with a large number of nodes and edges.\n4. UNKNOWN: The concept of partitioning a graph into \"bartenders\" is not a recognized method in graph theory or algorithms, so the truth of this statement cannot be determined.\n5. UNKNOWN: Without verifiable information on the Bartender algorithm, the role of each \"bartender\" in finding the shortest path within a subgraph cannot be confirmed or corrected.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "There are several web-based pedigree editors available, including:\n1. Pedigree Manager: This is a popular web-based tool that allows users to create and edit family trees, including photos, sources, and notes.\n2. Family Tree Builder: This is another popular web-based tool that allows users to create and edit family trees, including historical records and sources.\n3. MyHeritage: This is a genealogy research platform that includes a web-based pedigree editor, as well as access to historical records and family trees.\n4. GenoPro: This is a professional-grade web-based pedigree editor that allows users to create complex family trees with unlimited branches, photos, and sources.\n5. Legacy Family Tree: This is a web-based genealogy research platform that includes a pedigree editor, as well as access to historical records and family trees.\n6. Family Tree Maker: This is a web-based genealogy research platform that includes a pedigree editor, as well as access to historical records and family trees.\n7. Ancestry.com: This is a popular genealogy research platform that includes a web-based pedigree editor, as well as access to historical records and family trees.\n8. RootsMagic: This is a web-based genealogy research platform that includes a pedigree editor, as well as access to historical records and family trees.\n9. Family Historian: This is a web-based genealogy research platform that includes a pedigree editor, as well as access to historical records and family trees.\n10. Gramps: This is a free and open-source web-based genealogy research platform that includes a pedigree editor, as well as access to historical records and family trees.\nPlease note that this is not an exhaustive list, and there may be other web-based pedigree editors available.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree Manager is a web-based tool for creating and editing family trees.\n2. Family Tree Builder is a web-based tool that allows users to create and edit family trees with historical records and sources.\n3. MyHeritage is a genealogy research platform that includes a web-based pedigree editor.\n4. GenoPro is a professional-grade web-based pedigree editor that supports the creation of complex family trees.\n5. Gramps is a free and open-source web-based genealogy research platform that includes a pedigree editor.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree Manager is a web-based tool for creating and editing family trees.",
      "Family Tree Builder is a web-based tool that allows users to create and edit family trees with historical records and sources.",
      "MyHeritage is a genealogy research platform that includes a web-based pedigree editor.",
      "GenoPro is a professional-grade web-based pedigree editor that supports the creation of complex family trees.",
      "Gramps is a free and open-source web-based genealogy research platform that includes a pedigree editor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GenoPro is not web-based; it is a downloadable software application for creating and editing complex family trees.\n5. FALSE [correction]: Gramps is not web-based; it is a free and open-source genealogy software that requires download and installation on a user's computer.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases that exist for spider-venom toxins, including:\n1. ToxinDB: ToxinDB is a comprehensive database of toxins from various sources, including spider venoms. It contains information on the structure, function, and pharmacology of toxins, as well as their potential therapeutic applications.\n2. Spider Toxin Database (SpTox): SpTox is a database of spider venom toxins that provides information on their structure, function, and evolution. It also includes data on the pharmacological activities of these toxins and their potential applications in medicine.\n3. Venom-DB: Venom-DB is a database of venom peptides and proteins from various organisms, including spiders. It contains information on the structure, function, and evolution of these toxins, as well as their pharmacological activities and potential therapeutic applications.\n4. Natural Products Alliance (NPA): NPA is a database of natural products, including spider venom toxins. It provides information on the structure, function, and pharmacology of these toxins, as well as their potential therapeutic applications.\n5. Spider Venom Toxin (SVT): SVT is a database of spider venom toxins that provides information on their structure, function, and evolution. It also includes data on the pharmacological activities of these toxins and their potential applications in medicine.\n6. ToxinWeb: ToxinWeb is a comprehensive database of toxins from various sources, including spider venoms. It contains information on the structure, function, and pharmacology of toxins, as well as their potential therapeutic applications.\n7. VenomWeb: VenomWeb is a database of venom peptides and proteins from various organisms, including spiders. It contains information on the structure, function, and evolution of these toxins, as well as their pharmacological activities and potential therapeutic applications.\n8. Spider Toxin Gene Database (STGD): STGD is a database of genes encoding spider venom toxins. It provides information on the structure, function, and evolution of these toxins,",
    "llama-2-7b-chat-hf_fact_raw": "1. ToxinDB is a database that includes information on spider venom toxins and their potential therapeutic applications.\n2. The Spider Toxin Database (SpTox) provides information on the structure, function, and evolution of spider venom toxins.\n3. Venom-DB is a database that contains information on venom peptides and proteins from various organisms, including spiders.\n4. The Natural Products Alliance (NPA) database includes information on spider venom toxins and their potential therapeutic applications.\n5. The Spider Toxin Gene Database (STGD) is a database that provides information on genes encoding spider venom toxins.",
    "llama-2-7b-chat-hf_fact": [
      "ToxinDB is a database that includes information on spider venom toxins and their potential therapeutic applications.",
      "The Spider Toxin Database (SpTox) provides information on the structure, function, and evolution of spider venom toxins.",
      "Venom-DB is a database that contains information on venom peptides and proteins from various organisms, including spiders.",
      "The Natural Products Alliance (NPA) database includes information on spider venom toxins and their potential therapeutic applications.",
      "The Spider Toxin Gene Database (STGD) is a database that provides information on genes encoding spider venom toxins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information about a database named \"ToxinDB,\" it is not possible to confirm or deny the accuracy of this statement.\n2. UNKNOWN: The existence and content of a database named \"Spider Toxin Database (SpTox)\" cannot be confirmed without additional information.\n3. UNKNOWN: The existence and content of a database named \"Venom-DB\" cannot be confirmed without additional information.\n4. UNKNOWN: The existence and content of a database named \"The Natural Products Alliance (NPA)\" cannot be confirmed without additional information, especially in relation to spider venom toxins.\n5. UNKNOWN: The existence and content of a database named \"Spider Toxin Gene Database (STGD)\" cannot be confirmed without additional information.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Axitinib is a tyrosine kinase inhibitor that has been investigated for its potential therapeutic role in various types of cancer, including pancreatic cancer. While there is some evidence to suggest that axitinib may have antitumor activity in pancreatic cancer, there is currently no conclusive evidence to support its use in prolonging survival in these patients.\nA phase Ib clinical trial conducted by the National Cancer Institute (NCI) in 2017 found that axitinib was well-tolerated and showed evidence of antitumor activity in patients with advanced pancreatic cancer. However, the trial did not meet its primary endpoint of overall survival, and the study was discontinued due to a lack of efficacy.\nMore recent studies have also failed to demonstrate a significant survival benefit with axitinib in pancreatic cancer. For example, a phase II clinical trial published in 2020 found that axitinib did not improve overall survival in patients with metastatic pancreatic cancer compared to standard chemotherapy.\nWhile the current evidence suggests that axitinib is not a viable treatment option for prolonging survival in pancreatic cancer patients, ongoing research is exploring its potential use in combination with other therapies, such as chemotherapy or immunotherapy, to improve treatment outcomes. However, further clinical trials are needed to confirm these findings and establish axitinib's role in the treatment of pancreatic cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor that has been investigated for use in various types of cancer, including pancreatic cancer.\n2. A phase Ib clinical trial conducted by the National Cancer Institute in 2017 found that axitinib was well-tolerated and showed evidence of antitumor activity in patients with advanced pancreatic cancer.\n3. The same phase Ib clinical trial did not meet its primary endpoint of overall survival and was discontinued due to a lack of efficacy.\n4. A phase II clinical trial published in 2020 found that axitinib did not improve overall survival in patients with metastatic pancreatic cancer compared to standard chemotherapy.\n5. Ongoing research is exploring the potential use of axitinib in combination with other therapies, such as chemotherapy or immunotherapy, to improve treatment outcomes for pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor that has been investigated for use in various types of cancer, including pancreatic cancer.",
      "A phase Ib clinical trial conducted by the National Cancer Institute in 2017 found that axitinib was well-tolerated and showed evidence of antitumor activity in patients with advanced pancreatic cancer.",
      "The same phase Ib clinical trial did not meet its primary endpoint of overall survival and was discontinued due to a lack of efficacy.",
      "A phase II clinical trial published in 2020 found that axitinib did not improve overall survival in patients with metastatic pancreatic cancer compared to standard chemotherapy.",
      "Ongoing research is exploring the potential use of axitinib in combination with other therapies, such as chemotherapy or immunotherapy, to improve treatment outcomes for pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Microtubule-associated protein) regulates F-actin dynamics through its interaction with actin-related protein 2/3 (ARP2/3) complex. MLP binds to the ARP2/3 complex and inhibits its activity, thereby reducing the actin nucleation and polymerization, and promoting the depolymerization of F-actin. This leads to a decrease in the actin cytoskeleton and an increase in the membrane protrusions.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP (Microtubule-associated protein) regulates F-actin dynamics.\n2. MLP interacts with the actin-related protein 2/3 (ARP2/3) complex.\n3. MLP binding to the ARP2/3 complex inhibits its activity.\n4. The inhibition of ARP2/3 activity by MLP reduces actin nucleation and polymerization.\n5. MLP promotes the depolymerization of F-actin, leading to a decrease in the actin cytoskeleton.",
    "llama-2-7b-chat-hf_fact": [
      "MLP (Microtubule-associated protein) regulates F-actin dynamics.",
      "MLP interacts with the actin-related protein 2/3 (ARP2/3) complex.",
      "MLP binding to the ARP2/3 complex inhibits its activity.",
      "The inhibition of ARP2/3 activity by MLP reduces actin nucleation and polymerization.",
      "MLP promotes the depolymerization of F-actin, leading to a decrease in the actin cytoskeleton."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MLP (Microtubule-associated protein) is not typically associated with the regulation of F-actin dynamics. MLP usually refers to Myosin-like protein, which is involved in other cellular processes. However, MAPs (Microtubule-associated proteins) can regulate microtubule dynamics, not F-actin.\n2. UNKNOWN: Without specific information on which MLP is being referred to, it's unclear whether it interacts with the ARP2/3 complex. There are various proteins that could be abbreviated as MLP, and their interactions with ARP2/3 would depend on the specific protein in question.\n3. UNKNOWN: Since the interaction between MLP and the ARP2/3 complex is not established, the effect of MLP on ARP2/3 activity cannot be determined.\n4. UNKNOWN: The inhibition of ARP2/3 activity by MLP and its subsequent effect on actin nucleation and polymerization cannot be confirmed without knowing the specific interaction between MLP and ARP2/3.\n5. UNKNOWN: Without clear evidence of MLP promoting the depolymerization of F-actin, this statement cannot be confirmed as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "The number of pseudokinases in the human kinome is not a fixed or well-defined number, as the classification of protein kinases and pseudokinases can be complex and can vary depending on the source and methodology used. However, here are some general estimates based on different studies:\n1. According to the Protein Kinase Resource (PKR) database, which is a comprehensive database of protein kinases from various organisms, including humans, there are approximately 500-600 protein kinases in the human kinome. However, not all of these kinases are pseudokinases, as some of them are full-length kinases with catalytic activity.\n2. A study published in the journal Nature Communications in 2017 estimated that there are approximately 300-400 pseudokinases in the human kinome. This study used a machine learning approach to identify pseudokinases based on their structural and functional properties.\n3. Another study published in the journal Cell in 2018 estimated that there are approximately 200-300 pseudokinases in the human kinome. This study used a combination of computational and experimental approaches to identify pseudokinases.\nIt is important to note that the number of pseudokinases can vary depending on the criteria used to define them, and different studies may identify different sets of pseudokinases. Additionally, the functions of pseudokinases can be diverse and can vary depending on the context in which they are expressed.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Protein Kinase Resource (PKR) database lists approximately 500-600 protein kinases in the human kinome.\n2. A study published in Nature Communications in 2017 estimated that there are approximately 300-400 pseudokinases in the human kinome.\n3. A study published in the journal Cell in 2018 estimated that there are approximately 200-300 pseudokinases in the human kinome.",
    "llama-2-7b-chat-hf_fact": [
      "The Protein Kinase Resource (PKR) database lists approximately 500-600 protein kinases in the human kinome.",
      "A study published in Nature Communications in 2017 estimated that there are approximately 300-400 pseudokinases in the human kinome.",
      "A study published in the journal Cell in 2018 estimated that there are approximately 200-300 pseudokinases in the human kinome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The Protein Kinase Resource (PKR) database does list a range of protein kinases in the human kinome, and the number 500-600 is within the correct range for the total number of protein kinases identified in humans.\n2. UNKNOWN: Without the specific article from Nature Communications, it is difficult to confirm the exact number of pseudokinases estimated in the study. The number of pseudokinases in the human kinome is a subject of scientific research and can vary based on the criteria used for classification.\n3. UNKNOWN: Similarly, without access to the specific Cell article, the exact number of pseudokinases estimated cannot be confirmed. The number of pseudokinases is also subject to the definitions and methods used in the study.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "ApoE (apolipoprotein E) mimetics are compounds that mimic the structure and function of the apolipoprotein E protein, which plays a crucial role in lipid metabolism and clearance. Here are three examples of apoE mimetics:\n1. ApoEMimetic-1: This compound was developed by Isis Pharmaceuticals and is a synthetic peptide mimic of the apoE protein. It has been shown to have cholesterol-lowering and anti-inflammatory effects in preclinical studies.\n2. GW3965: This is a small molecule apoE mimetic developed by Gilead Sciences. It has been shown to increase HDL (high-density lipoprotein) cholesterol and reduce LDL (low-density lipoprotein) cholesterol in preclinical studies.\n3. CMB305: This is another small molecule apoE mimetic developed by CMBio, Inc. It has been shown to have anti-inflammatory and anti-atherosclerotic effects in preclinical studies.\nIt is important to note that these are just a few examples of apoE mimetics, and there are many other compounds in various stages of development as potential treatments for various diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoEMimetic-1 is a synthetic peptide mimic of the apoE protein developed by Isis Pharmaceuticals.\n2. GW3965 is a small molecule apoE mimetic developed by Gilead Sciences that has been shown to increase HDL cholesterol and reduce LDL cholesterol in preclinical studies.\n3. CMB305 is a small molecule apoE mimetic developed by CMBio, Inc. with anti-inflammatory and anti-atherosclerotic effects demonstrated in preclinical studies.",
    "llama-2-7b-chat-hf_fact": [
      "ApoEMimetic-1 is a synthetic peptide mimic of the apoE protein developed by Isis Pharmaceuticals.",
      "GW3965 is a small molecule apoE mimetic developed by Gilead Sciences that has been shown to increase HDL cholesterol and reduce LDL cholesterol in preclinical studies.",
      "CMB305 is a small molecule apoE mimetic developed by CMBio, Inc. with anti-inflammatory and anti-atherosclerotic effects demonstrated in preclinical studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific information on the development of these compounds and their developers, it is not possible to verify the accuracy of these statements. The development of pharmaceuticals is a complex process that often involves multiple entities and can be subject to confidentiality, making it difficult to confirm such details without access to the latest industry data or scientific publications.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (SAMHD1) is an enzyme that plays a crucial role in regulating the innate immune response to viral infections. There are sex differences in SAMHD1 activity, which have been observed in various studies. Here are some of the key findings:\n1. SAMHD1 expression: SAMHD1 is expressed at higher levels in females than in males in various tissues, including the brain, liver, and immune cells (1, 2).\n2. Viral sensitivity: Female mice are more susceptible to certain viral infections, such as HIV, than males (3). SAMHD1 has been shown to play a role in this sex difference in viral sensitivity, as it is involved in the regulation of the innate immune response to viral infections (4).\n3. Enzymatic activity: Studies have shown that SAMHD1 activity is higher in female cells than in male cells, particularly in the brain and immune cells (5, 6). This higher activity may contribute to the sex difference in viral sensitivity.\n4. Regulation by estrogen: Estrogen has been shown to regulate SAMHD1 expression and activity in various tissues, including the brain and immune cells (7, 8). Estrogen exposure has been shown to increase SAMHD1 expression and activity in females, which may contribute to the sex difference in viral sensitivity (9).\n5. Implications for HIV infection: The sex difference in SAMHD1 activity has important implications for HIV infection. Since HIV primarily infects CD4+ T cells, which are more abundant in females than in males, females may be more susceptible to HIV infection (10). The higher SAMHD1 activity in females may contribute to their increased resistance to HIV infection (11).\nIn summary, sex differences in SAMHD1 activity have been observed in various studies, with females having higher levels of SAMHD1 expression and activity than males. These differences may contribute to the sex difference in viral sensitivity and may have important implications for HIV infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAMHD1 is expressed at higher levels in females than in males in various tissues, including the brain, liver, and immune cells.\n2. Female mice are more susceptible to certain viral infections, such as HIV, than males.\n3. SAMHD1 activity is higher in female cells than in male cells, particularly in the brain and immune cells.\n4. Estrogen regulates SAMHD1 expression and activity in various tissues, including the brain and immune cells.\n5. HIV primarily infects CD4+ T cells, which are more abundant in females than in males.",
    "llama-2-7b-chat-hf_fact": [
      "SAMHD1 is expressed at higher levels in females than in males in various tissues, including the brain, liver, and immune cells.",
      "Female mice are more susceptible to certain viral infections, such as HIV, than males.",
      "SAMHD1 activity is higher in female cells than in male cells, particularly in the brain and immune cells.",
      "Estrogen regulates SAMHD1 expression and activity in various tissues, including the brain and immune cells.",
      "HIV primarily infects CD4+ T cells, which are more abundant in females than in males."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Generally, male mice are more susceptible to certain viral infections, such as HIV, than females, which is often attributed to differences in immune system function between the sexes.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Yes, RUNX2 (RUNX2/CBFα) has been shown to inhibit astrocyte differentiation.\nRUNX2 is a transcription factor that plays a crucial role in the regulation of hematopoiesis and has been implicated in the development and progression of various cancers. Recent studies have also highlighted its role in the regulation of neural stem cell differentiation, including the inhibition of astrocyte differentiation.\nIn fact, several studies have demonstrated that RUNX2 overexpression inhibits the differentiation of neural progenitor cells (NPCs) into astrocytes, while RUNX2 knockdown promotes astrocyte differentiation. This inhibition of astrocyte differentiation by RUNX2 is thought to be mediated by the repression of key transcription factors involved in astrocyte differentiation, such as PDGFRA and GFAP.\nFurthermore, RUNX2 has been shown to interact with the transcription factor BRN2, which is a key regulator of astrocyte differentiation. The interaction between RUNX2 and BRN2 leads to the repression of BRN2 target genes involved in astrocyte differentiation, such as GFAP and AQP4.\nOverall, these findings suggest that RUNX2 plays a critical role in regulating astrocyte differentiation and may be a potential therapeutic target for the treatment of neurological disorders characterized by abnormal astrocyte function, such as Alzheimer's disease and multiple sclerosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 has been shown to inhibit astrocyte differentiation.\n2. RUNX2 is a transcription factor that plays a role in the regulation of hematopoiesis.\n3. Overexpression of RUNX2 inhibits the differentiation of neural progenitor cells into astrocytes.\n4. Knockdown of RUNX2 promotes astrocyte differentiation.\n5. RUNX2 interacts with the transcription factor BRN2, leading to the repression of BRN2 target genes involved in astrocyte differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 has been shown to inhibit astrocyte differentiation.",
      "RUNX2 is a transcription factor that plays a role in the regulation of hematopoiesis.",
      "Overexpression of RUNX2 inhibits the differentiation of neural progenitor cells into astrocytes.",
      "Knockdown of RUNX2 promotes astrocyte differentiation.",
      "RUNX2 interacts with the transcription factor BRN2, leading to the repression of BRN2 target genes involved in astrocyte differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: RUNX2 is a transcription factor that plays a role in the regulation of bone development, not hematopoiesis.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "The Cobb-Stansby excision arthroplasty is a surgical procedure that is typically performed on the joints of the body, specifically the knee. It is a type of arthroplasty, which is a surgical procedure that replaces a damaged or arthritic joint with an artificial joint. The Cobb-Stansby excision arthroplasty is used to treat knee osteoarthritis, which is a condition where the cartilage in the joint wears down, causing pain and stiffness.\nDuring the procedure, the surgeon will make an incision in the knee to access the joint. The damaged or arthritic bone and cartilage are then removed, and the joint is resurfaced with an artificial implant. The implant is designed to replicate the natural movement of the joint and provide pain relief and improved mobility.\nThe Cobb-Stansby excision arthroplasty is a minimally invasive procedure, which means that it is performed through small incisions, resulting in less tissue damage and trauma to the body. This approach can lead to faster recovery times and less postoperative pain compared to traditional open surgery. However, the specific location of the incision may vary depending on the individual patient and the extent of the damage to the joint.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.\n2. This procedure is used to treat knee osteoarthritis.\n3. During the Cobb-Stainsby excision arthroplasty, damaged or arthritic bone and cartilage are removed.\n4. An artificial implant is used to resurface the joint during the procedure.\n5. The Cobb-Stainsby excision arthroplasty is considered a minimally invasive procedure.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.",
      "This procedure is used to treat knee osteoarthritis.",
      "During the Cobb-Stainsby excision arthroplasty, damaged or arthritic bone and cartilage are removed.",
      "An artificial implant is used to resurface the joint during the procedure.",
      "The Cobb-Stainsby excision arthroplasty is considered a minimally invasive procedure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the hip joint, not the knee joint.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: During the Cobb-Stainsby excision arthroplasty, a portion of the femoral head is removed, and the remaining part is capped with a prosthetic device, but it is not a resurfacing of the joint as in total hip replacement.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Yes, over-expression of GRHL2 has been shown to promote epithelial-to-mesenchymal transition (EMT) in various cell types. EMT is a process by which epithelial cells lose their epithelial characteristics and acquire mesenchymal properties, such as increased motility and invasiveness, and is a key step in tumor progression.\nStudies have shown that GRHL2 over-expression leads to EMT by suppressing the expression of epithelial markers and increasing the expression of mesenchymal markers, such as vimentin and N-cadherin, in various cell types, including breast cancer cells. GRHL2 over-expression also leads to the activation of key transcription factors involved in EMT, such as ZEB1 and Snail, and promotes the epithelial-to-mesenchymal transition.\nIn addition, GRHL2 over-expression has been shown to promote the migration and invasion of cancer cells, which are hallmarks of EMT. Therefore, GRHL2 over-expression is a key player in the regulation of EMT and tumor progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT) in various cell types.\n2. EMT is characterized by the loss of epithelial characteristics and the acquisition of mesenchymal properties, including increased motility and invasiveness.\n3. GRHL2 over-expression suppresses the expression of epithelial markers and increases the expression of mesenchymal markers such as vimentin and N-cadherin.\n4. Key transcription factors involved in EMT, such as ZEB1 and Snail, are activated by GRHL2 over-expression.\n5. GRHL2 over-expression promotes the migration and invasion of cancer cells, which are characteristics of EMT.",
    "llama-2-7b-chat-hf_fact": [
      "Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT) in various cell types.",
      "EMT is characterized by the loss of epithelial characteristics and the acquisition of mesenchymal properties, including increased motility and invasiveness.",
      "GRHL2 over-expression suppresses the expression of epithelial markers and increases the expression of mesenchymal markers such as vimentin and N-cadherin.",
      "Key transcription factors involved in EMT, such as ZEB1 and Snail, are activated by GRHL2 over-expression.",
      "GRHL2 over-expression promotes the migration and invasion of cancer cells, which are characteristics of EMT."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Over-expression of GRHL2 typically suppresses epithelial-to-mesenchymal transition (EMT) in various cell types.\n2. TRUE\n3. FALSE [correction]: GRHL2 over-expression typically increases the expression of epithelial markers and suppresses the expression of mesenchymal markers such as vimentin and N-cadherin.\n4. FALSE [correction]: Key transcription factors involved in EMT, such as ZEB1 and Snail, are typically inhibited by GRHL2 over-expression.\n5. FALSE [correction]: GRHL2 over-expression typically inhibits the migration and invasion of cancer cells, which are characteristics of EMT.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "T-bet, Eomesodermin (Eomes), and T-box transcription factor 1 (Tbfa1) are three T-cell-specific transcription factors that have been implicated in lung cancer.\n1. T-bet: T-bet is a transcription factor that plays a critical role in the differentiation and function of T cells. In lung cancer, T-bet has been shown to be downregulated in tumor-infiltrating T cells, leading to impaired anti-tumor immune responses. Overexpression of T-bet has been associated with better prognosis in lung cancer patients.\n2. Eomes: Eomes is another T-cell-specific transcription factor that has been implicated in lung cancer. Eomes is overexpressed in many types of cancer, including lung cancer, and promotes the development of a tumor-promoting T-cell subset. In lung cancer, Eomes has been shown to inhibit the expression of the tumor suppressor gene PD-1 on T cells, leading to impaired immune surveillance.\n3. T-box transcription factor 1 (Tbfa1): Tbfa1 is a T-cell-specific transcription factor that has been implicated in lung cancer. Tbfa1 is overexpressed in many types of cancer, including lung cancer, and promotes the development of a tumor-promoting T-cell subset. In lung cancer, Tbfa1 has been shown to inhibit the expression of the tumor suppressor gene PD-1 on T cells, leading to impaired immune surveillance.\nOverall, these T-UCRs play important roles in regulating the immune response in lung cancer and their dysregulation can lead to impaired immune surveillance and tumor progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-bet is a transcription factor implicated in lung cancer and is downregulated in tumor-infiltrating T cells in this disease.\n2. Overexpression of T-bet in lung cancer patients has been associated with a better prognosis.\n3. Eomes, a T-cell-specific transcription factor, is overexpressed in lung cancer and other types of cancer.\n4. Eomes has been shown to inhibit the expression of the tumor suppressor gene PD-1 on T cells in lung cancer.\n5. T-box transcription factor 1 (Tbfa1) is overexpressed in lung cancer and promotes the development of a tumor-promoting T-cell subset.",
    "llama-2-7b-chat-hf_fact": [
      "T-bet is a transcription factor implicated in lung cancer and is downregulated in tumor-infiltrating T cells in this disease.",
      "Overexpression of T-bet in lung cancer patients has been associated with a better prognosis.",
      "Eomes, a T-cell-specific transcription factor, is overexpressed in lung cancer and other types of cancer.",
      "Eomes has been shown to inhibit the expression of the tumor suppressor gene PD-1 on T cells in lung cancer.",
      "T-box transcription factor 1 (Tbfa1) is overexpressed in lung cancer and promotes the development of a tumor-promoting T-cell subset."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: T-bet is a transcription factor that is known to be involved in the differentiation of T cells and has been implicated in various diseases, including cancer. It can be downregulated in tumor-infiltrating T cells in lung cancer, which can affect the immune response to the tumor.\n2. TRUE: Overexpression of T-bet has been associated with a better prognosis in lung cancer patients, as it is thought to enhance the anti-tumor immune response.\n3. UNKNOWN: Eomes, also known as eomesodermin, is a T-cell-specific transcription factor that plays a role in the development and function of T cells. Whether it is overexpressed in lung cancer and other types of cancer is not specified in the provided statements and would require specific research data to confirm.\n4. FALSE [correction]: Eomes has been shown to regulate the expression of various genes in T cells, but the statement that it inhibits the expression of the tumor suppressor gene PD-1 (Programmed Death-1) is incorrect. PD-1 is not a tumor suppressor gene; it is an immune checkpoint that can be upregulated on T cells in the tumor microenvironment, leading to T cell exhaustion and an impaired immune response. Eomes may influence the expression of PD-1, but the specific interaction would depend on the context and is not as described.\n5. FALSE [correction]: The transcription factor mentioned is likely a typographical error. The correct name is T-box transcription factor 21 (TBX21), which encodes the T-bet protein. There is no widely recognized transcription factor named \"Tbfa1\" associated with lung cancer. If the statement is referring to T-bet (encoded by TBX21), then the statement about overexpression promoting a tumor-promoting T-cell subset would be context-dependent and requires specific evidence.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151, also known as free fatty acid receptor 1 (FFA1), is an orphan G protein-coupled receptor that was first identified in 2001. Since then, significant research has been conducted to understand its function and potential therapeutic applications. Here are some key points about GPR151:\n1. Structure and Function: GPR151 is a seven-transmembrane receptor that is primarily expressed in the brain, pancreas, and adipose tissue. It is activated by free fatty acids (FFAs), particularly palmitate, and mediates a variety of physiological responses, including glucose metabolism, lipid metabolism, and inflammation.\n2. Metabolic Regulation: GPR151 plays a key role in regulating glucose and lipid metabolism. Activation of GPR151 by FFAs stimulates glucose uptake in adipocytes and skeletal muscle cells, while inhibiting glucose production in the liver. GPR151 also regulates lipid metabolism by promoting lipolysis and inhibiting lipogenesis.\n3. Inflammation: GPR151 has been shown to play a role in the regulation of inflammation. Activation of GPR151 inhibits the production of pro-inflammatory cytokines, such as TNF-α, and promotes the production of anti-inflammatory cytokines, such as IL-10.\n4. Therapeutic Potential: GPR151 has been identified as a potential therapeutic target for various diseases, including metabolic disorders, such as type 2 diabetes and obesity, as well as neurological disorders, such as Alzheimer's disease and Parkinson's disease. GPR151 agonists have been shown to improve insulin sensitivity, reduce body weight, and improve cognitive function in animal models of these diseases.\n5. Tissue Distribution: GPR151 is primarily expressed in the brain, pancreas, and adipose tissue, but it is also expressed in other tissues, including the",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is also known as free fatty acid receptor 1 (FFA1).\n2. GPR151 was first identified in 2001.\n3. GPR151 is a seven-transmembrane receptor primarily expressed in the brain, pancreas, and adipose tissue.\n4. GPR151 is activated by free fatty acids, particularly palmitate.\n5. GPR151 plays a role in regulating glucose and lipid metabolism, as well as inflammation.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is also known as free fatty acid receptor 1 (FFA1).",
      "GPR151 was first identified in 2001.",
      "GPR151 is a seven-transmembrane receptor primarily expressed in the brain, pancreas, and adipose tissue.",
      "GPR151 is activated by free fatty acids, particularly palmitate.",
      "GPR151 plays a role in regulating glucose and lipid metabolism, as well as inflammation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GPR151 is not known as free fatty acid receptor 1 (FFA1). FFA1 is another name for GPR40.\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: GPR151 is not known to be activated by free fatty acids; this characteristic is associated with GPR40 (FFA1).\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "The Fluzone Intradermal Quadrivalent vaccine contains the following attenuated live viruses:\n1. H1N1\n2. H3N2\n3. B/Victoria\n4. B/Yamagata\nThe attenuated live viruses in the Fluzone Intradermal Quadrivalent vaccine are designed to stimulate an immune response in the body, which can help protect against infection with these specific types of influenza viruses. It is important to note that the vaccine is not a 100% guarantee against infection, but it can significantly reduce the risk of severe illness and complications associated with influenza.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus for H1N1.\n2. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus for H3N2.\n3. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus for B/Victoria.\n4. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus for B/Yamagata.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus for H1N1.",
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus for H3N2.",
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus for B/Victoria.",
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus for B/Yamagata."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine contains an inactivated virus for H1N1, not an attenuated live virus.\n2. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine contains an inactivated virus for H3N2, not an attenuated live virus.\n3. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine contains an inactivated virus for B/Victoria, not an attenuated live virus.\n4. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine contains an inactivated virus for B/Yamagata, not an attenuated live virus.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Systemic lupus erythematosus (SLE) is a complex autoimmune disease that is associated with genetic variations in several genes, including the tumor necrosis factor receptor 2 (TNFR2) gene. Specifically, genetic variations in the TNFR2 gene have been identified as a risk factor for SLE, particularly in certain ethnic groups.\nThe TNFR2 gene is located on chromosome 6q23 and consists of 12 exons that encode a protein of 450 kDa. The gene encodes for the TNFR2 protein, which is a key player in the immune system and plays a crucial role in the regulation of inflammation and immune responses.\nSeveral genetic variants in the TNFR2 gene have been identified as risk factors for SLE, including:\n1. TNFR2 gene promoter polymorphisms: Variants in the TNFR2 promoter region, such as -173G>C and -572G>C, have been associated with increased risk of SLE in several studies.\n2. TNFR2 gene mutations: Point mutations in the TNFR2 gene, such as R75W and Y78C, have been identified in some cases of SLE. These mutations can lead to constitutive activation of the TNFR2 protein and contribute to the development of autoantibodies and autoimmune responses.\n3. TNFR2 gene copy number variations: Some studies have identified copy number variations in the TNFR2 gene, particularly in the 1q21 region, which may also contribute to the risk of developing SLE.\nIt's worth noting that the genetic associations with SLE are complex and multiple genes are likely to contribute to the risk of developing the disease. Additionally, the genetic variants identified in TNFR2 gene are not exclusive to SLE and have also been associated with other autoimmune diseases, highlighting the shared genetic background between these diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Genetic variations in the TNFR2 gene have been identified as a risk factor for Systemic Lupus Erythematosus (SLE).\n2. The TNFR2 gene is located on chromosome 6q23 and consists of 12 exons.\n3. The TNFR2 gene encodes a protein that plays a role in the regulation of inflammation and immune responses.\n4. Variants in the TNFR2 promoter region, such as -173G>C and -572G>C, have been associated with an increased risk of SLE.\n5. Point mutations in the TNFR2 gene, such as R75W and Y78C, have been identified in some cases of SLE.",
    "llama-2-7b-chat-hf_fact": [
      "Genetic variations in the TNFR2 gene have been identified as a risk factor for Systemic Lupus Erythematosus (SLE).",
      "The TNFR2 gene is located on chromosome 6q23 and consists of 12 exons.",
      "The TNFR2 gene encodes a protein that plays a role in the regulation of inflammation and immune responses.",
      "Variants in the TNFR2 promoter region, such as -173G>C and -572G>C, have been associated with an increased risk of SLE.",
      "Point mutations in the TNFR2 gene, such as R75W and Y78C, have been identified in some cases of SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Genetic variations in the TNFR2 gene have been associated with various autoimmune diseases, including Systemic Lupus Erythematosus (SLE).\n2. FALSE [correction]: The TNFR2 gene is located on chromosome 1p36.22 and consists of 10 exons, not on chromosome 6q23 with 12 exons.\n3. TRUE: The TNFR2 gene encodes the tumor necrosis factor receptor 2, which is involved in the regulation of immune responses and inflammation.\n4. UNKNOWN: Without specific scientific references, it is difficult to confirm the association of these particular variants in the TNFR2 promoter region with an increased risk of SLE.\n5. UNKNOWN: Similarly, without specific references, the association of point mutations such as R75W and Y78C in the TNFR2 gene with SLE cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "There is currently no licensed vaccine available for the prevention of peanut allergy. However, researchers are actively working on developing a peanut allergy vaccine, and several promising candidates are in various stages of clinical trials.\nOne of the most advanced candidates is the Viaskin Peanut patch, which is a patch containing small amounts of peanut protein that is applied to the skin. The patch is designed to deliver the protein gradually over time, allowing the immune system to build up tolerance to it. Studies have shown that the Viaskin Peanut patch can reduce the risk of peanut allergy in high-risk individuals by up to 80%.\nAnother promising approach is the use of messenger RNA (mRNA) vaccines, which are designed to deliver genetic material to cells that instructs them to produce a specific protein. In the case of peanut allergy, mRNA vaccines could be used to deliver the genetic instructions for producing a protein that is similar to the peanut allergen. This could help the immune system build up tolerance to the allergen over time.\nWhile these vaccine candidates show promise, it is important to note that they are still in the experimental stage, and more research is needed to determine their safety and efficacy in larger, more diverse populations. Additionally, even if a peanut allergy vaccine is developed, it is unlikely to be a single-dose treatment, and repeated doses may be necessary to maintain tolerance.\nIn summary, while there is currently no licensed vaccine available for the prevention of peanut allergy, researchers are actively working on developing new and innovative approaches to prevent and treat this common and potentially life-threatening condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no licensed vaccine available for the prevention of peanut allergy as of the knowledge cutoff date.\n2. The Viaskin Peanut patch is a patch containing small amounts of peanut protein that is applied to the skin and is in clinical trials.\n3. Studies have indicated that the Viaskin Peanut patch can reduce the risk of peanut allergy in high-risk individuals by up to 80%.\n4. Researchers are exploring the use of messenger RNA (mRNA) vaccines as a potential treatment for peanut allergy.\n5. The vaccine candidates for peanut allergy are still in the experimental stage and require more research to determine their safety and efficacy.",
    "llama-2-7b-chat-hf_fact": [
      "There is no licensed vaccine available for the prevention of peanut allergy as of the knowledge cutoff date.",
      "The Viaskin Peanut patch is a patch containing small amounts of peanut protein that is applied to the skin and is in clinical trials.",
      "Studies have indicated that the Viaskin Peanut patch can reduce the risk of peanut allergy in high-risk individuals by up to 80%.",
      "Researchers are exploring the use of messenger RNA (mRNA) vaccines as a potential treatment for peanut allergy.",
      "The vaccine candidates for peanut allergy are still in the experimental stage and require more research to determine their safety and efficacy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: While studies have indicated that the Viaskin Peanut patch may help reduce the risk of peanut allergy reactions in individuals who are already allergic, there is no specific percentage reduction that can be universally applied, and the statement of \"up to 80%\" cannot be verified without a specific study reference.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene is located on the X chromosome at position Xq13.1. This means that the Fxy gene is located on the long arm of the X chromosome at position 13.1, which is a specific chromosomal location. The X chromosome is one of the sex chromosomes in mammals, and it carries a number of genes that are important for male and female reproductive development and function. The Fxy gene is one of the genes located on the X chromosome that plays a role in regulating the development and function of the female reproductive system.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on the X chromosome.\n2. The specific chromosomal position of the mouse Fxy gene is Xq13.1.\n3. The Fxy gene is situated on the long arm of the X chromosome.\n4. The X chromosome is a sex chromosome in mammals.\n5. The Fxy gene is involved in regulating the development and function of the female reproductive system.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on the X chromosome.",
      "The specific chromosomal position of the mouse Fxy gene is Xq13.1.",
      "The Fxy gene is situated on the long arm of the X chromosome.",
      "The X chromosome is a sex chromosome in mammals.",
      "The Fxy gene is involved in regulating the development and function of the female reproductive system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The specific chromosomal position of the mouse Fxy gene is not Xq13.1; this designation is typically used for human chromosome mapping. Mouse chromosomes are usually not described with the same nomenclature as human chromosomes.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "Methidiumpropyl-EDTA (MPE) sequencing is a method for sequencing DNA that is based on the cleavage of DNA by the enzyme Methidiumpropyl-EDTA (Mpe) in the presence of EDTA. Mpe is a DNA-cleaving enzyme that recognizes and cleaves the phosphodiester backbone of DNA at specific recognition sites.\nThe basis of the MPE-seq method is to use Mpe to cleave DNA at specific recognition sites, which are designed to be specific to the target DNA sequence. The cleaved DNA is then separated from the intact DNA using a variety of methods, such as gel electrophoresis or high-performance liquid chromatography (HPLC). The separated DNA fragments are then detected and quantified using various methods, such as fluorescence or mass spectrometry.\nThe advantages of MPE-seq include:\n1. High resolution: MPE-seq can resolve DNA fragments as small as 100 base pairs, which is much higher resolution than other sequencing methods such as Sanger sequencing.\n2. Specificity: The recognition sites used in MPE-seq are highly specific, which reduces the risk of non-specific cleavage and increases the accuracy of the sequencing results.\n3. Ease of use: MPE-seq is relatively simple to perform and does not require specialized equipment or expertise.\n4. Cost-effective: MPE-seq is less expensive than other sequencing methods, such as Sanger sequencing, which makes it a more accessible option for researchers.\n5. Flexibility: MPE-seq can be used to sequence a wide range of DNA templates, including genomic DNA, plasmids, and RNA.\nThe limitations of MPE-seq include:\n1. Limited depth: MPE-seq can only sequence a limited number of DNA fragments in parallel, which can limit the depth of the sequencing data.\n2. Limited read length: The length of the sequencing reads obtained using MPE-seq is typically shorter than other sequencing methods, such as Illumina sequencing.\n3. Limited accuracy: The accuracy of MPE-seq can be affected by the specificity of the recognition sites used and the quality of the DNA template.\n4. Limited multiplexing: MPE-seq can only sequence",
    "llama-2-7b-chat-hf_fact_raw": "1. Methidiumpropyl-EDTA (MPE) sequencing is a DNA sequencing method that involves the cleavage of DNA by the enzyme Methidiumpropyl-EDTA (Mpe) in the presence of EDTA.\n2. The MPE-seq method uses Mpe to cleave DNA at specific recognition sites designed to be specific to the target DNA sequence.\n3. The cleaved DNA fragments in MPE-seq can be separated using methods such as gel electrophoresis or high-performance liquid chromatography (HPLC).\n4. MPE-seq can resolve DNA fragments as small as 100 base pairs.\n5. The recognition sites used in MPE-seq are highly specific, which reduces the risk of non-specific cleavage.",
    "llama-2-7b-chat-hf_fact": [
      "Methidiumpropyl-EDTA (MPE) sequencing is a DNA sequencing method that involves the cleavage of DNA by the enzyme Methidiumpropyl-EDTA (Mpe) in the presence of EDTA.",
      "The MPE-seq method uses Mpe to cleave DNA at specific recognition sites designed to be specific to the target DNA sequence.",
      "The cleaved DNA fragments in MPE-seq can be separated using methods such as gel electrophoresis or high-performance liquid chromatography (HPLC).",
      "MPE-seq can resolve DNA fragments as small as 100 base pairs.",
      "The recognition sites used in MPE-seq are highly specific, which reduces the risk of non-specific cleavage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Methidiumpropyl-EDTA (MPE) sequencing is not a DNA sequencing method. MPE is a chemical nucleic acid cleavage reagent, not an enzyme. It cleaves DNA by intercalating into the DNA and cleaving it in the presence of light and oxygen, not EDTA.\n2. FALSE [correction]: Since MPE is not an enzyme and does not have recognition sites, it does not cleave DNA at specific recognition sites designed to be specific to the target DNA sequence. MPE-seq is not a standard term in DNA sequencing.\n3. TRUE: While the statement about MPE-seq is based on a misunderstanding, it is true that cleaved DNA fragments can be separated using methods such as gel electrophoresis or high-performance liquid chromatography (HPLC), which are common techniques in DNA analysis.\n4. UNKNOWN: Since MPE-seq is not a recognized DNA sequencing method, the ability to resolve DNA fragments as small as 100 base pairs cannot be confirmed or denied in this context.\n5. FALSE [correction]: The statement is based on the incorrect premise that MPE-seq uses specific recognition sites. MPE does not use recognition sites as it is not an enzyme but a chemical cleavage reagent. Therefore, the specificity of recognition sites is not applicable.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR (Genome-Wide Association Study) is typically implemented using a variety of programming languages and tools depending on the specific requirements and the research question being addressed. However, some popular programming languages used for GWAR include:\n1. Python: Python is a popular language for genomics analysis due to its simplicity, flexibility, and extensive libraries for genomics data analysis. Many GWAR studies use Python libraries such as scikit-learn, pandas, and scipy for data manipulation and analysis.\n2. R: R is a popular language for statistical computing and graphics. It has a wide range of packages for genomics data analysis, including the \"GenomicR\" package, which provides a comprehensive set of tools for GWAR.\n3. MATLAB: MATLAB is a high-level language for numerical computation and data analysis. It has a number of toolboxes for genomics data analysis, including the \"Genomic Toolbox\" and the \"Image Processing Toolbox\".\n4. Java: Java is a popular language for developing large-scale bioinformatics applications. It has a number of libraries and tools for genomics data analysis, including the \"Broad Institute's GWAS Toolkit\".\n5. C++: C++ is a powerful language for high-performance computing and is often used for large-scale genomics analysis. It has a number of libraries and tools for genomics data analysis, including the \"GenomeTools\" library.\nIt's worth noting that GWAR can be implemented using a variety of other programming languages and tools as well, depending on the specific requirements and goals of the analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Python is used for GWAR studies and utilizes libraries such as scikit-learn, pandas, and scipy.\n2. R is used for statistical computing and graphics in GWAR and has packages like \"GenomicR\" for genomics data analysis.\n3. MATLAB is used for numerical computation and data analysis in GWAR, with toolboxes such as \"Genomic Toolbox\" and \"Image Processing Toolbox\".\n4. Java is used for developing large-scale bioinformatics applications in GWAR, including the \"Broad Institute's GWAS Toolkit\".\n5. C++ is used for high-performance computing in GWAR and includes libraries like \"GenomeTools\" for genomics data analysis.",
    "llama-2-7b-chat-hf_fact": [
      "Python is used for GWAR studies and utilizes libraries such as scikit-learn, pandas, and scipy.",
      "R is used for statistical computing and graphics in GWAR and has packages like \"GenomicR\" for genomics data analysis.",
      "MATLAB is used for numerical computation and data analysis in GWAR, with toolboxes such as \"Genomic Toolbox\" and \"Image Processing Toolbox\".",
      "Java is used for developing large-scale bioinformatics applications in GWAR, including the \"Broad Institute's GWAS Toolkit\".",
      "C++ is used for high-performance computing in GWAR and includes libraries like \"GenomeTools\" for genomics data analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Python is commonly used in Genome-Wide Association Studies (GWAS) and utilizes libraries such as scikit-learn, pandas, and scipy for data analysis and statistical computing.\n2. TRUE - R is widely used for statistical computing and graphics, including in the field of GWAS, and has packages like \"GenomicR\" which could be a hypothetical package for genomics data analysis (although the actual package name for genomic data analysis in R might differ, such as \"Bioconductor\" or \"GenABEL\").\n3. TRUE - MATLAB is used for numerical computation and data analysis and could be used in GWAS, with toolboxes such as \"Bioinformatics Toolbox\" (the actual name, not \"Genomic Toolbox\") and \"Image Processing Toolbox\".\n4. UNKNOWN - While Java is used for developing bioinformatics applications, the \"Broad Institute's GWAS Toolkit\" is not a recognized toolkit. The Broad Institute does develop tools for genomics, such as the Genome Analysis Toolkit (GATK), but it is not specifically referred to as the \"Broad Institute's GWAS Toolkit\".\n5. TRUE - C++ is often used for high-performance computing tasks due to its speed and efficiency, and it includes libraries that could be used for genomics data analysis, such as \"GenomeTools\". However, the specific use of \"GenomeTools\" for GWAS is not well-known, and it might be more general-purpose for genomics rather than specifically designed for GWAS.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden (also known as masitinib) is a tyrosine kinase inhibitor that has been investigated for its potential therapeutic effects in amyotrophic lateral sclerosis (ALS). While the results of clinical trials have been mixed, some studies suggest that xaliproden may have a positive impact on the prognosis of ALS.\nA phase II clinical trial published in 2012 found that treatment with xaliproden for 24 weeks resulted in a slowing of the disease progression in patients with ALS. Specifically, the study found that the rate of decline in the patients' forced vital capacity (FVC) was significantly slower in the xaliproden group compared to the placebo group.\nAnother phase III clinical trial published in 2016 found that xaliproden did not meet the primary endpoint of slowing the progression of ALS compared to placebo. However, the study did show that xaliproden was associated with a significant improvement in the patients' quality of life, as measured by the ALS Functional Rating Scale (ALSFRS-R).\nIt is important to note that these studies had relatively small sample sizes and were not without limitations, so more research is needed to confirm these findings and establish the long-term safety and efficacy of xaliproden for the treatment of ALS. Additionally, xaliproden has been associated with certain side effects, including gastrointestinal disturbances, fatigue, and elevated liver enzymes, which may impact its use in clinical practice.\nIn summary, while the evidence is mixed, some studies suggest that xaliproden may have a positive impact on the prognosis of ALS by slowing the disease progression and improving the patients' quality of life. However, more research is needed to confirm these findings and establish the long-term safety and efficacy of xaliproden for the treatment of ALS.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden is a tyrosine kinase inhibitor that has been investigated for its potential therapeutic effects in amyotrophic lateral sclerosis (ALS).\n2. A phase II clinical trial published in 2012 indicated that xaliproden treatment for 24 weeks slowed the disease progression in patients with ALS.\n3. The same phase II clinical trial reported that the rate of decline in patients' forced vital capacity (FVC) was significantly slower in the xaliproden group compared to the placebo group.\n4. A phase III clinical trial published in 2016 found that xaliproden did not meet the primary endpoint of slowing the progression of ALS compared to placebo.\n5. The phase III clinical trial showed that xaliproden was associated with a significant improvement in patients' quality of life, as measured by the ALS Functional Rating Scale (ALSFRS-R).",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden is a tyrosine kinase inhibitor that has been investigated for its potential therapeutic effects in amyotrophic lateral sclerosis (ALS).",
      "A phase II clinical trial published in 2012 indicated that xaliproden treatment for 24 weeks slowed the disease progression in patients with ALS.",
      "The same phase II clinical trial reported that the rate of decline in patients' forced vital capacity (FVC) was significantly slower in the xaliproden group compared to the placebo group.",
      "A phase III clinical trial published in 2016 found that xaliproden did not meet the primary endpoint of slowing the progression of ALS compared to placebo.",
      "The phase III clinical trial showed that xaliproden was associated with a significant improvement in patients' quality of life, as measured by the ALS Functional Rating Scale (ALSFRS-R)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Xaliproden is not a tyrosine kinase inhibitor; it is a compound that has been investigated for its potential neuroprotective and neurotrophic effects in conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.\n2. UNKNOWN: Without access to the specific phase II clinical trial published in 2012, the outcome of xaliproden treatment for 24 weeks cannot be verified.\n3. UNKNOWN: The specific results of the phase II clinical trial regarding the rate of decline in patients' forced vital capacity (FVC) cannot be verified without access to the trial data.\n4. UNKNOWN: Without access to the specific phase III clinical trial published in 2016, the outcome of xaliproden not meeting the primary endpoint cannot be verified.\n5. UNKNOWN: The results of the phase III clinical trial regarding xaliproden's impact on patients' quality of life, as measured by the ALS Functional Rating Scale (ALSFRS-R), cannot be verified without access to the trial data.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "The LiPS-A3S line is a transgenic mouse line that expresses a humanized liver-specific promoter-driven albumin gene under the control of the albumin gene regulatory region. The transgene is inserted into chromosome 17 in these mice. Specifically, the transgene is located on chromosome 17p11.2, which is the long arm of chromosome 17.",
    "llama-2-7b-chat-hf_fact_raw": "1. The LiPS-A3S line is a transgenic mouse line.\n2. The LiPS-A3S line expresses a humanized liver-specific promoter-driven albumin gene.\n3. The transgene in the LiPS-A3S line is under the control of the albumin gene regulatory region.\n4. The transgene is inserted into chromosome 17 in the LiPS-A3S mice.\n5. Specifically, the transgene is located on chromosome 17p11.2, which is the long arm of chromosome 17.",
    "llama-2-7b-chat-hf_fact": [
      "The LiPS-A3S line is a transgenic mouse line.",
      "The LiPS-A3S line expresses a humanized liver-specific promoter-driven albumin gene.",
      "The transgene in the LiPS-A3S line is under the control of the albumin gene regulatory region.",
      "The transgene is inserted into chromosome 17 in the LiPS-A3S mice.",
      "Specifically, the transgene is located on chromosome 17p11.2, which is the long arm of chromosome 17."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific scientific literature or data on the LiPS-A3S transgenic mouse line, it is not possible to confirm the chromosome or the precise location of the transgene insertion. These details are typically determined through molecular biology techniques such as gene mapping or sequencing, which are not provided in the context of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "Several deep learning tools and models have been developed for predicting drug synergy, including:\n1. Drug2Drug: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets. It uses a convolutional neural network (CNN) architecture to predict the binding affinity of drug combinations.\n2. DeepSynth: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets, as well as their chemical and pharmacological properties. It uses a multi-layer perceptron (MLP) network to predict the synergy score of drug combinations.\n3. Synergizer: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets, as well as their gene expression profiles. It uses a CNN architecture to predict the synergy score of drug combinations.\n4. DrugCombination: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets, as well as their protein-protein interaction networks. It uses a graph convolutional neural network (GCNN) architecture to predict the synergy score of drug combinations.\n5. DrugSynergy: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets, as well as their gene expression profiles. It uses a MLP network to predict the synergy score of drug combinations.\n6. ChEA-Net: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets, as well as their chemical and pharmacological properties. It uses a CNN architecture to predict the synergy score of drug combinations.\n7. Drug-Drug-Interaction Predictor (DDIP): This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets, as well as their chemical and pharmacological properties. It uses a MLP network to predict the synergy score of drug combinations.\n8. DrugSynergyNet: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and",
    "llama-2-7b-chat-hf_fact_raw": "1. Drug2Drug is a deep learning model that uses a convolutional neural network (CNN) to predict drug synergy.\n2. DeepSynth is a deep learning model that uses a multi-layer perceptron (MLP) network to predict the synergy score of drug combinations.\n3. Synergizer is a deep learning model that uses a CNN architecture to predict the synergy score of drug combinations.\n4. DrugCombination is a deep learning model that uses a graph convolutional neural network (GCNN) to predict the synergy score of drug combinations.\n5. ChEA-Net is a deep learning model that uses a CNN architecture to predict the synergy score of drug combinations.",
    "llama-2-7b-chat-hf_fact": [
      "Drug2Drug is a deep learning model that uses a convolutional neural network (CNN) to predict drug synergy.",
      "DeepSynth is a deep learning model that uses a multi-layer perceptron (MLP) network to predict the synergy score of drug combinations.",
      "Synergizer is a deep learning model that uses a CNN architecture to predict the synergy score of drug combinations.",
      "DrugCombination is a deep learning model that uses a graph convolutional neural network (GCNN) to predict the synergy score of drug combinations.",
      "ChEA-Net is a deep learning model that uses a CNN architecture to predict the synergy score of drug combinations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information about a model named \"Drug2Drug,\" it is not possible to confirm the architecture it uses.\n2. UNKNOWN: Similarly, without specific information about a model named \"DeepSynth,\" it is not possible to confirm the architecture it uses.\n3. UNKNOWN: The statement about \"Synergizer\" using a CNN architecture is also not verifiable without additional context or information about the model.\n4. UNKNOWN: The statement about \"DrugCombination\" using a GCNN is not verifiable without additional context or information about the model.\n5. UNKNOWN: The statement about \"ChEA-Net\" using a CNN architecture is not verifiable without additional context or information about the model.\n\nIn the field of bioinformatics and computational biology, it is common for researchers to develop models with names like these, but without the specific context or a reference to the literature, it is not possible to confirm the details of these models.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "There are several cloud-based platforms that have been developed for comparing Genome-Wide Association Studies (GWAS). Here are a few examples:\n1. CloudGWAS: CloudGWAS is a cloud-based platform developed by the University of California, San Diego, that allows researchers to compare GWAS data across different populations and studies. It provides a user-friendly interface for uploading and analyzing GWAS data, as well as tools for visualizing and interpreting the results.\n2. GWASdb: GWASdb is a cloud-based platform developed by the University of California, Santa Cruz, that provides a centralized repository for storing and sharing GWAS data. It allows researchers to compare GWAS data across different studies and populations, and provides tools for analyzing and visualizing the results.\n3. WTCCC: The Wellcome Trust Case Control Consortium (WTCCC) is a cloud-based platform that provides a centralized repository for storing and sharing GWAS data. It allows researchers to compare GWAS data across different studies and populations, and provides tools for analyzing and visualizing the results.\n4. GWAS-Central: GWAS-Central is a cloud-based platform developed by the University of California, Los Angeles, that provides a user-friendly interface for uploading and analyzing GWAS data. It allows researchers to compare GWAS data across different studies and populations, and provides tools for visualizing and interpreting the results.\n5. OpenGWAS: OpenGWAS is an open-source cloud-based platform developed by the University of California, San Francisco, that allows researchers to compare GWAS data across different studies and populations. It provides a user-friendly interface for uploading and analyzing GWAS data, as well as tools for visualizing and interpreting the results.\nThese are just a few examples of the cloud-based platforms that have been developed for comparing GWAS. There are many other platforms available, each with its own unique features and capabilities.",
    "llama-2-7b-chat-hf_fact_raw": "1. CloudGWAS is a cloud-based platform developed by the University of California, San Diego.\n2. GWASdb is a cloud-based platform developed by the University of California, Santa Cruz.\n3. The Wellcome Trust Case Control Consortium (WTCCC) is a cloud-based platform for storing and sharing GWAS data.\n4. GWAS-Central is a cloud-based platform developed by the University of California, Los Angeles.\n5. OpenGWAS is an open-source cloud-based platform developed by the University of California, San Francisco.",
    "llama-2-7b-chat-hf_fact": [
      "CloudGWAS is a cloud-based platform developed by the University of California, San Diego.",
      "GWASdb is a cloud-based platform developed by the University of California, Santa Cruz.",
      "The Wellcome Trust Case Control Consortium (WTCCC) is a cloud-based platform for storing and sharing GWAS data.",
      "GWAS-Central is a cloud-based platform developed by the University of California, Los Angeles.",
      "OpenGWAS is an open-source cloud-based platform developed by the University of California, San Francisco."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: The Wellcome Trust Case Control Consortium (WTCCC) is not a cloud-based platform; it is a consortium that was established to conduct several large-scale genome-wide association studies.\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information on the development of CloudGWAS, GWASdb, GWAS-Central, and OpenGWAS, including their affiliations with the mentioned universities, it is not possible to determine the truthfulness of statements 1, 2, 4, and 5. These platforms may exist and may be associated with the universities mentioned, but without current and accurate data, their status cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "CMB305 is a bispecific antibody that targets both CD3 and CD19, and it has been shown to be effective in preclinical studies against various B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). However, there is limited information available on the use of CMB305 against sarcomas.\nSarcomas are a group of rare and complex cancers that arise from the mesenchyme, a type of connective tissue in the body. They can arise in various parts of the body, including the soft tissues, bones, and joints. Sarcomas are often aggressive and have a poor prognosis, particularly if they are not diagnosed and treated early.\nWhile CMB305 has shown promise in treating B-cell malignancies, it is unlikely to be effective against sarcomas due to their distinct biology and molecular characteristics. Sarcomas are characterized by a high degree of genetic instability and a lack of expression of CD3 and CD19, which are the target antigens for CMB305. Therefore, CMB305 is unlikely to bind to sarcoma cells and trigger an immune response against them.\nHowever, there are other immunotherapies that are being developed to target sarcomas, including checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines. These therapies have shown promise in early-stage clinical trials and may offer new treatment options for patients with sarcomas.\nIn summary, while CMB305 has shown promise in treating B-cell malignancies, it is unlikely to be effective against sarcomas due to their distinct biology and molecular characteristics. Further research is needed to develop immunotherapies that can effectively target sarcomas.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a bispecific antibody that targets both CD3 and CD19.\n2. CMB305 has been effective in preclinical studies against various B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL).\n3. Sarcomas are a group of cancers that arise from the mesenchyme, a type of connective tissue.\n4. Sarcomas can arise in various parts of the body, including the soft tissues, bones, and joints.\n5. Sarcomas often have a poor prognosis, particularly if not diagnosed and treated early.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a bispecific antibody that targets both CD3 and CD19.",
      "CMB305 has been effective in preclinical studies against various B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL).",
      "Sarcomas are a group of cancers that arise from the mesenchyme, a type of connective tissue.",
      "Sarcomas can arise in various parts of the body, including the soft tissues, bones, and joints.",
      "Sarcomas often have a poor prognosis, particularly if not diagnosed and treated early."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the Ehlers-Danlos Syndrome (EDS) Triad, is a group of three main symptoms that are commonly seen in individuals with EDS. These manifestations include:\n1. Hypermobile joints: Individuals with EDS have excessive joint mobility, which can lead to joint instability and dislocation. They may also experience joint pain and stiffness, particularly after exercise or activity.\n2. Skin hyperextensibility: EDS individuals have skin that stretches further than normal, which can lead to skin that is loose and fragile. They may also experience bruising, abrasions, and other skin injuries more easily than others.\n3. GI issues: EDS individuals are at increased risk of gastrointestinal (GI) problems, including abdominal pain, constipation, diarrhea, and gastroparesis. They may also experience gastroesophageal reflux disease (GERD) and small intestine bacterial overgrowth (SIBO).\nThese three main manifestations are often seen in individuals with EDS, although each person may experience a different degree of severity and frequency. Other symptoms may also be present, depending on the specific type of EDS an individual has.",
    "llama-2-7b-chat-hf_fact_raw": "1. Individuals with Ehlers-Danlos Syndrome (EDS) commonly have hypermobile joints.\n2. People with EDS often have skin that is more stretchable than normal, leading to loose and fragile skin.\n3. Those with EDS are at an increased risk of gastrointestinal problems such as abdominal pain, constipation, diarrhea, and gastroparesis.\n4. Gastroesophageal reflux disease (GERD) and small intestine bacterial overgrowth (SIBO) may also be experienced by individuals with EDS.\n5. The severity and frequency of symptoms in individuals with EDS can vary.",
    "llama-2-7b-chat-hf_fact": [
      "Individuals with Ehlers-Danlos Syndrome (EDS) commonly have hypermobile joints.",
      "People with EDS often have skin that is more stretchable than normal, leading to loose and fragile skin.",
      "Those with EDS are at an increased risk of gastrointestinal problems such as abdominal pain, constipation, diarrhea, and gastroparesis.",
      "Gastroesophageal reflux disease (GERD) and small intestine bacterial overgrowth (SIBO) may also be experienced by individuals with EDS.",
      "The severity and frequency of symptoms in individuals with EDS can vary."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Yes, overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients. Studies have shown that high levels of LY6K expression are associated with improved overall survival, disease-free survival, and response to chemotherapy in NSCLC patients.\nFor example, a study published in the journal Oncogene in 2016 found that high LY6K expression was associated with a longer overall survival in NSCLC patients, with a median survival time of 32.6 months in the high LY6K expression group compared to 16.3 months in the low expression group.\nAnother study published in the journal Clinical Cancer Research in 2018 found that high LY6K expression was associated with a better response to first-line chemotherapy in NSCLC patients, with a higher complete response rate and longer duration of response in the high expression group.\nThese findings suggest that overexpression of LY6K may be a promising prognostic marker and potential therapeutic target for improving outcomes in NSCLC patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n2. High levels of LY6K expression are associated with improved overall survival in NSCLC patients.\n3. A study published in the journal Oncogene in 2016 found that NSCLC patients with high LY6K expression had a median survival time of 32.6 months.\n4. The same study indicated that NSCLC patients with low LY6K expression had a median survival time of 16.3 months.\n5. A study published in the journal Clinical Cancer Research in 2018 found that high LY6K expression was associated with a better response to first-line chemotherapy in NSCLC patients.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients.",
      "High levels of LY6K expression are associated with improved overall survival in NSCLC patients.",
      "A study published in the journal Oncogene in 2016 found that NSCLC patients with high LY6K expression had a median survival time of 32.6 months.",
      "The same study indicated that NSCLC patients with low LY6K expression had a median survival time of 16.3 months.",
      "A study published in the journal Clinical Cancer Research in 2018 found that high LY6K expression was associated with a better response to first-line chemotherapy in NSCLC patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is generally associated with a poor prognosis for non-small cell lung cancer (NSCLC) patients.\n2. FALSE [correction]: High levels of LY6K expression are generally associated with a poor overall survival in NSCLC patients.\n3. UNKNOWN: Without access to the specific study from the journal Oncogene in 2016, the median survival time associated with high LY6K expression cannot be confirmed.\n4. UNKNOWN: Similarly, without access to the specific study, the median survival time associated with low LY6K expression cannot be confirmed.\n5. UNKNOWN: Without access to the specific study from the journal Clinical Cancer Research in 2018, the association between high LY6K expression and the response to first-line chemotherapy in NSCLC patients cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "During cytokinesis, the protein kinase Cdk1 (also known as Cyclin-dependent kinase 1) is inactivated by phosphorylation, leading to the dephosphorylation of its targets. Some of the known Cdk targets that are dephosphorylated during cytokinesis include:\n1. Separin: Separin is a cytoskeleton protein that is involved in the formation of the cytokinetic cleavage furrow. Dephosphorylation of Cdk1 at specific sites leads to the activation of separin, which promotes the separation of the daughter cells.\n2. Myosin light chain kinase (MLCK): MLCK is a serine/threonine kinase that regulates the contraction of actin-myosin filaments. During cytokinesis, MLCK is dephosphorylated by Cdk1, leading to the relaxation of the actin-myosin network and the formation of the cleavage furrow.\n3. Spectrin: Spectrin is a cytoskeleton protein that plays a crucial role in the formation of the cleavage furrow. Dephosphorylation of Cdk1 at specific sites leads to the activation of spectrin, which helps to stabilize the cleavage furrow and promote the separation of the daughter cells.\n4. β-Tubulin: β-Tubulin is a protein that makes up the microtubules of the cytoskeleton. During cytokinesis, dephosphorylation of Cdk1 leads to the depolymerization of microtubules, which is essential for the formation of the cleavage furrow.\n5. Aurora A: Aurora A is a serine/threonine kinase that is involved in the regulation of microtubule dynamics during cell division. Dephosphorylation of Cdk1 at specific sites leads to the activation of Aurora A, which helps to stabilize the cleavage furrow and promote the separation of the daughter cells.\n6. Polo-like kinase 1 (Plk1): Plk1 is a serine/threonine kinase that is involved in the regulation of the cell cycle and mitosis. Dephosphorylation of Cdk1",
    "llama-2-7b-chat-hf_fact_raw": "1. Cdk1 is inactivated by phosphorylation during cytokinesis.\n2. Separin is dephosphorylated by Cdk1 during cytokinesis, leading to its activation.\n3. Myosin light chain kinase (MLCK) is dephosphorylated by Cdk1 during cytokinesis.\n4. Spectrin is dephosphorylated by Cdk1 during cytokinesis, which helps stabilize the cleavage furrow.\n5. Dephosphorylation of Cdk1 leads to the depolymerization of microtubules made up of β-Tubulin during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Cdk1 is inactivated by phosphorylation during cytokinesis.",
      "Separin is dephosphorylated by Cdk1 during cytokinesis, leading to its activation.",
      "Myosin light chain kinase (MLCK) is dephosphorylated by Cdk1 during cytokinesis.",
      "Spectrin is dephosphorylated by Cdk1 during cytokinesis, which helps stabilize the cleavage furrow.",
      "Dephosphorylation of Cdk1 leads to the depolymerization of microtubules made up of β-Tubulin during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cdk1 is inactivated by dephosphorylation during cytokinesis.\n2. FALSE [correction]: Separase is activated by the degradation of securin, not by dephosphorylation by Cdk1 during cytokinesis.\n3. FALSE [correction]: Myosin light chain kinase (MLCK) is activated by phosphorylation, not dephosphorylated by Cdk1 during cytokinesis.\n4. UNKNOWN: The specific role of Cdk1 in the phosphorylation state of spectrin during cytokinesis is not well-established and may vary depending on the cell type.\n5. FALSE [correction]: Dephosphorylation of Cdk1 does not lead to the depolymerization of microtubules; rather, it is the inactivation of Cdk1 that triggers the exit from mitosis and subsequent steps like cytokinesis. Microtubule dynamics are regulated by other factors, not directly by the phosphorylation state of Cdk1.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a drug that is used to treat a variety of medical conditions, including:\n* Neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease\n* Movement disorders, such as dystonia and chorea\n* Mood disorders, such as depression and anxiety\n* Chronic pain\nXanamem works by increasing the levels of certain neurotransmitters in the brain, such as dopamine and serotonin, which can help to improve mood and reduce symptoms of neurodegenerative disorders. It is typically taken orally, once or twice daily, and may be used alone or in combination with other medications.\nIt is important to note that Xanamem is a prescription medication and should only be used under the guidance and supervision of a healthcare professional.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is used to treat neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.\n2. Xanamem is used to treat movement disorders, such as dystonia and chorea.\n3. Xanamem is used to treat mood disorders, including depression and anxiety.\n4. Xanamem works by increasing the levels of neurotransmitters like dopamine and serotonin in the brain.\n5. Xanamem is a prescription medication that is typically taken orally.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is used to treat neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.",
      "Xanamem is used to treat movement disorders, such as dystonia and chorea.",
      "Xanamem is used to treat mood disorders, including depression and anxiety.",
      "Xanamem works by increasing the levels of neurotransmitters like dopamine and serotonin in the brain.",
      "Xanamem is a prescription medication that is typically taken orally."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided about Xanamem are specific to its uses and mechanism of action. Without access to current, accurate medical information or a specific reference to Xanamem, it is not possible to verify these claims. Xanamem is not a widely recognized medication as of my last update, and it may be a hypothetical or brand-new drug not yet covered in available literature or databases. Therefore, the truthfulness of these statements cannot be determined without additional context or updated information.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "In yeast, the Hof1-Cyk3 interaction plays a critical role in regulating the cell cycle and mitotic progression. Here's a brief overview of the interaction and its functions:\nHof1 and Cyk3 are two proteins that interact in a complex manner to regulate the G1/S checkpoint in yeast. The Hof1 protein is a transcriptional repressor that is activated in response to nutrient starvation, while Cyk3 is a kinase that phosphorylates and activates the transcriptional activator SBF (Swi6-Brm1). The interaction between Hof1 and Cyk3 is critical for the proper progression of the cell cycle.\nDuring the G1 phase of the cell cycle, Hof1 is bound to the promoter of genes involved in the G1/S checkpoint, such as CDK8 and CDK9, and represses their transcription. When nutrients become limiting, the expression of Cyk3 is induced, leading to the phosphorylation and activation of SBF. This activation leads to the activation of the transcription of genes involved in DNA synthesis and cell division, and the progression from the G1 phase to the S phase.\nThe interaction between Hof1 and Cyk3 is crucial for this process, as it allows Cyk3 to phosphorylate and activate SBF only after Hof1 has been inactivated by nutrient starvation. This ensures that the cell is ready to progress to the next phase of the cell cycle only when the necessary nutrients are available.\nIn summary, the Hof1-Cyk3 interaction plays a crucial role in regulating the G1/S checkpoint in yeast by allowing Cyk3 to activate SBF only after Hof1 has been inactivated by nutrient starvation, thereby ensuring proper cell cycle progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction regulates the G1/S checkpoint in yeast.\n2. Hof1 is a transcriptional repressor that is activated in response to nutrient starvation in yeast.\n3. Cyk3 is a kinase that phosphorylates and activates the transcriptional activator SBF in yeast.\n4. Hof1 binds to the promoter of genes involved in the G1/S checkpoint, such as CDK8 and CDK9, and represses their transcription during the G1 phase of the cell cycle in yeast.\n5. The expression of Cyk3 is induced when nutrients become limiting, leading to the activation of genes involved in DNA synthesis and cell division in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction regulates the G1/S checkpoint in yeast.",
      "Hof1 is a transcriptional repressor that is activated in response to nutrient starvation in yeast.",
      "Cyk3 is a kinase that phosphorylates and activates the transcriptional activator SBF in yeast.",
      "Hof1 binds to the promoter of genes involved in the G1/S checkpoint, such as CDK8 and CDK9, and represses their transcription during the G1 phase of the cell cycle in yeast.",
      "The expression of Cyk3 is induced when nutrients become limiting, leading to the activation of genes involved in DNA synthesis and cell division in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hof1 is not a transcriptional repressor activated in response to nutrient starvation; it is a protein involved in cytokinesis.\n3. FALSE [correction]: Cyk3 is not a kinase and does not phosphorylate SBF; it is a protein involved in cell wall remodeling and cytokinesis.\n4. FALSE [correction]: Hof1 does not bind to promoters of genes like CDK8 and CDK9 to repress their transcription; it functions in the actomyosin ring during cytokinesis.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-bet (T-box transcription factor Eomesodermin) and Eomesodermin (Eomes) are two T-cell transcription factors that have been implicated in gastric cancer.\n1. T-bet: T-bet is a transcription factor that plays a critical role in the differentiation and function of T cells. In gastric cancer, T-bet has been shown to be downregulated, leading to the inhibition of T-cell activation and immune surveillance. The downregulation of T-bet has been associated with poor prognosis in gastric cancer patients.\n2. Eomes: Eomes is a transcription factor that is involved in the regulation of T-cell differentiation and function. In gastric cancer, Eomes has been shown to be upregulated, leading to the inhibition of T-cell activation and immune surveillance. The upregulation of Eomes has been associated with poor prognosis in gastric cancer patients.\nBoth T-bet and Eomes have been identified as potential therapeutic targets for the treatment of gastric cancer, and strategies to restore their expression or function are being explored as a means of improving immune surveillance and treatment outcomes in gastric cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-bet (T-box transcription factor Eomesodermin) has been implicated in gastric cancer.\n2. Eomesodermin (Eomes) is a T-cell transcription factor that has been implicated in gastric cancer.\n3. T-bet is downregulated in gastric cancer, which leads to the inhibition of T-cell activation and immune surveillance.\n4. The downregulation of T-bet in gastric cancer patients has been associated with poor prognosis.\n5. Eomes is upregulated in gastric cancer, which leads to the inhibition of T-cell activation and immune surveillance.",
    "llama-2-7b-chat-hf_fact": [
      "T-bet (T-box transcription factor Eomesodermin) has been implicated in gastric cancer.",
      "Eomesodermin (Eomes) is a T-cell transcription factor that has been implicated in gastric cancer.",
      "T-bet is downregulated in gastric cancer, which leads to the inhibition of T-cell activation and immune surveillance.",
      "The downregulation of T-bet in gastric cancer patients has been associated with poor prognosis.",
      "Eomes is upregulated in gastric cancer, which leads to the inhibition of T-cell activation and immune surveillance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: T-bet (T-box transcription factor TBX21) has been implicated in gastric cancer, not Eomesodermin.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Eomes is typically associated with the differentiation and function of T cells, but its specific role in gastric cancer and whether it is upregulated or downregulated can vary and is not clearly defined as leading to the inhibition of T-cell activation and immune surveillance.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects multiple organ systems. The LSI is a composite measure that takes into account various clinical and laboratory parameters, including:\n1. Serum levels of autoantibodies (such as anti-nuclear antibodies and anti-double-stranded DNA antibodies)\n2. Disease activity score (using a combination of symptoms, laboratory tests, and physical examination findings)\n3. Organ involvement (using a combination of laboratory tests and physical examination findings to assess the degree of involvement of various organs, such as the kidneys, skin, and joints)\n4. Patient's global assessment of their overall health status\nThe LSI is calculated by assigning weights to each of these parameters based on their relative importance in determining the severity of SLE, and then adding the scores for each parameter to obtain a total score. The score can range from 0 to 100, with higher scores indicating greater disease severity.\nThe LSI has been shown to be a useful tool in clinical practice for assessing the severity of SLE and monitoring the response to treatment. It can help clinicians to identify patients who require more aggressive treatment and to evaluate the effectiveness of treatment interventions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI includes serum levels of autoantibodies as one of its parameters.\n3. The LSI uses a disease activity score that combines symptoms, laboratory tests, and physical examination findings.\n4. Organ involvement is assessed in the LSI by using laboratory tests and physical examination findings.\n5. The LSI score can range from 0 to 100, with higher scores indicating greater disease severity.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI includes serum levels of autoantibodies as one of its parameters.",
      "The LSI uses a disease activity score that combines symptoms, laboratory tests, and physical examination findings.",
      "Organ involvement is assessed in the LSI by using laboratory tests and physical examination findings.",
      "The LSI score can range from 0 to 100, with higher scores indicating greater disease severity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The existence of a specific \"Lupus Severity Index (LSI)\" is not a well-established fact in medical literature. There are several indices used to assess the severity of systemic lupus erythematosus (SLE), such as the SLE Disease Activity Index (SLEDAI), the British Isles Lupus Assessment Group (BILAG) index, and the Systemic Lupus Activity Measure (SLAM). Without more context, it is unclear whether the LSI is a recognized tool or a fictional or less commonly used index.\n\n2. UNKNOWN: Since the validity of the LSI as a recognized medical tool is unknown, it is not possible to confirm whether serum levels of autoantibodies are included as one of its parameters.\n\n3. UNKNOWN: Similar to the previous statements, without confirmation of the LSI's existence and its components, it is not possible to determine the accuracy of this statement.\n\n4. UNKNOWN: Again, without specific information about the LSI, it is not possible to confirm the accuracy of this statement regarding organ involvement assessment.\n\n5. UNKNOWN: The range of scores for the LSI cannot be confirmed without knowing whether the LSI is a recognized index and what its scoring system entails.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several human disorders caused by de novo mutations. These disorders include:\n1. Neuronal ceroid lipofuscinosis 6 (NCL6): This is a rare and severe neurodegenerative disorder characterized by progressive loss of vision, seizures, and cognitive decline. De novo mutations in the ZSWIM6 gene are the primary cause of NCL6.\n2. Batten disease: This is a rare and severe neurodegenerative disorder that affects the brain and nervous system. De novo mutations in the ZSWIM6 gene have been identified as the cause of some cases of Batten disease.\n3. Intellectual disability: Some de novo mutations in the ZSWIM6 gene have been identified as a cause of intellectual disability in individuals.\n4. Autism spectrum disorder: Some studies have suggested that de novo mutations in the ZSWIM6 gene may be associated with an increased risk of autism spectrum disorder.\n5. Epilepsy: De novo mutations in the ZSWIM6 gene have been identified in individuals with epilepsy, suggesting a potential role for the gene in the development of this disorder.\nIt is important to note that the frequency and distribution of de novo mutations in the ZSWIM6 gene may vary depending on the population being studied and the specific disorder being investigated. Further research is needed to fully understand the role of ZSWIM6 in these disorders and to identify potential therapeutic targets for treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in the ZSWIM6 gene are the primary cause of Neuronal ceroid lipofuscinosis 6 (NCL6).\n2. De novo mutations in the ZSWIM6 gene have been identified as the cause of some cases of Batten disease.\n3. Some de novo mutations in the ZSWIM6 gene have been identified as a cause of intellectual disability.\n4. Studies have suggested that de novo mutations in the ZSWIM6 gene may be associated with an increased risk of autism spectrum disorder.\n5. De novo mutations in the ZSWIM6 gene have been identified in individuals with epilepsy.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in the ZSWIM6 gene are the primary cause of Neuronal ceroid lipofuscinosis 6 (NCL6).",
      "De novo mutations in the ZSWIM6 gene have been identified as the cause of some cases of Batten disease.",
      "Some de novo mutations in the ZSWIM6 gene have been identified as a cause of intellectual disability.",
      "Studies have suggested that de novo mutations in the ZSWIM6 gene may be associated with an increased risk of autism spectrum disorder.",
      "De novo mutations in the ZSWIM6 gene have been identified in individuals with epilepsy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: De novo mutations in the CLN6 gene, not the ZSWIM6 gene, are the primary cause of Neuronal ceroid lipofuscinosis 6 (NCL6).\n2. TRUE: Batten disease is a common name for a group of disorders called the neuronal ceroid lipofuscinoses (NCLs), and mutations in various genes, including ZSWIM6, have been associated with different forms of Batten disease.\n3. TRUE: De novo mutations in the ZSWIM6 gene have been associated with intellectual disability in some cases.\n4. UNKNOWN: While there may be studies suggesting associations between various genetic mutations and autism spectrum disorder, without specific evidence or references, it is difficult to confirm the truth of this statement for the ZSWIM6 gene.\n5. UNKNOWN: Similar to statement 4, without specific evidence or references, it is difficult to confirm the association between de novo mutations in the ZSWIM6 gene and epilepsy.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is a system used to classify neurodegenerative diseases based on the type of protein aggregates they produce. The classification system was developed by Dr. Bart Koos and colleagues and includes the following categories:\n1. Familial Parkinson's disease (FPD): This category includes diseases caused by mutations in genes encoding alpha-synuclein, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.\n2. Sporadic Parkinson's disease (SPD): This category includes Parkinson's disease that occurs in the absence of a known genetic mutation.\n3. Dementia with Lewy bodies (DLB): This category includes diseases characterized by the presence of Lewy bodies, which are protein aggregates composed of alpha-synuclein and ubiquitin.\n4. Multiple system atrophy (MSA): This category includes a group of diseases characterized by the progressive degeneration of various systems in the body, including the nervous system, autonomic nervous system, and cerebellum.\n5. Progressive supranuclear palsy (PSP): This category includes a group of diseases characterized by the progressive degeneration of the brain, leading to movement disorders, dementia, and other neurological symptoms.\nBy classifying diseases based on the type of protein aggregates they produce, the Koos Classification system provides a useful framework for understanding the underlying pathology of these diseases and for identifying potential therapeutic targets.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify neurodegenerative diseases based on the type of protein aggregates they produce.\n2. Familial Parkinson's disease (FPD) includes diseases caused by mutations in genes encoding alpha-synuclein.\n3. Sporadic Parkinson's disease (SPD) includes Parkinson's disease that occurs without a known genetic mutation.\n4. Dementia with Lewy bodies (DLB) is characterized by the presence of Lewy bodies, which are protein aggregates composed of alpha-synuclein and ubiquitin.\n5. Multiple system atrophy (MSA) is characterized by the progressive degeneration of various systems in the body, including the nervous system, autonomic nervous system, and cerebellum.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify neurodegenerative diseases based on the type of protein aggregates they produce.",
      "Familial Parkinson's disease (FPD) includes diseases caused by mutations in genes encoding alpha-synuclein.",
      "Sporadic Parkinson's disease (SPD) includes Parkinson's disease that occurs without a known genetic mutation.",
      "Dementia with Lewy bodies (DLB) is characterized by the presence of Lewy bodies, which are protein aggregates composed of alpha-synuclein and ubiquitin.",
      "Multiple system atrophy (MSA) is characterized by the progressive degeneration of various systems in the body, including the nervous system, autonomic nervous system, and cerebellum."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Koos Classification is not a recognized classification system for neurodegenerative diseases based on protein aggregates. Neurodegenerative diseases are often classified by their clinical symptoms and the predominant pathological protein aggregates, but not specifically by a \"Koos Classification.\"\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a specific inhibitor of the protein kinase CK2 (PKCα, PKCβ, and PKCγ). In vivo, AZD8601 has been shown to have a range of effects, including:\n1. Neuroprotection: AZD8601 has been shown to protect against neurodegeneration in various animal models of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.\n2. Anti-inflammatory effects: AZD8601 has been shown to reduce inflammation in various animal models of inflammation, including colitis and arthritis.\n3. Anti-tumor effects: AZD8601 has been shown to inhibit tumor growth and angiogenesis in various animal models of cancer, including breast, lung, and colon cancer.\n4. Cardiovascular effects: AZD8601 has been shown to improve cardiovascular function in various animal models of heart failure, including hypertension and heart failure.\n5. Metabolic effects: AZD8601 has been shown to improve glucose tolerance and insulin sensitivity in various animal models of type 2 diabetes.\n6. Anti-aging effects: AZD8601 has been shown to improve cognitive function and reduce age-related decline in various animal models of aging.\n7. Neuropsychiatric effects: AZD8601 has been shown to have anxiolytic and antidepressant effects in various animal models of neuropsychiatric disorders, such as anxiety and depression.\n8. Immune effects: AZD8601 has been shown to modulate the immune response in various animal models, including reducing the activity of immune cells and inhibiting the production of pro-inflammatory cytokines.\n9. Ophthalmological effects: AZD8601 has been shown to improve retinal function and reduce retinal degeneration in various animal models of retinal diseases, such as retinitis pigmentosa.\n10. Reproductive effects: AZD",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is a specific inhibitor of the protein kinase CK2 (PKCα, PKCβ, and PKCγ).\n2. AZD8601 has been shown to protect against neurodegeneration in various animal models of neurodegenerative diseases.\n3. AZD8601 has been shown to reduce inflammation in various animal models of inflammation.\n4. AZD8601 has been shown to inhibit tumor growth and angiogenesis in various animal models of cancer.\n5. AZD8601 has been shown to improve cardiovascular function in various animal models of heart failure.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is a specific inhibitor of the protein kinase CK2 (PKCα, PKCβ, and PKCγ).",
      "AZD8601 has been shown to protect against neurodegeneration in various animal models of neurodegenerative diseases.",
      "AZD8601 has been shown to reduce inflammation in various animal models of inflammation.",
      "AZD8601 has been shown to inhibit tumor growth and angiogenesis in various animal models of cancer.",
      "AZD8601 has been shown to improve cardiovascular function in various animal models of heart failure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not an inhibitor of protein kinase CK2 (PKCα, PKCβ, and PKCγ); it is an mRNA-based therapy that encodes for vascular endothelial growth factor A (VEGF-A).\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFs (Sperm-Associated Histone-Modifying Factor-Structured) chromatin structures are created through a complex process involving multiple proteins and post-translational modifications. Here's a general overview of how SAHFs are formed:\n1. Histone modification: The process of creating SAHFs starts with the modification of histones, which are the chief protein components of chromatin. Specifically, histones are modified by the addition of acetyl, methyl, or phosphoryl groups, which alter their interactions with DNA and other proteins. These modifications can create a more open or more compact chromatin structure.\n2. Recruitment of SAHF-associated proteins: Once histones are modified, specific proteins called SAHF-associated proteins (SAPs) bind to the modified histones. These proteins can include factors like H2A.Z, H3.3, and H2A.H3.\n3. Chromatin remodeling: The binding of SAPs to modified histones leads to the recruitment of chromatin remodeling complexes, which are enzymes that alter the structure of chromatin by sliding nucleosomes along DNA. This process can help create more compact or more open chromatin structures.\n4. Formation of the SAHF: The combination of modified histones, SAPs, and chromatin remodeling complexes leads to the formation of a stable, higher-order chromatin structure called a SAHF. SAHFs are typically 200-300 nucleosomes in length and have a distinctive \"barrel-like\" shape.\n5. Localization of SAHFs: SAHFs are localized to specific regions of the genome, such as gene promoters or gene bodies, where they play a role in regulating gene expression.\n6. Dynamics of SAHFs: SAHFs are dynamic structures that can be disrupted or re-formed in response to changes in cellular signaling or environmental cues. This allows SAHFs to play a role in regulating gene expression in response to different cellular conditions.\nOverall, the creation of SAHFs is a complex process that involves the coordinated action of multiple proteins and post-translational modifications. Under",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFs are created through a process involving multiple proteins and post-translational modifications.\n2. Histone modification is the first step in creating SAHFs, involving the addition of acetyl, methyl, or phosphoryl groups to histones.\n3. Specific proteins called SAHF-associated proteins (SAPs) bind to the modified histones during SAHF formation.\n4. Chromatin remodeling complexes are recruited to alter the structure of chromatin by sliding nucleosomes along DNA.\n5. SAHFs are localized to specific regions of the genome, such as gene promoters or gene bodies.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFs are created through a process involving multiple proteins and post-translational modifications.",
      "Histone modification is the first step in creating SAHFs, involving the addition of acetyl, methyl, or phosphoryl groups to histones.",
      "Specific proteins called SAHF-associated proteins (SAPs) bind to the modified histones during SAHF formation.",
      "Chromatin remodeling complexes are recruited to alter the structure of chromatin by sliding nucleosomes along DNA.",
      "SAHFs are localized to specific regions of the genome, such as gene promoters or gene bodies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Histone modification is a step in creating SAHFs, but it is not necessarily the first step. The process can involve various modifications such as methylation, phosphorylation, and ubiquitination, and the order of these modifications can vary.\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: SAHFs (Senescence-Associated Heterochromatin Foci) are typically not localized to specific regions such as gene promoters or gene bodies; instead, they are thought to represent a global chromatin reorganization that occurs during cellular senescence, affecting large regions of the genome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ (PSD-95, Dlg, ZO-1) domain is a protein-protein interaction module found in the SATB1 (Steroidogenic Acute Regulatory Protein) transcription factor. The PDZ domain is involved in the binding of SATB1 to specific proteins and lipids, which modulates its activity and localization in the cell.\nThe PDZ domain of SATB1 has several functions:\n1. Lipid modification: The PDZ domain of SATB1 can bind to phosphatidylinositol 3,4,5-trisphosphate (PIP3) and phosphatidylinositol 4,5-bisphosphate (PIP2), which are important lipids involved in cell signaling. This binding can modulate the activity of SATB1.\n2. Protein binding: The PDZ domain of SATB1 can bind to various proteins, including the transcription factor NF-κB, the DNA-binding protein p53, and the cytoskeleton protein β-catenin. This binding can regulate the localization and activity of these proteins.\n3. Chromatin remodeling: The PDZ domain of SATB1 can also interact with chromatin-modifying enzymes, such as histone acetyltransferases and histone deacetylases, to regulate chromatin structure and gene expression.\nIn summary, the PDZ domain of SATB1 plays a crucial role in regulating the activity and localization of SATB1, as well as interacting with other proteins and lipids to modulate various cellular processes, including gene expression, cell proliferation, and cell survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain in SATB1 is involved in the binding of SATB1 to specific proteins and lipids.\n2. The PDZ domain of SATB1 can bind to phosphatidylinositol 3,4,5-trisphosphate (PIP3) and phosphatidylinositol 4,5-bisphosphate (PIP2).\n3. The PDZ domain of SATB1 can bind to the transcription factor NF-κB, the DNA-binding protein p53, and the cytoskeleton protein β-catenin.\n4. The PDZ domain of SATB1 interacts with chromatin-modifying enzymes, such as histone acetyltransferases and histone deacetylases.\n5. The PDZ domain of SATB1 plays a role in regulating chromatin structure and gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain in SATB1 is involved in the binding of SATB1 to specific proteins and lipids.",
      "The PDZ domain of SATB1 can bind to phosphatidylinositol 3,4,5-trisphosphate (PIP3) and phosphatidylinositol 4,5-bisphosphate (PIP2).",
      "The PDZ domain of SATB1 can bind to the transcription factor NF-κB, the DNA-binding protein p53, and the cytoskeleton protein β-catenin.",
      "The PDZ domain of SATB1 interacts with chromatin-modifying enzymes, such as histone acetyltransferases and histone deacetylases.",
      "The PDZ domain of SATB1 plays a role in regulating chromatin structure and gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe PDZ domain is known for mediating protein-protein interactions, and SATB1 is a protein that regulates chromatin structure and gene expression. However, without specific literature references, it is difficult to confirm the exact binding partners of the PDZ domain in SATB1, such as PIP3, PIP2, NF-κB, p53, and β-catenin, or its interaction with chromatin-modifying enzymes. These details are highly specific and would require validation from scientific studies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "BLISS (Blocking, Loading, Isolation, Separation, and Hybridization) is a technique used to isolate and analyze specific RNA molecules in a complex sample. The basis of the BLISS technique is to use a combination of chemical and biochemical methods to isolate and purify the target RNA molecules, followed by hybridization with a probe that specifically binds to the target RNA.\nThe steps involved in the BLISS technique are:\n1. Blocking: The sample is treated with a blocking agent to prevent non-specific binding of the probe to other RNA molecules in the sample.\n2. Loading: The sample is then loaded with the probe, which specifically binds to the target RNA molecule.\n3. Isolation: The sample is then isolated using a series of washing steps to remove any unbound probe and other contaminants.\n4. Separation: The isolated RNA molecules are then separated based on their size and properties using a separation method such as gel electrophoresis.\n5. Hybridization: The separated RNA molecules are then hybridized with a labeled probe that specifically binds to the target RNA molecule.\n6. Detection: The labeled probe is then detected using a detection method such as chemiluminescence or fluorescence to visualize the target RNA molecule.\nThe BLISS technique is a powerful tool for analyzing specific RNA molecules in complex samples, and it has been used to study a wide range of biological processes, including gene expression, cell signaling, and RNA localization.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is used to isolate and analyze specific RNA molecules in a complex sample.\n2. It uses a combination of chemical and biochemical methods to isolate and purify the target RNA molecules.\n3. The BLISS technique involves a step where the sample is treated with a blocking agent to prevent non-specific binding.\n4. Gel electrophoresis is used as a separation method in the BLISS technique.\n5. The BLISS technique includes a detection step using methods such as chemiluminescence or fluorescence.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is used to isolate and analyze specific RNA molecules in a complex sample.",
      "It uses a combination of chemical and biochemical methods to isolate and purify the target RNA molecules.",
      "The BLISS technique involves a step where the sample is treated with a blocking agent to prevent non-specific binding.",
      "Gel electrophoresis is used as a separation method in the BLISS technique.",
      "The BLISS technique includes a detection step using methods such as chemiluminescence or fluorescence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: The BLISS technique does not typically involve gel electrophoresis as a separation method; it uses in situ hybridization to visualize RNA molecules.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Here are three known NK3R antagonists:\n1. GR 127935: This is a potent and selective NK3R antagonist that has been shown to reduce NK3R-mediated activity in various preclinical studies.\n2. MK-8628: This is a potent and orally available NK3R antagonist that has been shown to have efficacy in preclinical models of various conditions, including cancer and inflammatory disorders.\n3. RX-0201: This is a highly selective NK3R antagonist that has been shown to have efficacy in preclinical models of various conditions, including cancer and gastrointestinal disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. GR 127935 is a potent and selective NK3R antagonist.\n2. MK-8628 is an orally available NK3R antagonist.\n3. RX-0201 is a highly selective NK3R antagonist.",
    "llama-2-7b-chat-hf_fact": [
      "GR 127935 is a potent and selective NK3R antagonist.",
      "MK-8628 is an orally available NK3R antagonist.",
      "RX-0201 is a highly selective NK3R antagonist."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: RX-0201 is an Akt antisense oligonucleotide, not an NK3R antagonist.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is called BMS-986177. It was developed by Bristol-Myers Squibb and was studied in a phase 1 clinical trial in healthy volunteers. The trial was designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of BMS-986177, and it was shown to be well-tolerated and to have a good pharmacokinetic profile. The results of this trial were published in the journal Clinical Pharmacology & Therapeutics in 2013.",
    "llama-2-7b-chat-hf_fact_raw": "1. BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. BMS-986177 was developed by Bristol-Myers Squibb.\n3. BMS-986177 was studied in a phase 1 clinical trial in healthy volunteers.\n4. The phase 1 clinical trial was designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of BMS-986177.\n5. The results of the phase 1 clinical trial of BMS-986177 were published in the journal Clinical Pharmacology & Therapeutics in 2013.",
    "llama-2-7b-chat-hf_fact": [
      "BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "BMS-986177 was developed by Bristol-Myers Squibb.",
      "BMS-986177 was studied in a phase 1 clinical trial in healthy volunteers.",
      "The phase 1 clinical trial was designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of BMS-986177.",
      "The results of the phase 1 clinical trial of BMS-986177 were published in the journal Clinical Pharmacology & Therapeutics in 2013."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nWithout specific information on the date of publication for the phase 1 clinical trial results of BMS-986177, I cannot verify the accuracy of statement 5. Similarly, without additional context, I cannot confirm the veracity of statement 1 regarding BMS-986177 being the first of its kind.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora, also known as Shanchol, is an oral cholera vaccine that has been shown to provide protection against moderate to severe cholera in clinical trials.\nThe protective efficacy of Vaxchora against moderate to severe cholera was evaluated in a phase 3 clinical trial conducted in Bangladesh, where cholera is a major public health concern. The trial enrolled 32,000 participants, aged 1 year to 60 years, who were randomly assigned to receive either Vaxchora or a placebo. The participants were then monitored for 3 years for the development of cholera.\nThe results of the trial showed that Vaxchora provided 80% protection against moderate to severe cholera in the overall population, and 90% protection in children aged 1 to 11 years. The vaccine was also shown to reduce the duration of diarrhea and the risk of severe dehydration in individuals who did develop cholera.\nAnother phase 3 trial conducted in Africa also demonstrated the efficacy of Vaxchora against cholera, with 63% protection against moderate to severe cholera in the overall population.\nIt is important to note that while Vaxchora has been shown to be effective in preventing moderate to severe cholera, it is not 100% effective, and individuals may still develop mild or asymptomatic infections after vaccination. Therefore, vaccination should be combined with other cholera control measures, such as improved water and sanitation infrastructure, to provide comprehensive protection against cholera.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is an oral cholera vaccine that has been tested in clinical trials.\n2. A phase 3 clinical trial of Vaxchora in Bangladesh involved 32,000 participants aged 1 to 60 years.\n3. The trial in Bangladesh showed that Vaxchora provided 80% protection against moderate to severe cholera in the overall population.\n4. Vaxchora provided 90% protection against moderate to severe cholera in children aged 1 to 11 years according to the trial results.\n5. A separate phase 3 trial in Africa showed that Vaxchora offered 63% protection against moderate to severe cholera in the overall population.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is an oral cholera vaccine that has been tested in clinical trials.",
      "A phase 3 clinical trial of Vaxchora in Bangladesh involved 32,000 participants aged 1 to 60 years.",
      "The trial in Bangladesh showed that Vaxchora provided 80% protection against moderate to severe cholera in the overall population.",
      "Vaxchora provided 90% protection against moderate to severe cholera in children aged 1 to 11 years according to the trial results.",
      "A separate phase 3 trial in Africa showed that Vaxchora offered 63% protection against moderate to severe cholera in the overall population."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific details from the actual clinical trial results or publications, it is not possible to confirm the accuracy of statements 2 through 5. These statements would require access to the trial data or official reports to verify.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the United States was the oral cholera vaccine, also known as the \"Shanchol\" vaccine, which was approved by the Food and Drug Administration (FDA) in 2000. This vaccine was developed by the pharmaceutical company Wyeth (now owned by Pfizer) and is made from a killed, inactivated form of the cholera bacterium, Vibrio cholerae. The vaccine is given orally, in the form of a liquid or tablet, and provides protection against cholera infection for up to 6 years.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the United States was an oral vaccine known as \"Shanchol.\"\n2. The Shanchol vaccine was approved by the Food and Drug Administration (FDA) in 2000.\n3. The pharmaceutical company Wyeth, now owned by Pfizer, developed the Shanchol vaccine.\n4. The Shanchol vaccine is made from a killed, inactivated form of the Vibrio cholerae bacterium.\n5. The Shanchol vaccine provides protection against cholera infection for up to 6 years.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the United States was an oral vaccine known as \"Shanchol.\"",
      "The Shanchol vaccine was approved by the Food and Drug Administration (FDA) in 2000.",
      "The pharmaceutical company Wyeth, now owned by Pfizer, developed the Shanchol vaccine.",
      "The Shanchol vaccine is made from a killed, inactivated form of the Vibrio cholerae bacterium.",
      "The Shanchol vaccine provides protection against cholera infection for up to 6 years."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The first cholera vaccine approved in the United States was not known as \"Shanchol.\" The first licensed cholera vaccine in the United States was \"Vaxchora,\" approved in 2016.\n2. FALSE [correction]: The Shanchol vaccine was not approved by the FDA in 2000. It was prequalified by the World Health Organization (WHO) in 2011, but it is not specifically approved for use in the United States.\n3. FALSE [correction]: The Shanchol vaccine was not developed by Wyeth or Pfizer. It was developed by Shantha Biotechnics in India.\n4. TRUE\n5. FALSE [correction]: The Shanchol vaccine provides protection against cholera for about 3 years in adults and 2 years in children.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder that affects the immune system's ability to produce antibodies. The most common monogenic cause of CVID in Europeans is a mutation in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T cell receptor (TCR) genes. These genes are responsible for the production of immunoglobulins and T cells, which are crucial for the proper functioning of the immune system.\nApproximately 70% of CVID cases in Europeans are caused by mutations in the IGH gene, while the remaining 30% are caused by mutations in the TCR gene. The most common mutations in the IGH gene are found in the CDR3 region, which is responsible for the antibody's antigen binding site.\nIt's worth noting that CVID can also be caused by mutations in multiple genes, as well as by genetic variations that are not considered mutations. Additionally, some cases of CVID may be caused by acquired rather than inherited genetic changes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder that affects the immune system's ability to produce antibodies.\n2. The most common monogenic cause of CVID in Europeans is a mutation in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T cell receptor (TCR) genes.\n3. Approximately 70% of CVID cases in Europeans are caused by mutations in the IGH gene.\n4. The remaining 30% of CVID cases in Europeans are caused by mutations in the TCR gene.\n5. The most common mutations in the IGH gene associated with CVID are found in the CDR3 region.",
    "llama-2-7b-chat-hf_fact": [
      "Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder that affects the immune system's ability to produce antibodies.",
      "The most common monogenic cause of CVID in Europeans is a mutation in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T cell receptor (TCR) genes.",
      "Approximately 70% of CVID cases in Europeans are caused by mutations in the IGH gene.",
      "The remaining 30% of CVID cases in Europeans are caused by mutations in the TCR gene.",
      "The most common mutations in the IGH gene associated with CVID are found in the CDR3 region."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The most common monogenic cause of CVID in Europeans is not a mutation in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T cell receptor (TCR) genes. Instead, mutations in genes such as ICOS, TACI, and BAFFR are among the genetic causes identified in CVID patients.\n3. FALSE [correction]: It is not accurate to state that approximately 70% of CVID cases in Europeans are caused by mutations in the IGH gene. The genetic causes of CVID are diverse, and many cases do not have an identified genetic cause.\n4. FALSE [correction]: It is not accurate to state that the remaining 30% of CVID cases in Europeans are caused by mutations in the TCR gene. As with the IGH gene, the genetic causes of CVID are diverse, and many cases do not have an identified genetic cause.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene has been found to be mutated or dysregulated in various autoimmune diseases, including Systemic Lupus Erythematosus (SLE). The IFIT1 gene encodes a protein called Interferon-induced protein with tetralinked domains 1 (IFIT1), which is involved in the antiviral response and immune regulation.\nStudies have shown that IFIT1 is downregulated in SLE patients, and this dysregulation may contribute to the development and progression of the disease. Specifically, IFIT1 has been shown to:\n1. Inhibit the production of pro-inflammatory cytokines: IFIT1 has been shown to suppress the production of pro-inflammatory cytokines such as TNF-alpha and IL-1 beta, which are overproduced in SLE patients.\n2. Regulate the expression of autoantigens: IFIT1 has been shown to regulate the expression of autoantigens, such as DNA topoisomerase I, which are targeted by autoantibodies in SLE patients.\n3. Modulate the activity of autoreactive T cells: IFIT1 has been shown to inhibit the activation and proliferation of autoreactive T cells, which are thought to play a key role in the development of SLE.\n4. Induce apoptosis in activated T cells: IFIT1 has been shown to induce apoptosis in activated T cells, which may help to reduce the number of autoreactive T cells in the body.\nOverall, the dysregulation of IFIT1 in SLE may contribute to the development of the disease by disrupting the balance between the immune response and immune tolerance, leading to an overproduction of pro-inflammatory cytokines and the activation of autoreactive T cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene is mutated or dysregulated in various autoimmune diseases, including Systemic Lupus Erythematosus (SLE).\n2. The IFIT1 gene encodes a protein involved in the antiviral response and immune regulation.\n3. IFIT1 is downregulated in SLE patients, which may contribute to the development and progression of the disease.\n4. IFIT1 suppresses the production of pro-inflammatory cytokines such as TNF-alpha and IL-1 beta.\n5. IFIT1 regulates the expression of autoantigens and modulates the activity of autoreactive T cells in SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene is mutated or dysregulated in various autoimmune diseases, including Systemic Lupus Erythematosus (SLE).",
      "The IFIT1 gene encodes a protein involved in the antiviral response and immune regulation.",
      "IFIT1 is downregulated in SLE patients, which may contribute to the development and progression of the disease.",
      "IFIT1 suppresses the production of pro-inflammatory cytokines such as TNF-alpha and IL-1 beta.",
      "IFIT1 regulates the expression of autoantigens and modulates the activity of autoreactive T cells in SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The IFIT1 gene has been implicated in various autoimmune diseases, including Systemic Lupus Erythematosus (SLE), where it can be mutated or dysregulated.\n2. TRUE: The IFIT1 gene encodes a protein that is indeed involved in the antiviral response and immune regulation.\n3. UNKNOWN: The regulation of IFIT1 in SLE patients can vary, and without specific data or studies to reference, it's difficult to determine whether it is downregulated in all SLE patients.\n4. UNKNOWN: While IFIT1 is involved in immune regulation, the specific effects on cytokines such as TNF-alpha and IL-1 beta would require more detailed information from scientific studies to confirm.\n5. UNKNOWN: The role of IFIT1 in regulating the expression of autoantigens and modulating the activity of autoreactive T cells in SLE is a specific claim that would need to be supported by scientific research, which is not provided here.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a patient-reported outcome measure used to assess the severity of elbow pain and disability in patients with elbow conditions, such as tennis elbow (lateral epicondylitis) and golfer's elbow (medial epicondylitis). The score is based on a questionnaire that assesses the patient's level of pain, grip strength, and functional ability in the affected elbow.\nThe Liverpool Elbow Score consists of 12 questions that are rated on a 5-point Likert scale, with higher scores indicating greater severity of symptoms. The questions cover the following domains:\n1. Pain (4 questions)\n2. Grip strength (2 questions)\n3. Functional ability (6 questions)\nThe total score ranges from 0 to 48, with higher scores indicating greater severity of symptoms. The LES has been shown to have good reliability and validity in measuring elbow pain and disability in clinical and research settings. It is commonly used to evaluate the effectiveness of treatments for elbow conditions, such as surgery, physical therapy, and medication.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score is used to assess the severity of elbow pain and disability in patients with elbow conditions.\n2. The Liverpool Elbow Score includes a questionnaire with 12 questions.\n3. The questionnaire uses a 5-point Likert scale to rate symptoms.\n4. The total score of the Liverpool Elbow Score ranges from 0 to 48.\n5. The Liverpool Elbow Score has been shown to have good reliability and validity in clinical and research settings.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score is used to assess the severity of elbow pain and disability in patients with elbow conditions.",
      "The Liverpool Elbow Score includes a questionnaire with 12 questions.",
      "The questionnaire uses a 5-point Likert scale to rate symptoms.",
      "The total score of the Liverpool Elbow Score ranges from 0 to 48.",
      "The Liverpool Elbow Score has been shown to have good reliability and validity in clinical and research settings."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Liverpool Elbow Score includes a questionnaire with 10 questions.\n3. TRUE\n4. FALSE [correction]: The total score of the Liverpool Elbow Score ranges from 0 to 100.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project was a large-scale genomics initiative launched in the UK in 2012 with the goal of analyzing the genomes of 100,000 people with rare and/or undiagnosed genetic diseases, including sarcoma. Here are some key efforts and findings related to sarcoma from the 100,000 Genomes Project:\n1. Identification of novel sarcoma-specific mutations: The 100,000 Genomes Project identified novel mutations in genes known to be involved in sarcoma, such as TP53, KRAS, and PTEN. These findings have helped researchers better understand the genetic landscape of sarcoma and may lead to the development of new diagnostic markers and targeted therapies.\n2. Development of a sarcoma-specific genomic classification system: The 100,000 Genomes Project developed a genomic classification system for sarcoma that takes into account both the genetic and transcriptomic features of the disease. This system has the potential to improve the accuracy of sarcoma diagnosis and subtyping.\n3. Identification of driver mutations in specific sarcoma subtypes: The 100,000 Genomes Project identified driver mutations in specific sarcoma subtypes, such as leiomyosarcoma and chondrosarcoma. These findings may lead to the development of targeted therapies for these subtypes.\n4. Analysis of mutational load in sarcoma: The 100,000 Genomes Project found that sarcomas have a high mutational load compared to other cancers. This may contribute to the development and progression of sarcoma.\n5. Identification of potential therapeutic targets: The 100,000 Genomes Project identified potential therapeutic targets for sarcoma, including genes involved in cell cycle regulation, DNA repair, and angiogenesis. These findings may lead to the development of new therapies for sarcoma.\n6. Collaboration with clinical experts: The 100,000 Genomes Project collaborated with clinical",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in the UK in 2012 to analyze the genomes of 100,000 people with rare and/or undiagnosed genetic diseases, including sarcoma.\n2. The project identified novel mutations in genes such as TP53, KRAS, and PTEN that are involved in sarcoma.\n3. A genomic classification system for sarcoma was developed by the 100,000 Genomes Project, considering genetic and transcriptomic features of the disease.\n4. Driver mutations in specific sarcoma subtypes, such as leiomyosarcoma and chondrosarcoma, were identified by the 100,000 Genomes Project.\n5. The 100,000 Genomes Project found that sarcomas have a high mutational load compared to other cancers.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in the UK in 2012 to analyze the genomes of 100,000 people with rare and/or undiagnosed genetic diseases, including sarcoma.",
      "The project identified novel mutations in genes such as TP53, KRAS, and PTEN that are involved in sarcoma.",
      "A genomic classification system for sarcoma was developed by the 100,000 Genomes Project, considering genetic and transcriptomic features of the disease.",
      "Driver mutations in specific sarcoma subtypes, such as leiomyosarcoma and chondrosarcoma, were identified by the 100,000 Genomes Project.",
      "The 100,000 Genomes Project found that sarcomas have a high mutational load compared to other cancers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project was launched in the UK in 2013, not 2012.\n2. UNKNOWN: Without specific results from the project regarding these genes in sarcoma, it's not possible to confirm the truth of this statement.\n3. UNKNOWN: The statement may be true if the project developed such a system, but without specific information from the project's findings, it cannot be confirmed.\n4. UNKNOWN: Similar to statement 2, without specific results from the project regarding driver mutations in these sarcoma subtypes, the truth of this statement cannot be confirmed.\n5. UNKNOWN: The statement about the mutational load of sarcomas compared to other cancers would need to be supported by specific findings from the project to be confirmed as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Yes, the protein ALEX1 (Armadillo-like protein 1) contains multiple armadillo repeats. ALEX1 is a transcriptional regulator that is involved in the regulation of gene expression, particularly in the context of stem cell pluripotency and differentiation. ALEX1 is composed of multiple armadillo repeats, which are a characteristic structural motif found in the protein. These repeats are thought to play a role in the protein's ability to recognize and bind to specific DNA sequences and regulate gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains multiple armadillo repeats.\n2. ALEX1 is a transcriptional regulator.\n3. ALEX1 is involved in the regulation of gene expression related to stem cell pluripotency and differentiation.\n4. Armadillo repeats in ALEX1 are a structural motif.\n5. The armadillo repeats in ALEX1 are thought to help in recognizing and binding to specific DNA sequences.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains multiple armadillo repeats.",
      "ALEX1 is a transcriptional regulator.",
      "ALEX1 is involved in the regulation of gene expression related to stem cell pluripotency and differentiation.",
      "Armadillo repeats in ALEX1 are a structural motif.",
      "The armadillo repeats in ALEX1 are thought to help in recognizing and binding to specific DNA sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: Armadillo repeats are typically involved in protein-protein interactions, not in recognizing and binding to specific DNA sequences.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Enzymes that remove histone modifications are called histone demethylases. These enzymes are responsible for removing methyl groups from histone proteins, which can alter chromatin structure and gene expression. Some examples of histone demethylases include:\n1. histone demethylase (KDM4B): This enzyme specifically demethylates histone H3 lysine 4 (H3K4) and is involved in the regulation of gene expression during embryonic development and cell differentiation.\n2. histone demethylase (KDM5A): This enzyme demethylates histone H3 lysine 9 (H3K9) and is involved in the regulation of gene expression, particularly in the context of stem cells and development.\n3. histone demethylase (KDM6A): This enzyme demethylates histone H3 lysine 27 (H3K27) and is involved in the regulation of gene expression, particularly in the context of cell differentiation and immune response.\n4. histone demethylase (KDM7A): This enzyme demethylates histone H3 lysine 9 (H3K9) and is involved in the regulation of gene expression, particularly in the context of stem cells and development.\n5. histone demethylase (KDM1A): This enzyme demethylates histone H3 lysine 4 (H3K4) and is involved in the regulation of gene expression, particularly in the context of cell proliferation and differentiation.\n6. histone demethylase (KDM2A): This enzyme demethylates histone H3 lysine 9 (H3K9) and is involved in the regulation of gene expression, particularly in the context of cell differentiation and immune response.\n7. histone demethylase (KDM3A): This enzyme demethylates histone H3 lysine 4 (H3K4) and is involved in the regulation of gene expression, particularly in the context of cell proliferation and differentiation.\n8. histone demethylase (KDM4A): This enzyme demethylates histone H3",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases are enzymes responsible for removing methyl groups from histone proteins.\n2. Histone demethylase KDM4B specifically demethylates histone H3 lysine 4 (H3K4).\n3. Histone demethylase KDM5A demethylates histone H3 lysine 9 (H3K9).\n4. Histone demethylase KDM6A demethylates histone H3 lysine 27 (H3K27).\n5. Histone demethylase KDM1A demethylates histone H3 lysine 4 (H3K4).",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases are enzymes responsible for removing methyl groups from histone proteins.",
      "Histone demethylase KDM4B specifically demethylates histone H3 lysine 4 (H3K4).",
      "Histone demethylase KDM5A demethylates histone H3 lysine 9 (H3K9).",
      "Histone demethylase KDM6A demethylates histone H3 lysine 27 (H3K27).",
      "Histone demethylase KDM1A demethylates histone H3 lysine 4 (H3K4)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Histone demethylase KDM4B specifically demethylates histone H3 lysine 9 (H3K9) and lysine 36 (H3K36).\n3. FALSE [correction]: Histone demethylase KDM5A demethylates histone H3 lysine 4 (H3K4).\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Head CT scans, like any other medical imaging procedure, carry some risks and potential side effects. While they are generally considered safe when performed appropriately, there is some evidence to suggest that frequent or repeated head CT scans may increase the risk of certain health problems, including:\n1. Radiation exposure: CT scans involve exposure to ionizing radiation, which can increase the risk of cancer and other health problems over time. The more frequent the scans, the higher the radiation exposure.\n2. Brain tumors: Some studies have suggested that frequent head CT scans may be associated with an increased risk of brain tumors, particularly meningioma. However, these findings are still controversial and more research is needed to confirm this association.\n3. Neurodegenerative diseases: There is some evidence to suggest that head CT scans may increase the risk of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. However, these findings are also controversial and more research is needed to confirm this association.\nIt's important to note that the risks associated with head CT scans are generally considered to be low, and the benefits of the procedure often outweigh the risks. However, it's important to discuss any concerns you may have with your doctor before undergoing a head CT scan. They can help you weigh the potential risks and benefits and determine whether the scan is necessary for your specific condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. CT scans involve exposure to ionizing radiation.\n2. Frequent or repeated head CT scans may increase the risk of cancer and other health problems over time.\n3. Some studies have suggested that frequent head CT scans may be associated with an increased risk of brain tumors, particularly meningioma.\n4. There is evidence to suggest that head CT scans may increase the risk of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.\n5. The risks associated with head CT scans are generally considered to be low, and the benefits of the procedure often outweigh the risks.",
    "llama-2-7b-chat-hf_fact": [
      "CT scans involve exposure to ionizing radiation.",
      "Frequent or repeated head CT scans may increase the risk of cancer and other health problems over time.",
      "Some studies have suggested that frequent head CT scans may be associated with an increased risk of brain tumors, particularly meningioma.",
      "There is evidence to suggest that head CT scans may increase the risk of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.",
      "The risks associated with head CT scans are generally considered to be low, and the benefits of the procedure often outweigh the risks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: While there is ongoing research into the potential long-term effects of ionizing radiation from medical imaging on the brain, there is currently no conclusive evidence to suggest that head CT scans increase the risk of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is associated with neural pluripotency. Neural pluripotency refers to the ability of a cell to differentiate into any type of neuron in the nervous system, including neurons, astrocytes, oligodendrocytes, and microglia. Otx2 is a transcription factor that is expressed in neural progenitor cells and is important for maintaining neural pluripotency and regulating neural differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with neural pluripotency.\n2. Neural pluripotency is the ability of a cell to differentiate into any type of neuron in the nervous system.\n3. The nervous system cell types include neurons, astrocytes, oligodendrocytes, and microglia.\n4. Otx2 is a transcription factor.\n5. Otx2 is expressed in neural progenitor cells and is important for maintaining neural pluripotency and regulating neural differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with neural pluripotency.",
      "Neural pluripotency is the ability of a cell to differentiate into any type of neuron in the nervous system.",
      "The nervous system cell types include neurons, astrocytes, oligodendrocytes, and microglia.",
      "Otx2 is a transcription factor.",
      "Otx2 is expressed in neural progenitor cells and is important for maintaining neural pluripotency and regulating neural differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Otx2 is associated with neural development, but it is not directly associated with neural pluripotency. It is more specifically involved in the development of the brain and eye.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta-globin locus region has several DNase I hypersensitive sites (DHS). According to a study published in the journal Genomics, there are at least 14 DHS sites identified in the beta-globin locus region of mouse chromosome 11. These DHS sites are located upstream of the beta-globin gene cluster and are thought to play a role in regulating the expression of the beta-globin genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The murine beta-globin locus region contains several DNase I hypersensitive sites (DHS).\n2. At least 14 DHS sites have been identified in the beta-globin locus region of mouse chromosome 11.\n3. These DHS sites are located upstream of the beta-globin gene cluster.\n4. The DHS sites are thought to play a role in regulating the expression of the beta-globin genes.",
    "llama-2-7b-chat-hf_fact": [
      "The murine beta-globin locus region contains several DNase I hypersensitive sites (DHS).",
      "At least 14 DHS sites have been identified in the beta-globin locus region of mouse chromosome 11.",
      "These DHS sites are located upstream of the beta-globin gene cluster.",
      "The DHS sites are thought to play a role in regulating the expression of the beta-globin genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Here are some of the European influenza vaccines that are currently available or have been developed:\n1. Fluad: This is a quadrivalent influenza vaccine developed by GlaxoSmithKline (GSK) that contains four strains of influenza virus: two A strains and two B strains. Fluad is approved for use in individuals aged 65 years and older.\n2. Fluarix Tetra: This is a quadrivalent influenza vaccine developed by BioNTech that contains four strains of influenza virus: two A strains and two B strains. Fluarix Tetra is approved for use in individuals aged 18 years and older.\n3. Flucelvax: This is a quadrivalent influenza vaccine developed by Novartis that contains four strains of influenza virus: two A strains and two B strains. Flucelvax is approved for use in individuals aged 18 years and older.\n4. FluMist: This is a quadrivalent influenza vaccine developed by MedImmune that contains four strains of influenza virus: two A strains and two B strains. FluMist is approved for use in individuals aged 2-49 years.\n5. Fluarix: This is a trivalent influenza vaccine developed by BioNTech that contains three strains of influenza virus: two A strains and one B strain. Fluarix is approved for use in individuals aged 18 years and older.\n6. Flulaval: This is a trivalent influenza vaccine developed by GlaxoSmithKline (GSK) that contains three strains of influenza virus: two A strains and one B strain. Flulaval is approved for use in individuals aged 6 months and older.\n7. Influvac: This is a trivalent influenza vaccine developed by Novartis that contains three strains of influenza virus: two A strains and one B strain. Influvac is approved for use in individuals aged 6 months and older.\n8. Aggravax: This is a trivalent influenza vaccine developed by Sanofi Pasteur that contains three strains of influenza virus: two A strains and",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluad is a quadrivalent influenza vaccine developed by GlaxoSmithKline (GSK) for individuals aged 65 years and older.\n2. Fluarix Tetra is a quadrivalent influenza vaccine developed by BioNTech for individuals aged 18 years and older.\n3. Flucelvax is a quadrivalent influenza vaccine developed by Novartis for individuals aged 18 years and older.\n4. FluMist is a quadrivalent influenza vaccine developed by MedImmune for individuals aged 2-49 years.\n5. Flulaval is a trivalent influenza vaccine developed by GlaxoSmithKline (GSK) for individuals aged 6 months and older.",
    "llama-2-7b-chat-hf_fact": [
      "Fluad is a quadrivalent influenza vaccine developed by GlaxoSmithKline (GSK) for individuals aged 65 years and older.",
      "Fluarix Tetra is a quadrivalent influenza vaccine developed by BioNTech for individuals aged 18 years and older.",
      "Flucelvax is a quadrivalent influenza vaccine developed by Novartis for individuals aged 18 years and older.",
      "FluMist is a quadrivalent influenza vaccine developed by MedImmune for individuals aged 2-49 years.",
      "Flulaval is a trivalent influenza vaccine developed by GlaxoSmithKline (GSK) for individuals aged 6 months and older."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Fluad is a trivalent influenza vaccine developed by Seqirus for individuals aged 65 years and older.\n2. FALSE [correction]: Fluarix Tetra is a quadrivalent influenza vaccine developed by GlaxoSmithKline (GSK) for individuals aged 6 months and older.\n3. FALSE [correction]: Flucelvax is a quadrivalent influenza vaccine developed by Seqirus for individuals aged 4 years and older.\n4. TRUE\n5. FALSE [correction]: Flulaval is a quadrivalent influenza vaccine developed by GlaxoSmithKline (GSK) for individuals aged 6 months and older.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA. Paramyxoviruses are a family of viruses that include the viruses that cause measles, mumps, and respiratory diseases such as respiratory syncytial virus (RSV). The genome of these viruses is composed of several segments of RNA, each of which encodes a different protein.\nThe RNA genome of Paramyxoviruses is negative-sense, meaning that the RNA strand is complementary to the protein sequence. This is in contrast to positive-sense RNA viruses, such as influenza virus, where the RNA strand is the same as the protein sequence.\nEach segment of the Paramyxovirus genome is transcribed into mRNA, which is then translated into protein. The segments are usually named according to their position in the genome, with the largest segment being segment 1 and the smallest segment being segment 5.\nThe segmented nature of the Paramyxovirus genome allows for the regulated expression of different viral proteins during infection, which is important for the virus to replicate and infect cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Paramyxoviruses are a family of viruses that include the viruses that cause measles, mumps, and respiratory diseases such as respiratory syncytial virus (RSV).\n2. The genome of Paramyxoviruses is composed of several segments of RNA.\n3. The RNA genome of Paramyxoviruses is negative-sense, meaning that the RNA strand is complementary to the protein sequence.\n4. Each segment of the Paramyxovirus genome is transcribed into mRNA, which is then translated into protein.\n5. The segmented nature of the Paramyxovirus genome allows for the regulated expression of different viral proteins during infection.",
    "llama-2-7b-chat-hf_fact": [
      "Paramyxoviruses are a family of viruses that include the viruses that cause measles, mumps, and respiratory diseases such as respiratory syncytial virus (RSV).",
      "The genome of Paramyxoviruses is composed of several segments of RNA.",
      "The RNA genome of Paramyxoviruses is negative-sense, meaning that the RNA strand is complementary to the protein sequence.",
      "Each segment of the Paramyxovirus genome is transcribed into mRNA, which is then translated into protein.",
      "The segmented nature of the Paramyxovirus genome allows for the regulated expression of different viral proteins during infection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The genome of Paramyxoviruses is non-segmented, consisting of a single strand of RNA.\n3. TRUE\n4. FALSE [correction]: Since the Paramyxovirus genome is non-segmented, it does not have multiple segments; rather, it has a single strand of RNA that is transcribed into mRNA.\n5. FALSE [correction]: The Paramyxovirus genome is not segmented; therefore, this statement about the segmented nature allowing for regulated expression does not apply. The expression of viral proteins is regulated, but not through segmented genome mechanisms.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is effective for the treatment of plaque psoriasis. It is a topical cream that works by inhibiting the activity of inflammatory cells and reducing the production of inflammatory mediators, which helps to improve the symptoms of psoriasis, such as redness, itching, and scaliness. Roflumilast cream is applied directly to the affected skin areas and can be used in combination with other treatments, such as corticosteroids or vitamin D analogues, to enhance its effectiveness.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used for the treatment of plaque psoriasis.\n2. The cream works by inhibiting the activity of inflammatory cells.\n3. Roflumilast cream reduces the production of inflammatory mediators.\n4. It is applied directly to the affected skin areas.\n5. Roflumilast cream can be used in combination with other treatments like corticosteroids or vitamin D analogues.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used for the treatment of plaque psoriasis.",
      "The cream works by inhibiting the activity of inflammatory cells.",
      "Roflumilast cream reduces the production of inflammatory mediators.",
      "It is applied directly to the affected skin areas.",
      "Roflumilast cream can be used in combination with other treatments like corticosteroids or vitamin D analogues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Roflumilast is known as an oral medication for the treatment of severe chronic obstructive pulmonary disease (COPD). However, there is a topical form of roflumilast that is used for the treatment of plaque psoriasis, but it is important to specify that it is the topical form, not the cream, as the formulation can vary.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Several tools have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are some of the commonly used tools:\n1. RNAhybrid: RNAhybrid is a tool for identifying and visualizing ncRNA promoters by analyzing the proximity of RNA polymerase II (RNAPII) ChIP-seq peaks to ncRNA transcripts. It can also predict the strength of the promoter activity.\n2. PROMoterFinder: PROMoterFinder is a tool for identifying and visualizing ncRNA promoters by analyzing the proximity of RNAPII ChIP-seq peaks to ncRNA transcripts. It can also predict the strength of the promoter activity.\n3. Prognosticate: Prognosticate is a tool for identifying and visualizing ncRNA promoters by analyzing the chromatin structure and the proximity of RNAPII ChIP-seq peaks to ncRNA transcripts. It can also predict the strength of the promoter activity.\n4. CpGPlotr: CpGPlotr is a tool for identifying and visualizing the CpG dinucleotides in the promoter regions of ncRNAs. CpG dinucleotides are known to play a crucial role in the regulation of gene expression.\n5. RNAProfiler: RNAProfiler is a tool for identifying and visualizing the expression levels of ncRNAs in different cell types and tissues. It can also predict the promoter activity of ncRNAs based on their expression levels.\n6. NCRNAprofiler: NCRNAprofiler is a tool for identifying and visualizing the expression levels of ncRNAs in different cell types and tissues. It can also predict the promoter activity of ncRNAs based on their expression levels.\n7. RNAhybrid2: RNAhybrid2 is an updated version of RNAhybrid, which can predict the promoter activity of ncRNAs with higher accuracy. It uses a machine learning algorithm to analyze the proximity of RNAPII ChIP-seq peaks to ncRNA transcripts.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNAhybrid is a tool used for identifying and visualizing ncRNA promoters.\n2. PROMoterFinder is a tool that analyzes RNAPII ChIP-seq peaks proximity to ncRNA transcripts to identify and visualize ncRNA promoters.\n3. Prognosticate is a tool that identifies and visualizes ncRNA promoters by analyzing chromatin structure and RNAPII ChIP-seq peaks proximity to ncRNA transcripts.\n4. CpGPlotr is a tool designed to identify and visualize CpG dinucleotides in the promoter regions of ncRNAs.\n5. RNAProfiler is a tool that identifies and visualizes the expression levels of ncRNAs in different cell types and tissues.",
    "llama-2-7b-chat-hf_fact": [
      "RNAhybrid is a tool used for identifying and visualizing ncRNA promoters.",
      "PROMoterFinder is a tool that analyzes RNAPII ChIP-seq peaks proximity to ncRNA transcripts to identify and visualize ncRNA promoters.",
      "Prognosticate is a tool that identifies and visualizes ncRNA promoters by analyzing chromatin structure and RNAPII ChIP-seq peaks proximity to ncRNA transcripts.",
      "CpGPlotr is a tool designed to identify and visualize CpG dinucleotides in the promoter regions of ncRNAs.",
      "RNAProfiler is a tool that identifies and visualizes the expression levels of ncRNAs in different cell types and tissues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RNAhybrid is a tool used for predicting microRNA targets by finding the most favorable hybridization sites of a small RNA within a large RNA sequence.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and assessments are based on the information that RNAhybrid is known for its role in microRNA target prediction, not for identifying ncRNA promoters. The other tools mentioned are not well-known or standard tools with clearly defined purposes in the public domain, so without additional context, it is not possible to accurately determine the truthfulness of those statements.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "SWIM (Splicing Workbench for Integrative Molecular analysis) is a tool that uses RNA-seq data to identify differentially spliced genes between two or more sample groups. Here are some examples of genes that SWIM tool has identified as down-regulated in glioblastoma (GBM) based on RNA-seq data:\n1. TP53INP1: TP53-induced nuclear protein 1 (TP53INP1) is a tumor suppressor gene that is frequently mutated in GBM. SWIM analysis of RNA-seq data identified TP53INP1 as a down-regulated gene in GBM.\n2. PTEN: The phosphatase and tensin homolog (PTEN) is a tumor suppressor gene that is commonly mutated in GBM. SWIM analysis of RNA-seq data identified PTEN as a down-regulated gene in GBM.\n3. CDKN2A: The cyclin-dependent kinase inhibitor 2A (CDKN2A) gene is a tumor suppressor gene that is frequently mutated in GBM. SWIM analysis of RNA-seq data identified CDKN2A as a down-regulated gene in GBM.\n4. STK11: The serine/threonine kinase 11 (STK11) gene is a tumor suppressor gene that is commonly mutated in GBM. SWIM analysis of RNA-seq data identified STK11 as a down-regulated gene in GBM.\n5. BRCA1: The breast cancer 1 (BRCA1) gene is a tumor suppressor gene that is frequently mutated in GBM. SWIM analysis of RNA-seq data identified BRCA1 as a down-regulated gene in GBM.\n6. BRAF: The v-raf murine sarcoma viral oncogene homolog B (BRAF) gene is a tumor suppressor gene that is commonly mutated in GBM. SWIM analysis of RNA-seq data identified BRAF as a down-regulated gene in GBM.\n7. PTCH1: The patched 1 (PTCH1) gene is a tumor suppressor gene that is frequently mut",
    "llama-2-7b-chat-hf_fact_raw": "1. TP53INP1 has been identified by SWIM as a down-regulated gene in glioblastoma.\n2. PTEN has been identified by SWIM as a down-regulated gene in glioblastoma.\n3. CDKN2A has been identified by SWIM as a down-regulated gene in glioblastoma.\n4. STK11 has been identified by SWIM as a down-regulated gene in glioblastoma.\n5. BRCA1 has been identified by SWIM as a down-regulated gene in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "TP53INP1 has been identified by SWIM as a down-regulated gene in glioblastoma.",
      "PTEN has been identified by SWIM as a down-regulated gene in glioblastoma.",
      "CDKN2A has been identified by SWIM as a down-regulated gene in glioblastoma.",
      "STK11 has been identified by SWIM as a down-regulated gene in glioblastoma.",
      "BRCA1 has been identified by SWIM as a down-regulated gene in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information on the SWIM (which could be an acronym for a specific study, database, or research group) and its findings, it is not possible to verify the accuracy of these statements regarding the regulation of the genes mentioned in glioblastoma. Additionally, the regulation of genes such as TP53INP1, PTEN, CDKN2A, STK11, and BRCA1 can be context-dependent and may vary between studies.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Several R packages have been developed for studying Topologically Associating Domains (TADs), which are genomic regions that are organized into three-dimensional structures and are involved in regulating gene expression. Here are some of the commonly used R packages for TAD analysis:\n1. TADbit: This package provides a set of tools for identifying and characterizing TADs from chromatin interaction data. It can be used to identify TAD boundaries, predict TAD interactions, and infer the 3D structure of TADs.\n2. TADtrack: This package provides a set of tools for identifying and tracking TADs across different cell types and conditions. It can be used to identify TADs in gene expression data, ChIP-seq data, and other types of genomic data.\n3. TADmap: This package provides a set of tools for visualizing and interpreting TADs in the context of gene expression and other genomic data. It can be used to create interactive visualizations of TADs, identify TAD-associated genes, and infer the functional implications of TAD organization.\n4. ChromHMM: This package provides a set of tools for modeling the 3D structure of chromatin using a hidden Markov model (HMM) approach. It can be used to predict TADs, identify chromatin loops, and infer the functional implications of chromatin structure.\n5. Chromatin3D: This package provides a set of tools for analyzing the 3D structure of chromatin using a variety of methods, including Hi-C data and chromatin interaction data. It can be used to identify TADs, predict chromatin loops, and infer the functional implications of chromatin structure.\n6. 3DGenome: This package provides a set of tools for analyzing the 3D structure of chromatin using a variety of methods, including Hi-C data and chromatin interaction data. It can be used to identify TADs, predict chromatin loops, and infer the functional implications of chromatin structure.\n7. Chromosome conformation capture (3C) and related methods: This package provides a set of tools for analyzing the 3D structure of chromatin using chromosome conformation capture (3C) data. It can be used to identify TADs, predict chromatin loops, and infer the functional imp",
    "llama-2-7b-chat-hf_fact_raw": "1. TADbit is an R package designed for identifying and characterizing Topologically Associating Domains (TADs) from chromatin interaction data.\n2. TADtrack is an R package that helps identify and track TADs across different cell types and conditions, including gene expression and ChIP-seq data.\n3. TADmap is an R package that allows for the visualization and interpretation of TADs in the context of gene expression and other genomic data.\n4. ChromHMM is an R package that models the 3D structure of chromatin using a hidden Markov model approach to predict TADs and identify chromatin loops.\n5. Chromatin3D is an R package for analyzing the 3D structure of chromatin, including the identification of TADs and prediction of chromatin loops, using methods like Hi-C data.",
    "llama-2-7b-chat-hf_fact": [
      "TADbit is an R package designed for identifying and characterizing Topologically Associating Domains (TADs) from chromatin interaction data.",
      "TADtrack is an R package that helps identify and track TADs across different cell types and conditions, including gene expression and ChIP-seq data.",
      "TADmap is an R package that allows for the visualization and interpretation of TADs in the context of gene expression and other genomic data.",
      "ChromHMM is an R package that models the 3D structure of chromatin using a hidden Markov model approach to predict TADs and identify chromatin loops.",
      "Chromatin3D is an R package for analyzing the 3D structure of chromatin, including the identification of TADs and prediction of chromatin loops, using methods like Hi-C data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: ChromHMM is not an R package, and it does not specifically model the 3D structure of chromatin. It is a computational tool that uses a hidden Markov model to identify chromatin states based on histone modification data, not to predict TADs or identify chromatin loops.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "There are several bioconductor tools that have been developed for accessing bacterial regulatory networks. Here are a few examples:\n1. \"BioCyc\": This is a comprehensive collection of biochemical pathway and genomic information for a wide range of organisms, including bacteria. It includes a database of regulatory interactions and a tool for predicting gene expression profiles based on regulatory interactions.\n2. \"RegulonDB\": This is a database of bacterial gene regulation, which includes information on transcriptional regulators, target genes, and regulatory interactions. It also provides tools for predicting gene expression profiles and identifying regulatory networks.\n3. \"CycOX\": This is a tool for predicting the activity of transcriptional regulators in E. coli. It uses a combination of machine learning algorithms and a knowledge-based model of transcriptional regulation to predict the activity of regulators and their target genes.\n4. \"BioNetGen\": This is a bioconductor package for reconstructing and analyzing bacterial regulatory networks. It includes tools for inferring regulatory interactions from gene expression data, predicting gene expression profiles, and visualizing regulatory networks.\n5. \"RegulatoryGenomics\": This is a bioconductor package for analyzing the regulatory genomics of bacteria. It includes tools for predicting transcriptional regulators, identifying regulatory motifs, and reconstructing regulatory networks.\n6. \"BacterialGenomeAnalyzer\": This is a bioconductor package for analyzing the genomes of bacteria. It includes tools for predicting gene function, identifying gene clusters, and reconstructing regulatory networks.\n7. \"BacterialNetworkAnalysis\": This is a bioconductor package for analyzing the regulatory networks of bacteria. It includes tools for inferring regulatory interactions from gene expression data, predicting gene expression profiles, and visualizing regulatory networks.\n8. \"BacterialRegulatoryGenomics\": This is a bioconductor package for analyzing the regulatory genomics of bacteria. It includes tools for predicting transcriptional regulators, identifying regulatory motifs, and reconstructing regulatory networks.\nThese are just a few examples of the many",
    "llama-2-7b-chat-hf_fact_raw": "1. \"BioCyc\" is a bioconductor tool that includes a database of regulatory interactions and a tool for predicting gene expression profiles based on regulatory interactions.\n2. \"RegulonDB\" is a database of bacterial gene regulation that provides tools for predicting gene expression profiles and identifying regulatory networks.\n3. \"CycOX\" is a tool for predicting the activity of transcriptional regulators in E. coli using machine learning algorithms and a knowledge-based model.\n4. \"BioNetGen\" is a bioconductor package for reconstructing and analyzing bacterial regulatory networks, including tools for inferring regulatory interactions from gene expression data.\n5. \"RegulatoryGenomics\" is a bioconductor package for analyzing the regulatory genomics of bacteria, including tools for predicting transcriptional regulators and reconstructing regulatory networks.",
    "llama-2-7b-chat-hf_fact": [
      "\"BioCyc\" is a bioconductor tool that includes a database of regulatory interactions and a tool for predicting gene expression profiles based on regulatory interactions.",
      "\"RegulonDB\" is a database of bacterial gene regulation that provides tools for predicting gene expression profiles and identifying regulatory networks.",
      "\"CycOX\" is a tool for predicting the activity of transcriptional regulators in E. coli using machine learning algorithms and a knowledge-based model.",
      "\"BioNetGen\" is a bioconductor package for reconstructing and analyzing bacterial regulatory networks, including tools for inferring regulatory interactions from gene expression data.",
      "\"RegulatoryGenomics\" is a bioconductor package for analyzing the regulatory genomics of bacteria, including tools for predicting transcriptional regulators and reconstructing regulatory networks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: \"BioCyc\" is a collection of Pathway/Genome Databases (PGDBs) that provides information on metabolic pathways and gene products, not a bioconductor tool for predicting gene expression profiles.\n2. TRUE\n3. FALSE [correction]: There is no widely recognized tool called \"CycOX\" for predicting the activity of transcriptional regulators in E. coli. This might be a fictional or less-known tool, or the name might be incorrect.\n4. FALSE [correction]: \"BioNetGen\" is a software for modeling and simulating the kinetics of molecular interactions, not specifically for reconstructing and analyzing bacterial regulatory networks or inferring regulatory interactions from gene expression data.\n5. FALSE [correction]: There is no bioconductor package specifically named \"RegulatoryGenomics.\" However, there are various tools and packages available for analyzing regulatory genomics, but without the exact name, it's unclear which specific package this statement refers to.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The end products of the shikimate pathway are several aromatic amino acids, including:\n1. Aromatic amino acids:\n* Tyrosine (Tyr)\n* Tryptophan (Trp)\n* Phenylalanine (Phe)\n* Tyrosine (Tyr)\n* Dopamine (DA)\n* Serotonin (5-HT)\nThese amino acids are important for various physiological processes, including neurotransmission, immune response, and melanin synthesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Tyrosine is an end product of the shikimate pathway.\n2. Tryptophan is an end product of the shikimate pathway.\n3. Phenylalanine is an end product of the shikimate pathway.\n4. Dopamine is listed as an end product of the shikimate pathway.\n5. Serotonin is listed as an end product of the shikimate pathway.",
    "llama-2-7b-chat-hf_fact": [
      "Tyrosine is an end product of the shikimate pathway.",
      "Tryptophan is an end product of the shikimate pathway.",
      "Phenylalanine is an end product of the shikimate pathway.",
      "Dopamine is listed as an end product of the shikimate pathway.",
      "Serotonin is listed as an end product of the shikimate pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Tyrosine is not an end product of the shikimate pathway; it is synthesized from phenylalanine, which is an end product of the pathway.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Dopamine is not listed as an end product of the shikimate pathway; it is a neurotransmitter synthesized from tyrosine.\n5. FALSE [correction]: Serotonin is not listed as an end product of the shikimate pathway; it is a neurotransmitter synthesized from tryptophan.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome, which is a rare condition that occurs after the removal of a pituitary tumor. Nelson's syndrome is characterized by the rapid growth of the remaining pituitary tissue, leading to an overproduction of hormones and a variety of symptoms, including headache, visual disturbances, and hyperpituitarism.\nCabergoline, a dopamine receptor agonist, has been shown to be effective in reducing the symptoms of Nelson's syndrome by suppressing the production of hormones by the remaining pituitary tissue. It is typically used in combination with surgery to remove as much of the remaining tumor tissue as possible.\nWhile cabergoline can help manage the symptoms of Nelson's syndrome, it is important to note that it is not a cure for the condition, and the underlying cause of the hormonal imbalance must be addressed through surgery and/or other treatments.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is used to treat Nelson's syndrome.\n2. Nelson's syndrome is a rare condition that can occur after the removal of a pituitary tumor.\n3. Nelson's syndrome is characterized by rapid growth of remaining pituitary tissue and an overproduction of hormones.\n4. Symptoms of Nelson's syndrome include headache, visual disturbances, and hyperpituitarism.\n5. Cabergoline works by suppressing the production of hormones by the remaining pituitary tissue.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is used to treat Nelson's syndrome.",
      "Nelson's syndrome is a rare condition that can occur after the removal of a pituitary tumor.",
      "Nelson's syndrome is characterized by rapid growth of remaining pituitary tissue and an overproduction of hormones.",
      "Symptoms of Nelson's syndrome include headache, visual disturbances, and hyperpituitarism.",
      "Cabergoline works by suppressing the production of hormones by the remaining pituitary tissue."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used to treat Nelson's syndrome. It is used to treat conditions associated with hyperprolactinemia, such as Parkinson's disease and prolactinomas.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Cabergoline works by binding to dopamine receptors in the pituitary gland, which leads to a decrease in the production of prolactin. It does not directly suppress the production of all hormones by the remaining pituitary tissue. Nelson's syndrome involves an overproduction of ACTH (adrenocorticotropic hormone), and treatment options may include surgery, radiation therapy, and medications that are not typically dopamine agonists like cabergoline.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare genetic disorder that affects the development and function of the nervous system. The main manifestations of Liebenberg syndrome include:\n1. Spasticity: Muscle stiffness and spasms are the most common symptoms of Liebenberg syndrome, which can affect any part of the body but is most commonly seen in the legs, hips, and lower back.\n2. Scoliosis: Many individuals with Liebenberg syndrome develop curvature of the spine (scoliosis), which can lead to breathing difficulties and other complications.\n3. Intellectual disability: Liebenberg syndrome can also cause intellectual disability, which can range from mild to severe.\n4. Seizures: Some individuals with Liebenberg syndrome may experience seizures, which can be caused by abnormal electrical activity in the brain.\n5. Vision problems: Liebenberg syndrome can also cause vision problems, including blurred vision, double vision, and other eye movements.\n6. Hearing loss: Some individuals with Liebenberg syndrome may experience hearing loss or other auditory problems.\n7. Respiratory problems: Liebenberg syndrome can also lead to respiratory problems, including breathing difficulties and sleep apnea.\n8. Gastrointestinal problems: Individuals with Liebenberg syndrome may experience gastrointestinal problems, such as constipation, diarrhea, and other digestive issues.\n9. Sleep disturbances: Liebenberg syndrome can also cause sleep disturbances, including insomnia and other sleep disorders.\n10. Autism: Some individuals with Liebenberg syndrome may also have autism spectrum disorder (ASD), which can affect communication, social interaction, and behavior.\nIt's important to note that the severity and specific manifestations of Liebenberg syndrome can vary widely between individuals, and some people may experience only a few of these symptoms while others may have more severe and widespread effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder that affects the development and function of the nervous system.\n2. Muscle stiffness and spasms, commonly seen in the legs, hips, and lower back, are symptoms of Liebenberg syndrome.\n3. Individuals with Liebenberg syndrome may develop scoliosis, a curvature of the spine.\n4. Liebenberg syndrome can cause intellectual disability, which can range from mild to severe.\n5. Some individuals with Liebenberg syndrome may experience seizures due to abnormal electrical activity in the brain.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a rare genetic disorder that affects the development and function of the nervous system.",
      "Muscle stiffness and spasms, commonly seen in the legs, hips, and lower back, are symptoms of Liebenberg syndrome.",
      "Individuals with Liebenberg syndrome may develop scoliosis, a curvature of the spine.",
      "Liebenberg syndrome can cause intellectual disability, which can range from mild to severe.",
      "Some individuals with Liebenberg syndrome may experience seizures due to abnormal electrical activity in the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Liebenberg syndrome is not a recognized medical condition in the scientific literature as of my knowledge cutoff date in 2023. Therefore, the truthfulness of these statements cannot be determined, and they are marked as UNKNOWN. If Liebenberg syndrome is a fictional or hypothetical condition created for the purpose of this task, there is no factual basis to confirm or correct the statements provided.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "There are several orally bioavailable MPS1 kinase inhibitors that have been identified and developed for the treatment of various diseases, including cancer and neurodegenerative disorders. Here are some examples:\n1. PF-06260958: This is a potent and selective MPS1 kinase inhibitor that has shown activity against various cancer cell lines, including those resistant to other MPS1 inhibitors.\n2. GSK2801: This is a small molecule inhibitor of MPS1 that has shown activity against various cancer cell lines and has been evaluated in clinical trials for the treatment of hematological malignancies.\n3. BAY-1000394: This is a potent and selective MPS1 kinase inhibitor that has shown activity against various cancer cell lines and has been evaluated in preclinical studies for the treatment of breast cancer.\n4. LY3023414: This is a highly selective MPS1 kinase inhibitor that has shown activity against various cancer cell lines and has been evaluated in preclinical studies for the treatment of pancreatic cancer.\n5. S63845: This is a potent and selective MPS1 kinase inhibitor that has shown activity against various cancer cell lines and has been evaluated in preclinical studies for the treatment of colorectal cancer.\n6. R5502005: This is a highly selective MPS1 kinase inhibitor that has shown activity against various cancer cell lines and has been evaluated in preclinical studies for the treatment of ovarian cancer.\n7. BMS-911597: This is a potent and selective MPS1 kinase inhibitor that has shown activity against various cancer cell lines and has been evaluated in preclinical studies for the treatment of multiple myeloma.\n8. MLN0128: This is a potent and selective MPS1 kinase inhibitor that has shown activity against various cancer cell lines and has been evaluated in clinical trials for the treatment of multiple myeloma.\n9. AZD-0530: This is a potent and selective MPS1 kinase inhib",
    "llama-2-7b-chat-hf_fact_raw": "1. PF-06260958 is an orally bioavailable MPS1 kinase inhibitor that has shown activity against various cancer cell lines.\n2. GSK2801 is an orally bioavailable MPS1 kinase inhibitor that has been evaluated in clinical trials for the treatment of hematological malignancies.\n3. BAY-1000394 is an orally bioavailable MPS1 kinase inhibitor that has been evaluated in preclinical studies for the treatment of breast cancer.\n4. LY3023414 is an orally bioavailable MPS1 kinase inhibitor that has been evaluated in preclinical studies for the treatment of pancreatic cancer.\n5. S63845 is an orally bioavailable MPS1 kinase inhibitor that has been evaluated in preclinical studies for the treatment of colorectal cancer.",
    "llama-2-7b-chat-hf_fact": [
      "PF-06260958 is an orally bioavailable MPS1 kinase inhibitor that has shown activity against various cancer cell lines.",
      "GSK2801 is an orally bioavailable MPS1 kinase inhibitor that has been evaluated in clinical trials for the treatment of hematological malignancies.",
      "BAY-1000394 is an orally bioavailable MPS1 kinase inhibitor that has been evaluated in preclinical studies for the treatment of breast cancer.",
      "LY3023414 is an orally bioavailable MPS1 kinase inhibitor that has been evaluated in preclinical studies for the treatment of pancreatic cancer.",
      "S63845 is an orally bioavailable MPS1 kinase inhibitor that has been evaluated in preclinical studies for the treatment of colorectal cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: GSK2801 is not an MPS1 kinase inhibitor; it is a BAZ2A/B inhibitor.\n3. UNKNOWN\n4. FALSE [correction]: LY3023414 is not an MPS1 kinase inhibitor; it is a PI3K/mTOR inhibitor.\n5. FALSE [correction]: S63845 is not an MPS1 kinase inhibitor; it is an MCL1 inhibitor.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Golimumab, a tumor necrosis factor-alpha (TNF-alpha) inhibitor, has been tested for the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. However, it has not been specifically tested for the treatment of diabetes.\nGolimumab works by blocking the activity of TNF-alpha, a protein that is involved in the immune system and can cause inflammation in the body. By blocking the activity of TNF-alpha, golimumab can help to reduce inflammation and alleviate symptoms in people with autoimmune diseases.\nWhile there have been some studies on the use of TNF-alpha inhibitors, including golimumab, for the treatment of type 2 diabetes, these studies have been limited and have not shown a significant benefit in reducing blood sugar levels or improving insulin sensitivity. Therefore, golimumab is not approved for the treatment of diabetes by the US Food and Drug Administration (FDA) or other regulatory agencies.\nIt is important to note that diabetes is a complex disease that is caused by a combination of genetic and lifestyle factors, and there is currently no cure for the disease. Treatment for diabetes typically involves a combination of medications, lifestyle changes, and insulin therapy, and the most effective treatment approach may vary depending on the individual patient. If you have diabetes, it is important to work closely with your healthcare provider to develop a personalized treatment plan that meets your needs and helps you manage your condition effectively.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor.\n2. Golimumab has been tested for the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.\n3. Golimumab has not been specifically tested for the treatment of diabetes.\n4. TNF-alpha inhibitors, including golimumab, have not shown a significant benefit in reducing blood sugar levels or improving insulin sensitivity in type 2 diabetes.\n5. Golimumab is not approved for the treatment of diabetes by the US Food and Drug Administration (FDA) or other regulatory agencies.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor.",
      "Golimumab has been tested for the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.",
      "Golimumab has not been specifically tested for the treatment of diabetes.",
      "TNF-alpha inhibitors, including golimumab, have not shown a significant benefit in reducing blood sugar levels or improving insulin sensitivity in type 2 diabetes.",
      "Golimumab is not approved for the treatment of diabetes by the US Food and Drug Administration (FDA) or other regulatory agencies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Yes, progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by an autosomal recessive gene mutation. This means that a child must inherit two copies of the mutated gene, one from each parent, in order to develop the condition. The mutation leads to a deficiency of the protein Lamin A, which is essential for maintaining the structure and function of the cell nucleus. The lack of Lamin A causes cells to age prematurely, leading to the characteristic features of progeria, such as accelerated aging, hair loss, and distinctive facial features.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).\n2. Progeria is caused by an autosomal recessive gene mutation.\n3. A child must inherit two copies of the mutated gene, one from each parent, to develop progeria.\n4. The mutation in progeria leads to a deficiency of the protein Lamin A.\n5. The lack of Lamin A causes cells to age prematurely, which is characteristic of progeria.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).",
      "Progeria is caused by an autosomal recessive gene mutation.",
      "A child must inherit two copies of the mutated gene, one from each parent, to develop progeria.",
      "The mutation in progeria leads to a deficiency of the protein Lamin A.",
      "The lack of Lamin A causes cells to age prematurely, which is characteristic of progeria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Progeria is caused by a mutation in the LMNA gene, which is typically a de novo (new) mutation rather than an inherited autosomal recessive gene mutation.\n3. FALSE [correction]: Progeria is not inherited in an autosomal recessive manner. Most cases are sporadic, resulting from a new mutation that occurs during the early stages of embryo development.\n4. FALSE [correction]: The mutation in progeria leads to the production of an abnormal form of the protein Lamin A, known as progerin, not a deficiency of Lamin A.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Variants at chromosome 12q14 and 12q24 have been associated with several genetic disorders and complex traits. Here are some of the most common variants associated with these regions:\n12q14:\n* BRAF mutations: BRAF mutations are commonly found in melanoma and are associated with resistance to BRAF inhibitors.\n* CDKN2A mutations: CDKN2A mutations are associated with various cancers, including melanoma, colorectal cancer, and ovarian cancer.\n* PTEN mutations: PTEN mutations are associated with Cowden syndrome, a rare genetic disorder characterized by multiple hamartomas and an increased risk of developing cancer.\n* PIK3CA mutations: PIK3CA mutations are associated with various cancers, including breast cancer, colorectal cancer, and thyroid cancer.\n* MAP3K5 mutations: MAP3K5 mutations are associated with various cancers, including breast cancer, ovarian cancer, and colorectal cancer.\n12q24:\n* HMGA2 amplification: HMGA2 amplification is associated with various cancers, including breast cancer, ovarian cancer, and lung cancer.\n* HMGA2 overexpression: HMGA2 overexpression is associated with various cancers, including breast cancer, ovarian cancer, and lung cancer.\n* TP53 mutations: TP53 mutations are associated with various cancers, including breast cancer, ovarian cancer, and lung cancer.\n* CDKN2A mutations: CDKN2A mutations are associated with various cancers, including breast cancer, ovarian cancer, and lung cancer.\n* PTEN mutations: PTEN mutations are associated with various cancers, including breast cancer, ovarian cancer, and lung cancer.\nThese are just a few examples of the genetic variants associated with these regions. The specific variants and their associated cancers can vary depending on the individual and the population being studied.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRAF mutations at chromosome 12q14 are commonly found in melanoma and are associated with resistance to BRAF inhibitors.\n2. CDKN2A mutations at chromosome 12q14 are associated with various cancers, including melanoma, colorectal cancer, and ovarian cancer.\n3. PTEN mutations at chromosome 12q14 are associated with Cowden syndrome and an increased risk of developing cancer.\n4. PIK3CA mutations at chromosome 12q14 are associated with various cancers, including breast cancer, colorectal cancer, and thyroid cancer.\n5. HMGA2 amplification at chromosome 12q24 is associated with various cancers, including breast cancer, ovarian cancer, and lung cancer.",
    "llama-2-7b-chat-hf_fact": [
      "BRAF mutations at chromosome 12q14 are commonly found in melanoma and are associated with resistance to BRAF inhibitors.",
      "CDKN2A mutations at chromosome 12q14 are associated with various cancers, including melanoma, colorectal cancer, and ovarian cancer.",
      "PTEN mutations at chromosome 12q14 are associated with Cowden syndrome and an increased risk of developing cancer.",
      "PIK3CA mutations at chromosome 12q14 are associated with various cancers, including breast cancer, colorectal cancer, and thyroid cancer.",
      "HMGA2 amplification at chromosome 12q24 is associated with various cancers, including breast cancer, ovarian cancer, and lung cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BRAF mutations are commonly found in melanoma and are associated with resistance to BRAF inhibitors, but they are located at chromosome 7q34, not 12q14.\n2. FALSE [correction]: CDKN2A mutations are associated with various cancers, including melanoma, but they are located at chromosome 9p21, not 12q14.\n3. FALSE [correction]: PTEN mutations are associated with Cowden syndrome and an increased risk of developing cancer, but they are located at chromosome 10q23, not 12q14.\n4. FALSE [correction]: PIK3CA mutations are associated with various cancers, including breast cancer, colorectal cancer, and thyroid cancer, but they are located at chromosome 3q26, not 12q14.\n5. FALSE [correction]: HMGA2 amplification is associated with various cancers, but it is located at chromosome 12q14.3, not 12q24.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The Roundabout (Robo) receptors are a family of transmembrane receptors that play a crucial role in regulating cellular behavior, including cell migration, differentiation, and survival. There are four known ligands that bind to Robo receptors:\n1. Roundabout ligand (RoboL): RoboL is the most well-studied ligand of the Robo receptors. It is a secreted protein that binds to Robo1 and Robo2 receptors with high affinity, promoting repulsive axon guidance and regulating cell migration.\n2. Delta-like ligand (Dll): Dll proteins (Dll1, Dll3, and Dll4) are also known ligands of Robo receptors. They bind to Robo1, Robo2, and Robo3 receptors, respectively, and modulate their activity. Dll1 and Dll3 are primarily involved in the regulation of cell adhesion and migration, while Dll4 is involved in the regulation of angiogenesis and lymphangiogenesis.\n3. Jewel (Jewelry) ligand (Jewel): Jewel is a secreted protein that binds to Robo2 receptor with high affinity, promoting repulsive axon guidance and regulating cell migration.\n4. Rhomboid (Rho) ligand (Rho): Rho is a secreted protein that binds to Robo1 receptor with low affinity, modulating its activity. Rho is primarily involved in the regulation of cell adhesion and migration.\nIt is worth noting that these ligands can interact with Robo receptors in a context-dependent manner, and their specific functions can vary depending on the cellular environment and the specific receptor isoform involved.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roundabout ligand (RoboL) binds to Robo1 and Robo2 receptors with high affinity.\n2. Delta-like ligand (Dll) proteins bind to Robo1, Robo2, and Robo3 receptors.\n3. Jewel ligand (Jewel) binds to Robo2 receptor with high affinity.\n4. Rhomboid ligand (Rho) binds to Robo1 receptor with low affinity.\n5. Dll4 is involved in the regulation of angiogenesis and lymphangiogenesis.",
    "llama-2-7b-chat-hf_fact": [
      "Roundabout ligand (RoboL) binds to Robo1 and Robo2 receptors with high affinity.",
      "Delta-like ligand (Dll) proteins bind to Robo1, Robo2, and Robo3 receptors.",
      "Jewel ligand (Jewel) binds to Robo2 receptor with high affinity.",
      "Rhomboid ligand (Rho) binds to Robo1 receptor with low affinity.",
      "Dll4 is involved in the regulation of angiogenesis and lymphangiogenesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Delta-like ligand (Dll) proteins do not bind to Robo receptors; they typically bind to Notch receptors.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Yes, TFII-I has been shown to play a role in megakaryopoiesis, which is the process of developing platelets in the bone marrow. TFII-I is a transcription factor that belongs to the general transcription factor II (TFIID) complex, which is essential for the initiation of transcription in eukaryotic cells.\nStudies have shown that TFII-I is required for the proper differentiation of megakaryocytes, which are the cells that give rise to platelets. TFII-I deficiency in mice leads to impaired megakaryopoiesis and a reduction in platelet numbers, which can result in bleeding disorders.\nTFII-I regulates the expression of genes involved in platelet function and signaling, such as the platelet-derived growth factor receptor alpha (PDGFRA) and the integrin alphaIIb beta3 (ITGA2B). TFII-I also regulates the expression of genes involved in the maintenance of platelet homeostasis, such as the platelet-specific gene, glycoprotein (GP) IIb-IIIa.\nIn addition, TFII-I has been shown to interact with other transcription factors, such as GATA1 and NF-κB, which are also involved in megakaryopoiesis. These interactions suggest that TFII-I may play a role in coordinating the expression of multiple genes involved in platelet development and function.\nOverall, the evidence suggests that TFII-I plays a critical role in megakaryopoiesis, and that dysregulation of TFII-I activity may contribute to bleeding disorders and other platelet-related diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I plays a role in the process of megakaryopoiesis, which is the development of platelets in the bone marrow.\n2. TFII-I is a transcription factor that is part of the general transcription factor II (TFIID) complex.\n3. TFII-I deficiency in mice leads to impaired megakaryopoiesis and a reduction in platelet numbers.\n4. TFII-I regulates the expression of genes involved in platelet function and signaling, such as PDGFRA and ITGA2B.\n5. TFII-I interacts with other transcription factors like GATA1 and NF-κB, which are involved in megakaryopoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I plays a role in the process of megakaryopoiesis, which is the development of platelets in the bone marrow.",
      "TFII-I is a transcription factor that is part of the general transcription factor II (TFIID) complex.",
      "TFII-I deficiency in mice leads to impaired megakaryopoiesis and a reduction in platelet numbers.",
      "TFII-I regulates the expression of genes involved in platelet function and signaling, such as PDGFRA and ITGA2B.",
      "TFII-I interacts with other transcription factors like GATA1 and NF-κB, which are involved in megakaryopoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TFII-I is a transcription factor, but it is not part of the general transcription factor II (TFIID) complex. It is an independent transcription factor that can regulate gene expression.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6. CYP2D6 is one of the most important enzymes responsible for the metabolism of atenolol, and it accounts for a significant portion of the drug's metabolism in most individuals.\nAtenolol is converted to its active metabolite, carbamylated atenolol, by CYP2D6. This metabolic pathway is responsible for approximately 70-80% of the drug's total clearance. The activity of CYP2D6 can vary greatly between individuals, leading to inter-individual differences in the metabolism and efficacy of atenolol. Approximately 20-30% of Caucasians are poor metabolizers of CYP2D6, which can result in reduced drug efficacy and increased side effects.\nIn addition to CYP2D6, atenolol is also metabolized by other enzymes, including CYP3A4, CYP2C9, and CYP2C19. However, the contribution of these enzymes to atenolol metabolism is generally less significant than that of CYP2D6.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\n2. CYP2D6 is responsible for a significant portion of atenolol's metabolism in most individuals.\n3. Atenolol is converted to its active metabolite, carbamylated atenolol, by CYP2D6.\n4. Approximately 70-80% of atenolol's total clearance is due to the metabolic pathway involving CYP2D6.\n5. Around 20-30% of Caucasians are poor metabolizers of CYP2D6.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.",
      "CYP2D6 is responsible for a significant portion of atenolol's metabolism in most individuals.",
      "Atenolol is converted to its active metabolite, carbamylated atenolol, by CYP2D6.",
      "Approximately 70-80% of atenolol's total clearance is due to the metabolic pathway involving CYP2D6.",
      "Around 20-30% of Caucasians are poor metabolizers of CYP2D6."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the liver and does not undergo significant metabolism by the cytochrome P450 enzyme system, including CYP2D6.\n2. FALSE [correction]: Since atenolol is not significantly metabolized by CYP2D6, this enzyme is not responsible for a significant portion of atenolol's metabolism in most individuals.\n3. FALSE [correction]: Atenolol does not have an active metabolite called carbamylated atenolol, and it is not converted by CYP2D6 as it is not significantly metabolized by the liver.\n4. FALSE [correction]: Atenolol's total clearance is primarily renal, with approximately 50-60% of an oral dose being excreted unchanged in the urine.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "ExpansionHunter is a tool developed by the University of California, Santa Cruz, for the detection of transcriptional gene body expansions in genomic DNA sequences. Here are some versions of ExpansionHunter:\n1. ExpansionHunter 1.0: This was the initial version of the tool, released in 2013. It could detect expansions in genomic regions with a minimum length of 100 bp and a maximum length of 1000 bp.\n2. ExpansionHunter 1.1: Released in 2014, this version improved the accuracy of expansion detection and added a new feature to detect expansions in regions with high GC content.\n3. ExpansionHunter 2.0: Launched in 2016, this version introduced a new algorithm that improved the speed and accuracy of expansion detection, as well as a new feature to detect expansions in regions with complex repeat structures.\n4. ExpansionHunter 2.1: Released in 2017, this version included several new features, such as the ability to detect expansions in non-coding regions and to identify potential regulatory elements.\n5. ExpansionHunter 3.0: The latest version, released in 2020, includes several significant updates, including improved algorithms for expansion detection, the ability to detect expansions in regions with high repeat content, and the integration of new databases and tools for expansion analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter is a tool for the detection of transcriptional gene body expansions in genomic DNA sequences developed by the University of California, Santa Cruz.\n2. ExpansionHunter 1.0 was released in 2013 and could detect expansions with a minimum length of 100 bp and a maximum length of 1000 bp.\n3. ExpansionHunter 1.1 was released in 2014 and improved the accuracy of expansion detection and added a feature for regions with high GC content.\n4. ExpansionHunter 2.0 was launched in 2016 with a new algorithm for improved speed and accuracy and a feature to detect expansions in regions with complex repeat structures.\n5. ExpansionHunter 3.0 was released in 2020 and included improved algorithms for expansion detection and the ability to detect expansions in regions with high repeat content.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter is a tool for the detection of transcriptional gene body expansions in genomic DNA sequences developed by the University of California, Santa Cruz.",
      "ExpansionHunter 1.0 was released in 2013 and could detect expansions with a minimum length of 100 bp and a maximum length of 1000 bp.",
      "ExpansionHunter 1.1 was released in 2014 and improved the accuracy of expansion detection and added a feature for regions with high GC content.",
      "ExpansionHunter 2.0 was launched in 2016 with a new algorithm for improved speed and accuracy and a feature to detect expansions in regions with complex repeat structures.",
      "ExpansionHunter 3.0 was released in 2020 and included improved algorithms for expansion detection and the ability to detect expansions in regions with high repeat content."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ExpansionHunter is a tool for the detection of repeat expansions in genomic DNA sequences, but it was developed by the research team at Illumina, not the University of California, Santa Cruz.\n2. UNKNOWN: Without specific release notes or a version history from the developers, it is difficult to confirm the exact capabilities and release date of ExpansionHunter 1.0.\n3. UNKNOWN: Similar to statement 2, without specific release notes or a version history, it is difficult to confirm the features and release date of ExpansionHunter 1.1.\n4. UNKNOWN: The details about the launch of ExpansionHunter 2.0, including the new algorithm and features, cannot be confirmed without official documentation or release notes.\n5. UNKNOWN: The release year and features of ExpansionHunter 3.0 cannot be confirmed without official documentation or release notes. However, it is worth noting that ExpansionHunter does indeed have versions that improve upon algorithms and features over time, but the specifics provided here cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 (A disintegrin and metalloproteinase domain-containing protein 18) is a secreted protein that plays a role in hormone receptor signaling, particularly in the regulation of estrogen receptor (ER) signaling.\nAdamts18 functions as a decoy receptor for ER, binding to ER ligands and preventing them from binding to their cognate receptors. This inhibits the activation of ER signaling, which is involved in various physiological processes, including cell growth, differentiation, and survival. By inhibiting ER signaling, Adamts18 can regulate the response to estrogen and play a role in the development and progression of estrogen-dependent cancers, such as breast cancer.\nAdamts18 also interacts with other signaling proteins, including the epidermal growth factor receptor (EGFR) and the protease activated receptor 1 (PAR1), and can modulate their activity. For example, Adamts18 has been shown to enhance the activity of EGFR, leading to increased cell proliferation and migration, while inhibiting the activity of PAR1, leading to decreased inflammation.\nOverall, Adamts18 plays a complex role in hormone receptor signaling, modulating the activity of ER and other signaling proteins to regulate various cellular processes and contributing to the development and progression of certain diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is a secreted protein that plays a role in hormone receptor signaling.\n2. Adamts18 functions as a decoy receptor for the estrogen receptor (ER), binding to ER ligands and preventing them from binding to their cognate receptors.\n3. By inhibiting ER signaling, Adamts18 can regulate the response to estrogen.\n4. Adamts18 is involved in the development and progression of estrogen-dependent cancers, such as breast cancer.\n5. Adamts18 interacts with other signaling proteins, including the epidermal growth factor receptor (EGFR) and the protease activated receptor 1 (PAR1), and can modulate their activity.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is a secreted protein that plays a role in hormone receptor signaling.",
      "Adamts18 functions as a decoy receptor for the estrogen receptor (ER), binding to ER ligands and preventing them from binding to their cognate receptors.",
      "By inhibiting ER signaling, Adamts18 can regulate the response to estrogen.",
      "Adamts18 is involved in the development and progression of estrogen-dependent cancers, such as breast cancer.",
      "Adamts18 interacts with other signaling proteins, including the epidermal growth factor receptor (EGFR) and the protease activated receptor 1 (PAR1), and can modulate their activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Adamts18 is not known to function as a decoy receptor for the estrogen receptor (ER). It is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family, which are involved in various biological processes, but not typically as decoy receptors for hormone signaling.\n3. FALSE [correction]: Since Adamts18 is not a decoy receptor for the estrogen receptor, it does not inhibit ER signaling in the manner described.\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about Adamts18's specific interactions with hormone receptors and other signaling proteins are highly specialized, and without specific scientific literature or evidence to confirm these claims, they cannot be verified. Therefore, the responses to statements 1, 4, and 5 are UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the enzyme p53-activated protein 1 (AP1). It works by binding to the AP1 site on the DNA and preventing the recruitment of transcription factors, such as c-Jun, c-Fos, and AP-1, which are involved in the regulation of gene expression. By inhibiting the binding of these transcription factors, thiazovivin reduces the expression of genes involved in cell proliferation, survival, and angiogenesis, leading to the inhibition of tumor cell growth and proliferation. Additionally, thiazovivin also inhibits the activity of the PI3K/Akt signaling pathway, which is commonly activated in cancer cells, thereby further reducing cell survival and proliferation. Overall, the mode of action of thiazovivin is to inhibit the expression of pro-proliferative genes and to disrupt the PI3K/Akt signaling pathway, leading to the inhibition of tumor cell growth and proliferation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is a small molecule inhibitor of the enzyme p53-activated protein 1 (AP1).\n2. Thiazovivin prevents the recruitment of transcription factors such as c-Jun, c-Fos, and AP-1 by binding to the AP1 site on DNA.\n3. The inhibition of these transcription factors by thiazovivin reduces the expression of genes involved in cell proliferation, survival, and angiogenesis.\n4. Thiazovivin inhibits the activity of the PI3K/Akt signaling pathway.\n5. The PI3K/Akt signaling pathway is commonly activated in cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is a small molecule inhibitor of the enzyme p53-activated protein 1 (AP1).",
      "Thiazovivin prevents the recruitment of transcription factors such as c-Jun, c-Fos, and AP-1 by binding to the AP1 site on DNA.",
      "The inhibition of these transcription factors by thiazovivin reduces the expression of genes involved in cell proliferation, survival, and angiogenesis.",
      "Thiazovivin inhibits the activity of the PI3K/Akt signaling pathway.",
      "The PI3K/Akt signaling pathway is commonly activated in cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not an inhibitor of the enzyme p53-activated protein 1 (AP1). It is actually a small molecule that enhances the survival of human pluripotent stem cells during cell culture.\n2. FALSE [correction]: Thiazovivin does not prevent the recruitment of transcription factors such as c-Jun, c-Fos, and AP-1 by binding to the AP1 site on DNA. Instead, it is known to act as a Rho-associated kinase (ROCK) inhibitor, which is involved in cell adhesion and survival.\n3. FALSE [correction]: Since thiazovivin is not an inhibitor of transcription factors like c-Jun, c-Fos, and AP-1, the statement about it reducing the expression of genes involved in cell proliferation, survival, and angiogenesis by inhibiting these transcription factors is incorrect. Thiazovivin's primary known action is to enhance stem cell survival, potentially by inhibiting ROCK.\n4. UNKNOWN: There is no direct evidence provided here that thiazovivin inhibits the activity of the PI3K/Akt signaling pathway. While ROCK inhibitors can have various effects on cellular signaling pathways, without specific evidence, we cannot confirm the effect of thiazovivin on the PI3K/Akt pathway.\n5. TRUE: The PI3K/Akt signaling pathway is indeed commonly activated in cancer cells and is associated with processes such as cell growth, proliferation, and survival.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "true"
    ]
  }
]